



# INBORN ERRORS *of* METABOLISM

DAVID YI YUNG HSIA, M D

*Associate Professor of Pediatrics Northwestern University Medical School Attending Biochemist and Director of Research Children's Memorial Hospital Chicago Associate Attending Physician Cook County Hospital and Evanston Hospital*

*Director Genetic Clinic Children's Memorial Hospital Chicago*

THE YEAR BOOK PUBLISHERS • INC

200 EAST ILLINOIS STREET • CHICAGO

**COPYRIGHT 1959 BY THE YEAR BOOK PUBLISHERS, INC.**

*Reprinted February 1960*

**LIBRARY OF CONGRESS CATALOG CARD NUMBER 59 5949**

**PRINTED IN U S A**

**To MY PARENTS**



## Foreword

TO THE AVERAGE physician the diseases included in most textbooks under the heading of "inborn errors of metabolism" have represented an esoteric group unlikely to be encountered in clinical practice. A true understanding of these disorders is made doubly difficult because two disciplines are required: a knowledge of genetics and an acquaintance with fairly specialized biochemistry. However, during the past few years so many additions have been made to the known inborn errors of metabolism that the group can no longer be considered a rarity and the physician must expend the effort required to understand the problems involved. The present volume has been designed to review basic concepts and clinical aspects for the physician who is neither geneticist nor enzyme chemist.

The evolution of the author's interest in this field is worthy of reconstruction. His investigative work dealt originally with physiological jaundice and later with the problem of jaundice in erythroblastosis and its relationship to kernicterus. Problems of obstructive jaundice next engaged his interest, and at this time he encountered infants with galactosemia, an inborn error of metabolism which frequently presents with obstructive jaundice. Shortly afterward he became involved in the study of constitutional hepatic dysfunction and congenital, familial nonhemolytic icterus. It became obvious to both Dr. Hsia and his friends that a basic understanding of these disorders could be obtained only through a knowledge of both human genetics and enzyme chemistry, and so he embarked on a program which would furnish him with such knowledge. This book is the culmination of these studies.

Despite the exciting recent advances in knowledge regarding inborn errors of metabolism, it is clear that we have only begun to explore a

## 8 FOREWORD

field with apparently unlimited possibilities. In the near future not only will we acquire additional understanding of the diseases reviewed here but we will also see the addition of numerous conditions not previously considered to be inborn errors of metabolism.

SYDNEY S. GELLIS

## Preface

IN RECENT YEARS, unprecedented progress in the field of biochemical genetics has permitted, for the first time, a logical approach to the various inborn errors of metabolism in man. The present volume is an attempt to present this approach in a simple and understandable form for physicians, but it should be emphasized that the book does not in any way represent a comprehensive or complete survey of the field. The investigative worker in biochemistry, genetics, or medicine should consult the excellent reviews which are marked by an asterisk in each section. However, despite its limitations, it is hoped that this volume will be helpful to the general practitioner and the house officer when they next come face to face with a patient who has a hereditary disease. In the same way, it is hoped that the Appendix will act as a readily available laboratory manual for their use in the detection of these conditions.

In looking back over the past eight years, I realize that it would be impossible to acknowledge all of the many friends and colleagues who have helped in the preparation of the manuscript. Of those in the Department of Pediatrics at Harvard University, I would first like to express my

this work but has also been a constant source of personal guidance and support. To no less degree, I would like to express my sincere thanks to Dr. Sydney S. Gellis. Through him I first became interested in pediatric research and he has remained a loyal colleague and friend.

Among those at the Department of Biological Chemistry at Harvard University to whom I owe acknowledgment, I wish to express my debt to Dr. W. Eugene Knox. It was while working with him that the idea of preparing such a volume arose, and he was most helpful in our



the approaches to be taken during the early phases I am also grateful to Dr A Baird Hastings and his M D Luncheon group, who devoted their meetings during the spring of 1955 to discussing various phases of the material covered in this book. It is largely through their encouragement that the manuscript was initiated.

Recalling my stay at the Galton Laboratory in London, I wish to acknowledge first the kindness of Professor L S Penrose. His mature philosophy and understanding of biochemical genetics were most helpful in clarifying many points. I also want to acknowledge the many helpful ideas and detailed information given to me by Dr H Harris during our many talks together. Finally, it was a real privilege to get to know and learn from Professors J B S Haldane and H Gruneberg and Drs H Kalmus, Sylvia Lawler, J Renwick, and C A B Smith—all of the University College, London.

I would also like to acknowledge my indebtedness to Dr Arthur Steinberg for his many suggestions and to Drs John A Bigler and Joseph D Boggs of the Children's Memorial Hospital of Chicago for giving me the moral support and necessary time to complete the manuscript.

*During the period of preparation of the manuscript the author was the recipient of a fellowship from the Playtex Park Research Institute and a traveling fellowship from the Elizabeth McCormick Memorial Fund and also was a Wellcome Associate of the Royal Society of Medicine. All of this assistance is gratefully acknowledged.*

I would like to express my appreciation to the following for giving suggestions on specific chapters: Dr H Kalmus (Chapter 1), Dr Aaron Josephson (Chapter 2), Dr John Hartmann (Chapter 5), Dr Albert Renold (Chapter 7), Dr Matthew Steiner (Chapter 8), Dr Allen Crocker (Chapter 12), and Dr Robert Dowben (Chapter 13). Their contributions have added greatly to the book, but the responsibility for any mistakes lies with the author.

Finally, I wish to express my thanks to Dr Shirley Driscoll for the pathological descriptions and Dr Jean Naylor for proofreading the manuscript, to Dr Harvey White for preparing the roentgenograms, to Miss Grace Lawrence for checking the section on laboratory procedures, to Mr Hsio Chang Shih and my wife, Mrs Hsio Hsuan Hsia, for preparing the illustrations, to Miss Marilyn Holmquist for typing the manuscript, and to the Year Book Publishers for their helpful co operation in completing the volume in such a satisfactory manner.

# Table of Contents

<b>1 GENERAL CONSIDERATIONS</b>	<b>15</b>
<i>How Do the Inborn Errors of Metabolism Arise? 17. How Are the Inborn Errors of Metabolism Transmitted? 19</i>	
<i>Conditions Transmitted as an Autosomal Dominant, 19</i>	
<i>Conditions Transmitted as an Autosomal Recessive, 20</i>	
<i>Conditions That Are Sex Linked, 22 Factors That Influence Gene Expression 24. Influence of Environment, 26</i>	
<i>How Are the Inborn Errors of Metabolism Expressed? 27</i>	
 <b>PART I. DISTURBANCES IN MOLECULAR STRUCTURE</b>	
<b>2. SICKLE CELL ANEMIA AND THE OTHER ABNORMAL HEMOGLOBINS</b>	<b>37</b>
<i>Sickle Cell Anemia, 38 Other Abnormal Hemoglobin Variants, 43 Mixed Heterozygous Hemoglobin Diseases, 50</i>	
<i>The Thalassemia Syndrome, 52 Other Mixed Disturbances, 54.</i>	
 <b>3 OTHER "STRUCTURAL" DISTURBANCES</b>	 <b>56</b>
<i>Thalassemia, 56 Hereditary Elliptocytosis 62 Acanthrocytosis, 65 Erythropoietic Porphyria, 67. Pelger-Huet Anomaly of the Leukocytes, 70</i>	
 <b>PART II. DISTURBANCES IN MOLECULAR SYNTHESIS (PROTEIN DEFICIENCIES)</b>	
<b>4 DEFICIENCIES OF PLASMA PROTEIN FRACTIONS</b>	<b>74</b>
<i>Congenital Agammaglobulinemia, 74 Ceruloplasmin Deficiency (Wilson's Disease), 78 Congenital Afibrinogenemia, 82</i>	

## 5 DEFICIENCIES OF CLOTTING FACTORS

85

*Deficiency of Antihemophilic Globulin (AHG) (Classical Hemophilia) 87 Deficiency of Plasma Thromboplastin Component (Christmas Disease) 91 Deficiency of Plasma Thromboplastin Antecedent (PTA) 93 Deficiency of Fourth Plasma Thromboplastin Component 94 Hageman Trait 96 Ac Globulin Deficiency (Parahemophilia) 97 Deficiency of Serum Prothrombin Conversion Accelerator (SPCA) 99 Stuart Clotting Defect 101 Other Deficiencies 103*

PART III DISTURBANCES IN MOLECULAR FUNCTION  
(ENZYME DEFECTS)

## 6 DISTURBANCES IN AMINO ACID METABOLISM

107

*Aromatic Amino Acid Disturbances Phenylketonuria 108 Tyrosinosis 112 Alkaptonuria 114 Total Albinism 116 Partial Albinism 119 Other Amino Acid Disturbances Maple Sugar Urine Disease 120 H Disease 122*

## 7 DISTURBANCES IN CARBOHYDRATE METABOLISM

126

*Metabolic Disturbance Involving a Five Carbon Sugar Pentosuria (l Xyloketosuria) 126 Metabolic Disturbance Involving Six Carbon Sugars Fructosuria 129 Galactosemia 132 Glycogen Storage Disease Glycogen Storage Disease of the Liver and Kidneys (von Gierke's Disease) 138 Glycogen Storage Disease of the Heart 142 Diffuse Glycogenosis with Hepatic Cirrhosis 144 Glycogen Storage Disease of Liver and Muscle 146 Other Carbohydrate Disturbances Hereditary Spherocytosis 149 Hereditary Nonspherocytic Hemolytic Anemia 152*

## 8 DISTURBANCES IN ENDOCRINE METABOLISM

156

*Familial Cretinism with Gout Cretinism from Failure of Organic Iodine to Form 157 Cretinism from Failure of Iodotyrosines to Couple 160 Cretinism from Failure of Iodotyrosine to Deiodinate 161 The Adrenogenital Syndrome Adrenal Hyperplasia with Virilism Only 164 Adrenal Hyperplasia with Hypertension 169 Adrenal Hyperplasia with Electrolyte Disturbances 171*

## 9 DISTURBANCES IN PIGMENT METABOLISM

174

*The Methylglobinemias Congenital Methemoglobinemia Type I 174 Congenital Methemoglobinemia Type II*

## CONTENTS 13

- 178 *Congenital Methemoglobinemia, Type III*, 180  
*Other Pigment Disturbances Hepatic Porphyrin*, 180  
*Congenital Nonhemolytic Jaundice with Kernicterus*, 186  
*Familial Nonhemolytic Jaundice (Gilbert's Disease)*, 189

## 0 OTHER PROBABLE ENZYME DISTURBANCES 192

- Hypophosphatasia*, 192 *Cystic Fibrosis of the Pancreas*,  
 196 *Deficiency of Glucose-6-PO<sub>4</sub> Dehydrogenase*, 201  
*Deficiency of Pseudocholinesterase*, 204

## PART IV. DISTURBANCES IN RENAL TRANSPORT MECHANISMS

### 11. RENAL TRANSPORT DEFECTS 209

- Single Defects Nephrogenic Diabetes Insipidus*, 209 *Renal Glycosuria*, 211 *Resistant Rickets*, 214 *Cystinuria*, 217  
*Multiple Defects Fanconi Syndrome*, 221 *Cystinosis (Lignac's Disease)*, 224

## PART V DISTURBANCES IN WHICH THE ETIOLOGY IS UNKNOWN

### 12 DISTURBANCES IN LIPID METABOLISM 230

- Idiopathic Hyperlipemia (Buerger-Grutz Disease)*, 230  
*Primary Hypercholesterolemia*, 235 *Gaucher's Disease*, 238  
*Niemann Pick Disease*, 242 *Amaurotic Familial Idiocy*,  
 245 *Tay-Sachs Disease*, 246 *Bielschowsky-Jansky Dis-*  
*ease*, 248 *Spielmeyer-Vogt Disease*, 249 *Kufs's Disease*,  
 250 *Gargoylism (Hurler's Syndrome)*, 251

### 13 THE MUSCULAR DYSTROPHIES 256

- Severe Generalized Familial Muscular Dystrophy*, 256 *Mild*  
*Restricted Muscular Dystrophy*, 260 *Progressive Dystro-*  
*phia Ophthalmoplegia*, 261. *Myotonia Dystrophica*, 263

### 14 MISCELLANEOUS METABOLIC DISORDERS 265

- Idiopathic Spontaneous Hypoglycemia*, 265 *Pituitary Dia-*  
*betes Insipidus*, 267 *Diabetes Mellitus*, 269 *Gout*, 271  
*Hereditary Periodic Paralysis*, 276 *Congenital Pancyto-*  
*penia with Multiple Congenital Anomalies*, 279

**PART VI   EXTENSION OF THE CONCEPT OF "INBORN  
ERRORS OF METABOLISM" TO CLINICAL  
MEDICINE**

<b>15   THE FUTURE OF BIOCHEMICAL GENETICS</b>	<b>284</b>
<b>APPENDIX   LABORATORY PROCEDURES FOR DETECTION OF                   INBORN ERRORS OF METABOLISM</b>	<b>289</b>
<b>INDEX</b>	<b>345</b>

## General Considerations

THE CONCEPT OF 'inborn errors of metabolism' was first suggested by Sir Archibald Garrod in 1908. In the Croonian Lectures delivered at the Royal College of Physicians he suggested that four metabolic disorders—albinism, alkaptonuria, cystinuria, and pentosuria—had certain features in common. First, in all four conditions the onset of the particular abnormality could be dated to the first days or weeks of life, especially when a special effort was made to do so. A second characteristic was their familial occurrence in a considerable number of cases. A third feature was that the conditions were relatively benign and compatible with a normal life-expectancy. A fourth feature, noted by other clinicians in his day, was the frequency with which these disorders occurred among the offspring of consanguineous marriages.

Garrod made the following comments about the pathogenesis of these conditions:

Nowadays very different ideas are in the ascent. The concept of metabolism in blocks is giving place to that of metabolism in compartments. The view is daily gaining ground that each successive step in the building up and breaking down not merely of proteins, carbohydrates, and fats in general, but even of individual fractions of proteins and of individual sugars is the work of special enzymes set apart for each particular purpose.

It may well be that the intermediate products formed in the several stages have only momentary existence as such, being subjected to further changes almost as soon as they are formed, and that the course of metabolism along

foot in air. All that is known of catabolism tends to show that in such circumstances the intermediate product is being wont to be excreted as such rather than that it is further dealt with along abnormal lines. Indeed it is an arguable

question whether, under abnormal conditions, the metabolic processes are ever thrown out of their ordinary lines into entirely fresh paths with the result that products are formed which have no place in the normal body chemistry. It is commonly assumed that this happens, but if the concept of metabolism in compartments, under the influence of enzymes, be a correct one, it is unlikely a process, that alternative paths are provided which may be formed when for any reason the normal paths are blocked. It is far easier to suppose in such circumstances, normal intermediate products are excreted without further changes.

Half a century later, rapid progress in the basic sciences has given body and substance to what was, by necessity, supposition in Garrod's time. The original four inborn errors of metabolism have now been increased to well over fifty. We know more not only about how these conditions are transmitted from one generation to another but also about the very biochemical processes responsible for these changes. Much of this information is highly technical and known only to the biochemist, geneticist, or clinical investigator working on specialized studies in this field. The present volume attempts to make this knowledge available to the practicing physician.

This will be done first by formulating in general terms what we know today about how a gene produces its effect in a person. We shall then review each of the hereditary disorders, taking up first those conditions in which the pathogenesis is fairly well understood and then those clearly genetic entities about whose etiology we know little. A final chapter will consider how these concepts might be extended to other situations in which heredity may play a role. The chemical procedures which are useful in the diagnosis and treatment of these inborn errors of metabolism will be given in the Appendix. The failure to include morphologically inherited differences does not imply that they do not represent examples of inborn errors of metabolism and do not ultimately have a biochemical basis. Their bases will become known only when we eventually understand enough embryology to know how chemistry affects structure.

It is hoped that, by summarizing here the information that we do have, this work not only will be helpful to the clinician in treating his patients but will also point out to him the gaps in our knowledge of these patients' conditions which will have to be filled out by proper clinical and laboratory observations as the opportunities arise. We should take the view that the study of such disorders in human beings can contribute valuable information to the development of biochemical and genetic knowledge. In the same way, the latter can be of immense help in the diagnosis and management of patients with clinical disease.

We might well start off by considering three basic problems which concern all inborn errors of metabolism (1) How do they arise? (2) How are they transmitted? (3) How is the abnormality expressed in the affected individual? Since this is not a textbook on genetics, the discussion will, of necessity, appear to be oversimplified, however, it is hoped that it will provide some of the necessary background for a proper understanding of the subsequent chapters

### HOW DO THE INBORN ERRORS OF METABOLISM ARISE?

It has been well established that all of us are endowed with *chromosomes*—small bodies of various sizes and shapes located in the cell nuclei. The chromosomes can be easily identified because they take up certain dyes with avidity and appear quite dark in the usual stained preparation of a cell. With a few exceptions, every cell in the human body contains 23 pairs of chromosomes, one member of each pair being derived from the father and the other member from the mother. A *gene* is a submicroscopic substance on the chromosome which determines the inherited characteristics of an organism. For instance, there is a gene which determines the character of the MN blood groups, another that determines whether a person develops thalassemia, and yet a third that determines whether he or she will show homogentisic acid in the urine, and so on. Suitable experiments have shown that the genes are arranged in a linear sequence along the length of the chromosomes and that the sequence in which the genes are arranged tends to be the same for all individuals of a particular species.

During fertilization the father contributes one of each pair of his chromosomes and the mother contributes one of each pair of her chromosomes, and these two make up the pair of chromosomes in their offspring. Since the genes are located along the length of the chromosome, usually there is for each gene on a maternal chromosome a corresponding homologous gene on the paternal chromosome in the same position. Most of the time, the two homologous genes are identical and of the type most common to the species—and that is "normal," as we say. For example, most of us have the normal form of the gene for sickle cell anemia, and therefore we have normal hemoglobin in our blood. But, here and there along the line of genes on a chromosome there is likely to be found an "abnormal," or, as we say, a *mutant*, gene. If this should occur in the gene for sickle cell anemia, the individual carrying the abnormal gene would have some Type S hemoglobin as well as Type A hemoglobin, and if both genes in that position should be abnormal, the person would have



only Type  $\beta$  hemoglobin (Hgb S) All inborn errors of metabolism are the result of mutations of one or another of the genes

The exact reason why a normal gene becomes a mutant gene is not known Investigators have suggested that environmental factors, such as temperature atmospheric oxygen, and nutrition, may play a role There is considerable evidence that radiation from x rays or ultraviolet light can cause fresh mutations Regardless of the cause, once a mutation occurs the abnormal characteristic will be transmitted to future generations Mutant genes may, however, be removed from the general population by one of several means The mutant gene may have a lethal effect on the affected individual and he will fail to reproduce, thereby permanently removing that gene from circulation Environmental circumstances may favor the reproduction and survival of normal genes over the reproduction and survival of abnormal genes Finally, a mutant gene may spontaneously revert back to normal This is a rare event, but it has been known to occur

Medically, we have tended to emphasize the similarity of the characteristics of a given hereditary disease For instance, the clinical manifestations of one patient with the adrenogenital syndrome are very similar to those of another Chemically, all such patients excrete excessive amounts of 17 ketosteroids Finally, the condition is usually transmitted as an autosomal recessive It is not surprising therefore, that we have always regarded the adrenogenital syndrome as one uniform entity During the past 2 or 3 years, careful studies have revealed that there are at least two or three different varieties of the adrenogenital syndrome Although the patients appear to be quite similar clinically, they show definite chemical differences, and genetic studies have shown that, in any given family, only one of the three types of the condition appears This is not surprising if one remembers that fresh mutations are occurring constantly, also it seems unlikely that all of the present cases of the adrenogenital syndrome stem from a single mutation that occurred many generations ago Instead of thinking of the syndrome as a single homogeneous entity, one should think of it in terms of the occurrence of many separate fresh mutations Some of these may involve the same genes and will give an identical laboratory and clinical picture, others may involve entirely separate genes, located in different positions on perhaps other chromosomes It is only our inability to determine these differences clinically, or even in the laboratory, that has led us to believe they were all a single homogeneous entity Other examples of probable differences in mutations are the dominant and recessive forms of alkaptonuria, the several different forms of cystinuria, and the three different types of methemoglobinemia If

one appreciates the fact that every inborn error of metabolism encountered may represent a fresh mutation, this will lead to a more flexible approach to their study

### HOW ARE THE INBORN ERRORS OF METABOLISM TRANSMITTED?

We turn next to the problem of how abnormal genes are transmitted from one generation to the next. Classically, a genetic defect has been




FIG. 1.—Dominant inheritance *A* only one parent affected with the defect. *B* both parents affected.

shown to be transmitted by one of three modes: dominant, recessive, or sex linked. We shall, therefore, discuss these modes first.

**CONDITIONS TRANSMITTED AS AN AUTOSOMAL DOMINANT**—A dominant condition, such as renal glycosuria, is transmitted in the manner shown in Figure 1, *A*. Let us assume that the father of such a mating has one abnormal gene for renal glycosuria. Since he has two genes which are

different, he is described as a *heterozygote* for the trait. The mother, on the other hand, has two genes which are both normal, and she is described as being *normal* for the trait. Since the condition is a dominant one, the character will show up in the heterozygote and the father will have sugar in his urine, however, the mother, being normal, will not have renal glycosuria.

When two such individuals mate, the father can contribute either a normal or an abnormal gene as gametes, while the mother can only contribute two normal genes as gametes. Two types of offspring can arise from such a mating. Half of the offspring would have one normal and one abnormal gene for renal glycosuria and be heterozygotes like the father, the other half will have two normal genes and be normal like the mother.

In dominant inheritance, most of the affected individuals are heterozygotes for the abnormality and the trait is carried through each successive generation. Thus, the mode of transmission of a dominant defect is an indication of how the chromosomes actually behave, just as if we could observe the chromosomes themselves at each reduction division and at each fertilization. If an investigator can study only one family properly, he can describe the way the abnormal gene is transmitted.

Very rarely, two affected individuals will mate and produce an offspring with two abnormal genes, the offspring being a *homozygote* for the trait (Fig. 1, B). Such an individual usually has a more severe form of the disease than either of his affected parents. In many disorders the homozygote may die either before birth or shortly thereafter.

**CONDITIONS TRANSMITTED AS AN AUTOSOMAL RECESSIVE**—A *recessive* gene, such as the one for phenylketonuria, can be transmitted in the manner shown in Figure 2. If one of the parents is a heterozygote and the other is completely normal, half of the offspring will be heterozygotes and the other half completely normal, as shown in Figure 2, A. Since the condition is a recessive one, the heterozygote cannot usually be identified by simple means, and the abnormal gene is passed from one generation to another without the condition being known.

However, when two such heterozygotes mate, a rather different picture emerges, as shown in Figure 2, B. Each of the heterozygotes will contribute one normal and one abnormal gene at the gamete stage. Three types of offspring will result. One quarter of them will receive one normal gene from the father and a similar normal gene from the mother and will be completely normal, in the genetic sense. One half of the offspring will receive one normal and one abnormal gene from each of the parents and be heterozygotes, just like their parents. The final quarter of the offspring will receive one abnormal gene from the father and one abnormal gene

from the mother, they will be homozygotes with two abnormal genes for the trait and will have the full-blown clinical picture of phenylketonuria.

As a general rule, a recessive mode of inheritance is suggested by the following genetic findings (1) the great majority of affected persons are




FIG. 2.—RECESSIVE INHERITANCE. A, only one parent a carrier of the defect. B, both parents carriers.

the offspring of parents who are normal to all outward appearances, (2) the condition tends to affect the siblings in a family (with a ratio of 1 affected to 3 unaffected) but does not usually affect parents or offspring unless there is intermarriage between close blood relatives, and (3) there is usually an undue proportion of consanguineous marriages among the parents of affected persons. The reasons for this increased incidence can be shown as follows:

Let us say that there is a marriage between two first cousins, where the father of the woman and the mother of the man are brother and sister,

as shown in Figure 3. If one assumes that the woman (*A*) is heterozygous for phenylketonuria, she must have received the abnormal gene either from her father or from her mother, so that the chance of her father (*B*) also being a heterozygote is 1 in 2, or  $\frac{1}{2}$ . If the father (*B*) is heterozygous, then he must have received the abnormal gene from his father or mother, and if so, the chance of his sister (*C*) being heterozygous is  $\frac{1}{2} \times \frac{1}{2}$ , or 1 in 4. Finally, if *C* is a heterozygote, the chance of her son (*D*) being a heterozygote is  $\frac{1}{2} \times \frac{1}{2} \times \frac{1}{2}$ , or 1 in 8. Therefore, one




FIG. 3—Genetic tree of a marriage of two first cousins

can say that the probability of a heterozygote mating another heterozygote for the same trait in a first-cousin marriage is 1 in 8.

Estimates have shown that about 1 out of every 100 persons in the general population is a heterozygote for the phenylketonuria trait. Assuming random mating, the chance of a case of phenylketonuria occurring among offspring of unrelated marriages is  $1/100 \times 1/100 \times \frac{1}{4}$ , or less than 1 in 40,000. On the other hand, if first cousins were to marry each other, the chance would be increased by  $1/100 \times \frac{1}{8} \times \frac{1}{4}$ , or 1 in 3,200. In other words, there is a 12.5 times greater likelihood of such a mating's getting an affected child than would a union from the general population. In the same way, consanguinity occurs in about 8 per cent of the parents of phenylketonurics, which is considerably higher than the 1 per cent seen in the population as a whole. Generally, the more rare the defect, the higher the proportion of consanguineous marriages.

**CONDITIONS THAT ARE SEX LINKED**—In most cells in the human body the members of each of the 23 pairs of chromosomes are identical in appearance with one exception. Males possess one unequal pair of chromosomes, termed the "XY pair." The chromosomes in this pair differ in that the length of the X-chromosome is appreciably longer than that of the Y-chromosome, a difference which is easily detectable under the ordinary microscope. Females, on the other hand, possess two chromosomes of the X type and none of the Y type. Because of this difference, these chro-

mosomes are described as *sex chromosomes*, in contrast to the other chromosomes, which are called *autosomes*.

The sex-linked genes are carried on the X-chromosomes. We can illustrate this by describing the mode of inheritance of the gene for hemophilia, which is probably carried in the upper portion of the X-chromosome, as shown in region *A* in Figure 4. When a female who is hetero-




FIG. 4.—Sex linked inheritance

zygous for this gene mates with a normal male, one of four situations can occur. (1) the female and male can each contribute one normal X-chromosome and produce a normal female offspring, (2) the female can contribute one normal X-chromosome and the male a Y-chromosome and produce a normal male offspring, (3) the female can contribute an abnormal X-chromosome and the male a normal X-chromosome and produce a female offspring who is a heterozygous carrier just like her mother. Since hemophilia is a recessive trait, this offspring will show no clinical disease but can transmit the abnormality to her male offspring,

and (4) the female can contribute an abnormal X-chromosome and the male a Y-chromosome and produce an affected male. If this male hemophiliac mates with a normal female, he can transmit the trait to his daughters, who will be carriers. There is also the possibility that he will mate with a female who is a heterozygote and that both male and female hemophiliacs can result from such a marriage. However, the probability of this occurring is so small that only one or two such instances have been reported.

**FACTORS THAT INFLUENCE GENE EXPRESSION**—Before leaving the question of how genes are transmitted, we should consider the factors that influence the proper expression of genes. First, we must remember




FIG. 5—Illustrating gene expression. *H* is incompletely dominant in hereditary spherocytosis; neither dominant nor recessive in sickle cell anemia; and incompletely recessive (where the heterozygotes are detectable) in phenylketonuria.

that genetic conditions are seldom completely dominant or completely recessive. Rather, they appear to be relatively so, depending upon how well one can distinguish between the heterozygote and the normal, and also between the heterozygote and the homozygote with two abnormal genes. This can be illustrated by three examples as shown in Figure 5.

In hereditary spherocytosis, the heterozygote (Fig. 5, *Aa*) has anemia, spherocytosis, increased fragility of erythrocytes, and all of the characteristics of the clinical disease. The homozygote with the two abnormal genes (*aa*) occurs rarely, but when such an individual is investigated his or her condition is little different from that of the heterozygote except that

the hemolytic process may be a little more severe. Yet, genetically the heterozygote and the homozygote are quite different. As a result, we regard the condition as being transmitted as a "dominant," or at least almost completely so. In sickle cell anemia, the heterozygote (Ss) has about 40% Hgb S and 60% Hgb A in the blood. This places it as intermediate between the affected homozygote (ss) and the normal (SS). Such conditions are regarded as being neither completely dominant nor completely recessive. Finally, in phenylketonuria, the heterozygote (Pp) is almost normal in every way except that he has some difficulty in handling large amounts of phenylalanine, as compared with the normal individual (PP). We classify this condition as a "recessive," although it is not completely so. By viewing most of the inborn errors of metabolism as being neither completely dominant nor recessive, we get a truer picture of the disease process and how it is transmitted.

Second, we should mention that genes are regularly transmitted but may not be regularly expressed. For instance, in a dominant mode of inheritance, one would expect the abnormality to be transmitted from parent to child to grandchild. In some families the abnormality is well documented in the first generation, skips the second generation, and reappears in several members of the third generation, indicating that the abnormal gene was transmitted but not expressed. In such instances, careful studies have shown that the individual in the "missed" generation did, in fact, show a minor degree of the abnormality but that it was too slight to be detected. In other instances, no abnormalities of any kind could be detected. For some unknown reason, the abnormal gene was not expressed in the second generation but reappeared in the typical manner in the third generation.

Third, one has to remember that a trait which is truly inherited need not necessarily be present at birth. In some cases, it may appear later in life. Huntington's chorea will serve as an example. This disease is characterized by the development, at about age 30 or 40, of mental deterioration, accompanied by involuntary movements of the face, body, and extremities. These symptoms are due to an actual degeneration of certain brain centers, and family studies have shown that, when the age of onset is taken into consideration, this disorder meets all the requirements of a dominant mode of inheritance.

Another problem to be faced is the fact that in some disorders only a few of the affected individuals actually show clinical signs and symptoms of disease. For instance, there are published pedigrees which show that many individuals in the family have hyperuricemia but that only a few of these develop gout clinically. Diabetes mellitus is probably another exam-



ple of a condition in which only a few of the affected individuals show the full clinical picture

**INFLUENCE OF ENVIRONMENT**—Although geneticists prefer to deal with characteristics that are relatively unaffected by the environment, this is frequently not possible, especially when one is dealing with human genetics. Therefore, no data regarding the genetic behavior of a trait are




FIG 6—Method for delineating hereditary and environmental factors in the pathogenesis of disease

adequate without a specification of the environmental circumstances in which the trait has developed

The environmental events which may intervene between the basic biochemical activities of a gene and the resulting finished characteristics in man run a wide gamut. They may be overtly traumatic or subtly psychological, they may be related to geographical location, to climate, to socioeconomic status or to rural or urban habitat, they may be infectious in nature or they may involve immunological response to invasions, they may be nutritional or they may relate to the psychological status of the mother.

One convenient method for delineating hereditary and environmental influences is illustrated in Figure 6. The horizontal axis shows the extent

of genetic influences, and the vertical axis shows the role played by environmental influences. Thus, a disease like hemophilia or phenylketonuria, which is entirely genetically determined, would fit in position A5. Most workers would agree that diabetes mellitus is at least in part genetically determined. Yet, diet and mode of living may play a major role in its pathogenesis, and hence it should properly be placed in position C3. A condition like epilepsy cannot be considered as a hereditary disease in the classical sense, yet, similar abnormal electroencephalogram tracings are noted with great frequency among families, and especially among the twins of affected individuals. This would probably place epilepsy in position D2. Finally, chickenpox and lead poisoning, although they may run in families, are almost certainly due only to environmental factors, and these diseases should be placed in position E1.


### HOW ARE THE INBORN ERRORS OF METABOLISM EXPRESSED?

We might start off by speculating on what happens to a fresh mutation. In some instances the abnormality may be so severe as to be lethal while the fetus is still in utero. This could occur when the embryo is at the 4- or 8- or 16-cell stage, or it may occur close to term. Careful studies with mice have shown that death can occur and the fetuses become absorbed at any stage of gestation and that only the unaffected members of a litter will be born. Early miscarriages among humans must in part be due to lethal genes.

In addition, certain mutant genes exert a definite but usually not lethal effect upon the fetus during the early stages of embryonic development. This accounts for the long list of structural disorders which we know to be determined on a genetic basis. How the genes affect morphology is not entirely clear at the present time. It is believed that most probably they induce chemical abnormalities during the early stages of embryonic development and that this in turn causes structural malformations. If this is the case, then these conditions should also be included among the inborn errors of metabolism. However, such disorders will not be discussed here because so little is known about the chemical changes that a discussion of the pathogenesis of the disorders would be fruitless.

Finally, we come to the group of conditions caused by abnormal genes where the biochemical abnormalities are relatively minor. As a result, the fetus can survive to term, permitting us to make proper clinical and biochemical observations. Garrod quite correctly defined such conditions as "inborn errors of metabolism", however, we should extend that definition to include any genetically determined condition where there is clear-

# **CHART 1** **SICKLE CELL ANEMIA**



A "pedigree of causes" of sickle cell anemia. The mode of transmission of the abnormal gene is given at the top of the chart. A thick line then separates the genetic information, which can only be deduced mathematically from the chemical properties, which can be measured by physical means. The primary gene effect is given in capital letters, immediately under the family data, and the secondary gene effects follow from the primary gene effect. For symbols, see Figure 9, and for further description of charts, see text, page 32. (This pedigree is taken from Neel, J. V. The inheritance of the sickling phenomenon, with particular reference to sickle-cell disease, Blood 6:389, 1951.)




FIG 8.—Distribution of plasma phenylalanine levels intelligence head size and hair color in normal persons (*left*) and in those with phenylketonuria (*right*) (From Penrose L S Measurement of pleiotropic effects in phenylketonuria Ann Eugenics (London) 16 134 1951)

acid is more important than say intelligence where there is some overlap between normal and abnormal and certainly more so than some thing like hair color, where the correlation is only on the order of 0.203

Rapid biochemical progress during the past decade has made it possible for us to name the primary gene changes of many of the hereditary disorders Up to the present the changes seem to involve only protein molecules however it is probable that other types of molecules will also

be involved in the future. The disturbances in protein molecules may be divided into four types:

- 1 Disturbances in the structure of the protein molecules, where there appears to be a change in the actual shape or arrangement of the molecules themselves
- 2 Disturbances in the synthesis of the protein molecule, where the protein is not being made properly or may be entirely absent.
- 3 Disturbances in the function of the protein molecule, where an enzyme does not appear to be functioning properly. In such conditions we are often not certain as to whether the protein is completely absent or is abnormal and hence cannot function.
- 4 Disturbances in renal transport mechanisms, which probably are similar to enzyme disturbances.

It should be emphasized that this classification is highly tentative. Also, it should be remembered that, since we know so little about how a gene acts, the observed "primary" gene effect may, in fact, be several stages removed from the fundamental action of the gene. As we acquire more information, what we now regard as primary gene action may turn out to be very secondary after all. The very fact that we see the gene acting in different ways—by causing a disturbance in protein structure, in protein synthesis, and in protein function—is a clear indication that we have not reached the ultimate stage of understanding how a gene acts.

We shall now discuss each of the disorders individually, illustrating the disorder by means of a specially prepared chart. At the top of each chart (see Chart 1, p. 30) will be shown the pertinent information on the gene and how it is transmitted. Whenever possible, a typical family with the condition has been chosen from the literature to illustrate the heredity of the condition. The symbols used in the charts are shown in Figure 9.

The MIDDLE portion of the chart will be devoted to the *primary gene effect*. As discussed above, this reflects the first effect of the gene which is detectable by physical or chemical means. While it is not the purpose of the present book to take up all of the biochemical background of each disorder, clinical formulas and the site of the metabolic block will be shown whenever possible. Also, useful laboratory procedures for the diagnosis of each condition will be given in the Appendix.

The LOWER portion of each chart will be devoted to *secondary clinical signs and symptoms* which result from the primary gene effect. Where there is doubt as to how the mechanism operates, a question mark is placed along that pathway.

In the discussion of the disorder, particular emphasis will be placed upon clinical features, heredity, pathogenesis, diagnosis, and treatment. A list of the most useful references, including reviews (marked with an asterisk), will be given at the end of each section.

A book of this nature must, of necessity, be incomplete, and many important things have had to be left out. It is hoped, however, that it will




FIG 9—Symbols used in charts

be of some help to the general practitioner and the house officer when they are next confronted with a disorder that seems to "run in the family."

Beadle, G. W. *Biochemical genetics* Chem Rev 37 15, 1945

Inc., 1947)  
 Haldane J. B. S. *The Biochemistry of Genetics* (London George Allen & Unwin Ltd 1944)

## 34 INBORN ERRORS OF METABOLISM

- \*Harris, H *An Introduction to Human Biochemical Genetics* (London Cambridge University Press, 1953)
- Hsia, H Y Y The laboratory detection of heterozygotes, *Am J Human Genet* ■ 98, 1957
- Knox, W E The hereditary molecular diseases in man *Bull New England Center Hosp* 2 1, 1956
- Neel, J V The inheritance of the sickling phenomenon, with particular reference to sickle-cell disease, *Blood* 6 389, 1951
- and Schull, W J *Human Heredity* (Chicago University of Chicago Press, 1954)
- Pauling, L Abnormalities of hemoglobin molecules in hereditary hemolytic anemias, *Harvey Lect* 49 216 1954
- Roberts, J A F *An Introduction to Medical Genetics* (London Oxford University Press 1940)
- Sorsby A (ed) *Clinical Genetics* (St Louis C V Mosby Company, 1953)
- Snyder L H Human heredity and its modern application, *Am Scientist* 43 391, 1955
- \*Symposium on inborn errors of metabolism (Dent, C E, guest editor), *Am J Med* 22 671 783, 1957

## PART I

# Disturbances in Molecular Structure

A NUMBER OF THE inborn errors of metabolism result from abnormalities of molecular structure and arrangement. These defects are particularly important because they probably reflect closely the direct action of the abnormal gene. In fact, some workers believe that the specific protein molecules concerned are actual direct products of the gene itself. In any event, the study of structural disturbances is likely to give us information on how a gene acts. Ultimately it may be found that all inborn errors of metabolism involve some disturbance of molecular structure.

The structural disturbances may be of two kinds. First we have the group of conditions where there is clearly a disturbance of structure within the molecule itself. This group would include *sickle cell anemia* and the *other abnormal hemoglobins*. The finding of a structural abnormality first in hemoglobin is not surprising since hemoglobin is the protein most readily available in the body and has been intensively studied for years.

Then we have the group of conditions in which there is a difference in the make up of the 'stroma,' or wall of cells. It is not clear at present whether these changes represent a disturbance of structure within the molecule itself or an abnormality in the arrangement of the molecules in relation to each other. However, these conditions have many features in common with the abnormal hemoglobins and should be considered together, they include *thalassemia*,



*hereditary elliptocytosis, acanthrocytosis, erythropoietic porphyria and the Pelger-Huet anomaly of the leukocytes*

Finally, it should be mentioned that all of the blood groups, such as Rh, ABO, and MN, represent structural differences of molecules in individuals. Some of the serum protein groups described by Smithies and his co-workers probably should be regarded as molecular differences also. These variations, however, affect all human beings and probably should not be regarded as examples of errors of metabolism.

## Sickle Cell Anemia and the Other Abnormal Hemoglobins

IN 1949, Pauling, Itano, Singer, and Wells made the fundamental discovery that the erythrocytes of patients with sickle cell anemia contain hemoglobin with an isoelectric point which is significantly different from that of normal individuals. This provided the first positive evidence that adult human hemoglobin exists in more than one molecular form, and it implied for the first time that many of the hereditary diseases of a biochemical nature may be caused by genetically determined abnormalities

TABLE 1.—PHYSICAL CHARACTERISTICS OF THE ABNORMAL HEMOGLOBINS

	ALKALI pH 8.6	ISO- ELECTRIC POINT	ANODIC MOBIL- ITY ON PAPER ELECTROPHO- RESIS	SOLUBILITY OF REDUCED HGB IN 80% ETHANOL	RELATIVE ABNORMALITY	RELATIVE ABNORMALITY
Hgb S	Normal	7.09	7	Very low	Normal*	Yes

of protein synthesis. Since then, additional examples of abnormal hemoglobins have been described, together, they may be described as a "family of hemoglobin disorders" (Table 1).

At the present time, there appear to be at least three separate loci responsible for hemoglobin production. (1) It has been shown that the

genes responsible for Hgbs S and C are alleles, or closely linked. These have been designated  $h_1^S$  for Hgb S,  $h_1^C$  for Hgb C, and  $h_1^A$  for its normal allele. (2) The production of Hgb G is inherited independently of the genes mentioned above. This state has been designated  $h^G$  for Hgb G, and  $h^A$  for its normal allele. (3) Finally, evidence has been presented showing that the genes responsible for Hgbs S and G and for thalassemia are not allelic. Therefore, the thalassemia gene has been designated  $h_t^T$ , and its normal allele as  $h_t^A$ . The relationship of the genes responsible for Hgbs D, E, H, I, J, and K to these three loci remains to be worked out. These genes could be alleles of those responsible for Hgbs S and C or for Hgb G, or they may occur at independent loci. For the present purposes, they will be defined as  $h^D$ ,  $h^E$ ,  $h^H$ ,  $h^I$ ,  $h^J$ , and  $h^K$ .

The abnormal hemoglobins will be discussed under the following headings: (1) *sickle cell anemia*, (2) *other abnormal hemoglobin variants*, (3) *mixed heterozygous hemoglobin diseases*, (4) *the thalassemia syndrome*, and (5) *other mixed disturbances*.

## I SICKLE CELL ANEMIA

The red blood cells of certain individuals possess the peculiar property of undergoing a reversible alteration in shape in response to changes in the partial pressure of oxygen within the cell. When oxygen tension is lowered, these cells change from their normal biconcave form to elongated filamentous or crescentic forms. The peculiar shape of such cells in man was first recognized by Herrick. However, in retrospect, the same phenomenon had been noted in 1840 by Gullivar in some blood films prepared from deer in the London Zoo. This peculiar ability of red cells to sickle under conditions of reduced oxygen tension is the primary feature of sickle cell disease.

**CLINICAL FEATURES**—Patients with *sickle cell anemia* ( $h_1^S/h_1^S$ ) normally show only a moderate anemia, a subicteric tint of the scleras, and little or no enlargement of the spleen. Some changes in the tissues such as extramedullary hematopoiesis, hemosiderosis, and hyperplasia of the bone marrow, are sometimes found, depending on the severity of the anemia.

From time to time, the patients develop recurrent attacks of weakness, fatigue, anorexia, abdominal pain, icterus of the scleras, and pallor. Examination during or shortly after such a hemolytic crisis will show an icteric tinge to the scleras, increased pallor of the lips and mucous membranes, and frequently enlargement of the liver, and as the anemia be-

comes more severe, enlargement of the heart with hemic murmurs occurs. Such hemolytic crises are frequently precipitated by an acute infection.

The course and prognosis of patients with sickle cell anemia vary with the severity of the sickling tendency, the frequency and duration of the hemolytic crises, and the age of the patient. Younger patients seem to fare less well, since recurrent severe anemia often interferes with proper growth and nutrition and thus restricts general activity. Older individuals frequently suffer from arthritic symptoms, leg ulcers, and aseptic necrosis




FIG. 10—Smear from the peripheral blood of a patient with sickle cell anemia.

of the hip. Hematuria and hyposthenuria are not infrequent complications. Death may result from a rapidly developing severe anemia or intercurrent infection.

A relatively benign condition is *sickle cell trait* ( $h_1^s/h_1^A$ ), which is characterized only by the ability of the erythrocytes to sickle under reduced oxygen tension. Two complications have occasionally been noted among those with the sickle cell trait. Hematuria may occur, especially during periods of low oxygen tension. Also, splenic infarction has been known to occur during flights at high altitude. When this occurs, massive hemorrhages and infarctions are found and the sinusoids in the spleen are packed with masses of sickled erythrocytes.

Sickling may be demonstrated by preparing a fresh blood film and excluding air by sealing with oil or petrolatum or by replacing the air with carbon dioxide (Fig. 10). Patients with sickle cell anemia usually have erythrocyte levels which are below normal, and during a sickle cell crisis the level will frequently drop to less than  $1,000,000/\text{mm}^3$ . In most

cases, there is no reduction of the hemoglobin content within the cells. The life span of the sickle cell is shorter than normal, and such patients have to compensate for this by increasing their erythropoietic activity, as shown by the large number of reticulocytes, nucleated red cells, and hyperplasia of the bone marrow.

**HEREDITY**—In 1949, Beut and Neel independently demonstrated that the sickle cell trait was the heterozygous manifestation of a gene which, when homozygous, resulted in sickle cell anemia. This manifestation can be shown in the laboratory as follows: (1) a normal individual having only normal genes at the sickle cell locus ( $h_1^A/h_1^A$ ) will have only normal adult hemoglobin (Hgb A), (2) the heterozygote with one normal and one abnormal gene ( $h_1^S/h_1^A$ ) has about 40% sickle cell hemoglobin (Hgb S) and 60% normal adult hemoglobin (Hgb A), and (3) the patient with two abnormal genes ( $h_1^S/h_1^S$ ), who has sickle cell anemia, produces only sickle cell hemoglobin (Hgb S).

Hemoglobin S trait occurs in 7-9% of the American Negroes, and the rate may increase up to 45% among certain African tribes. The trait is limited almost entirely to the Negro race. The occasional reports of sickle cell disease among Caucasians have almost always arisen in areas where admixture with Negro blood could not be completely ruled out. At the present time, Hgb S trait can be found in three areas outside of America and Africa: (1) in Greece, in the vicinity of Lake Copais and in northern Greece, (2) among the primitive Veddooids of southern India, and (3) among the Achdam of southern Arabia. The spread of this trait can be attributed to people from Africa being transported in the Mediterranean area and the Americas through invasion, the use of African mercenaries, and the slave trade.

The genetics of Hgb S trait is of special interest because of the possibility that persons with the sickle cell trait may have increased resistance to falciform malaria. These observations are based on several pieces of evidence: (1) there seems to be a different rate of parasitemia by the malaria parasite among sicklers and nonsicklers in the same region, (2) there seems to be a difference in susceptibility to experimental malaria among sicklers and nonsicklers in two small studies, and (3) a correlation exists between the distribution of malaria and the distribution of the sickle cell trait in Africa. Against this hypothesis is the finding that malaria occurs in certain regions where sickle cell disease is unknown. Also, we know very little about the normal pathogenesis of malaria without sickle cell disease complicating the picture. Nevertheless, the possible relation between the two is an attractive hypothesis and could be of great significance clinically.

**PATHOGENESIS**—Sickle cell anemia occurs as a result of an abnormality in the structure of the hemoglobin molecule. Ingram has recently shown that if the globin portion of the hemoglobin molecule is broken down by tryptic digests, some 28 peptides, each with an average chain length of 9-10 amino acids, will result. These can then be separated on paper first by electrophoresis and then by chromatography. The peptides prepared from Hgb S differ from those of Hgb A only in the location of one peptide group. Studies on the arrangement of amino acids within this abnormal peptide revealed that in sickle cell hemoglobin a valine unit had replaced the glutamic acid unit (Fig. 11).

This difference is useful in interpreting the differences in the physical properties of Hgbs S and A, which are as follows:

1 Hemoglobin S has a distinctive electrophoretic pattern. In the epoch making discovery of Pauling and his co-workers it was found that Hgb S migrates as a positive ion, whereas Hgb A migrates as a negative ion in a 0.1 M phosphate buffer, pH 6.9. These variations in mobility correspond to a difference of 0.22 pH units in the isoelectric point of the two compounds. A difference in the rate of migration in an electric field can also be shown by the more simple technique of paper electrophoresis.

2 In their reduced form, crystals of Hgb S are birefringent, whereas those of Hgb A are not.

3 The difference in solubility between oxygenated Hgbs S and A is not striking. If one assigns an arbitrary value of 1 (one) to the solubility of oxyhemoglobin A, oxyhemoglobin S is found to have the same solubility. Reduced Hgb A has only half the solubility of its corresponding oxy-compound. Reduced Hgb S, on the other hand, has approximately 50 times less the solubility of reduced Hgb A and has only one one hundredth the solubility of its oxy-compound.

As a consequence of this insolubility a marked increase of viscosity takes place as concentrated solutions of Hgb S are reduced. Indeed, after sufficient reduction the entire hemoglobin mass forms a semisolid gel, which can be liquefied and solidified at will by the alternative use of oxygen and carbon dioxide. These Hgb S crystals have the appearance of crescents and strongly resemble sickled erythrocytes. Harns has described the sickled erythrocyte as "a hemoglobin tactoid thinly veiled and somewhat distorted by a red-cell membrane." Upon this unique biochemical phenomenon—the striking insolubility of reduced Hgb S with the subsequent formation of sickle shaped tactoids—depends all the clinical tests for the demonstration of sickling and all the signs and symptoms of sickle cell disease which are shown in Chart 1 on page 30.



Sickling is probably responsible for the abdominal pain and specific renal effects, including hematuria and the inability to concentrate urine, which occur during hemolytic crises. The excessive breakdown of sickled cells causes anemia, formation of fetal hemoglobin (Hgb F), cardiac enlargement, icterus, and hyposthenuria, which are characteristic. The body tries to compensate for this anemia by extramedullary hematopoiesis, and the latter accounts for the hepatosplenomegaly, hyperplasia of the bone marrow, and reticulocytosis. Thus, the whole picture of sickle cell anemia can ultimately be attributed to the peptide abnormality in the hemoglobin molecule itself.

**DIAGNOSIS**—Sickle cell anemia may be diagnosed by the detection of sickling in the peripheral blood (see Procedure 1, in Appendix), the identification of Hgb S by solubility (see Procedure 2), and paper electrophoresis studies (Procedure 3).

**TREATMENT**—No treatment is required for those with the sickle cell trait. Among those with sickle cell anemia, the administration of oxygen is useful during a sickle cell crisis. However, whole-blood transfusions should be used only during an aplastic phase.

Allison A C. Protection afforded by sickle-cell trait against subtertian malarial infection, *Brit M J* 1:290, 1954.

Beet E A. The genetics of the sickle-cell trait in a Bantu tribe. *Ann Eugenics* 14:279, 1949.

\*Chernoff A I. The sickle-cell trait in the Negro population of England.

..... Molecular Biol &

..... of normal

.....

..... ns and per

..... cell anemia

## 2 OTHER ABNORMAL HEMOGLOBIN VARIANTS

The differentiation of Hgb S from Hgb A was quickly followed by a series of reports on the identification of other abnormal hemoglobins. Each appeared to be inherited according to Mendelian laws and manifested itself, whether in the homozygous or heterozygous state, by specific changes in the hemoglobin pattern in the individual, much in the same way as does Hgb S (see Fig. 12). These hemoglobins do not differ significantly from each other. They have identical molecular weights, the



#### 44 DISTURBANCES IN MOLECULAR STRUCTURE

isolated heme portions are alike, and the quantitative differences in the composition of the amino acids of the globulin portion of the molecule have not always been striking. There are some suggestions that the differences in their physical properties are due to alterations in amino acid arrangement, types of end groups, or in the folding of the amino acid chains in the hemoglobin molecule.




FIG 12—Other abnormal hemoglobin variants (After Huisman *et al* 1955)

Anderson and Griffith have suggested that abnormal hemoglobins may be complexes of normal hemoglobins with some other macromolecule which is constantly present and genetically inherited. In some instances the differences may so alter the solubility properties of the hemoglobin as to give rise to sickling. If this is the case, these complexes might be comparable to the polysaccharides responsible for the blood group characteristics.

#### HEMOGLOBIN C

In 1950 Itano and Neel examined by electrophoresis the hemoglobin derived from members of two unusual families. In these families there occurred one or more children with the hematological picture of sickle cell anemia, but the disease was somewhat less severe than that usually encountered and the situation was peculiar in that the erythrocytes of only one parent in each case could be induced to sickle. Those of the other parent were apparently normal. Electrophoretically, it was found that the hemoglobin from two of these anemic children separated into two distinct components: one corresponding to that of Hgb S, and the other migrating as an even more positive ion than that of Hgb S. In another anemic child, both of these components were present as well as a small proportion of hemoglobin with a mobility corresponding to Hgb A. Studies of the parents in each case showed the findings typical of sickle cell trait in one parent while the other parent was found to have hemoglobins resolving into two types: Hgb A and the new component, which Itano and Neel designated as Hgb C.

Hemoglobin C (see Table 1) differs from the other hemoglobins in

three respects (1) it has an electrophoretic mobility faster than either Hgb S or Hgb A, (2) its solubility is greater than that of the reduced compounds of Hgbs F, S, and A, and (3) studies in molecular structure have revealed that in the same abnormal peptide the glutamic acid unit has been replaced by a lysine unit (Fig. 11)

*Hemoglobin C trait* ( $h_1^C/h_1^A$ ) is present in about 2% of the American Negro population. In certain parts of western Central Africa, a prevalence up to 15% has been observed. Clinically, the hematological findings are entirely normal except for an increase in the number of target cells and a very mild hypochromia of the red cells. Sickling does not occur.

*Homozygous Hgb C disease* ( $h_1^C/h_1^C$ ) is a rare condition, calculated as occurring once in every 6 000 Negroes in America. The condition is considerably more mild than the homozygous form of Hgb S (sickle cell anemia), with only vague intermittent arthralgia and occasional abdominal pain being present. Persons with this condition do not usually develop a true crisis as in sickle cell anemia. Hemoglobin C disease is not incompatible with a normal life span.

Huisman T H J, Jonus J H P and Schaaf P C. Amino acid composition of four different kinds of human hemoglobin. *Nature* 175 902, 1955.

——— Schaaf P C and Sar A. Some characteristic properties of hemoglobin C. *Blood* 10 1079, 1955.

Itano H A and Neel J V. A new inherited abnormality of human hemoglobin. *Proc. Nat. Acad. Sci.* 36 613, 1950.

Neel J V, Kaplan, E and Zuelzer W W. Further studies on hemoglobin C. I. A description of three additional families segregating for Hgb C and sickle cell hemoglobin. *Blood* 8 724, 1953.

Spaet, T H, Alway R H and Ward G. Homozygous Type C hemoglobin. *Pediatrics* 12 483, 1953.

## HEMOGLOBIN D

In 1934, Cooke and Mack described a family apparently of American ancestry, in which the father and two children all exhibited slow sickling of the red cells on reduction. In 1951, Itano re-examined the hemoglobin of these offspring and found that, electrophoretically, the hemoglobin in these children corresponded closely to that generally found in sickle cell anemia. However, in the mother and two siblings, none of whom showed the sickle cell trait, there were, nevertheless, two electrophoretically different components in their hemoglobin. Between 35 and 49% of their hemoglobin was found to migrate as Hgb S and the remainder as Hgb A. Thus electrophoretically these persons could be regarded as sickle cell heterozygotes even though they failed to show the sickling phenomenon.

The explanation of this anomalous result was found as a result of solu-

bility studies It was learned that Hgb D (Table 1) was much more soluble than Hgb S and that its solubility corresponded to that of reduced Hgb A Thus, tactoids, the gelling phenomenon, and sickling cannot be elicited from the red cells of individuals with Hgb D trait In its alkali resistance, Hgb D reacts in a manner similar to that of Hgbs A, S, and C

*Hemoglobin D trait ( $h^D/h^A$ ) and homozygous Hgb D disease ( $h^D/h^D$ )* have been observed in several parts of the world, including Caucasian families in America, Sikhs, Turks, and Negroes

Bird G W G and Lehmann H The finding of haemoglobin D disease in a Sikh *Man* 55:1 1946

———, and Maurant A ■ A third example of hemoglobin D *Tr Roy Soc Trop Med & Hyg* 49:399, 1955

Cabannes R Sendra L, and Dalaut Hemoglobin D a hereditary hemoglobin abnormality in an Algerian Moslem Observations of two families, *Algeria med* 59:387, 1955

Cooke, J V and Mack J A Sickie cell anemia in a white family *J Pediat* 5:601 1934

Itano H A A third abnormal hemoglobin associated with hereditary hemolytic anemia *Proc Nat Acad Sc* 37:775, 1951

Sturgeon P Itano H A and Bergren W R Clinical manifestations of inherited and abnormal hemoglobins I The interaction of Hgb S and D *Blood* 10:389 1955

## HEMOGLOBIN E

In 1954, Itano, Bergren, and Sturgeon identified a fourth abnormal hemoglobin, which they designated as Hgb E (Table 1), in a child with an atypical anemia At approximately the same time, Chernoff, Minnich and Chongchareonsuk detected the same pigment in a group of patients in Thailand who although having a clinical picture resembling Mediterranean anemia, failed to fulfill the genetic criteria postulated for that disease

Hemoglobin E can be differentiated from the other hemoglobins by its electrophoretic pattern In ultraviolet and visual absorption spectra, solubility, amino acid composition, and resistance to alkali denaturation it is similar to Hgb A

*Hemoglobin E trait ( $h^E/h^A$ )* has been observed in about 13% of the Thai population It has also been found among the Burmese, Malays, the Veddas of Ceylon and in about 6% of the Indonesians in Djakarta The condition however, has not been reported from other parts of the world From the anthropological viewpoint, the condition is of interest because, although it is seen among peoples of similar racial background, many of whom are believed to have originated in northern China and to have been driven southward by successive invasions, the

trait has not been seen among some 200 pure Chinese living in Thailand

*Homozygous Hgb E disease ( $h^E/h^E$ )* may be expected to occur in approximately 1 out of 250 Thais. At present, 6 instances of this syndrome have been encountered in patients ranging from 19 to 40 years of age. All are in good to fair health, although a history of easy fatigability and mild arthralgia can be elicited.

Chernoff, A. I., Minnich V, and Chongcharonsuk, S. Hemoglobin E, a hereditary abnormality of human hemoglobin, *Science* 120: 605, 1954

\_\_\_\_\_, Na Nakorn, S., Tuchinda, S., Kashemsant, C., and Chernoff, A. I. genetic char-  
47: 455, 1956  
a fourth ab-

Jonas, J. H. P., Huisman, T. H. J., van der Schaaf, P. C., and Prins, H. K. Amino acid composition of Hgb E, *Nature* 177: 627, 1956

Lehmann H., Story, P., and Thien, H. Haemoglobin E in Burmese. *Brit. M. J.* 1: 544, 1956

Na Nakorn, S., Minnich V., and Chernoff, A. I. Studies on hemoglobin E. II The incidence of hemoglobin E in Thailand, *J. Lab. & Clin. Med.* 47: 490, 1956

## HEMOGLOBIN G

In the course of a survey among Gold Coast Africans, Edington and Lehmann described an individual who had both normal hemoglobin and a form hitherto not known, which they designated as Hgb G (Table 1). Family studies revealed that he was the offspring of a mother who had only normal hemoglobin ( $h_2^A/h_2^A$ ) and a father who had only this abnormal hemoglobin ( $h_2^G/h_2^G$ ). All except one of the siblings were heterozygotes ( $h_2^G/h_2^A$ ). The homozygote was not anemic, and it was not possible to detect fetal hemoglobin in his blood. Sickling was not observed either in the individuals with Hgb G trait or in the one with homozygous hemoglobin G disease. A second example of Hgb G trait has been described by Schwartz and Spaet in a white family.

Hemoglobin G differs from all other known hemoglobins in its mobility by paper electrophoresis at pH 8.6. This hemoglobin can be differentiated from Hgb F (which has a similar mobility) by its not being resistant to denaturation by alkaline reagents, and from Hgb S by the failure of the cells to sickle. The solubility of Hgb G is consistently higher than that of Hgb S but is lower or similar to that of Hgb A.

Edington, G. M., and Lehmann, H. Hemoglobin G. New hemoglobin found in West Africa. *Lancet* 2: 173, 1954

\_\_\_\_\_, \_\_\_\_\_, and Schneider, R. G. Characterization and genetics of Haemoglobin G, *Nature* 175: 850, 1955

Schwartz, H. and Spaet, T. H. Hemoglobin G. Fifth abnormal hemoglobin, *Clin. Res. Proc.* 3: 51, 1955

## HEMOGLOBIN H

In 1955, Rigas, Koler, and Osgood described three members of a Chinese family with a hypochromic, microcytic anemia with blood smears resembling thalassemia. The electrophoretic pattern, however, revealed an abnormal hemoglobin migrating more rapidly than normal hemoglobin. Other features included refractoriness to iron therapy, reticulocytosis, poikilocytosis, intraerythrocytic inclusion bodies, and changes in erythrocytic fragility. The abnormal hemoglobin accounted for 35-40% of the total hemoglobin, the fetal hemoglobin was slightly increased, and the remainder was normal hemoglobin.

Family studies on the inheritance of Hgb H have failed to demonstrate the abnormal pigment in the parents of known cases. Instead, one of the parents and several other members of the family have the thalassemia trait without Hgb H. Since small population surveys have failed to reveal any carriers of the Hgb H trait, Motulsky has suggested that heterozygotes either do not exist or have poor penetrance.

Eng L. I. L., Hin, P. S., Keng K. L. and Eadenburg H. M. Chronic hypochromic microcytic anaemia associated with haemoglobin H. *Acta haemat.* 18: 156, 1957.

Motulsky A. G. Genetic and haematological significance of haemoglobin H. *Nature* 178: 1055, 1956.

Rigas D. A., Koler R. D. and Osgood H. A. New hemoglobin possessing a higher electrophoretic mobility than normal adult hemoglobin, *Science* 121: 372, 1955.

———, and ———. Hemoglobin H. *J. Lab. & Clin. Med.* 47: 51, 1956.

## HEMOGLOBIN I

Also in 1955, Rucknagel, Page, and Jensen reported a similar hemoglobin in three generations of a single family possessing a mobility on paper electrophoresis at pH 8.6 which was similar to that of Hgb H. There was, however, a marked dissimilarity at pH 7.0. Furthermore, the Hgb H of Rigas precipitates on standing, whereas that of Rucknagel and his co-workers does not. This hemoglobin appears, therefore, to represent a new type, which has now been designated as Hgb I.

The Hgb I trait has only been demonstrated in this one family. No homozygote for Hgb I has been described.

Rucknagel D. L., Page, E. B., and Jensen W. N. Hemoglobin I. An inherited hemoglobin anomaly, *Blood* 10: 999, 1955.

## HEMOGLOBIN J

In 1956, Thorup, Itano, Wheby, and Leavell described another new abnormal hemoglobin in a young Negro female with bilateral cystosarcoma phylloides. The same abnormality was found in 7 out of 13 other members of the family examined, but so far, no case of *homozygous Hgb J disease* ( $h^J/h^J$ ) has been found. In the cases of *Hgb J trait* ( $h^J/h^A$ ), there is more Hgb J than Hgb A in all of the individuals examined, which is different from the proportions in all the other abnormal hemoglobins.

By using boundary electrophoresis, Hgb J has a mobility between that of Hgb A and that of Hgb I. The solubility of Hgb J is higher than Hgb A, and sickling has not been observed in the cases studied.

Ager, J. A. M., Lehmann, H., and Vella, F. Haemoglobin "Norfolk." A new haemoglobin found in an English family, *Brit. M. J.* 2: 539, 1958.

Eng, L. I. L. Haemoglobin J in an Indonesian family, *Acta haemat.* 11: 126, 1958.

Huisman, T. H. J., Noordhoek, K., and da Costa, G. J. A case of haemoglobin J in an Indonesian family, *Nature* 179: 322, 1957.

Robinson, A. R., Zuelzer, W. W., Neel, J. V., Livingstone, F. B., and Miller, M. J. Two "fast" hemoglobin components in Liberian blood samples, *Blood* 11: 902, 1956.

Thorup, O. A., Itano, H. A., Wheby, M., and Leavell, B. S. Hemoglobin J, *Science* 123: 889, 1956.

## HEMOGLOBIN K

In 1956, Cabannes described a new, fast-moving abnormal hemoglobin which he designated as Hgb K. This has since been described in three Berber families in North Africa, among Liberian natives, and East Indians.

Ager, J. A. M., and Lehmann, H. Haemoglobin K in an East Indian and his family, *Brit. M. J.* 1: 1449, 1957.

Cabannes, R., Buhr, J. L., and Sendra, L. Hemoglobin J. A new hereditary hemoglobinopathy described in certain Kabyle families of Algeria, *Blood* 11: 591, 1957.

Robinson, A. R., Zuelzer, W. W., Neel, J. V., Livingstone, F. B., and Miller, M. J. Two "fast" hemoglobin components in Liberian blood samples, *Blood* 11: 902, 1956.

Vella, F. Haemoglobin K in Singapore, *Brit. M. J.* 1: 755, 1958.

## UNCLASSIFIED ABNORMAL HEMOGLOBINS

In addition to the above, a number of new abnormal hemoglobins have recently been described under the terms. Hopkins-1, Hopkins-2, IV (Barts), O (Buginese X), (Galveston type), and Q. The proper

classification of these new entities will have to await more agreement on nomenclature

Ager, J A M, and Lehmann, H Observations on some 'fast' haemoglobins K, J, N and Barts,' Brit. M J 1 929, 1958

Eng L I L., and Sadona Haemoglobin O (Buginese X) in Sulawesi, Brit M J 1 1461, 1958

Schneider, R. G., and Haggard, M E Haemoglobin F (the Galveston type) Nature 182 322, 1958

Smith, E. W., and Torbert, J V Study of two abnormal hemoglobins with evidence for a new genetic locus for hemoglobin formation, Bull Johns Hopkins Hosp 101 38, 1958

Vella F, Wells, R H C, Ager, J A M, and Lehmann, H A haemoglobinopathy involving haemoglobin H and a new (Q) haemoglobin, Brit. M J 1 752, 1958

### 3. MIXED HETEROZYGOUS HEMOGLOBIN DISEASES

Four hemolytic diseases are now recognized as falling into the group of mixed hemoglobin disturbances S-C disease, S-D disease, S-E disease, and S-G disease

#### SICKLE CELL-HEMOGLOBIN C DISEASE

In this disease, the genes are either alleles or closely linked at the same locus One of the parents is heterozygous for Hgb S ( $h_1^s/h_1^A$ ),




FIG 13 —Mixed heterozygous hemoglobin diseases (After Neel Kaplan, and Zuelzer, 1953)

the other is heterozygous for Hgb C ( $h_1^C/h_1^A$ ), and the patient is heterozygous for both ( $h_1^S/h_1^C$ ), as shown in Figure 13

The disease was first suspected in patients with atypical sickle cell anemia who did not fulfill all the criteria for that diagnosis Among the atypical features were (1) only one parent showed sickling, (2) the spleen was usually easily palpable, and (3) the anemia was often mild requiring few, if any, transfusions In retrospect, about 15-20% of the cases previously classified as sickle cell anemia must be considered as having sickle cell-Hgb C disease

Neel, J V, Kaplan, E., and Zuelzer, W W Further studies on hemoglobin

## SICKLE CELL ANEMIA; OTHER ABNORMAL HEMOGLOBINS 51

C I A description of three additional families segregating for Hgb C and sickle cell hemoglobin, *Blood* 8 724, 1953

Schneider, R. G. Incidence of hemoglobin C trait in 505 normal Negroes, family with homozygous hemoglobin C and sickle cell trait union, *J Lab & Clin. Med.* 44 133, 1954

Smith, E. W., and Conley, C. L. Filter paper electrophoresis of human hemoglobins with special reference to the incidence and clinical significance of Hgb C, *Bull Johns Hopkins Hosp* 93 94 1953

### SICKLE CELL—HEMOGLOBIN D DISEASE

In 1956 Stewart and MacIver reported on a mulatto woman with sickle cell-Hgb D disease ( $h_1^S/h_1^D$ ). She had inherited one abnormality from her mother, who was heterozygous for Hgb D ( $h_1^D/h_1^A$ ). The father, a West African Negro, was dead and is assumed to have supplied the gene for the Hgb S. One of the patient's brothers had also inherited the abnormal Hgb D.

Stewart J. W., and MacIver, J. E. Sickle cell/haemoglobin D disease in a mulatto girl. *Lancet* 1 23 1957

### SICKLE CELL—HEMOGLOBIN E DISEASE

The combination of sickle cell and Hgb E in the same patient ( $h_1^S/h_1^E$ ) has been reported once.

Avisoy M., and Lehmann H. The first observation of sickle cell-haemoglobin E disease, *Nature* 179 1248 1957

### SICKLE CELL—HEMOGLOBIN G DISEASE

In 1957, Schwartz and his co-workers reported on a 28 year-old white male who had frequently been transfused because of persistent anemia. Laboratory studies revealed that not only was he a carrier of Hgbs E and G but also that he had thalassemia minor ( $h_1^S/h_1^A$ ,  $h_2^S/h_2^A$ ,  $h_1^T/h_1^A$ ). His wife had always been healthy, and all laboratory studies, including sickling preparation, were negative ( $h_1^A/h_1^A$ ,  $h_2^A/h_2^A$ ,  $h_1^A/h_1^A$ ). His son showed no abnormal hemoglobins but had signs of thalassemia minor ( $h_1^A/h_1^A$ ,  $h_2^A/h_2^A$ ,  $h_1^T/h_1^A$ ). Further investigation revealed that the propositus had inherited the Hgb S abnormality from his father's side of the family and the Hgb E and thalassemia traits from his mother's side, as shown in Figure 14.

This family is of considerable importance because from it the following conclusions can be drawn: (1) The genes responsible for hemoglobins E and S cannot be alleles. If they were, the son would have inherited



## 52 DISTURBANCES IN MOLECULAR STRUCTURE

one or the other abnormality from the father (2) The genes responsible for hemoglobin G and thalassemia cannot be alleles The propositus could not have inherited both of these genes from his mother (3) Since




FIG 14—Thalassemia-hemoglobin disease (After Schwartz *et al* 1957)

it has previously been shown that the genes responsible for Hgb S and thalassemia are not allelic, one must conclude that there are at least three different loci in hemoglobin production

Schwartz, H and Spaet T H Hemoglobin G A fifth abnormal hemoglobin Clin Res Proc 3 51 1955

\* ——— Zuelzer W W Neel J V Robinson A R and Kaufman F Combinations of hemoglobin G hemoglobin S and thalassemia occurring in one family Blood 12 238 1957

## 4 THE THALASSEMIA SYNDROME

Patients with this syndrome inherit the thalassemia gene from one of the parents and a gene for one of the abnormal hemoglobins from the other parent, as shown in Figure 14 Since the gene for thalassemia and the genes for the abnormal hemoglobins are located at different loci they have to be expressed separately

### THALASSEMIA-HEMOGLOBIN E

This mixed condition ( $h_1^S/h_1^A$ ,  $h_2^E/h_2^A$ ) was first described by Silvestroni and Bianco in Italy and is now being recognized with increasing frequency in other parts of Europe and in the United States

Clinically, the symptoms start before the age of 10. In addition to the symptoms usually encountered in severe hemolytic anemias, patients complain of bone and joint pains, occasional abdominal discomfort, and rare clinical crises. Jaundice is usually mild. The hematological findings closely resemble those of thalassemia major, with moderately severe anemia and the presence of target cells and normoblasts on smear. Also, sickling can be found in the peripheral blood. Hemoglobin studies reveal a complex mixture of pigments, with Hgbs S, F, and A all being present.

Neel, J. V., Itano, H. A., and Lawrence, J. S. Two cases of sickle cell disease presumably due to the combination of the genes for thalassemia and sickle cell hemoglobin. *Blood* 8: 434, 1953.

Silvestroni, E., and Bianco, I. Microcytemia constitutional microcytic anemia, and Cooley's anemia. *Am. J. Human Genet.* 1: 83, 1949.

——— and ———. Genetic aspects of sickle cell anemia and microdrepanocytic disease. *Blood* 7: 429, 1952.

### THALASSEMIA—HEMOGLOBIN C

This condition ( $h_1^0/h_1^A$ ,  $h_1^F/h_1^A$ ) has been diagnosed in only three patients. The combination sometimes causes a severe chronic microcytic anemia.

Singer, K., Kraus, A. P., Singer, L., Rubinstein, H. M., and Goldberg, S. R. Studies on abnormal hemoglobins. X. A new syndrome hemoglobin C—thalassemia disease. *Blood* 9: 1032, 1954.

Zuelzer, W. W., and Kaplan, E. Thalassemia hemoglobin C disease, *Blood* 9: 1047, 1954.

### THALASSEMIA—HEMOGLOBIN E

This is a severe hemolytic syndrome which closely mimics Cooley's anemia in its manifestations. In all of the cases studied, one parent was found to have Hgb E ( $h_1^F/h_1^A$ ) and the other had what appears to be, at best, a very mild thalassemia ( $h_1^F/h_1^A$ ). Whether the parents without Hgb E really have thalassemia minor and whether this syndrome is correctly named remains to be proved.

Chernoff, A. I., Minnich, V., Na Nakorn, S., Tuchinda, S., Kashemsant, C., and Chernoff, R. R. Studies on hemoglobin E. I. The clinical, hematologic, and genetic characteristics of the hemoglobin E syndromes. *J. Lab. & Clin. Med.* 47: 455, 1956.

Lie-Injo, L. E. Haemoglobin E in Indonesia. *Nature* 176: 468, 1955.

Na<sup>2+</sup> — — — — —  
Pu<sup>t</sup> . . . . .

## THALASSEMIA—HEMOGLOBIN G

Two patients with what is believed to be thalassemia-Hgb G disease were observed by Schwartz and his associates. The details are discussed in the previous section.

Schwartz, H. C., Spaet, T. H., Zuelzer, W. W., Neel, J. V., Robinson, A. R., and Kaufman, S. P. Combinations of hemoglobin G, hemoglobin S and thalassemia occurring in one family, *Blood* 12:238, 1957.

## 5. OTHER MIXED DISTURBANCES

A similar combination of abnormal hemoglobins with hereditary spherocytosis and hereditary elliptocytosis has been reported. Again, the genes for spherocytosis, elliptocytosis, and the abnormal hemoglobins are undoubtedly located at separate loci.

## SPHEROCYTOSIS-HEMOGLOBIN DISEASE

De Torregrasa and his co-workers have reported both the sickle cell trait and spherocytosis in the same patient. Family studies show that the




FIG. 15—Spherocytosis hemoglobin disease (After de Torregrasa, 1956)

spherocytosis trait was inherited from the father's side of the family and the sickle cell trait from the mother's side (Fig. 15). In this condition the patient suffered more from the effects of spherocytosis than from those of sickle cell trait. Splenectomy was of considerable value in treating the anemia.

De Torregrasa, M. V., Ortiz, A., and Vargas, D. Sickle cell-spherocytosis associated with hemolytic anemia, *Blood* 11:260, 1956.

Smith, E. W., and Conley, C. L. Genetic variants of sickle cell disease, *Bull. Johns Hopkins Hosp.* 94:289, 1954.

## ELLIPTOCYTOSIS HEMOGLOBIN DISEASE

At least three cases of elliptocytosis hemoglobin disease have been recorded. In 1949, Fadem described hereditary elliptocytosis in association with the sickle cell trait in a 25-year-old Negro male. More recently, Avery has reported on two patients who manifested both hereditary elliptocytosis and the Hgb C trait. Genetic studies in the latter two cases clearly show how the two abnormal genes are transmitted through different members of the family to the affected individuals (Fig 16)




FIG 16—Elliptocytosis hemoglobin disease (After Avery, 1956)

It is interesting to note that elliptocytosis and Hgb C trait in association do not produce a summation of effect. In fact, these patients show no clinical stigmata that can be attributed to their hematologic abnormalities. It appears that the two separate genetic effects can be manifested in the same cell, since some of the elliptical cells appear to contain abnormal hemoglobin.

Avery M F Hereditary elliptocytosis and hemoglobin C trait. A report of two cases. *Bull Johns Hopkins Hosp* 98:184 1956  
 Fadem H S Ovalocytosis associated with the sickle cell trait. *Blood* 4:505 1949

## Other "Structural" Disturbances

WE NOW TURN to other conditions which may represent examples of disturbances in the structure of the stroma, or cell walls. These include (1) *thalassemia*, (2) *hereditary elliptocytosis*, (3) *acanthrocytosis*, (4) *erythropoietic porphyria*, and (5) the *Pelger-Huet anomaly of the leukocytes*.

\*Ponder, E. Analytic review. Present concepts of the structure of the mammalian red cell. *Blood* 9: 227, 1954.

### 1. THALASSEMIA (Cooley's, or Mediterranean, anemia)

Thalassemia is characterized by chronic hemolytic anemia associated with a hereditary defect in the synthesis of hemoglobin. The defect leads to the production of cells which are abnormal in shape, deficient in hemoglobin, and destroyed at an excessive rate. The condition was first described by Cooley in Detroit, and for some time it seemed to be limited exclusively to persons whose familial origins were in certain countries bordering the northern Mediterranean coast, particularly Italy, Greece, and Sicily.

**CLINICAL FEATURES**—The onset of the condition is indicated by severe and progressive anemia early in infancy. Anemia is not present at birth but seems to develop in relation to the gradual decrease in production of fetal hemoglobin, which is normally expected. Pallor is usually marked, and there is often mild icterus. Splenomegaly is found early in the course of the disease and is progressive, and the spleen attains enormous proportions within a few years. If no supportive transfusion therapy is given, the anemia becomes progressive and leads to cardiorespiratory distress and eventual death.

With transfusions, hemosiderosis develops as a result of iron stores,

causing the skin to become a muddy bronze color. The liver also becomes markedly enlarged because of extramedullary hematopoiesis. The skeletal changes associated with chronic hemolytic anemia become strikingly evident and exceed by far the changes found in other hemolytic anemias. Thickening of the membrane bones of the face and skull (Fig. 17) leads to a mongoloid facies, with a tendency toward protrusion of the



FIG. 17.—Lateral view of skull of a patient with thalassemia major. Marked thickening of the calvarium with multiple striations at right angles with the skull results in the "hair-on-end" appearance.

teeth. The hands become heavy and broad in appearance, owing to alterations in the metacarpal bones (Fig. 18).

The peripheral blood picture is typical and persists throughout life. There is severe anemia with a profound hypochromia. The erythrocyte count is below the normal range, and the hemoglobin is reduced to an even greater extent. The erythrocytes show marked anisocytosis and poikilocytosis. There are many microcytes, with a minority of contrasting large hypochromic cells 12-18  $\mu$  in diameter. The hemoglobin in these large cells is irregularly distributed, creating bizarre shapes. The presence



FIG 18—Anteroposterior view of hands in thalassemia major, showing marked coarsening of the trabecular pattern of metacarpals and phalanges. Owing to the pressure effects of the hyperplastic bone marrow, the trabecular pattern has coalesced and become coarse and heavy, producing the characteristic "bamboo" appearance.

of a small central mass of hemoglobin may give these cells a target-cell appearance. The rapid turnover of erythrocytes is shown by a moderate increase of reticulocytes and stippled cells. The indirect bilirubin is also increased.

**HEREDITY**—The gene for thalassemia is expressed in two forms: (1) The homozygotes (those with a double dose of the abnormal gene) show the full clinical picture, which is known as *thalassemia major*. (2) The heterozygotes (those with only a single dose of the abnormal gene) show only minimal disturbances in hemoglobin synthesis, and this condition is known as *thalassemia minor*. The latter is characterized by mild anemia with moderate hypochromia, anisocytosis, and poikilocytosis. In most of the affected families, both parents are heterozygotes and, assuming a normal distribution, one offspring has *thalassemia major*, two have *thalassemia minor*, and a fourth is completely normal. The condition is seldom transmitted by homozygotes, since it is usually lethal before the age of reproduction.

A few years ago, Silvestroni and Bianco showed that certain persons may inherit one sickle cell gene from one parent and one thalassemia gene from the other, resulting in a clinical condition which is not very

different from thalassemia major (The condition is described in more detail in the section on sickle cell hemoglobins [p. 52] ) If such a person should reproduce, either or both traits can be passed on to his (or her) children, since the genes for thalassemia and sickle cell hemoglobin are both autosomal and probably not allelic

In a study of a predominantly Italian population in Rochester, New York, Neel and Valentine have estimated that thalassemia major occurs once in each 2,568 births (an incidence of 0.042%) and thalassemia minor once in each 25 births (an incidence of 4.1%) The incidence is probably higher in Mediterranean countries, since Banton showed that 20% of the total population in a remote part of Sicily carried the thalassemia trait Although most of the cases of thalassemia originate in the Mediterranean area, cases have been reported in almost every part of the world

**PATHOGENESIS**—The exact nature of the defect in Cooley's anemia remains uncertain The mutant gene may prevent some step necessary in the production of adult hemoglobin, or it may prevent the synthesis of normal adult stromal material, or in some other way impair normal red cell production There are several pieces of evidence to suggest this

First Smith and his co-workers have shown that patients with thalassemia major have a high serum iron content and an absent iron binding capacity (Fig. 19) In normal adults or children, serum iron comprises one third of the total iron binding capacity In thalassemia major patients, the two values are about equal, suggesting that the iron binding capacity is fully saturated and quantitatively lower than in normal children The administration of fraction IV-7 of plasma results in a rise in serum iron values and an appearance of a latent capacity to further bind iron This suggests that there is a release of iron from tissues to the blood when additional metal-combining globulin is supplied in this disease

Second the hemoglobin in thalassemia major consists of Hgb A<sub>2</sub> and Hgb F<sub>1</sub> still present and in a severe hematological disorder such as thalassemia major Hgb F<sub>1</sub> is produced to compensate for the lack of Hgb A production Recently Kunkel and Wallenius have shown that there is an increase of the slow component of Hgb A in patients with thalassemia minor There seems to be no correlation between fetal hemoglobin levels and the clinical and hematological severity of the disease process

Finally Hoffman and his associates have studied the plasma membranes of erythrocytes by electron microscopy and have found that the



surface texture of ghost cells from all of the thalassemia major bloods are distinctly different from ghost cells from thalassemia minor and normal bloods. These differences are observable whether the specimens for comparison are prepared at the same time or on different days. They conclude that these morphological changes in thalassemia major ghost cells constitute an expression of an alteration in the molecular structure of the plasma membranes of the cells.





FIG 19—Serum iron (crosshatched) and latent iron binding capacity (clear area) (After Smith C. H., Sisson T. R. C., Floyd W. H. Jr. and Siegal S. Serum iron and iron binding capacity of the serum in children with severe Mediterranean [Cooley's] anemia. *Pediatrics* 5:799, 1950.)

Until recently, it has always been assumed that the defect in thalassemia is purely in the blood corpuscle itself and that splenectomy would not be helpful in such patients. However, Lichtman and his co-workers have shown that, if normal erythrocytes are transfused to patients with thalassemia major, the life span of the erythrocytes is shortened, and that if splenectomy is performed, the survival of the transfused cells becomes normal. It is difficult to interpret this new finding, except that it contributes partially to the increased destruction of erythrocytes in thalassemia.


If one postulates that thalassemia represents a basic defect in the proper production of Hgb A with possibly a defect of the cell membrane, the clinical signs and symptoms can all be attributed to these defects, as shown in Chart 2. The increased hemolysis and red-cell

## CHART 2

### THALASSEMIA



(Van der Berg, 1941)



destruction causes an elevation of indirect bilirubin which in turn causes the formation of gallstones and deposits of iron throughout the body. To compensate for this the patient overproduces erythrocytes and there are many sites of extramedullary hematopoiesis.

**DIAGNOSIS**—Thalassemia major can be diagnosed by the characteristic hematological findings on a smear of the peripheral blood and by measurements of serum iron (see Procedure 4) and iron binding capacity (see Procedure 5). The clinical picture for thalassemia minor is highly variable. In most instances mild anemia and typical cell changes on a peripheral smear are sufficient to make the diagnosis.

**TREATMENT**—Transfusions of whole blood to maintain an adequate hemoglobin concentration are essential. Despite this most patients die from intercurrent infections before the age of puberty. Transfusion reactions can become serious problems, also. Splenectomy should only be performed for comfort when the spleen gets too large.

Cooley T B and Lee P. A series of cases of anemia with splenomegaly and peculiar bone changes. *Am J Dis Child* 30:447 1925.

Hoffman J F, Wolman I J, Miller J and Parpart A L. Ultra structure of erythrocyte membranes in thalassemia major and minor. *Blood* 11:946 1956.

Lichtman H C, Watson R J, Felman F, Ginzberg V and Roberson J. Studies on thalassemia. *J Clin Invest* 32:1229 1953.

Silvestroni E and Bianco I. Microcytic constitutional microcytic anemia and Cooley's anemia. *Am J Human Genet* 1:83 1949.

Smith C H. Detection of mild types of Mediterranean (Cooley's) anemia. *Am J Dis Child* 75:505 1948.

———, Sisson T R C, Floyd W H Jr and Segal S. Serum iron and iron binding capacity of the serum in children with severe Mediterranean (Cooley's) anemia. *Pediatrics* 5:799 1950.

Sturgeon P and Finch C A. Erythrokinetics in Cooley's anemia. *Blood* 12:64 1957.

Valentine W N and Neel J V. Hematologic and genetic study of transmission of thalassemia. *Arch Int Med* 74:185 1944.

## 2 HEREDITARY ELLIPTOCYTOSIS

Oval or elliptically shaped erythrocytes (Fig. 20) normally occur in the camel and llama but are comparatively unusual as a hereditary trait in humans. Only about 400 cases of this anomaly have been reported.

**CLINICAL FEATURES**—The patients with hereditary elliptocytosis may be divided into three groups: (1) those with no signs of hemolysis; (2) those with hemolysis but no anemia; and (3) those with hemolytic disease and anemia. In the first group, the condition is entirely benign and of no medical significance. Patients in the second group show reticulocytosis, mild icterus and increased excretion of urobilinogen in the stools.

there is also a hyperplasia of the bone marrow and there may be changes in the osmotic fragility of the erythrocytes. Patients in the third group, in addition to having hemolytic disease, show a moderate to severe degree of anemia which may require transfusions. These patients show a




FIG. 20.—Smear from peripheral blood of a patient with elliptocytosis (left) compared with that of a normal person (right) (From Goodale H ■ Hendry D W W and Lawler ■ D Data on linkage in man. *Elliptocytosis and blood groups* ■ Family three Ann Eugenics 17 272 1952)

shortened life span of erythrocytes as measured by the Ashby technique. Approximately 12% of all individuals with elliptocytosis belong in the last two groups.

**HEREDITY**—The incidence of elliptocytosis in the general population has been estimated to be between 0.02 and 0.04%. The genetic mechanism responsible for this defect is similar to that present in thalassemia and sickle cell anemia. Most of the affected individuals are heterozygous for the trait. When 1 gene for elliptocytosis is combined with another abnormal gene a more severe hemolytic process occurs. Instances of elliptocytosis-Hgb S and elliptocytosis-Hgb C trait have been recorded. The homozygous form of hereditary elliptocytosis has only been recorded twice. This is not surprising in view of the fact that known carriers are unlikely to mate other known carriers.

Recently Lawler and her co-workers have shown that linkage exists

destruction causes an elevation of indirect bilirubin which in turn causes the formation of gallstones and deposits of iron throughout the body. To compensate for this the patient overproduces erythrocytes and there are many sites of extramedullary hematopoiesis.

**DIAGNOSIS**—Thalassemia major can be diagnosed by the characteristic hematological findings on a smear of the peripheral blood and by measurements of serum iron (see Procedure 4) and iron binding capacity (see Procedure 5). The clinical picture for thalassemia minor is highly variable. In most instances mild anemia and typical cell changes on a peripheral smear are sufficient to make the diagnosis.

**TREATMENT**—Transfusions of whole blood to maintain an adequate hemoglobin concentration are essential. Despite this most patients die from intercurrent infections before the age of puberty. Transfusion reactions can become serious problems also. Splenectomy should only be performed for comfort when the spleen gets too large.

Cooley T B and Lee P. A series of cases of anemia with splenomegaly and peculiar bone changes. *Am J Dis Child* 30:447 1925.

Hoffman J F, Wolman I J, Miller J and Parpart A K. Ultra structure of erythrocyte membranes in thalassemia major and minor. *Blood* 11:946 1956.

Lichtman H C, Watson R J, Felman F, Ginzberg V and Robison J. Studies on thalassemia. *J Clin Invest* 32:1229 1953.

Silvestroni E and Banco I. Microcytemia, constitutional microcytic anemia and Cooley's anemia. *Am J Human Genet* 1:83 1949.

Smith C H. Detection of mild types of Mediterranean (Cooley's) anemia. *Am J Dis Child* 75:505 1948.

———, Sisson T R C, Floyd W H Jr and Segal S. Serum iron and iron binding capacity of the serum in children with severe Mediterranean (Cooley's) anemia. *Pediatrics* 5:799 1950.

Sturgeon P and Finch C A. Erythrokinetics in Cooley's anemia. *Blood* 12:64 1957.

Valentine W N and Neel J V. Hematologic and genetic study of transmission of thalassemia. *Arch Int Med* 74:185 1944.

## 2 HEREDITARY ELLIPTOCYTOSIS

Oval or elliptically shaped erythrocytes (Fig. 20) normally occur in the camel and llama but are comparatively unusual as a hereditary trait in humans. Only about 400 cases of this anomaly have been reported.

**CLINICAL FEATURES**—The patients with hereditary elliptocytosis may be divided into three groups: (1) those with no signs of hemolysis; (2) those with hemolysis but no anemia; and (3) those with hemolytic disease and anemia. In the first group the condition is entirely benign and of no medical significance. Patients in the second group show reticulocytosis, mild icterus, and increased excretion of urobilinogen in the stools.

There is also a hyperplasia of the bone marrow and there may be changes in the osmotic fragility of the erythrocytes. Patients in the third group, in addition to having hemolytic disease, show a moderate to severe degree of anemia which may require transfusions. These patients show a




FIG. 20—Smear from peripheral blood of a patient with elliptocytosis (*left*) compared with that of a normal person (*right*). (From Goodale, H. B., Hendry, J. W. W., and Lawler, J. D. Data on linkage in man. *Elliptocytosis and blood groups II. Family three*, *Ann. Eugenics* 17: 272, 1952.)

shortened life span of erythrocytes as measured by the Ashby technique. Approximately 12% of all individuals with elliptocytosis belong in the last two groups.


**HEREDITY**—The incidence of elliptocytosis in the general population has been estimated to be between 0.02 and 0.04%. The genetic mechanism responsible for this defect is similar to that present in thalassemia and sickle cell anemia. Most of the affected individuals are heterozygous for the trait. When a gene for elliptocytosis is combined with another abnormal gene, a more severe hemolytic process occurs. Instances of elliptocytosis-Hgb S and elliptocytosis-Hgb C trait have been recorded. The homozygous form of hereditary elliptocytosis has only been recorded twice. This is not surprising, in view of the fact that known carriers are unlikely to mate other known carriers.

Recently, Lawler and her co-workers have shown that linkage exists

between the locus for hereditary elliptocytosis and that for the cde (Rh) blood groups

**PATHOGENESIS**—Hereditary elliptocytosis represents an intrinsic defect of the erythrocyte itself. All attempts to show an extracorporeal factor have been unsuccessful. Lipton has suggested that the microsphe

CHART 3



rocytes and microelliptocytes result in fragmentation of the erythrocytes. This increased destruction of red cells accounts for the shortened life span of elliptocytes, which in turn causes jaundice, increase of fecal urobilinogen, and compensatory hyperplasia of the bone marrow (Chart 3).

Splenectomy is usually successful in decreasing the degree of hemolysis. Although the reason for this is not known, some have suggested that this procedure results in the increased life span of the 'fragmentation spherocytes' which had been selectively destroyed by the spleen.

**DIAGNOSIS**—Elliptocytosis can easily be identified in the peripheral blood. Lipton has also outlined methods by which the cell eccentricity can be calculated by measuring the short and long diameter of each cell (see Procedure 6).

**TREATMENT**—Splenectomy is the treatment of choice, especially when anemia or pancytopenia are serious problems.

Goodale H B, Hendry H W W and Lawler S D. Data on linkage in man. Elliptocytosis and blood groups II. Family three. *Ann. Eugenics* 17:272, 1952.

Lipton E L. Elliptocytosis with hemolytic anemia. The effects of splenectomy. *Pediatrics* 15:67, 1955.

Motulsky A H, Singer K, Crosby W H and Smith V. The life span of the elliptocyte. Hereditary elliptocytosis and its relationship to other familial hemolytic disease. *Blood* 9:57, 1954.

Wyandt H, Bancroft P M and Winship T O. Elliptic erythrocytes in man. *Arch. Int. Med.* 88:1043, 1941.

### 3 ACANTHROCYTOSIS

In 1950 Bassen and Kornzweig reported a hitherto undescribed malformation of the circulating erythrocytes. Since these misshapen cells have a thorny appearance, Singer coined the term *acanthrocytosis* to describe the condition.

**CLINICAL FEATURES**—Acanthrocytosis seems to be characterized by a number of unrelated clinical features. The affected individuals show





FIG. 21—Smear from peripheral blood of a patient with acanthrocytosis (from Singer K, Fisher H and Perlstein M A. Acanthrocytosis. A genetic erythrocyte malformation. *Blood* 7:577, 1952.)



evidence of celiac disease during early childhood. This state lasts for several years and then disappears. As they grow older, the patients develop a neurological picture which is not unlike Friedreich's ataxia: they walk on a broad base and waddle, there are extraneous athetoid movements of the head and arms, accompanied by tremor and poor coordination; there is impairment of vibratory and position sense, and the deep reflexes are absent.

CHART 4  
ACANTHROCYTOSIS



The erythrocyte anomaly represents an unusual type of crenation of the cells. The deformed cells show several irregularly spaced, large, and coarse projections and resemble spherocytes with pseudopods (Fig. 21). There are slight changes of osmotic, and more marked changes of mechanical, fragility but no evidence of increased hemolysis *in vivo*. Electrophoretic studies show that none of the abnormal hemoglobins are present.

**HEREDITY**—Consanguinity was a factor in both of the two affected

families that have been reported. This would suggest that acanthrocytosis is transmitted by a rare recessive gene. Presumably, the parents must be heterozygotes for the condition, but they have not been extensively studied.

The gene frequency of the condition is unknown. Both of the reported families are Jewish, but this may be a coincidence.

**PATHOGENESIS**—Ponder has pointed out that there are two kinds of crenation. Type 1 represents an intermediary phase in the transformation of an erythrocyte from a disk to a sphere. In this type, the crenations tend to be fine and small, and they may be caused by extraneous lysis. Type 2 occurs when the cells undergo crenation spontaneously. Here the crenations are large and coarse and seem to be associated with gelation or crystallization of hemoglobin. Singer thinks that acanthrocytosis belongs to the second type, but he has not been able to identify any intra-erythrocyte factor which may be responsible for the alteration in the shape of the erythrocyte.

Thus far, it has not been possible to relate acanthrocytosis to the celliac syndrome and to ataxic neuropathy (Chart 4).

**DIAGNOSIS**—Acanthrocytosis is diagnosed by the thorny appearance of the erythrocyte on a smear of peripheral blood.

**TREATMENT**—None is required.

Bassen F. A. and Kornzweig A. L. Malformation of the erythrocytes in a case of atypical retinitis pigmentosa. *Blood* 5: 381, 1950.

Singer K., Fisher B. and Perlstein H. A. Acanthrocytosis. A genetic erythrocyte malformation. *Blood* 7: 577, 1952.

#### 4 ERYTHROPOIETIC PORPHYRIA (congenital or photosensitive porphyria)

Erythropoietic porphyria is an inborn error of metabolism characterized by photosensitivity, increased hemolysis and erythropoiesis, splenomegaly and excessive and abnormal porphyrin formation in the bone marrow. The condition first came into prominence during the early decades of the present century, when Hans Fischer and his co-workers made most of the basic chemical observations on the porphyrins from studies on their celebrated patient, Petry, who suffered from this disorder.

**CLINICAL FEATURES**—The signs and symptoms of erythropoietic porphyria appear very early in infancy. The first finding usually is red urine on the diaper. If the urine is examined under a Woods light, the characteristic red fluorescence of porphyria can be easily noted.

The skin photosensitivity is a striking feature of the disease. When exposed to sunlight, such infants form extensive bullous eruptions on the exposed surfaces (*hydraea aestivale*). Subsequently these eruptions break down and become infected, leaving shallow, slow healing ulcers and, ultimately, extensive scarring. It is believed that the photosensitivity is a reaction to the longer wavelengths of ultraviolet light (3200-4500 Å). Ordinary window glass offers no protection from the sun for such patients ■ factor of considerable practical importance.

Other complications include hypertrichosis (resembling that of Cushing's syndrome) along the hairline, and reddish brown staining of the deciduous teeth, caused by the deposition of porphyrins in the tooth substance. Sometimes splenomegaly is also seen.

A hemolytic process is nearly always present in patients with erythropoietic porphyria. This is shown by an increase of reticulocytes and circulating normoblasts, a short survival of erythrocytes (by the Ashby technique), an increase of urobilinogen in the stools and a normoblastic hyperplasia of the bone marrow. Examination of the bone marrow under fluorescent light discloses the presence of porphyrins in the normoblasts.


In such patients, the urine contains large amounts of uroporphyrin I and smaller amounts of coproporphyrin I, while the reverse is found in the feces. Porphobilinogen is not encountered in erythropoietic porphyria and the porphyrins in the excreta are in the free state, in contrast to their appearance as zinc complexes in hepatic porphyria.

**HEREDITY**—Erythropoietic porphyria is an exceedingly rare disease, only about 40 cases having been reported. The condition has been seen among siblings in six families, but never among parents or offspring. Because of this, it is probably transmitted as an autosomal recessive. The heterozygous carriers of the abnormality have not been detected.

**PATHOGENESIS**—Schmid and his associates have suggested that erythropoietic porphyria represents a constitutional fault in porphyrin synthesis in developing normoblasts in the bone marrow. They have shown that there exist two morphologically different varieties of normoblasts, which might be designated as normal and abnormal cells. The abnormal variety exhibits nuclear inclusion bodies, containing hemoglobin and red fluorescence. The fluorescence seems to originate predominantly from the normoblastic nucleus, while the cytoplasm around it shows only little fluorescence. Also the polychromatophilic erythrocytes exhibit only weak fluorescence. These workers interpret these findings to indicate that there must coexist in the bone marrow two different lines of normoblasts. The nuclei of cells belonging to the abnormal line probably form excessive amounts of porphyrins and these are released into the plasma at a rela

# CHART 5

## ERYTHROPOIETIC PORPHYRIA



(Kearch Long et al. 1953)

### ABNORMAL NORMOBLAST

Release uroporphyrin I  
into plasma



Uroporphyrin III  
in urine

Intracorporeal abnormality  
of erythrocyte

Shortened life span  
of erythrocyte

Increase  
fecal urobilinogen

Reticulocytosis

Normoblastic  
hyperplasia  
of bone marrow



Coproporphyrin III  
in urine

tively rapid rate as uroporphyrin I, which in turn is excreted in excess in the urine

The abnormal normoblasts presumably are also responsible for producing erythrocytes with an intracorpuseular abnormality. This would result in the shortened life span of the erythrocytes in such patients and would result in increased hemolysis and erythropoiesis. The increase of coproporphyrin I in the urine is believed to be more of a reflection of the abnormally rapid hemoglobin synthesis stimulated by hemolysis than being related to the excess of uroporphyrin I (Chart 5)

**DIAGNOSIS**—The diagnosis of erythropoietic porphyria is confirmed by (1) intense red fluorescence of normoblasts in the bone marrow by fluorescence microscopy (see Procedure 7), (2) marked increase of uroporphyrin I in the urine and erythrocytes (see Procedure 8), (3) increase of coproporphyrin I in the urine and erythrocytes (Procedure 9) and (4) absence of porphobilinogen in the urine (Procedure 10). The condition can also be differentiated from hepatic porphyria by the lack of involvement of the liver and central nervous system and the age of onset.

**TREATMENT**—Management consists of (1) preventing the effects of photosensitivity and (2) controlling hemolysis. The former can be done by keeping the child in a shaded area away from direct sunlight and by putting protective clothing on him at all times. The hemolysis can be partially arrested by splenectomy which also has a favorable effect on the photosensitivity. If the individual can be made to live with the disease the ultimate outlook is good.

Aldrich R. A., Hawkinson V., Grinstein M. and Watson C. J. Photosensitivity or congenital porphyria with hemolytic anemia. I. Clinical and fundamental studies before and after splenectomy. *Blood* 6: 685, 1951.

\*———, Labbe H. F. and Talman E. L. A review of porphyrin metabolism with special reference to childhood. *Am. J. Med. Sc.* 230: 675, 1955.

Fischer H., Hilmer H., Linder P. and Putzer H. Zur Kenntnis der natürlichen Porphyrine. XVIII. Mitteilung chemischer Befunde bei einem Fall von Porphyrinurie (Petty). *Ztschr. physiol. Chem.* 150: 44, 1925.

Kench J. H., Langley P. A. and Wilkinson J. F. Biochemical and pathological studies of congenital porphyria. *Quart. J. Med.* 22: 285, 1953.

\*Schmid R., Schwartz S. and Sundberg H. Erythropoietic (congenital) porphyria. A rare abnormality of the normoblast. *Blood* 10: 416, 1955.


## 5. PELGER HUET ANOMALY OF THE LEUKOCYTES

This is a rare anomaly of the leukocytes characterized by an arrested segmentation of the granulocyte nucleus at the two lobe level. The phenomenon was first noticed by Pelger, a Dutch physician, in 1928, and the


familial nature of the condition was reported by Huet, another Dutch physician, 3 years later. Up to 1940 the anomaly had been noted in some 210 patients in 32 families from all over the world

**CLINICAL FEATURES**—Persons with this condition are completely

CHART 6  
PELGER-HUET ANOMALY



(Ken et al 1955)



free of clinical symptoms and remain in good health throughout their lives

Laboratory studies show that the total white blood count is normal. A diagnosis of Pelger-Huet anomaly is made by examining the granulocytes in the peripheral blood smear. In normal persons, there is found: non-segmentation in about 3-5% of the neutrophils, two segments in 15-20%, three or four segments in 70-75%, and more than four segments in about 5%. In persons with Pelger-Huet anomaly, an arrest of segmentation

seems to have occurred at the two lobe level. As a result, there is an increase of stab or younger neutrophils, and only an occasional three segmented nucleus. The eosinophils and basophils are similarly affected.

Surprisingly, the Pelger-Huet anomaly does not cause a deficient defense mechanism against infection. The mature Pelger cells have essentially the same functional capacity as have normal mature white cells. However, there is some suggestion that the immature Pelger neutrophils may have less phagocytic activity than normal cells. Despite this, affected individuals do not suffer from infections or other illnesses any more than usual, and, when they do, their resistance is satisfactory.

**HEREDITY**—The Pelger-Huet anomaly is transmitted as an autosomal dominant, with all of the affected individuals being heterozygotes.

Nachtsheim has mated heterozygous Pelger rabbits and shown that the Pelger anomaly is lethal in the homozygotes. Out of 39 rabbits, 27 died during parturition or shortly thereafter, and out of the 12 that survived, only 2 lived to maturity. The homozygous state has been seen in humans only once. This patient, a child, showed on peripheral smear that 92% of the neutrophils had round eccentric nuclei and 6% had indented stab forms, leaving only 2% with segmented forms.

It is estimated that the Pelger-Huet anomaly occurs about once in every 1,000 births.

**PATHOGENESIS**—Essentially nothing is known about the etiology of this anomaly except that there seems to be an arrested segmentation of the granulocytic nuclei for some unknown reason (Chart 6).

**DIAGNOSIS**—A careful differential count of the white-cell series will reveal the abnormality.

**TREATMENT**—None is required.

Huet G J. Familial anomaly of leukocytes. *Nederl tijdschr geneesk.* 75 5956 1931.

\*Klein A, Husson A E, and Bornstein S. Pelger Huet anomaly of the leukocytes, *New England J Med* 253 1057 1955.

Nachtsheim H. Pelger anomaly in man and rabbit. Mendelian character of nuclei of leukocytes. *J Hered* 41 131, 1950.

Pelger K. Demonstratie van een paar zeldzaam voorkomende typen van bloedlichaampjes en bespreking der patienten. *Nederl tijdschr geneesk.* 72 1178 1928.

## PART II

# Disturbances in Molecular Synthesis (Protein Deficiencies)

SOME HEREDITARY DISEASES are the result of a quantitative deficiency or absence of one of the plasma proteins. Although the details have not been properly worked out, there is strong evidence suggesting that in these conditions the plasma protein in question is actually missing from the plasma. This defect is, therefore, a different type of defect from an alteration in the structure of the protein molecule, as has been described in Part I, and also from a functional change in the action of the protein, as will be described in Part III, on enzyme defects.

The disturbances in molecular synthesis may be divided into two groups: (1) the deficiencies of the plasma protein fractions, and (2) the deficiencies of clotting factors.



## Deficiencies of Plasma Protein Fractions

THE THREE congenital deficiencies of plasma proteins are (1) *agammaglobulinemia*, (2) *ceruloplasmin deficiency* (Wilson's disease), and (3) *afibrinogenemia*

### I CONGENITAL AGAMMAGLOBULINEMIA

In 1952 Colonel Ogden C Bruton of the Walter Reed Army Medical Center described a new condition characterized by repeated episodes of infection during infancy and early childhood. Laboratory studies showed a failure to develop antibodies following antigenic stimulation and by electrophoresis, the absence of gamma globulin in the plasma. Accordingly, the condition was named 'agammaglobulinemia'.

**CLINICAL FEATURES**—All patients with this condition suffer from numerous severe bacterial infections, which may take any number of forms (Fig 22). Some patients have repeated episodes of pneumonia or septicemia. Others have recurrent sinusitis and otitis media, which may eventually lead to meningitis. Although these infections respond satisfactorily to antibiotic therapy, sequelae frequently develop owing to the very frequency of attacks. Some of the children have irreversible bronchiectasis following numerous attacks of bronchopneumonia, others develop deafness, cerebral palsy, and mental retardation following meningitis. Some patients develop arthritis associated with tissue injury from repeated infections. On the other hand, all of these patients seem to respond normally to virus infections.

Patients with agammaglobulinemia fail to develop antibodies following antigenic stimulation. For example, repeated immunizations with

pertussis vaccine fail to produce the usual antibodies. Similarly, children with blood group O fail to develop anti-A and anti B isohemagglutinins. Vaccination with vaccine virus results in a low antibody production even after three or four tries at different sites. However, revaccination 6 months later usually reveals an accelerated type of reaction, suggesting immunity.




FIG 22.—The infections repeated during a 5 year period in a patient with congenital agammaglobulinemia (After Bruton O C Agammaglobulinemia Med Ann District of Columbia 22 648 1953 )

**HEREDITY**—Preliminary studies based on a small number of families, suggest that the condition is probably transmitted by a sex linked recessive gene. This form of transmission is suggested by the fact that in all the cases diagnosed up to the present except for one instance, the patients have been boys. Frequently it has been found that other male members of the immediate family have died of presumably the same con-

dition, and in three families, maternal uncles or maternal male cousins have been similarly affected. The appearance of a female with all the stigmata of the disease suggests that there may be a second mode of inheritance for the condition, about which we know little. The heterozygotes have not, as yet, been detectable by measurements of gamma globulin levels.

**PATHOGENESIS**—The cause of this disease is poorly understood. The most striking abnormality is the marked deficiency of gamma globulin in the plasma. As a general rule, no gamma globulin can be detected by electrophoresis. However, by more sensitive immunochemical methods, amounts of less than 30 mg/100 ml have been found (normal, 600-1,200 mg/100 ml). Careful study by Gitlin and his associates has shown that this deficiency occurs because of a lack of production of gamma globulin; there is no evidence to suggest an increased rate of destruction in such patients.


Pathologically, the condition is characterized by an almost total absence of plasma cells in the body. Antigenic stimulation fails to produce specific antibodies in various parts of the body. Recently, Gitlin has demonstrated that there is a deficiency of at least two other beta globulins in the plasma of these patients. This clearly suggests that the deficiency of gamma globulin is not the primary defect in this condition. Rather, it appears that all the complications result from the absence of plasma cells and that this deficiency in turn results from an unknown, but probably more basic, process (Chart 7).

**DIAGNOSIS**—The absence of isohemagglutinins is useful as a simple laboratory screening test for patients with blood groups O, A, or B. Very recently, Gitlin has developed a quantitative immunochemical procedure for measuring gamma globulin (see Procedure 11) which is more reliable and accurate than electrophoresis at very low concentrations.


Congenital agammaglobulinemia should be differentiated from adult agammaglobulinemia and from transient or physiological agammaglobulinemia, neither of which is hereditary or congenital.

**TREATMENT**—The antibiotics, although useful in controlling an immediate infection in these children, have been only partially successful in prevention. On the other hand, gamma globulin administered intramuscularly in dosages of from 0.6 to 1.0 ml per kilogram body weight once a month has given considerable protection against infection.

# **CHART 7** **CONGENITAL AGAMMAGLOBULINEMIA**



(Johansen & G. n. 357)





**PATHOGENESIS**—The etiology of this rather diffuse condition presents a fascinating story. Wilson originally thought that the disease might be due to an unidentified toxin which damaged the brain and liver only. Later it was thought that the disease was due to copper intoxication. For a period all of the signs were attributed to the aminoaciduria which is a complication of this disease. At present it is believed to be due to a deficiency of ceruloplasmin, a blue copper-containing protein in the serum.

Plasma copper occurs in two forms. In one form a small fraction of the copper reacts with diethylthiocarbamate and is known as the direct




FIG. 23.—Photomicrograph of a section of liver from a patient with Wilson's disease. Prominent fibrous septa circumscribe irregular pseudolobules of liver tissue. The vacuolated hepatic cells indicate an associated fatty metamorphosis.

reacting fraction (this has been shown to be bound to albumin). In the other form the greater part of the copper does not react and is known as the indirect reacting fraction (this corresponds to ceruloplasmin). In the normal individual an intravenous injection of  $\text{Cu}^{64}$  results in a rapid fall in serum radioactivity followed by a large increase some time later. In patients with Wilson's disease there is a slightly slower fall and no secondary rise whatsoever. Since the latter rise is due to the  $\text{Cu}^{64}$  being incorporated into ceruloplasmin, the failure to rise indicates a deficiency of that protein. This reaction has also been demonstrated with immunochemical techniques by Scheinberg and Gitlin.

Ceruloplasmin deficiency results (see Chart 8) in a decrease or absence of the indirect-reacting fraction of copper. This causes two effects: (1) an increased absorption of copper through the gastrointestinal tract, and (2) an increase of the direct-reacting fraction of copper in plasma. The excess copper is deposited in the tissues of the body. Some of the copper is chelated with amino acids and excreted in the urine, and this explains both the increased absorption and the excretion of copper among patients with Wilson's disease. The deposition of copper in various organs is responsible for the signs and symptoms of the disease: in the brain, lenticular degeneration, in the liver, cirrhosis, and in the cornea, Kayser Fleischer rings.

Finally, copper is deposited in the kidneys and appears to interfere with the enzyme systems responsible for the transport of a variety of substances across the tubular epithelium. This results in: (1) a generalized aminoaciduria (described first by Dent in 1947). Although most of the amino acids are involved, the loss is particularly marked in threonine, cystine, serine, glycine, asparagine, valine, tyrosine, and lysine, (2) a glycosuria with considerable reduction in glucose  $T_m$ , (3) a phosphaturia which eventually causes bony irregularities and sclerosis, and (4) an increased loss of uric acid, resulting in hypouricemia in the serum. The relatively late onset of the clinical symptoms in Wilson's disease is in part due to the effect of the gradual increase in the amounts of copper in the tissues over a period of years. For example, at least one child has been described in whom aminoaciduria was not present early in life but became increasingly marked as the child grew older.

**DIAGNOSIS**—Wilson's disease can be diagnosed by the deficiency of ceruloplasmin in plasma (see Procedure 12) and the proportion of the direct-reacting plasma copper fraction (see Procedure 13).


**TREATMENT**—Replacement with injections of ceruloplasmin is impractical at the present time because of the very limited quantities of the protein available in pure form. However, BAL (British anti-lewisite) is effective in greatly increasing the urinary output of copper, and Denny Brown feels that great improvement may ensue if such treatment is vigorously pursued. Also, favorable results have been reported with the use of penicillamine.

Bearn, A. G. Genetic and biochemical aspects of Wilson's disease, *Am J Med* 15:442, 1953.


— Wilson's disease, *Am J Med* 22:747, 1957.

Cartwright, G. E., Hodges, R. E., Gubler, C. J., Mahoney, J. P., Daum, K., and Wintrobe, M. M. Studies on copper metabolism. XIII. Hepatolenticular degeneration, *J Clin Invest* 33:1487, 1954.

# **CHART 8** **CERULOPLASMIN DEFICIENCY (WILSON'S DISEASE)**



(See p. 955)





Denny Brown, D., and Porter, H. The effect of BAL on hepatolenticular degeneration. *Am. J. Path.* 47: 353-365, 1951.

H

Sc

hepatolenticular degeneration, *Science* 116: 484, 1952.

Wilson S. A. K. Progressive lenticular degeneration, *Brain* 34: 295, 1912.

### 3. CONGENITAL AFIBRINOGENEMIA

The congenital absence of fibrinogen is a rare condition which was first described in 1920 by Rabe and Salomon.

**CLINICAL FEATURES**—Bleeding is the primary manifestation of congenital afibrinogenemia. It usually begins at an early age, frequently at birth, and it recurs in association with the eruption and shedding of teeth, with trauma, with infections, and after surgery. It is surprising, however, that, despite the complete incoagulability of the blood, patients with afibrinogenemia have, on the average, less difficulty with bruising and bleeding than have those with hemophilia. Also, despite the lack of a fibrin net, the healing of wounds is not usually retarded.

**HEREDITY**—Congenital afibrinogenemia is probably transmitted by a rare recessive gene. This is suggested by the fact that one third of the cases come from cousin marriages, and the condition is seen frequently among siblings without the parents being affected. Up to the present, the sex distribution has been 21 males and 8 females, a difference which may be significant.

About half of the parents and many of the near relatives of known patients show a moderate decrease of plasma fibrinogen levels without clinical symptoms of bleeding. This would suggest that the heterozygotes are sometimes detectable, although there is considerable overlap with the normal range.

**PATHOGENESIS**—The primary defect in this condition appears to be a marked deficiency of fibrinogen in the plasma. Using immunochemical methods, Gutlin and Borges have shown that there is no more than 12 mg/100 ml of fibrinogen or fibrinogen-like material present in such patients, as compared with 300-500 mg/100 ml in normal controls. It appears unlikely that the protein is present in another form, since one

of this protein fraction when it is transfused to affected individuals. The deficiency of fibrinogen is responsible for the bleeding tendency.



84      DISTURBANCES IN MOLECULAR SYNTHESIS

Frick, J. G., and McQuarrie, I. Congenital afibrinogenemia, Pediatrics 13 44 1954

Gitlin, D., and Borges, W. H. Studies on the metabolism of fibrinogen in two patients with congenital afibrinogenemia Blood 8 679, 1953

Henderson, J. L., Donaldson, G. M. M., and Scarborough, H. Congenital afibrinogenemia Quart J Med 14 101, 1945

## Deficiencies of Clotting Factors

DURING THE PAST half century the field of blood coagulation has become so complex that we might do well to start off by reviewing a few of the fundamental concepts involved. First, we should remember that these represent deficiencies of "trace proteins." Unlike gamma globulin or fibrinogen, the amounts of these proteins normally present are so small that they cannot be detected by chemical or electrophoretic methods. Most of the clotting factors have not been isolated, purified, or characterized in the chemical sense. Rather, their absence can only be implied by the failure of blood to clot. This is a functional demonstration of deficiency, much like the enzyme defects to be described in the next section. Second, the existence of these proteins can only be established by deductive reasoning. For example, when the plasma from an apparent case of hemophilia corrects the clotting defect in the plasma from a patient with known hemophilia, the diseases are assumed to be due to deficiencies of entirely different substances. When the exceptional plasma is found to correct the clotting defect in all other types of hemophilia-like deficient plasmas, it is generally agreed that this plasma is unique and the patient is considered to be suffering from a new, previously undescribed condition. Despite these limitations, the deficiency or absence of certain specific clotting factors appears to be quite definite. These factors can be distinguished by the genetic and biochemical characteristics, and they will be discussed in some detail.

At the present time, the exact role that each of the specific factors plays in the formation of the blood clot is not entirely settled. In order to avoid this highly controversial subject, I have chosen to adopt Graham's simplification of Marowitz's theory of blood coagulation, as illustrated in Figure 24. It is generally agreed that there are at least two essential steps in the formation of a clot: (1) prothrombin is converted to thrombin in

the presence of  $\text{Ca}^{++}$  and certain thromboplastic effects, and (2) fibrinogen is converted to fibrin in the presence of thrombin. All of the clotting factors have something to do with the first step and can be classi-

# PLATELETS

+

- |   |  |
|---|--|
| 1 | Antihemophilic globulin (classical hemophilia)     |
| 2 | Plasma thromboplastin component (Christmas factor) |
| 3 | Plasma thromboplastin antecedent                   |
| 4 | Fourth thromboplastin component                    |
| 5 | Hageman factor                                     |
| 6 | Ac globulin  |
| 7 | SPCA   |
| 8 | Stuart factor                                      |

↓  
THROMBOPLASTIC EFFECT  
 $\text{Ca}^{++}$

PROTHROMBIN —————→ THROMBIN

FIBRINOGEN —————<sup>THROMBIN</sup>→ FIBRIN

FIG. 24—A modification of the Matowitz theory of blood coagulation (Proposed by Graham J. B. The genetic biochemistry of human blood coagulation. *Am J Human Genet* 8:63, 1956.)

fied under the over-all term of "thromboplastic effects" without specifying the specific role of each.

Eight congenital deficiencies of specific clotting factors have been described: (1) deficiency of antihemophilic globulin (classical hemophilia), (2) deficiency of plasma thromboplastin component (Christmas disease), (3) deficiency of plasma thromboplastin antecedent, (4) deficiency of a fourth thromboplastin component, (5) Hageman trait, (6) deficiency of Ac-globulin, (7) SPCA deficiency, and (8) Stuart defect. There is still considerable controversy as to whether idiopathic hypo-

thrombinemia is a true inborn error of metabolism, or, for that matter, whether such a defect exists at all

- \*Brinkhous K M, Langdell R D, Penick, III D, Graham, J B, and Wagner, H H Newer approaches to the study of hemophilia and hemophiloid states, J.A.M.A. 154 481 1954
- \*Graham J B The genetic biochemistry of human blood coagulation Am J Human Genet. 8 63, 1956
- Rosenthal H L Hemophilia and hemophilia like diseases caused by deficiencies in plasma thromboplastin factors Anti hemophilic globulin (AHG), plasma thromboplastin component (PTC), and plasma thromboplastin antecedent (PTA), Am J Med 17 57, 1954

# I DEFICIENCY OF ANTIHEMOPHILIC GLOBULIN (AHG) (classical hemophilia, hemophilia A; deficiency of thromboplastinogen, alpha prothrombin deficiency)

Hemophilia is of particular interest because it is probably the oldest hereditary disease known Both the Jews and Arabs knew of the condition in ancient times, and more recently its mode of transmission has been recorded among many of the royal houses of Europe (Chart 10)

CLINICAL FEATURES—Hemophilia is usually diagnosed early in childhood by signs of a hemorrhagic tendency following circumcision, by easy bruising, and by difficulty in stopping bleeding after a cut In older children, uncontrollable bleeding following the extraction of teeth or removal of tonsils may be the first serious sign of hemophilia Bleeding may also affect the internal organs, and death may result from intracranial hemorrhage Hemarthrosis is a characteristic lesion of hemophilia and, after repeated hemorrhages, the joints tend to become fixed

HEREDITY—In most instances the defect is transmitted as a sex-linked recessive character This means that an affected male will transmit the defect to all of his daughters, who will become carriers All of his sons, however, will escape the defect and be perfectly normal If a woman is a carrier, one half of her male offspring will be active bleeders, while the other half will be normal Similarly, one half of her female offspring will be carriers, while the other half will be normal In this condition most of the affected individuals will be males A homozygous female is possible if an affected male mates with a female carrier Only one or two instances of this situation have been noted, but this mode of transmission has been well worked out in hemophilic dogs

The female carriers of hemophilia do not show any consistent clotting defect Apparently, the overlap between normals and carriers is so great that no definite trend emerges from such a study

At least two other types of antihemophilic globulin (AHG) defi-


ciency have been reported. In 1953, Graham, McLendon, and Brinkhous described a pedigree in which the AHG was not completely absent but was reduced to about a quarter that of normal. Bleeding was much less severe among the affected individuals. The condition was transmitted as a sex linked recessive. However, the heterozygous females showed some definitely detectable deficiency of AHG. In 1956, Schulman and his co-workers and Matter and his associates described families with 'vascular hemophilia'. In addition to a deficiency of AHG, the affected individuals showed vascular abnormalities characteristic of pseudohemophilia (von Willebrand's disease). The trait appears to be transmitted by an autosomal dominant gene with high penetrance and variable expressivity. At the present time, it is not clear whether these latter forms represent variants of the classical disease, are alleles in the same locus, or are separate entities, all showing a deficiency of AHG. It may be that the production of AHG requires both a normal sex linked and another autosomal locus. If so, the forms studied by Graham are probably alleles of the former, and those described by Schulman and Matter represent a defect in the latter.

**PATHOGENESIS**—Classical hemophilia is the direct result of a congenital deficiency of the AHG in the plasma (Chart 10). The absence of this factor reduces the thromboplastic effect and causes the failure of the blood to clot. Hemorrhagic diathesis is the direct result of prolonged clotting time. The AHG is carried in the fraction I of Cohn and can be precipitated by  $\text{CO}_2$  saturation of diluted plasma. It is quite labile when stored under blood bank conditions, and as much as 50% will disappear in 24 hours. However, if plasma is frozen or lyophilized, the antihemophilic activity is maintained for long periods of time.

**DIAGNOSIS**—The diagnosis of classical hemophilia is based on certain negative findings, such as normal fibrinogen, prothrombin, clotting inhibitors, and platelet numbers, coupled with the positive findings suggesting delayed conversion of prothrombin to thrombin. For example, the findings may show (1) that the whole blood clotting time (see Procedure 16) and plasma clotting time (see Procedure 17) are abnormal, (2) that the plasma clots relatively slowly, despite normal prothrombin levels as shown by the one stage method (Procedure 18), (3) that there is slow disappearance of prothrombin from clotting blood, as shown by prothrombin utilization or consumption tests (Procedure 21), and (4) that the thromboplastin generation test (Procedure 23), where the patient's adsorbed plasma, normal serum, platelets, and calcium are incubated together, is delayed. Further localization of the clotting defect is dependent on special studies. In the main, these consist of determining


# CHART 10

## DEFICIENCY OF ANTIHEMOPHILIC GLOBULIN



(After Brabhuus 1954)


### DEFICIENCY OF AHG





prothrombin utilization test (Procedure 21). The AHG (Procedure 20) is normal in the patient with PTC deficiency

The principal findings in PTC deficiency are shown in Table 2. Fresh normal plasma, aged normal plasma, and normal serum will correct the defect. This is because PTC is not destroyed by aging or clot forms



tion. However, the PTC is adsorbed by  $\text{BaSO}_4$ , and therefore adsorbed normal plasma will not correct the defect.

Final diagnostic proof requires that the clotting defect be corrected by plasma from patients with every other type of known hemophilic disorder.

**TREATMENT**—The condition can be effectively controlled by transfusions of fresh plasma or whole blood, but fraction I of Cohn is of no therapeutic value.

Aggeler, P. M., White, S. G., Glending, M. B., Page, E. W., Leake, T. B. and Bates, G. Plasma thromboplastin component (PTC), a new disease resembling hemophilia, *Proc Soc Exper Biol & Med* 79:692, 1952.

Biggs, P., Douglas, A. S., MacFarlane, R. G., Dacie, J. V., Pitts, W. R., Merskey, C., and O'Brien, J. R. Christmas disease, a condition previously mistaken for hemophilia, *Brit M J* 2:1378, 1952.

Pavlovsky, A. Contribution to the pathogenesis of hemophilia, *Blood* 2:185, 1947.


Ramot, B., Angelopoulos, B., and Singer, H. Variable manifestations of plasma thromboplastin deficiency, *J Lab & Clin Med* 46:80, 1955.

Soulier, J. P., and Larrieu, M. J. Differentiation of hemophilia into two groups. A study of 33 cases, *New England J Med* 249:547, 1953.

### 3 DEFICIENCY OF PLASMA THROMBOPLASTIN ANTECEDENT (PTA) (hemophilia C)

In 1953, Rosenthal, Dreskin, and Rosenthal described still another hemophilia like condition, which appears to be due to the deficiency of a third thromboplastic factor, which they named 'plasma thromboplastin antecedent (PTA)'. The coagulation disorder in these patients is cor-

CHART 12  
DEFICIENCY OF PTA



rected by both AHG and PTC-deficient plasma as well as by normal plasma or serum

**CLINICAL FEATURES**—Clinically, the bleeding tendency is very slight occurring usually after the extraction of teeth or tonsillectomy. Purpura and joint involvement rarely occur.

**HEREDITY**—Rosenthal has suggested that the condition is transmitted as a simple autosomal dominant and affects both males and females about equally. The condition can also occur to a lesser degree in individuals without bleeding tendencies. For instance, he reports a PTA carrier who is the mother of one patient and the sister of another. The mother showed an abnormal utilization of prothrombin, and her plasma failed to correct the clotting defect in her daughter.

**PATHOGENESIS**—This bleeding tendency is due to the deficiency of the PTA factor in the plasma (Chart 12). The PTA can be partially purified by ammonium sulfate fractionation (it is present in the 25–35% fraction). It is stable on storage at temperatures ranging from  $-20^{\circ}\text{C}$  to  $28^{\circ}\text{C}$ , is chiefly present in Cohn's fraction IV-1, and is localized in the beta<sub>2</sub> globulin fraction of serum separated by paper electrophoresis. Seitz filtration and  $\text{BaSO}_4$  treatment of normal plasma and serum irregularly remove slight amounts of PTA, which can then be eluted by  $\text{NaCl}$  and sodium citrate.

**DIAGNOSIS**—The condition is suggested by a delay in the generation of thromboplastin and also by a prolongation of the partial thromboplastin time (see Procedure 22).

The principal findings in PTA deficiency are shown in Table 2. All of the plasmas and normal serum will partially correct the defect. This is because aging and clotting only partially destroy the PTA factor and because only a portion of PTA is adsorbed by  $\text{BaSO}_4$  treatment.

Final diagnostic proof requires that the clotting defect be corrected by plasma from patients with every other type of known hemophilic disorder.

**TREATMENT**—The administration of stored, refrigerated plasma has been found to correct the clotting defect and is effective in controlling hemorrhage or as a prophylactic measure prior to surgery.

Rosenthal R. L. Hemophilia and hemophilia like diseases caused by deficiencies in plasma thromboplastin factors. Anti hemophilic globulin (AHG) plasma thromboplastin component (PTC) and plasma thromboplastin antecedent (PTA). *Am J Med* 17:57, 1954.

— Dreskin O. H. and Rosenthal N. New hemophilia like disease caused by deficiency of a third thromboplastin factor. *Proc Soc Exper Biol & Med* 82:171, 1953.

— and Gendelman E. Properties of plasma thromboplastin antecedent (PTA) in relation to blood coagulation. *J Lab & Clin Med* 45:123, 1955.

#### 4 DEFICIENCY OF A FOURTH PLASMA THROMBOPLASTIN COMPONENT (PTF D)



**CLINICAL FEATURES**—In 1954, Spaet, Aggeler, and Kinsell reported on a patient with a persistent tendency to bleed following injury, surgery and dental extractions. Clotting studies revealed a prolonged prothrombin utilization and retarded generation of plasma thromboplastin. No anti coagulant was demonstrable, and all previously described coagulation factors were normally present. As a result, the condition was described as due to a deficiency of a fourth plasma thromboplastin component.

**HEREDITY**—The bleeding tendency has been present in both male

and female bleeders in the patient's family for three generations. It is presumed, therefore, to be transmitted as an autosomal dominant, with the affected individuals being heterozygous for the condition.

**PATHOGENESIS**—The hemorrhagic diathesis is presumably due to a deficiency of the fourth thromboplastin component (Chart 13). The fac-

CHART 13

DEFICIENCY OF 4<sup>th</sup> PLASMA THROMBOPLASTIN COMPONENTDEFICIENCY OF 4<sup>th</sup> PLASMA THROMBOPLASTIN COMPONENT

tor is found in Cohn's fractions III and IV and in the 50% ammonium sulfate precipitation of normal plasma. The activity is heat labile and storage stable, and the factor is not adsorbed on  $\text{BaSO}_4$  but is removed only by high-concentration asbestos Seitz filters.

**DIAGNOSIS**—This condition is suggested by prolonged prothrombin utilization (see Procedure 21) and the thromboplastin generation test (Procedure 23). The defect can be corrected by the plasmas from patients with AHG, PTC and PTA deficiencies.

**TREATMENT**—Transfusion with whole blood or its fractions does not improve the clotting condition in the patient


Spaet T H Aggeler P M and Kinsell H C A possible fourth thromboplastin component *J Clin Invest* 33 1095 1954

## 5 HAGEMAN TRAIT


**CLINICAL FEATURES**—In 1956, Margolius and Ratnoff described three patients with a new clotting defect. The patients were remarkable in being totally free from bleeding difficulties and there was no evidence

CHART 14

### HAGEMAN TRAIT



### DEFICIENCY OF HAGEMAN FACTOR



of hemorrhagic diathesis despite operations and dental extractions. The clotting defect was uncovered only in routine preoperative studies.

**HEREDITY**—The condition occurs in both males and females. It is probably familial, since two of the patients were sisters. However, none of some 15 relatives in four generations tested showed any clotting abnormalities.

**PATHOGENESIS**—The clotting abnormality is presumably due to a deficiency of the Hageman factor in the serum (Chart 14). The fraction can be purified by precipitating the  $\text{BaSO}_4$  treated aged serum with

30-40% ammonium sulfate, it can then be adsorbed onto kaolin and eluted with some selectivity, resulting in apparent concentration (about 500-fold, compared with the original serum). However, the globulin will still not be homogeneous electrophoretically. Small amounts of this purified substance will shorten the prolonged recalcified clotting time and restore the thromboplastic effect to normal.

**DIAGNOSIS**—The defect can be shown by the thromboplastin generation test (see Procedure 23) and by prothrombin activity of the serum. Hageman factor can be differentiated from some of the other factors in that it is not destroyed by aging of the serum (which excludes fibrinogen, prothrombin, Ac-globulin, and AHP), adsorption with  $\text{BaSO}_4$  (which excludes PTC and SPCA), and heating at  $56^\circ \text{C}$  for 30 minutes (which excludes the fourth thromboplastin component).

The final diagnosis of the clotting defect depends on the plasma being corrected by plasma from patients with deficiencies of AHP, PTC, PTA, and fourth thromboplastin component.

**TREATMENT**—None is required. A small transfusion of 50 ml of 20-day-old blood will normalize clotting tests.

Margolius, A., Jr., and Ratnoff, O. D. Observations on the hereditary nature

(HF)

associated  
laxest.

# 6 DEFICIENCY OF AC-GLOBULIN (parahemophilia; deficiencies of factor V, prothrombin A, prothrombin accelerator; labile factor; plasma accelerator globulin, plasma prothrombin conversion factor; and proaccelerin)

**CLINICAL FEATURES**—In 1944, Owren described the case of a 29-year-old woman who gave a history of abnormal bleeding time since the

fresh normal plasma. This represented a new coagulation defect, which was called "parahemophilia."

Clinically, such patients have mucous membrane bleeding, and epistaxis and menorrhagia are common features. The latter can be very severe; two affected women have bled to death at the first menstrual period.


**HEREDITY**—The condition appears to be transmitted by an autosomal

mal recessive gene Consanguinity has been reported in a large pedigree from South Africa The heterozygous carriers of the abnormal gene can be detected by a partial deficiency of Ac globulin although they show no hemorrhagic tendencies

The incidence of the condition in the population is not known

**PATHOGENESIS**—The hemorrhagic diathesis is caused by a congenital absence of Ac-globulin factor in the plasma (Chart 15) This

CHART 15  
AC-GLOBULIN DEFICIENCY



factor precipitates from plasma with the globulins at pH 5.3 and is found preponderantly in fractions II and III of plasma. It is not adsorbed by  $\text{BaSO}_4$ , and only slightly by  $\text{Mg}(\text{OH})_2$  and Seitz filters. The distinguishing characteristic of Ac globulin is that it is relatively labile, deteriorates rapidly in plasma. It tends to deteriorate more rapidly in the absence of calcium and is more labile in oxalated than in citrated plasma.

**DIAGNOSIS**—The coagulation time (see Procedure 16) and muc

stage prothrombin time (Procedure 18) are prolonged. The presence of Ac globulin can quickly be detected by its ability to reduce the prothrombin time of stored human plasma (Procedure 24).

**TREATMENT**—Transfusions with fresh whole blood or plasma will correct the deficiency to a clinically significant degree for about a day. The administration of vitamin K has been uniformly unsuccessful.

Kingsley C S. Familial factor V deficiency. The pattern of heredity. *Quart. J. Med.* 23:323, 1954.

Owren P A. Parahemophilia. Hemorrhagic diathesis due to absence of a previously unknown clotting factor. *Lancet* 1:446, 1947.

Ware A G and Seegers W H. Plasma accelerator globulin. Partial purification, quantitative determination and properties. *J. Biol. Chem.* 172:699, 1948.

## 7 DEFICIENCY OF SERUM PROTHROMBIN CONVERSION ACCELERATOR (SPCA) (deficiencies of cothromboplastin, prothrombin convertor factor, prothrombinogen, proconvertin-convertin and factor VII)

**CLINICAL FEATURES**—After the discovery of the Ac globulin factor it was soon realized that some other factor was also important for the conversion of prothrombin into thrombin. Studies with Dicumarol<sup>®</sup> suggested that the compound caused a decrease not only of prothrombin but of an additional factor as well. In 1949, Alexander and his associates made the first complete observations on a patient lacking this factor and named the factor the serum prothrombin conversion accelerator (SPCA).


Congenital lack of SPCA constitutes a clinical entity which is difficult to distinguish from true congenital hypoprothrombinemia. In fact several cases of true SPCA deficiency were previously misdiagnosed as being due to hypoprothrombinemia. Patients with SPCA deficiency show an excessive tendency to bleed early in life. In fact infants will frequently bleed to death at delivery from this defect. Later in life, patients suffer from recurrent epistaxis, excessive bruising, subarachnoid hemorrhage and melena.

**HEREDITY**—The condition is probably transmitted by an autosomal recessive gene, although very few complete families have been described. Parents and some siblings of known patients have been shown to have a normal concentration of prothrombin but a moderate delay of prothrombin conversion by the modified two-stage method for determining prothrombin (see Procedure 19). This defect can be corrected by the addition of small amounts of partially purified SPCA.

**PATHOGENESIS**—The congenital deficiency of SPCA is responsible



for the bleeding difficulties (Chart 16) The SPCA factor has been partially purified from human serum Its main characteristics are (1) it can be quantitatively adsorbed from serum by  $\text{BaSO}_4$ , (2) it is nondialyzable, (3) it is not precipitated from dilute serum at pH 5.8, (4) it is destroyed at  $56^\circ \text{C}$  in 2 minutes, and (5) it is stable at  $4^\circ \text{C}$  for at



least 3 days in serum and 9 days in purified fractions. Also the coagulation of hemophilic or heparinized blood is accelerated by SPCA.

**DIAGNOSIS**—The SPCA deficiency is characterized by a prolongation of the one-stage prothrombin time (see Procedure 18) and by the modified two stage prothrombin determination (Procedure 19). The defect can be readily corrected by the addition of partially purified SPCA. The deficiency can also be detected by adding normal serum and observing the enhancement of prothrombin activity (Procedure 25).

**TREATMENT.**—The transfusion of serum appears to be the treatment of choice during periods of bleeding

Alexander B, Goldstein R and Landwehr G The prothrombin conversion accelerator of serum (SPCA) Its partial purification and its properties compared with serum A<sub>2</sub> globulin *J Clin Invest* 29 881 1950

----- and Cook C D Congenital SPCA deficiency A hitherto unrecognized coagulation defect with hemorrhage rectified by serum and fractions *J Clin Invest* 30 596 1951

DeVries A, Alexander B, and Goldstein A A factor in serum which accelerates the conversion of prothrombin to thrombin I Its determination and some physiologic and biochemical properties *Blood* 4 247 1949

Frick P G and Hagen P S Congenital familial deficiency of the stable prothrombin conversion factor Restudy of case originally reported as "idiopathic hypoprothrombinemia," *J Lab & Clin Med* 42 212 1953

Quick A J, Piccolotta A V and Hussey C V Congenital hypoprothrombinemic states *Arch Int Med* 93 2 1953

## 8 STUART CLOTTING DEFECT

In 1957, Houghie, Barrow, and Graham restudied a patient who had previously been diagnosed as having SPCA deficiency They showed by cross matching techniques that the bleeding tendency was due to a lack, not of SPCA, but of a hitherto undescribed clotting factor They named this the 'Stuart factor,' after the patient's surname

**CLINICAL FEATURES**—The patient with this deficiency appeared clinically to be identical with patients having SPCA deficiency He gave a history of frequent episodes of epistaxis and hematomata, and on one occasion developed a severe hemarthrosis with severe anemia

**HEREDITY**—The Stuart factor appears to be transmitted as a highly penetrant, but incompletely recessive, autosomal characteristic (Chart 17) In the family studied by Graham consanguinity was present The heterozygotes are only mildly affected clinically but show 1½- to 3-second prolongations of the prothrombin time and the thromboplastin generation test

Graham has suggested that about 2 in 1,000 individuals are heterozygous carriers of this abnormality

**PATHOGENESIS**—Stuart factor, like SPCA, can be adsorbed from serum by BaSO<sub>4</sub>, it is stable at pH 6-9 and will remain so when heated up to 56° C It is essential for the formation of blood thromboplastin at an early stage and is required for the optimal activity of brain, lung, and platelet thromboplastin and of cephalin and Stypven<sup>2</sup>


Stuart factor will correct the clotting defect in SPCA deficiency in the prothrombin time test Similarly, SPCA will correct the clotting defect in Stuart factor deficiency A mixture of equal parts of plasmas of patients

## 102 DISTURBANCES IN MOLECULAR SYNTHESIS


with SPCA and Stuart factor deficiency will give 50% proconvertin activity in the Owren assay

**DIAGNOSIS**—Stuart factor deficiency is characterized by an abnormal thromboplastin generation test (see Procedure 23) The defect can readily be corrected by normal serum or by serum from a patient with

CHART 17  
STUART DEFECT



### DEFICIENCY OF STUART FACTOR



**SPCA deficiency** The deficiency can also be detected by adding Dicumarol<sup>®</sup> plasma to oxalated plasma from a patient with Stuart defect and observing the enhancement of prothrombin activity (see Procedure 25)

**TREATMENT**—The transfusion of serum appears to be the treatment of choice in correcting the bleeding

- Graham J B Barrow E M and Houghie C. Stuart clotting defect II Genetic aspects of a "new" hemorrhagic state *J Clin Invest* 36 497 1957  
Houghie C. Barrow E M and Graham J B. Stuart clotting defect I Segregation of an hereditary hemorrhagic state from the heterogeneous group heretofore called "stable factor" (SPCA proconvertin, factor VII) deficiency *J Clin Invest* 36 485 1957

## 9 OTHER DEFICIENCIES

The conditions described above probably do not represent all of the known congenital defects in blood coagulation. For example, the existence of two other defects is still questionable. The Swiss have reported the deficiency of an unknown plasma factor which they have called 'factor X,' but its existence requires confirmation. Also there probably exists a true congenital deficiency of prothrombin, however, except for the cases reported by Quick, no cases have appeared.

In addition, combined coagulation defects have been reported in the literature. Two examples of AHG and PTC deficiency occurring in the same patient have been suggested by the failure of the patients' plasmas to correct the defect of either type of hemophilia. And instances of combined AHG and Ac globulin deficiency and of combined PTC and SPCA deficiency have also been found.

It is apparent that in regard to coagulation we should retain an open mind about these inborn errors of metabolism until we have had more success in chemically isolating and identifying the missing factors.

Nell W. N. and Alton H. G. Christmas disease associated with factor VII deficiency. *Brit. M. J.* 1:330 1955.

Duckert F., Fluckiger P., Matter M. and Koller F. Clotting factor V: physiologic and physicochemical properties. *Proc. Soc. Exper. Biol. & Med.* 90:17 1955.

Fluckiger P., Duckert F. and Koller F. Die Bedeutung des Factor X für die Antikoagulantientherapie. *Schweiz. med. Wchnschr.* 84:1127 1954.

Hill J. M. and Speer E. J. Combined hemophilia and PTC deficiency. *Blood* 10:357 1955.

Iversen T. and Bastrup-Madsen P. Congenital familial deficiency of factor V (parahemophilia) combined with deficiency of antihemophilic globulin. *Brit. J. Haemat.* 2:263 1956.

Quick A. J., Pisciotto A. V. and Hussey C. V. Congenital hypoprothrombinemic states. *Arch. Int. Med.* 95:2 1955.

Soulier J. P. and Larricou M. J. Differentiation of hemophilia into two groups: A study of 33 cases. *New England J. Med.* 249:547 1953.



## PART III

# Disturbances in Molecular Function (Enzyme Defects)

IT WAS Sir Archibald Garrod who first postulated that all hereditary diseases were due to metabolic blocks which occurred because of the absence of specific "enzymes." In looking back, it appears probable that he had only a vague idea as to what the term meant, and certainly he could not have conceived of the complex protein molecules which we call enzymes. In the intervening years, some of the hereditary conditions have, in fact, been shown to be due to enzyme deficiencies. Alkaptonuria and albinism, two of the original diseases described by Garrod, are almost certainly in that group. Others, including cystinuria, do not appear to represent primary enzyme defects at the present time. It would be better, therefore, to regard the deficiency of an enzyme as one of several mechanisms responsible for inborn errors of metabolism in man.

It should be noted that when we refer to an "enzyme defect," we mean that we can demonstrate the defect only indirectly. None of the enzymes to be described herein have been crystallized, and there are no physical means of showing whether they are absent or present. All we can say is that a specific enzyme, such as the one responsible for the conversion of phenylalanine to tyrosine, does not appear to be working properly. The enzyme could be absent, and hence unable to do its work. It could be present but have a slight structural abnormality, such as having one more or one less



## PART III

# Disturbances in Molecular Function (Enzyme Defects)

It was Sir Archibald Garrod who first postulated that all hereditary diseases were due to metabolic blocks which occurred because of the absence of specific "enzymes." In looking back, it appears probable that he had only a vague idea as to what the term meant, and certainly he could not have conceived of the complex protein molecules which we call enzymes. In the intervening years, some of the hereditary conditions have, in fact, been shown to be due to enzyme deficiencies. Alkaptonuria and albinism, two of the original diseases described by Garrod, are almost certainly in that group. Others, including cystinuria, do not appear to represent primary enzyme defects at the present time. It would be better, therefore, to regard the deficiency of an enzyme as one of several mechanisms responsible for inborn errors of metabolism in man.

It should be noted that, when we refer to an "enzyme defect," we mean that we can demonstrate the defect only indirectly. None of the enzymes to be described herein have been crystallized, and there are no physical means of showing whether they are absent or present. All we can say is that a specific enzyme, such as the one responsible for the conversion of phenylalanine to tyrosine, does not appear to be working properly. The enzyme could be absent, and hence unable to do its work. It could be present but have a slight structural abnormality, such as having one more or one less



*of the amino acids, making it incapable of performing its function properly* It might differ from the normal enzyme much in the same way that sickle cell hemoglobin differs from normal hemoglobin Finally, it is possible that the enzyme could be both present and structurally normal but unable to function in the environment because of alterations in the host or within the cell

The hereditary diseases which probably are caused by enzyme defects may be divided into five groups disturbances in amino acid metabolism, disturbances in carbohydrate metabolism, disturbances in endocrine metabolism, disturbances in pigment metabolism and miscellaneous disturbances

## Disturbances in Amino Acid Metabolism

### AROMATIC AMINO ACID DISTURBANCES

During the past few years rapid strides in biochemistry have permitted a proper understanding of the normal pathway for the degradation of phenylalanine and tyrosine in man. This occurs in a series of separate steps, each of which is catalyzed by an enzyme system (Fig. 25).

Phenylalanine is first converted to tyrosine in the presence of the enzyme system "phenylalanine hydroxylase." The absence of this enzyme is responsible for the clinical condition *phenylketonuria*.

Tyrosine is next converted to *p*-hydroxyphenylpyruvic acid in the presence of the enzyme "tyrosine transaminase."

The *p*-hydroxyphenylpyruvate is converted to homogentisic acid in one step in the presence of the enzyme "*p*-hydroxyphenylpyruvic oxidase." An absence of this enzyme is apparently responsible for the condition known as *tyrosinosis*.

Homogentisic acid is then converted to maleylacetoacetate in the presence of the enzyme "homogentisic oxidase." An absence of this enzyme is responsible for the third metabolic defect, known as *alkaptonuria*.

Maleylacetoacetate is then converted, by two additional steps, to acetoacetate and fumarate by enzymes which will be discussed later.

As another pathway of metabolism, tyrosine is also converted to 3,4-dihydroxyphenylalanine (dopa) and eventually to melanin by the action of the enzyme "tyrosinase." The absence of this enzyme is responsible for the hereditary defect *total albinism* and probably is responsible for *partial albinism*.




FIG 25—The normal pathway for the degradation of phenylalanine and tyrosine in man. The known metabolic defects are I, phenylketonuria, II tyrosinosis, III, alkaptonuria, and IV, albinism.

## 1 PHENYLKETONURIA (phenylpyruvic oligophrenia)

Phenylketonuria is a hereditary condition characterized by mental retardation and the presence of phenylpyruvic acid in the urine. Nearly 400 cases have been reported from all parts of the world since the first cases were described by Folling, a Norwegian biochemist, in 1934.

**CLINICAL FEATURES**—Though patients seem to be ordinary imbeciles, they are noted for their unusually attractive features in early child-

hood Unlike other mental defectives, they show only a slight reduction in stature and head size, as compared with the normal average of same age and sex Many of the children have blond hair, blue eyes, and fair skin A few show a tendency toward developing dermatitis or eczema

Neurologically, phenylketonurics show no paralysis and no changes in muscle tone However, there is usually a marked accentuation of both the superficial and deep tendon reflexes The majority of patients have an I Q of 30 or less However, a few high-grade cases with near normal intelligence have been described recently, it is believed that these atypical cases represent less than 1% of all cases of phenylketonuria


HEREDITY —It is estimated that phenylketonuria accounts for about 1% of all mental defectives in institutions The condition arises once in every 40,000 births in the United States and is transmitted by a rare recessive gene In any given family with one affected child, the chances of another case occurring in a subsequent pregnancy is 1 in 4, or 25% The heterozygous carriers of the phenylketonuric gene can be identified by means of phenylalanine tolerance tests

PATHOGENESIS —Phenylalanine is converted to tyrosine by the enzyme system "phenylalanine hydroxylase" Mitoma and his co-workers have shown that two protein fractions are involved in this reaction a labile fraction I, which is present only in the liver, and a more stable fraction II, found also in the kidney and heart The system requires DPNH and  $\text{Fe}^{++}$ , and the over all reaction appears to occur in one step, with no intermediates Recent studies have shown that in phenylketonurics, fraction II is present in the tissues in normal amounts and that the disease occurs because of a deficiency of fraction I in this enzyme system


The deficiency of phenylalanine hydroxylase causes an excessive accumulation of l phenylalanine in the blood and spinal fluid This in turn causes three kinds of effects (Chart 18) (1) The excessive phenylalanine is converted, by its transaminase, to phenylpyruvic acid This in turn is converted to phenyllactic acid, phenylacetic acid, and phenylacetylglutamine and excreted in the urine For reasons which are still obscure, o-hydroxyphenylacetic acid, m-hydroxyphenylacetic acid, and indole products derived from tyrosine and tryptophane are also found in the urine of such patients (2) The excessive phenylalanine also inhibits the normal pathways of tyrosine metabolism There is a decreased production of melanin, and this is responsible for the light pigment in the skin and hair of such patients There is also a disturbance in adrenalin production, since phenylketonurics have unusually low blood adrenalin levels (3) The excessive phenylalanine or one of its products probably causes some as yet unexplained, damage to the central nervous system, this is

# CHART 18

## PHENYLKETONURIA



(H a 1957)



characterized by mental retardation, epileptic seizures, and abnormal electroencephalogram changes

**DIAGNOSIS**—A diagnosis of phenylketonuria can be established by (1) the presence of phenylpyruvic acid in the urine (see Procedure 26) and (2) an increase of *l* phenylalanine level in the plasma (see Procedure 27)

**TREATMENT**—Young infants should be treated by a special diet low in phenylalanine content. This consists of (1) low phenylalanine protein




FIG. 26.—Reduction of plasma phenylalanine levels after administration of low phenylalanine diet in patient with phenylketonuria. The reduction in urine phenylpyruvate and urine phenylalanine excretion also parallels that of the plasma phenylalanine (From Hsia D Y Y Recent developments in the study of hereditary diseases in children Postgrad Med 22 203 1957)

hydrolysate manufactured by Mead Johnson and Merck & Company, Inc., (2) 1% protein fruits and vegetables, (3) gluten free bread, (4) sugar, (5) butter or lipomal, and (6) vitamins and minerals. This diet is effective in reducing plasma phenylalanine levels down to the normal range (Fig. 26). At present, it is felt that this diet is effective in bring-

ing about normal development if started shortly after birth, it has less value in older infants, and appears to have no effect upon phenylketonuric children after the age of 5 years

- Armstrong M D and Robinson K ■ On the excretion of indole derivatives in phenylketonuria Arch Biochem 52 287 1954
- Bickel H Gerrard J and Hickmans E M Influence of phenylalanine intake on phenylketonuria Lancet 2 812, 1953
- Dancis J and Balis M E A possible mechanism for disturbance in tyrosine metabolism in phenylpyruvic oligophrenia Pediatrics 15 63 1955
- Hsia, D Y Y Recent developments in the study of hereditary diseases in children Postgrad Med 22 203 1957
- , Driscoll K. W Troll W, and Knox W E Detection of the heterozygous carrier for phenylketonuria by phenylalanine tolerance tests Nature 178 1239 1956
- Knox W E and Paine R S A case of phenylketonuria with borderline intelligence A.M.A. J Dis. Child 1957
- et al A one year controlled study on the effect of a low phenylalanine diet on phenylketonuria Pediatrics 21 178 1958
- \*Jervis G A Phenylpyruvic oligophrenia Nerv & Ment Dis 33 259 1954
- \*Knox W E and Hsia D Y Y Pathogenetic problems in phenylketonuria Am J Med 22 687, 1957
- Mitoma C Auld R. M and Udenfriend S On the nature of enzymatic defect in phenylpyruvic oligophrenia Proc Soc Exper Biol & Med 94 634 1957

## 2. TYROSINOSIS

In 1932, Medes described the first authentic case of tyrosinosis. In this patient there was a continuous excretion of large quantities of *p* hydroxyphenylpyruvic acid but no other clinical symptoms. Recently Felix and his co workers have made similar observations on two patients with liver disease. It would appear that tyrosinosis should be included among the conditions defined as inborn errors of metabolism.

**HEREDITY**—The mode of transmission of tyrosinosis is completely unknown. The condition certainly appears to occur very rarely. Blatherwick has examined the urine of 26 000 persons and could not find a single individual showing a positive reaction to the Millon test.


**PATHOGENESIS**—Tyrosinosis appears to occur as the result of a metabolic block at the conversion of *p* hydroxyphenylpyruvic acid to homogentisic acid, as shown in Chart 19. This reaction is catalyzed by the liver enzyme, *p* hydroxyphenylpyruvic acid oxidase and requires glutathione and either ascorbic acid or dichlorophenolendophenol as cofactors.

If the protein intake is increased, or if tyrosine itself is fed to these patients, the amount of *p* hydroxyphenylpyruvate in the urine is increased. The following substances will also appear in the urine, in this order: tyrosine, *p* hydroxyphenyllactic acid, and 3,4 dihydroxyphenyl

# CHART IV

## TYROSINOSIS

UNKNOWN





alanine. On the other hand, if homogentisic acid is fed to the patient *p*-hydroxyphenylpyruvate does not appear in the urine, and it exerts an influence upon the excretion of any of the other compounds.

The absence of *p*-hydroxyphenylpyruvic acid in the urine is due to its reaction to the Millon reaction to the enol form.

#### TREATMENT

Blatherwick N R. Tyrosinosis. A search for additional cases. JAMA 103 1933 1934

Edwards S Hsia H Y Y and Knox W E. The first oxidative enzyme of tyrosine metabolism *p*-hydroxyphenylpyruvate oxidase. Fed Proc 14 206 1955

Felix L, Leonhardt G, and Glaservapp J. Über Tyrosinosis. Ztschr physol Chem 287 141 1951

Medes G. A new error of tyrosine metabolism. Tyrosinosis. Biochem J 26 917, 1932

### 3 ALKAPTONURIA

Alkaptonuria is an inborn error of aromatic amino acid metabolism characterized by the excretion of homogentisic acid in the urine.

**CLINICAL FEATURES**—The condition is compatible with long life. Except for the discoloration of the urine there are no clinical manifestations until the second or third decade, when ochronosis begins to appear. This consists of deposits of ocher like pigments in various parts of the body. The deposits are particularly prominent in the scleras on either side of the corneal limbus, in the ear and nasal cartilages, and in the superficial tendons of the hand.

By the time alkaptonurics reach middle age, they generally complain of pain and stiffness in the large joints, owing to a deforming arthritis. The spine becomes rigid, there is kyphosis in the dorsal region and motion of the hip, knee, or shoulder joints becomes limited and painful. On x ray examination the presence of thin densely calcified intervertebral disks is characteristic.

**HEREDITY**—Alkaptonuria can be transmitted by two means. In the majority of cases the condition is transmitted by a single recessive gene in such families the expectation will be that 1 out of 4 children will be affected. So far, no method has been worked out for detecting the heterozygotes for this condition but the occurrence of a very high incidence of parental consanguinity makes such a conclusion almost certain.

In a few families the condition appears to be transmitted as a simple dominant. In these pedigrees, individuals in a series of successive generations are affected and there are no indications of any cousin marriages.





albinos of the colored races frequently have blue or light brown eyes. The majority of albinos are both mentally and physically below par, although exceptions have been noted.

**HEREDITY**—The condition is transmitted as a simple recessive. This is shown by the fact that 20-30% of the cases result from cousin marriages, also, there are several recorded instances of monozygotic twins,



FIG. 27—Total albinism. No pigment in hair.

both presenting the affliction. As a general rule, one would expect 1 out of 4 children in an affected family to have the disease. The heterozygous carrier for the condition cannot be detected by present methods. Total albinism occurs in all races, varying in frequency from 1/7% in the San Blas Indians of Darien to 1 in 20,000 in Great Britain and 1 in 100,000 in France.

**PATHOGENESIS**—Total albinism appears to be caused by the absence of tyrosinase inside the melanocytes in the skin. Fitzpatrick and his co-workers have shown that these melanin-producing cells are present in

nurics results in almost quantitative recovery of that substance in the urine, while no such accumulation occurs in normal individuals it is postulated that the condition represents a metabolic block at the stage of homogentisic acid, as shown in Figure 25

Homogentisic acid is converted to fumarate and acetoacetate in three successive steps, as shown in Chart 20. Homogentisic acid is first converted to maleylacetoacetate by homogentisic oxidase. It is then converted to fumarylacetoacetate by a *cis*- and *trans* isomerase, and finally the fumarylacetoacetate is rapidly split into its component parts by a third enzyme and the pieces enter the general metabolic reaction of the body. Since the absence of the last two enzymes does not result in homogentisic accumulation, the first enzyme must, therefore, be the one which is defective or absent in alkaptonuria. Recently this hypothesis has been confirmed in an actual patient with alkaptonuria.

Homogentisic acid accumulates in the blood and is excreted in the urine. Apart from homogentisic acid itself, no other abnormal substances are excreted in the urine as a result of the metabolic block. The homogentisic acid is at least in part responsible for the deposition of pigment and ochronosis in the tissues.

**DIAGNOSIS**—Alkaptonuria can be diagnosed by the presence of homogentisic acid in the urine (see Procedure 29)

**TREATMENT**—Symptomatic treatment for arthritis

\*Galdston M, Steele J M and Dobrinier K. Alcaptonuria and ochronosis. *Am J Med* 13 432 1952

Knorr W E and Edwards S W. Homogentisic acid oxidase of liver. *J Biol Chem* 216 479 1955

\_\_\_\_\_ and \_\_\_\_\_. The properties of maleylacetoacetate the initial product

The nature of  
230 251 1958  
h D G AJ

1925

#### 4 TOTAL ALBINISM

Albinism is a hereditary condition characterized by the complete absence of pigment in the skin, eyes, and hair.

**CLINICAL FEATURES**—Patients with this condition have white or very pale yellow hair which is silky in texture (Fig 27). The pupils of the eye appear to be red, and the iris is pink or bluish from reflected light, astigmatism, photophobia, and nystagmus are present in varying degrees. Traces of the pigment, however, can be found in the uveal border and

albinos of the colored races frequently have blue or light brown eyes. The majority of albinos are both mentally and physically below par, although exceptions have been noted.

**HEREDITY** —The condition is transmitted as a simple recessive. This is shown by the fact that 20-30% of the cases result from cousin marriages, also, there are several recorded instances of monozygotic twins,




FIG. 27 —Total albinism. No pigment in hair.

both presenting the affliction. As a general rule, one would expect 1 out of 4 children in an affected family to have the disease. The heterozygous carrier for the condition cannot be detected by present methods. Total albinism occurs in all races, varying in frequency from 0.7% in the San Blas Indians of Darien to 1 in 20,000 in Great Britain and 1 in 100,000 in France.


**PATHOGENESIS** —Total albinism appears to be caused by the absence of tyrosinase inside the melanocytes in the skin. Fitzpatrick and his co-workers have shown that these melanin producing cells are present in

# CHART 21

## TOTAL ALBINISM



(Fanceschell A. B. Kendall 1948)



normal numbers in such patients but that the enzyme is not present within the cells and hence melanin is not produced

The action of tyrosinase is shown in Chart 21 Tyrosine is oxidized to 3,4 dihydroxyphenylalanine (dopa) in the presence of molecular oxygen and tyrosinase Dopa is then further changed to dopa quinone in the presence of tyrosinase Ultimately, dopa quinone is converted to melanin without tyrosinase However, it should be noted that in the absence of dopa tyrosinase cannot act on tyrosine Even when dopa is present, there is a lag period in the action of the first step No such lag is noted in the second step of the reaction

These findings seem to support the concept that total albinism arises as a result of the absence of a single enzyme and a block in the normal pathway of metabolism, and, therefore, albinism can be included among the conditions known as the inborn errors of metabolism

**DIAGNOSIS**—The diagnosis can usually be made on clinical grounds alone

**TREATMENT**—Prevention of exposure to sunlight and proper protection of the eyes by dark glasses

Fitzpatrick T B Human melanogenesis The tyrosinase reaction in pigment cell neoplasia with particular reference to malignant melanoma Preliminary report A M A Arch Dermat 65 379 1952

— and Lerner A B Pigment and pigment tumors Biochemical basis of human melanin pigmentation A M A Arch Dermat 69 133 1954

Franceschetti A and Klein D Réunion dominante avec surdit  Confinia neurol 8 339 1948

\*Lerner A B and Fitzpatrick T B Biochemistry of melanin formation Physiol Rev 30 91, 1950

## 5 PARTIAL ALBINISM

Partial albinism is characterized by a congenital absence of pigment in specific parts of the body The areas affected are of irregular distribution but sometimes follow the course of cutaneous nerves There are many varieties of partial albinism, each of which probably arose from a different mutation

**CLINICAL FEATURES AND HEREDITY**—At least three well-defined types have been described piebald albinism, white forelock and spotting of the skin and albinism of the eye alone

1 *Piebald albinism*—This form was first described in 1934 by Keeler who interpreted it as a dominant mutation It was found in 25 out of 100 individuals in four generations of one family Members of this family have exhibited themselves in sideshows since the nineteenth cen-



ture The condition appears to be transmitted as a dominant no normal individuals within the family have ever transmitted the condition to their offspring, while the affected ones have transmitted it to about half of their children

✓ 2 *White forelock and spotting of the skin*—In the majority of instances, the affected persons in these families have the white forelock and also moderately well distributed white spotting of the skin The condition is again believed to be transmitted as a simple dominant since in a recent study it was found that more than half of some 769 children born of parents with this trait also inherited it, while only 15 out of 474 born of unaffected normal parents in these same families inherited the trait

✓ 3 *Albinism of the eye alone*—This form is characterized by albinism in the fundus hypoplasia of the macula, head nodding nystagmus and amblyopia Unlike the other types of partial albinism this condition is transmitted as a sex linked recessive, where only male offspring of mothers who are carriers are affected The heterozygous carriers of the abnormal gene show a permeability of the iris to light on transillumination of the scleras, and macular retinal pigmentation which is stippled, cocoa brown in color, and very sparse

PATHOGENESIS—The pathogenesis is not known

DIAGNOSIS—This can usually be established on clinical grounds

TREATMENT—None is required except for proper protection of the eyes

Cooke J V Familial white skin spotting with white forelock J Pediat. 41 1 1952

Falls II F Sex linked ocular albinism displaying typical fundus changes in the female heterozygote Am J Ophth 34 41 1951



## OTHER AMINO ACID DISTURBANCES

### 6 MAPLE SUGAR URINE DISEASE (progressive familial cerebral dysfunction associated with an unusual urinary substance)

In 1954, Menkes, Hurst, and Craig described a new syndrome characterized by cerebral symptoms and the passage of urine with an odor strikingly similar to that of maple sugar This has recently been shown to represent a defect in the branched chain amino acids

CLINICAL FEATURES—All of the affected infants begin to show clinical symptoms between the third and fifth days of life There is difficulty in feeding an absence of the Moro reflex, and the development of irregular, jerky respirations This is followed by signs of spasticity and opisthotonos, and the infants go rapidly downhill and die within a few

# CHART 22 MAPLE SUGAR URINE DISEASE



weeks or months. Surprisingly, convulsions and paralyses are not usually noted in this disease.

In all instances the odor of the urine resembles that of maple sugar. This seems to become more striking as the disease progresses. At post mortem, none of the findings are specific or unusual; rather they are consistent with those of very acute diseases or with those occurring during the agonal period of any systemic condition.

**HEREDITY**—The mode of transmission of maple sugar urine disease is yet to be worked out. Out of the six children in the original family studied by Menkes and his co-workers, four had a maple sugar odor in the urine, developed cerebral signs, and died. There were three boys and one girl in the affected group. The two remaining siblings and their parents did not have maple sugar odor in the urine and were perfectly healthy.

**PATHOGENESIS**—Westall and his associates have studied the urine and blood of a patient with this condition. Using a Dowex 50 column for separation, they showed that the three branched chain amino acids—valine, leucine, and isoleucine—were greatly increased in both the blood and urine. On the other hand, threonine, serine, and alanine showed exceptionally low figures. A single enzymatic defect involving the branched chain amino acids could explain these changes.

At present, the material in the urine giving rise to the maple sugar odor has not been identified. Similarly, the relationship between the central nervous system symptoms and the amino acid abnormalities has not been clarified (Chart 22).

**DIAGNOSIS**—The diagnosis can be established by the typical neurological signs and by demonstrating excessive amounts of the branched chain amino acids in the blood and urine by means of paper chromatography (see Procedure 30).

**TREATMENT**—None is of any avail.

Menkes J. H., Hurst P. L., and Craig J. M.: A new syndrome: Progressive familial infantile cerebral dysfunction associated with an unusual urinary substance. *Pediatrics* 14: 462, 1954.

Westall R. G., Dancis J., and Miller S.: Maple sugar urine disease—a new molecular disease. *AMA J. Dis. Child* 94: 571, 1957.

**7 H DISEASE** (hereditary pellagra like skin rash with temporary cerebellar ataxia, constant renal ammoniaemia, and other bizarre biochemical features)

In 1956, Baron, Dent, Harris, Hart, and Jepson described a new clinical syndrome characterized by a pellagra like skin rash, neurological

changes resembling cerebellar ataxia, a constant aminoaciduria, and other biochemical changes suggesting a disturbance of nicotinic acid utilization. They named the condition "H disease," after the surname of the affected family.

**CLINICAL FEATURES**—The first patient who was studied showed skin changes similar to those in pellagra. There was a rash over the exposed surfaces of the face, neck, hands, and legs. After being exposed to the sun, the skin became very red, raw, and started to ooze. Neurologically, the patient presented a varied picture. At times he had only a mild ataxia. On other occasions he showed a coarse nystagmus, ptosis, an increase of deep reflexes, and poor performance of fine movements. There was a tremor of the outstretched hands, and his hands and tongue showed spontaneous involuntary movements. With the passage of time, he became more irritable and hard to handle. Psychological tests indicated that he was mentally retarded, and there was some suggestion of increased mental deterioration.

The most consistent laboratory finding was a gross generalized aminoaciduria. Except for proline, all of the amino acids in the urine were increased. The aminoaciduria was renal in origin, since the plasma  $\alpha$ -ammonitrogen was within normal limits.

There was also an increase in the urinary excretion of indole compounds. In addition to an increase in indican, there was an excess of tryptophane, indole-acetic acid, and an unidentified indolic material, U I. However, tryptamine, serotonin, 5-hydroxyindole acetic acid, and indole-lactic acid were not detectable.

The patients in the H family have been followed over a period of years. The skin changes persist and are accentuated by sunlight. The neurological signs come and go, but they tend to get worse when the rash is marked and also following infections without rash. The youngest sibling shows only aminoaciduria, without skin rash or neurological signs. It is not clear whether these symptoms will develop as he grows older.

**HEREDITY**—Among the eight children in this family, three males and one female are affected. Also, the parents are first cousins. This suggests that the condition is transmitted as an autosomal recessive. The heterozygous carriers for H disease have not, so far, been detected either clinically or in the laboratory.



Although only one family has so far appeared in the literature, several other families with what appears to be the same condition are known to exist.

**PATHOGENESIS**—Baron and his co-workers have suggested that H

## 124 DISTURBANCES IN MOLECULAR FUNCTION

disease represents a disorder of tryptophane metabolism whereby a metabolic block exists somewhere along the pathway from tryptophane to nicotinic acid. If one also postulates that some enzyme systems in the body require nicotinic acid or nicotinamide as prosthetic groups and that

CHART 23  
H DISEASE



they can only get these from tryptophane, this could explain the pellagra-like lesions and disturbances in indole metabolism (Chart 23)

The aminoaciduria, cerebellar ataxia, and mental deficiency would be more difficult to interpret. The only possible explanation for these is that the former is a consequence, on the level of cellular metabolism, of an apparent nicotinamide deficiency and that the latter may in some way

be similar to the disturbances in indole metabolism in phenylketonuria which is another cause for mental deficiency

**DIAGNOSIS**—A gross aminoaciduria (see Procedure 30) plus the characteristic skin and nervous system changes would strongly suggest this condition

**TREATMENT**—Nicotinamide has been used as a form of therapy, but there is considerable skepticism as to whether it is really of any value

Baron D N Dent C E Harns H Hart E W and Jepson J H  
Hereditary pellagra like skin rash with temporary cerebellar ataxia constant renal amino-aciduria and other bizarre biochemical features *Lancet* 2 421 1956

## Disturbances in Carbohydrate Metabolism

UP TO THE PRESENT, the disturbances in carbohydrate metabolism have been divided into four groups (1) an inborn error of metabolism involving a five-carbon sugar, which results in the clinical condition *pentosuria* or *l xyloketosuria* (2) inborn errors of metabolism involving two six carbon sugars, which result in the clinical conditions *fructosuria* and *galactosemia*, (3) disturbances in glycogen metabolism, which result in four clinical conditions Type I, *glycogen storage disease of the liver and kidneys* (von Gierke's disease), Type II, *glycogen storage disease of the heart*, Type III, *diffuse glycogenosis with hepatic cirrhosis*, Types IVa and IVb, *glycogen storage of liver and muscle*, and (4) disturbances in the glycolysis of red cells which appear to be responsible for *hereditary spherocytosis* and *hereditary nonspherocytic hemolytic anemia*. These disturbances will now be described.


### METABOLIC DISTURBANCE INVOLVING A FIVE-CARBON SUGAR

#### 1. PENTOSURIA (*l xyloketosuria*)


The presence of pentose in the urine was first described by Salkowski and Jastrowitz in 1892. The condition is of historic interest because it is one of the four inborn errors of metabolism described by Garrod in the Croonian Lectures of 1908.

**CLINICAL FEATURES**—The condition seems to be compatible with health and well being. Patients excreting this substance show no symptoms, the diagnosis usually being made by examiners for life insurance.

CHART 24  
L-XYLOKETOSURIA



(Lasker et al 1936)



companies. It should be remembered, however, that pentosuria can occur in normal people after they have eaten large amounts of fruits and berries, and it is also sometimes seen in patients with muscular dystrophy.

**HEREDITY**—The incidence of essential pentosuria is estimated to be 1 in 50,000, the condition is found almost exclusively in people of Jewish ancestry from a certain part of Russia, but recently a few cases have been reported among non-Jews. Lasker and her co-workers believe that pentosuria is transmitted by a recessive gene. The condition has



been found more often in males than females, but this may merely reflect the fact that more males than females apply for life insurance. The heterozygotes for this condition have not been identified.

**PATHOGENESIS**—Touster and his associates have suggested that glucuronic acid is metabolized by a series of steps, as shown in Chart 24. (1) Glucuronic acid is first converted to *l*-xylulose by one or more intermediate steps which are as yet poorly defined. There is good evidence that *l*-xylulose is the end product of this series of reactions, since it has been isolated in the urine of normal subjects and guinea pigs fed glucuronolactone. (2) Then *l*-xylulose is degraded to *l*-xylitol by an enzyme present in the mitochondrial fraction of guinea pig liver homogenate. This enzyme requires MgCl<sub>2</sub>, *l*-glutamate, and atmospheric oxygen. The reaction occurs without the accumulation of any known intermediates or xylulose phosphate, and the product, *l*-xylitol, has been identified by its pentose acetate.

In 1936, Enklewitz and Lasker showed that there is a direct relationship between the amount of glucuronic acid administered and the extra amount of xylulose excreted. Since feeding glucuronic acid to normal individuals does not produce this effect, they postulated that there was a defect in the system that decarboxylates glucuronic acid to xylulose. Now that *l*-xylulose has been identified as an intermediate in the normal pathway of glucuronic acid metabolism, it is believed the defect must occur at the stage immediately following *l*-xylulose. Pentosuria must, therefore, represent a deficiency of the enzyme described by Touster, however, this remains to be demonstrated in a patient with known pentosuria.

**DIAGNOSIS**—The diagnosis of pentosuria is established by identifying *l*-xylulose in the urine (see Procedure 31). Up until the present, no authentic case of *l*-arabinosuria, the isomer of *l*-xylulose, has been reported.

**TREATMENT**—None is required.

Barnes H. D. and Bloomberg H. M. Paper chromatography of the urinary sugar in essential pentosuria. *South African J. M. Sc.* 18: 93, 1953.

Enklewitz, M., and Lasker, M. The origin of *l*-xyloketosuria. *J. Biol. Chem.* 110: 443, 1935.

Lasker, M., Enklewitz, M., and Lasker, G. W. The inheritance of *l*-xyloketosuria. *Human Biol.* 8: 243, 1936.

Touster O., Hutcheson, R. M., and Rice, L. The influence of *d*-glucuronolactone and the excretion of *l*-xylulose by humans and guinea pigs. *J. Biol. Chem.* 215: 677, 1955.

———, Reynolds V. H., Hutcheson, R. M., and Hollmann S. Reduction of *l*-xylulose to xylitol by an enzyme of guinea pig liver mitochondria. *Fed. Proc.* 15: 372, 1956.

## METABOLIC DISTURBANCE INVOLVING SIX-CARBON SUGARS

## 2. FRUCTOSURIA

Essential fructosuria is an extremely rare error of metabolism characterized by a congenital inability to utilize fructose completely. The first cases were probably described by Zimier and Czapek in 1876.

**CLINICAL FEATURES**—Individuals who excrete fructose in their urine show no clinical symptoms, and the condition is completely harmless. It is only important as a differential for diabetes mellitus, and most cases are discovered by life insurance examiners.

**HEREDITY**—Fructosuria is transmitted by an autosomal recessive gene. The condition usually occurs among siblings and is not found in parents or other relatives. The heterozygous carrier for the abnormality has not yet been detected. Lasker has estimated that fructosuria occurs only once in every 120,000 births.

**PATHOGENESIS**—The exact pathogenesis of fructosuria is not known at the present time. Hers has recently outlined the major metabolic pathway for fructose in the liver, as shown in Figure 28. (1) Fructose is converted to fructose 1- $\text{PO}_4$  by the action of ATP in the presence of the enzyme "fructokinase." (2) Fructose 1- $\text{PO}_4$  cleaves to form two three-carbon fragments—glyceraldehyde phosphate and dihydroxyacetone phosphate—in the presence of the enzyme "aldolase." (3) Glyceraldehyde is phosphorylated by ATP in the presence of the enzyme "triose kinase." (4) Glyceraldehyde phosphate and dihydroxyacetone phosphate are also interconvertible in the presence of the enzyme "triosephosphate isomerase." (5) The glyceraldehyde phosphate is subsequently converted to 1,3 diphosphoglyceric acid by the enzyme "phosphoglyceraldehyde dehydrogenase" and is subsequently converted to pyruvic and lactic acid in the usual way. (6) The two isomeric triose phosphates, dihydroxyacetone phosphate and glyceraldehyde phosphate, can be reconverted to fructose-1,6-diphosphate in the presence of aldolase. (7) Fructose 1,6-diphosphate is converted to fructose 6- $\text{PO}_4$  and ATP in the presence of the enzyme "hexose diphosphatase." (8) Finally, fructose-6  $\text{PO}_4$  is converted to glucose-6  $\text{PO}_4$  by the enzyme "phosphohexose isomerase."

In addition to the above pathway, fructose is undoubtedly utilized in two other ways: (a) in the brain and muscle, fructose is converted directly to fructose 6- $\text{PO}_4$  in the presence of hexokinase and ATP, and (b) fructose-1  $\text{PO}_4$  can also be phosphorylated in position 6 to fructose-1,6-diphosphate.

In the normal individual, when fructose is ingested there is a rapid





FIG 28—Postulated metabolic pathway for fructose

rise of the respiratory quotient and an elevation of lactic acid in the blood. Patients with fructosuria do not show this characteristic response (Chart 25), which would suggest that the metabolic defect in the liver in fructosuria must occur in the first three steps of fructose metabolism since a block beyond glyceraldehyde phosphate would not result in a disturbance of lactic acid metabolism.


Recently, Froesch and his associates have reported on a family of fructosurics presenting an, as yet unknown, inborn error of fructose me-

tabolism, distinguished from the so-called "essential fructosuria" by the occurrence of severe symptoms upon ingestion of fructose. The mode of inheritance of this disorder seems to be of the autosomal recessive type. The administration of fructose leads to an excessive and prolonged rise of

CHART 25  
FRUCTOSURIA



(Lusk 1941)



the fructose concentration in the blood, 10% of the ingested fructose is excreted in the urine, and, simultaneously with the rise in blood fructose, the blood glucose falls to levels as low as 10 mg/100 ml. This severe hypoglycemia lasts for several hours and is accompanied by nausea, hemorrhagic vomiting, trembling, profuse sweating, and somnolence. After cessation of the acute symptoms a slight and transient icterus, albuminuria, and aminoaciduria are observed. An allergy toward fructose can be excluded as a cause of this disorder, which seems likely to be due to a congenital lack of an enzyme responsible for one of the steps of fructose metabolism by the fructose-1- $\text{PO}_4$ -triose pathway. The red

cells of these patients respire normally with fructose as a substrate, meaning that the hexokinase system functions normally. Instead, it is believed that the accumulation of fructose-1-PO<sub>4</sub> leads to a block of gluconeogenesis by inhibiting the aldolase which splits fructose-1,6 phosphate.

**DIAGNOSIS**—Fructosuria can be diagnosed by the presence of fructose in the urine (see Procedure 32) and a delayed fructose tolerance test (see Procedure 33).

**TREATMENT**—None is required.

Froesch E R, Prader, A, Labhart, A, Stuber, H W, and Wolf H P. Die hereditäre Fructose Intoleranz, eine bisher nicht bekannte kongenitale Stoffwechselstörung. *Schweiz Med* 87 1168 1957.

Hers H G. The conversion of fructose 1 C<sup>14</sup> and sorbitol 1 C<sup>14</sup> to liver and muscle glycogen in the rat, *J Biol Chem* 214 373, 1955.

Lasker M. Essential fructosuria, *Human Biol* 13 51 1941.

Renold A E, and Thorn, G W. Editorial. Clinical usefulness of fructose. *Am J Med* 19 163, 1955.

### 3. GALACTOSEMIA

Galactosemia is a hereditary condition characterized by an inability to convert galactose to glucose in a normal manner. The disease was first described by von Reuss, a German physician, in 1908.

**CLINICAL FEATURES**—Infants with this condition appear to be normal at birth, but after a few days of milk feeding, they begin to vomit, become lethargic, fail to gain weight, and show enlargement of the liver. Prolonged jaundice during the neonatal period is a common finding. As cures and edema may develop (Fig 29), and in severe cases death occurs owing to malnutrition and wasting. Those who survive are usually malnourished and dwarfed at 2 or 3 months of age, and mental retardation and cataracts may be discerned. Others may develop cirrhosis of the liver months or years after the acute phase of the disease. In all instances, the signs and symptoms regress after the deletion of milk and milk products from the diet. Laboratory studies reveal the constant presence of a reducing substance in the urine which is not glucose. An excessive excretion of amino acids in the urine is also a common finding.

**HEREDITY**—Galactosemia is transmitted as an autosomal recessive. The defect has been noted among siblings in about half of the families reported, and it would be expected to occur in 1 out of 4 births in such families in a normal distribution. The heterozygous carrier of the abnormal gene can be detected by means of galactose tolerance tests. Recently, we have also found a decrease of P-gal-uridyl transferase among parents of such children.

The incidence of the condition in the population is not known. Galac

tosemia is probably quite rare, only about 75 cases have been reported from all over the world

**PATHOGENESIS**—LeLoir and his co-workers have shown that galactose is converted to glucose in a series of four separate steps, as shown in Figure 30A. Each step is catalyzed by a specific enzyme (in capital letters in the chart)

The site of the metabolic defect in galactosemia was found by two ingenious experiments. In 1955, Schwarz and his associates in Manches-



FIG. 29—Infant with galactosemia. Note the massive hepatomegaly and abdominal distention.

ter, England, showed that when milk was given to a galactosemic child there was an abnormal accumulation of galactose-1- $\text{PO}_4$  in the red cells, while this metabolite was not found in normal children. This meant that the block must have occurred somewhere beyond galactose-1  $\text{PO}_4$  and that galactokinase, the enzyme needed for the first reaction, was present in adequate amounts. In 1956, Kalckar and his co-workers in the United States demonstrated that uridine diphosphogalactose-4-epimerase and uridine diphosphoglucose pyrophosphorylase, the enzymes needed for the third and fourth steps, were present in normal amounts in the erythrocytes of galactosemic children. However, P-gal-uridyl-transferase, the enzyme needed for the second step, was barely detectable in 10 such children. They therefore concluded that galactosemia occurs as a result of an enzyme deficiency which causes a metabolic block in step 2 and that all other pathways of metabolism in such patients are normal and intact.




FIG 30A—Normal pathway of galactose metabolism in erythrocytes. The enzymes for each step are denoted by capital letters. The metabolic block in galactosemia is marked by an X.



FIG 30B—Alternate pathway of galactose metabolism in the liver.

CHART 26  
GALACTOSEMIA



(Hazel B. Kermack 1953)

P GAL URIDYL  
TRANSFERASE



Accumulation of Galactose-1- $PO_4$  (in erythrocytes)

Accumulation of Galactose in blood

Accumulation of  
Galactose in tissues

Galactose  
in  
urine

Decrease of  
Glucose in blood

Cirrhosis · Kidney · Cataracts

Convulsions

Amino-aciduria

Mental deficiency

The pedigree of causes of galactosemia is shown in Chart 26. The decrease or absence of P gal-undyl-transferase results in the accumulation of galactose-1- $PO_4$  in the red cells, and this in turn is responsible for the accumulation of galactose in the blood. The excessive galactose can have three types of effects: (1) Galactose and galactose-1- $PO_4$  can accumulate in the tissues, and over a period of time are probably responsible for cirrhosis of the liver, cataracts, and renal changes which are also responsible for aminoaciduria. (2) Galactose can be excreted in the urine (easily detectable as a reducing substance). (3) Galactose depresses the



blood glucose level, and this in turn may cause convulsions and mental retardation

**DIAGNOSIS**—Galactosemia can be diagnosed by the presence of galactose in the urine (see Procedure 34) and by the excessively high galactose levels in the blood (Fig 31) (see Procedure 35)

**TREATMENT**—Withholding all milk and milk products will clear up all acute symptoms, and no long term effects will result if the lactose or




FIG 31—Galactose tolerance curve of patient with galactosemia. The continued elevation of the galactose levels is characteristic (From Hsia Hs a Green Kay and Gellis 1954)

galactose is withdrawn from the diet in the first few weeks of life. No tramugen® or protein hydrolysates can be substituted satisfactorily for milk.

As the child gets older, small amounts of milk products can be tolerated without any ill effects. Presumably, this occurs because an accessory pathway of galactose metabolism is present in the liver which can convert small amounts of galactose to glucose (Fig 30B).

Holzel A and Komrower G M. A study of the genetics of galactosemia. Arch Dis Childhood 30:155 1955


- Hsia, H Y Y, Hsia, H H; Green, S, Kay, M., and Gellis, S ■ Amino-aciduria in galactosemia, *AMA Am J Dis Child* 88 458, 1954
- Hsia H Y Y, Huang, J., and Driscoll, S G The heterozygous carrier in galactosemia, *Nature* 16 1389, 1958
- Kalckar, H M, Anderson E P, and Isselbacher, K J Galactosemia, a congenital defect in a nucleotide transferase, *Biochim et biophys acta* 20 262, 1956
- \*Komrower, G M, Schwarz, V; Holzel, A, and Golberg L A clinical and biochemical study of galactosemia *Arch Dis Childhood* 31 254, 1956
- LeLoir, L F The metabolism of hexose phosphates, in McElroy W D, and Glass, H B (eds) *Phosphorus Metabolism* (Baltimore Johns Hopkins Press 1951), p 67
- Schwarz, V, Golberg, L, Komrower, G M, and Holzel, A Some disturbances of erythrocyte metabolism in galactosemia, *Biochem J* 62 34, 1956

### GLYCOGEN STORAGE DISEASE

'Glycogen storage disease' is an over-all term applied to a group of congenital and familial disorders characterized by the deposition of abnormally large quantities of glycogen in the tissues. At least three of the several types of the disease represent metabolic blocks in the normal pathway of glycogen metabolism (see Fig 32). Glucose is converted to glycogen by three separate steps (1) Glucose reacts with ATP to form glucose-6-PO<sub>4</sub> and ADP. This reaction is catalyzed by the enzyme "hexokinase" (2) Glucose-6-PO<sub>4</sub> is then converted to glucose-1-PO<sub>4</sub> in the presence of the enzyme "phosphoglucomutase." (3) Glucose-1-PO<sub>4</sub> is then converted to glycogen by the action of two separate enzymes. Phosphorylase acts to remove the phosphate group from glucose-1-PO<sub>4</sub> and attaches the bared first carbon atom to the fourth carbon atom of a glucose residue on the glycogen nidus. This addition occurs on the nonreducing end of the molecule. In this way, successively longer 1,4-glucose chains are added. When the chain has been lengthened to a critical level of eight glucose residues, the molecule becomes the substrate for the second enzyme, brancher enzyme amylo-(1,4- to 1,6)-transglucosidase. The enzyme transfers the  $\alpha$ -1,4-linkage to an  $\alpha$ -1,6-linkage, thus establishing a branch point of the molecule. The absence of this branching enzyme appears to be responsible for the glycogen storage disease characterized by *diffuse glycogenosis with hepatic cirrhosis* (Type III).

Glycogen is also converted back to glucose by three separate steps. (4) Glycogen is converted to glucose-1-PO<sub>4</sub> by the action of two enzymes. Phosphorylase first acts to remove the 1,4-linked glucose residues from the outermost tier and converts these to glucose-1-PO<sub>4</sub> and leaves the 1,6-links. The debrancher enzyme (amylo-1,6-glucosidase) causes hydrolytic cleavage of the 1,6-linkage and liberates glucose. The absence of this debrancher enzyme appears to be responsible for *glycogen*

storage disease of the liver and muscle (Type IV) (5) The glucose 1- $\text{PO}_4$  is then converted to glucose 6- $\text{PO}_4$  by the enzyme action of phosphoglucomutase. (6) Finally, the glucose-6- $\text{PO}_4$  is transformed to glucose by the enzyme glucose-6-phosphatase. An absence of this en-



1-4 - A Hinc

is responsible for *von Gierke's disease* (Type I, glycogen storage disease of the liver and kidneys)

\*Cori G T Glycogen structure and enzyme deficiencies in glycogen storage disease Harvey Lect. 48 145 1953

\*Recant L Recent developments in the field of glycogen metabolism and diseases of glycogen storage Am J Med 19 610 1955

#### 4 TYPE I GLYCOGEN STORAGE DISEASE OF THE LIVER AND KIDNEYS (von Gierke's disease)

In 1928, van Crevald and von Gierke independently reported on a condition characterized by excessive enlargement of the liver and of other organs during early infancy, owing to the accumulation of glycogen. It has since been found to be a hereditary disease resulting from an inborn error of glycogen metabolism.

**CLINICAL FEATURES**—The condition is usually diagnosed during the first year of life because of asymptomatic liver enlargement. Initially, the infant appears to be completely well but it may develop anorexia, weight loss, and vomiting, and in the later stages hypoglycemia, convulsions, and coma. Since it is essential to differentiate this form of glycogen storage disease from the other types, Holt has recommended that, to establish the diagnosis, these five criteria be met: (1) marked enlargement of the liver; (2) rapid development of hypoglycemia and ketosis when food is




FIG. 33.—Photomicrograph of section from liver of a patient with glycogen storage disease of liver and kidney (Type I). The hepatic cells show clear cytoplasm and small nuclei; there is also a suggestion of fine cytoplasmic granules. These cells contain abundant stored glycogen which is unstained, producing the clear swollen appearance.

withheld; (3) subnormal or absent response of the blood sugar to an injection of epinephrine; (4) glycogen content of the liver representing 12–16% of the wet weight and no marked increase in fat (Fig. 33); and (5) an abnormal stability of the liver glycogen both *in vitro* and after death.

It is interesting to note that despite the low blood sugar levels and failure to respond to epinephrine, infants with this disease seldom show symptoms of hypoglycemia. However, they do show a low resistance to infection, and some retardation of growth and development is a frequent finding. In most cases, death ensues in the first two years of life, but an occasional patient may reach adult life and do moderately well.

**HEREDITY**—The incidence of glycogen storage disease of the liver in the population is not known. The condition appears to be transmitted as a simple autosomal recessive. Many of the reported cases are among siblings, and consanguinity is not an unusual finding. The heterozygous carrier of the abnormal gene can be detected by elevated glucose 6  $\text{PO}_4$  and fructose 6  $\text{PO}_4$  levels in the red cells.


**PATHOGENESIS**—Since the condition represents an inborn error of converting glycogen back to glucose, it appears improbable that the defect represents a block in steps 1, 2, and 3 (see p 137). Also step 5 can be excluded because it is merely a reverse reaction of step 2. In 1952, Cori and Cori showed that von Gierke's disease represents a block in step 6. First they showed that the structure of glycogen in the liver of these patients did not differ from that of normal individuals. Then they demonstrated that glucose 6 phosphatase either was absent or was present in greatly reduced amounts in every sample of liver from patients tested. Recently this has also been indirectly confirmed by the studies of Schwartz and his co-workers. They found that although such infants show a normal response to intravenous galactose tolerance tests, the galactose is not converted to glucose, as in the normal infant, but is excreted as lactic acid, indicating an inability to convert glucose 6  $\text{PO}_4$  to glucose.

The pedigree of causes for glycogen storage disease of the liver is shown in Chart 27. The absence of glucose 6 phosphatase is responsible for at least three major effects. By depriving the patient of readily accessible sources of glucose, hypoglycemia is likely to ensue. This in turn causes ketosis, convulsions, increased gluconeogenesis from proteins, starvation diabetes, and a poor response to glucose tolerance tests. The absence of glucose 6 phosphatase also deprives the patient of a proper response to epinephrine injections. Finally, the absence of this enzyme causes the body organs to be loaded with glycogen. This in turn is responsible for obesity, impaired liver function, and poor resistance to infection.

**DIAGNOSIS**—Von Gierke's disease should be seriously considered when a patient shows a poor response to epinephrine (see Procedure 36) and a flat glucose tolerance curve. The final diagnosis can only be established by the absence of glucose 6 phosphatase in the liver (see Procedure 37), obtained either by biopsy or at autopsy.

**TREATMENT**—Frequent feedings and a high protein diet are believed to be useful in reducing the rate of glycogen deposition, but the results of such therapy have not been impressive. ACTH or cortisone

## CHART 27

GLYCOGEN STORAGE DISEASE OF LIVER & KIDNEYS  
(TYPE I)

may be of value in controlling the hypoglycemia episodes. Sodium lactate is given for the acidosis, which can be quite marked.

Bridge, E. M. and Holt, L. E., Jr. Glycogen storage disease. Observations on pathologic physiology of two cases of hepatic form of disease, *J Pediatr* 27: 299, 1945.

Cori G. T. and Cori C. F. Glucose 6-phosphatase of the liver in glycogen storage disease, *J Biol Chem* 199: 661, 1952.

Hsia, D. Y. Y., and Kot. Detection of the heterozygous carrier in von Gierke's disease. *Nature* 183: 1331, 1959.

Holmstrom. A. Ziegler, M., Doeden, D., and McQuarrie, I. J. Metabolic and

clinical effects of ACTH on essential glycogenesis *Metabolism* 1 197 1952  
 Mason, H. H., and Andersen, H. H. Glycogen disease *Am J Dis Child*  
 61 795, 1941

Schwartz, R., Ashmore, J., and Renold, A. E. Galactose tolerance in glycogen storage disease *Pediatrics* 19 585 1957

## 5 TYPE II GLYCOGEN STORAGE DISEASE OF THE HEART

In 1950, di Sant'Agnese and his associates showed that glycogen storage disease of the heart should be regarded as a clinical entity separate from other forms of glycogen storage disease

**CLINICAL FEATURES**—The condition becomes manifest in early infancy. The infants feed poorly, become listless, and fail to gain weight.




FIG. 34.—Glycogen storage disease of the heart. The weight of the organ is six times the normal weight owing to marked myocardial glycogen deposition.


properly. This is followed by episodes of intermittent cyanosis, especially during feeding and attacks of dyspnea without specific cause. Many parents report 'excessively rapid breathing' as the reason for their bringing the baby to the doctor. All infants suffering from this disease die of heart failure, and in some instances bronchopneumonia, during the first 2 years of life.

The heart is usually enlarged, and systolic murmurs are sometimes heard. An x-ray examination shows the cardiac silhouette to be globular, and an electrocardiogram reveals inverted T waves, left-axis deviation and ST depression with a normal PR interval. At autopsy the heart is


found to weigh from 2 to 5.6 times the normal weight for the age (Fig 34). Histologically, there is noted massive infiltration of the cardiac fibers by glycogen, and microscopically, a distinctive lacework appearance of the myocardium. Similar depositions are noted in the skeletal muscle, smooth muscle, and other organs of the body.

**HEREDITY**—The condition is probably transmitted as a rare recessive. The condition is known to occur among siblings, and in one instance

CHART 28

GLYCOGEN STORAGE DISEASE OF HEART (TYPE II)

(D. Sant Agnese et al., 1950)



the parents were first cousins. The heterozygous carrier for this abnormality has not been detected.

**PATHOGENESIS**—The etiology of this condition is completely unknown (Chart 28). The Coris have found that both the structure of the glycogen and the glucose 6 phosphatase activity of the liver and kidney are within normal limits. However, the possibility of a metabolic block in some other stage of glucose metabolism has not been completely ruled out. For instance, a reduction of phosphohexoisomerase or phosphofructokinase content might lead to a moderate decrease in the rate of glycogen



breakdown With a normal rate of glycogen synthesis, this could lead to storage of glycogen The predilection of glycogen for the heart and muscles also remains to be explained

**DIAGNOSIS**—Glycogen storage disease of the heart is suggested by cardiac enlargement or electrocardiographic changes during life At post mortem the deposition of glycogen in the muscle fibers of the heart is found to be typical

**TREATMENT**—None is available

Cori G T Glycogen structure and enzyme deficiencies in glycogen storage disease Harvey Lect 48 145, 1953

\*Di Sant'Agnese P A Andersen D H Mason H H and Bauman W A Glycogen storage disease of the heart I Report of 2 cases in siblings with chemical and pathologic studies *Pediatrics* 6 402 1950

———, and ——— Glycogen storage disease of the heart II Critical review of the literature *Pediatrics* 6 607, 1950

## 6 TYPE III DIFFUSE GLYCOGENOSIS WITH HEPATIC CIRRHOSIS

In 1952, Andersen reported on a 17 month-old white male infant whose liver showed glycogen which on analysis was less branched and had longer inner and outer branches than normal


**CLINICAL FEATURES**—This form of glycogen storage disease becomes manifest in late infancy or early childhood The complaints are primarily hepatic, with such features as edema, ascites, and occasional bleeding tendencies being prominent Liver function tests are usually abnormal, but blood sugar is normal and no acidosis is present When the glucose tolerance test is performed a moderate rise and a slow fall of the blood sugar is observed The response to epinephrine is moderate, but less than in normal individuals The clinical course appears to be highly variable, and children with this condition may survive up to 10 years of age

At postmortem, the liver is found to have a finely nodular surface Microscopic examination shows a diffuse, finely nodular cirrhosis with large amounts of glycogen in the liver cells In the spleen there are accumulations of what appear to be reticulum cells loaded with glycogen Phagocytic cells loaded with glycogen are also found in the lymph nodes and lymph follicles and in the intestinal mucosa No glycogen appears to be present in the kidneys The glycogen has been observed to be different in physical characteristics from that of von Gierke's disease, being sticky hard to handle, and slow to precipitate

**HEREDITY**—Although the sibling of the first described case also died of glycogen storage disease, the diagnosis of Type III diffuse glycogenosis was not confirmed biochemically

**PATHOGENESIS**—Illingworth and Cori have studied the character of glycogen in the liver from a patient with this condition. End group analysis showed branch points of 4.7% (normal, 7.1-8.4%), and the average chain length was 21.2 (normal, 11.9-14.1). The average outer

CHART 29  
DIFFUS GLYCOGENOSIS WITH HEPATIC CIRRHOSIS



chain length had 14.7 residues (normal, 7.1-8.9), and the inner chain length had 6.5 residues (normal, 3.0-5.6). Thus there were fewer branch points and significantly longer chains. It would appear that this form of glycogen storage disease is caused by a deficiency of brancher enzyme amylo-(1,4 to 1,6)-transglucosidase."

The pedigree of causes for this condition is given in Chart 29. The

deficiency of the brancher enzyme causes an accumulation of glycogen in the liver. Over a length of time the glycogen behaves as a foreign body, to which there is a tissue reaction. This causes cirrhosis of the liver, and all the ultimate complications of this disease can be attributed to liver damage.

**DIAGNOSIS** — Demonstration of the glycogen abnormality (see Procedure 38) by liver biopsy will confirm the diagnosis.

**TREATMENT** — None is available.

\*Andersen, D. H. Studies on glycogen disease with a report of a case in which the glycogen was abnormal, in Najjar, V. A. (ed.) *Symposium on the Clinical and Biochemical Aspects of Carbohydrate Utilization in Health and Disease* (Baltimore: Johns Hopkins Press, 1952).

——— Familial cirrhosis of the liver with storage of abnormal glycogen. *Lab Invest* 5:11, 1956.

Illingworth, B., and Cori, G. T. Structure of glycogens and amylopectins. III. Normal and abnormal human glycogens. *J Biol Chem* 199:633, 1952.

## 7 TYPE IV, GLYCOGEN STORAGE DISEASE OF LIVER AND MUSCLE

In 1953, Forbes reported on a fourth type of glycogen storage disease of the liver which was apparently caused by a deficiency of debrancher enzyme. In the same year, Krivit and his co-workers described a similar deficiency but with glycogen storage primarily in the skeletal muscle. It would appear that these two conditions represent different manifestations of the same basic defect and that they should be considered together.

### TYPE IVa, GLYCOGEN STORAGE DISEASE OF LIVER

**CLINICAL FEATURES** — The child described by Forbes was essentially well until age 12, when she was noted to have progressive hepatomegaly. Liver function tests showed a positive cephalin flocculation test and brom sulfalein retention. There was slightly less response to epinephrine than normal. A moderate amount of acetone was detected in the urine. Otherwise, the child was perfectly well, and she did not appear to be incapacitated by the defect.


Liver biopsy showed the parenchymal cells to be packed with glycogen, and a slight increase of connective tissue was noted in the perportal spaces. Both muscle and liver biopsies, however, showed increased amounts of glycogen.

**HEREDITY** — The mode of transmission of this condition is not known. None of the siblings or near relatives of this patient were affected.

**PATHOGENESIS** — Illingworth and Cori characterized the glycogen in

this patient (see Procedure 38) End group analysis revealed branch points of 10.8% for liver and 13.1% for muscle (normal, 7.1-8.4%), and the over-all chain length was 9.3 for liver and 7.6 for muscle (normal, 7.1-8.4). Degradation by phosphorylase was 12.2% for liver and 2.6% for muscle (normal, 25-41%). The average outer chain length had 5.1

### CHART 30 GLYCOGEN STORAGE IN LIVER (TYPE IVa)



residues for liver and 4.0 for muscle (normal, 7.1-8.9), and the inner chain length, 4.2 for liver and 3.6 for muscle (normal, 3.0-5.6). This indicates that the glycogen had an enormous number of branches and very short outer chains and suggests that there is a deficiency of the debrancher enzyme (see Procedure 38) (amylo-1,6-glucosidase) in step 4 of the glycogen pathway (Chart 30).


### TYPE IVb, GLYCOGEN STORAGE DISEASE OF SKELETAL MUSCLE

**CLINICAL FEATURES**—A number of cases of glycogen storage disease of skeletal muscle have been reported. The condition resembles Werdnig-Hoffmann disease clinically, with progressive weakness, difficulty in swallowing, and regurgitation of food. Also, there is macroglossia, car-


diomegalia, and hepatomegalia. Laboratory studies show a normal response to glucose tolerance tests and to epinephrine. However, histochemically the muscles are found to be loaded with glycogen. Autoglycogenesis occurs to a degree but is less than in normal tissues.

**HEREDITY**—The condition appears to be genetically determined.

CHART 31

GLYCOGEN STORAGE IN MUSCLE (TYPE IVB)

AMYLO 1 6 GLUCOSIDASE  
(DEBRANCHER ENZYME)



Consanguinity has been found in one instance, and several siblings in other families have been found to have the same disease. This suggests that the disease is inherited as a rare recessive.

**PATHOGENESIS**—The molecular structure of the glycogen in muscle has been studied in one case. An excessive number of branched linkage were found in the glycogen molecule, with a shorter than average chain length. Since this is similar to the changes in glycogen storage of the

liver (Type IVa), it would appear that this condition should be regarded as a variant of the deficiency of the debrancher enzyme (Chart 31).

Forbes, G ■ Glycogen storage disease, *J Pediat* 42 645, 1953

Illingworth, B, and Cori, G T Structures of glycogen and amylopectins III Normal and abnormal human glycogen, *J Biol Chem* 199 653, 1952

Krivit, W, Polglase, W J, Gunn, P D, and Tyler F H Studies in disorders of muscle IX Glycogen storage disease primarily affecting skeletal muscle and clinically resembling amyotonia congenita, *Pediatrics* 12 165, 1953

## OTHER CARBOHYDRATE DISTURBANCES

### 8 HEREDITARY SPHEROCYTOSIS

Hereditary spherocytosis is a congenital hemolytic disorder characterized by the presence of spherocytes in the peripheral blood. The condition was first accurately described by Valair and Masius in 1871, but the merit of their observations was not appreciated until recent times. The disorder is believed to be due to a derangement in the energy-yielding reactions of glycolysis within the membranes of the erythrocytes.

**CLINICAL FEATURES**—Patients with hereditary spherocytosis have a mild degree of anemia. The degree varies from patient to patient, but the anemia is rarely severe. This is because a balance seems to occur between the rate of red cell production and destruction, the hemoglobin and hematocrit values show little variation. The slight increase of red cell breakdown is characterized by an increase of indirect bilirubin in the serum, increased excretion of urobilinogen in the stools, and mild to moderate reticulocytosis. Cholecystitis and cholelithiasis are frequent complications. Some of the children show physical retardation but all show marked improvement following splenectomy.

From time to time, the patients develop a sudden crisis. This is characterized by malaise, anorexia, and mild fever in association with bouts of jaundice. There is a sudden destruction of the circulating erythrocytes, and also a decrease of erythropoiesis with maturation arrest in the bone marrow. The cause for these crises is not well understood, but they are frequently associated with infections.

Laboratory studies show increased osmotic fragility of the red cells. The fragility is increased because the spherocytes can absorb less water from hypotonic media than do normal cells. Similarly, erythrocytes from patients with hereditary spherocytosis show a markedly increased mechanical fragility. In 1941, Dacie reported that in hereditary spherocytosis such cells underwent lysis 5-10 times as rapidly as normal cells when incubated at body temperature for 48 hours. These cells take in sodium


at about the same rate as do normal cells, but they lose potassium slightly more rapidly than do normal cells. The rate of cell destruction is slowed down if glucose is added to the defibrinated blood so that its concentration is approximately 500 mg/100 ml. Since cells from patients break down more easily after incubation at body temperature, this approach is frequently used to demonstrate increased osmotic or mechanical fragility in patients who show no abnormalities when the tests are done on fresh blood.

**HEREDITY**—Hereditary spherocytosis is transmitted as an autosomal dominant characteristic, with most of the affected individuals being heterozygotes. It is not clear at present whether the dominance is complete since there are fewer affected siblings than one would expect on a purely mathematical basis. Also, Young has encountered five patients whose parents on repeated testing showed no demonstrable hematologic abnormalities. Although these patients could represent fresh mutations it is possible that the condition did not manifest itself in these parents. The homozygous form of spherocytosis has not yet been demonstrated with certainty, although its occurrence has been suspected in two families.


Hereditary spherocytosis occurs once in about 20 000 live births.

**PATHOGENESIS**—Pranker and associates have demonstrated that in hereditary spherocytosis there is a defect in intracellular glycolysis involving a smaller flux of  $P^{32}$  into ATP and 2,3 diphosphoglycerate with a concurrent increase in the flux into orthophosphate. The turnover of  $P^3$  into ATP and 2,3 diphosphoglycerate in the stromal fraction tends to be lower than normal. These changes can largely be restored to normal upon incubation of the cells with adenosine. Although the actual enzyme defect has yet to be described, Altman and Young have presented some preliminary findings suggesting that it may involve a disturbance of enolase, the enzyme which converts 2 phosphoglycerate to phosphoenolpyruvate. They have suggested that the maintenance of the biconcave shape of the normal erythrocyte requires an adequate availability of energy rich phosphate bonds. Such bonds are apparently lacking in the erythrocytes of patients with hereditary spherocytosis, because these erythrocytes show a greater susceptibility to destruction and lysis upon the depletion of glucose or any of the metabolites necessary for energy production in vitro. The addition of adenosine in some way replaces this deficit, at least in part. Splenectomy improves the clinical picture and one can therefore assume that passage of the blood cells through the spleen is in many ways similar to incubating the blood in vitro. Presumably, in patients with hereditary spherocytosis, the stagnation and

## CHART 32

HEREDITARY SPHEROCYTOSIS

? DEFECT IN INTRACELLULAR GLYCOLYSIS



hemoconcentration in the spleen results in the erythrocytes being deprived of glucose and other energy-producing metabolites and the cells break down from "relative starvation". Splenectomy effectively removes this difficulty without fundamentally correcting the defect itself.

All of the signs and symptoms in hereditary spherocytosis can be attributed to the increased destruction of erythrocytes, as shown in Chart 32. The biochemical disturbances, such as the low potassium content found in these cells, the deficiency in phospholipids with an excess of



cholesterol, and the increased transport of sodium across the cell membranes, must be regarded as secondary manifestations of the basic defect in glycolysis

**DIAGNOSIS**—The spherocytosis of the peripheral blood is characteristic. Also, the diagnosis is suggested by changes in the osmotic fragility (see Procedures 39 and 41) and the mechanical fragility (Procedures 40 and 41) of the erythrocytes

**TREATMENT**—Splenectomy after the age of 2 years effectively removes all of the complications of this defect and should be performed on every patient with hereditary spherocytosis. The operation should not be done in infancy because of the danger of recurrent infections, which have been reported.

\*Dacie J V *The Haemolytic Anemias Congenital and Acquired* (London J & A Churchill Ltd 1954)

Morulsky A G, Giblett, E., Colman D, Gabrio B W and Finch C A Life span glucose metabolism and osmotic fragility of erythrocytes in hereditary spherocytosis *J Clin Invest* 34 911, 1955

Prankerd T A J, Altman K I, and Young L E Abnormalities of carbohydrate metabolism of red cells in hereditary spherocytosis *J Clin Invest* 34 1268 1955

Race R R On the inheritance and linkage relations of acholuric jaundice *Ann Eugenics* 11 365 1942

Selwyn J G and Dacie J V Autohemolysis and other changes resulting from the incubation in vitro of red cells from patients with congenital hemolytic anemia *Blood* 9 414 1954

Tabechian H, Altman, K I and Young L E Inhibition of  $P^{32}$ -orthophosphate exchange by sodium fluoride in erythrocytes from patients with hereditary spherocytosis *Proc Soc Exper Biol & Med* 92 712 1956

\*Young L E Hereditary spherocytosis *Am J Med* 18 486, 1955

———, Izzo M J, and Platzer, R F Hereditary spherocytosis 1 Clinical hematologic and genetic features in 28 cases, with particular reference to the osmotic and mechanical fragility of incubated erythrocytes *Blood* 6 1073, 1951

## 9. HEREDITARY NONSPHEROCYTIC HEMOLYTIC ANEMIA


Hereditary nonspherocytic hemolytic anemia is characterized by macrocytosis, basophilic stippling, hepatosplenomegaly, and jaundice. In recent years hematologists have been able to differentiate this disease from thalassemia, hereditary spherocytosis, hemolytic processes associated with the abnormal hemoglobins, and erythroblastosis fetalis by the distinctive laboratory findings

**CLINICAL FEATURES**—Patients with this disease usually come to the attention of physicians because of jaundice and anemia. In the very young age group, the condition is frequently mistaken for erythroblastosis fetalis, except that no blood-group incompatibility can be found and the reaction

to the Coombs test is negative. In older people, there may be a history of intermittent jaundice, weakness, malaise, or right upper quadrant pain, sometimes accompanied by liver or splenic enlargement.

A study of the peripheral blood will reveal a moderate decrease of hemoglobin and red-cell count. Smears of the peripheral blood will show

CHART 33

HEREDITARY NONSPHEROCYTIC HEMOLYTIC ANEMIA

normal rouleaux formation, and there is no stippling, sickling, fragmentation, or other morphological changes. A mild anisocytosis and poikilocytosis is seen in all cases, however, careful studies will reveal all of the signs of a hemolytic process. There is a hyperplasia of the erythroid series in the bone marrow, reticulocytosis, hyperbilirubinemia, increased urobilinogen in the stools, and a rapid turnover of tracer iron in the plasma (Chart 33). There is no marked change in osmotic or mechanical fragility.

of the erythrocytes, although they tend to be more fragile after incubation for 24 hours. Electrophoretic studies show that the predominant hemoglobin is Type A, with a slight increase of Hgb F.

Patients with hereditary nonspherocytic hemolytic anemia are not greatly handicapped by the disease and lead relatively normal lives.

**HEREDITY**—The condition has been reported in about a dozen families, it has been seen in both Europe and the United States. Undoubtedly many more affected persons exist but have not been reported because clinically they appear to be so similar to persons with other hematological conditions.

Although genetic studies in the reported families are, as yet, incomplete, the condition appears to be transmitted as an autosomal dominant. However, there seems to be a variable degree of penetrance, and expressivity is usually incomplete.

Several workers have suggested that this group of patients is not homogeneous. For instance, in some families autohemolysis is not increased, but the addition of glucose does not reduce the amount of hemolysis to the degree that it does in a normal control. In other families there is an increased degree of autohemolysis which is not prevented by the addition of glucose.

**PATHOGENESIS**—At the present time, at least two separate forms of hereditary nonspherocytic hemolytic anemia are known to exist. (1) In some patients there is a normal rate of glycolysis and  $P^{32}$ -orthophosphate exchange, but increased intracellular contents of 2,3-diphosphoglucose and (2) in others there is a low content of ATP, deficient glucose consumption, and decreased  $P^{32}$ -orthophosphate exchange. Further studies are needed to decide whether we are dealing with a single disease or with two or more separate diseases.

**DIAGNOSIS**—Hereditary nonspherocytic hemolytic anemia can be differentiated (1) from hereditary spherocytosis by the absence of spherocytes and essentially normal fragility tests, (2) from thalassemia by the clinical course, fetal hemoglobin content, and peripheral smear, (3) from the abnormal hemoglobins by electrophoretic and solubility studies, and (4) from erythroblastosis fetalis by blood grouping studies.

**TREATMENT**—None is required. Splenectomy is probably not helpful, and transfusions only serve to increase the degree of hemosiderosis.

Dacie J V, Mollison P L, Richardson N, Selwyn J G, and Shapiro L. Atypical congenital haemolytic anemia, *Quart. J. Med.* 22: 79, 1953.  
Kaplan E, and Zuelzer W W. Familial nonspherocytic hemolytic anemia. *Blood* 5: 811, 1950.

\*Motulsky, A G, Crosby W H, and Rappaport H. Hereditary nonspherocytic hemolytic disease. *Blood* 9: 749, 1954.

# DISTURBANCES IN CARBOHYDRATE METABOLISM 155

- Gibso B W Burkhardt J and Finch C A Erythrocyte carbohydrate metabolism in hereditary hemolytic anemias Am J Med 19 291 1955
- Frankel T A J Inborn errors of metabolism in red cells of congenital hemolytic anemias Am J Med 22 724 1957
- Smiley H K Denipsey H Villeneuve P and Campbell J S Atypical familial hemolytic anemia Blood 11 324 1956

of the erythrocytes, although they tend to be more fragile after incubation for 24 hours. Electrophoretic studies show that the predominant hemoglobin is Type A, with a slight increase of Hgb F.

Patients with hereditary nonspherocytic hemolytic anemia are not greatly handicapped by the disease and lead relatively normal lives.

**HEREDITY**—The condition has been reported in about a dozen families, it has been seen in both Europe and the United States. Undoubtedly, many more affected persons exist but have not been reported because clinically they appear to be so similar to persons with other hematological conditions.

Although genetic studies in the reported families are, as yet, incomplete, the condition appears to be transmitted as an autosomal dominant. However, there seems to be a variable degree of penetrance, and expressivity is usually incomplete.

Several workers have suggested that this group of patients is not homogeneous. For instance, in some families autohemolysis is not increased, but the addition of glucose does not reduce the amount of hemolysis to the degree that it does in a normal control. In other families there is an increased degree of autohemolysis which is not prevented by the addition of glucose.

**PATHOGENESIS**—At the present time, at least two separate forms of hereditary nonspherocytic hemolytic anemia are known to exist. (1) In some patients there is a normal rate of glycolysis and  $P^{32}$ -orthophosphate exchange, but increased intracellular contents of 2,3-diphosphoglucose and (2) in others there is a low content of ATP, deficient glucose consumption, and decreased  $P^{32}$ -orthophosphate exchange. Further studies are needed to decide whether we are dealing with a single disease or with two or more separate diseases.

**DIAGNOSIS**—Hereditary nonspherocytic hemolytic anemia can be differentiated (1) from hereditary spherocytosis by the absence of spherocytes and essentially normal fragility tests, (2) from thalassemia by the clinical course, fetal hemoglobin content, and peripheral smear, (3) from the abnormal hemoglobins by electrophoretic and solubility studies, and (4) from erythroblastosis fetalis by blood grouping studies.

**TREATMENT**—None is required. Splenectomy is probably not helpful, and transfusions only serve to increase the degree of hemosiderosis.

Dacie J V, Mellison P L, Richardson N, Selwyn J G, and Shapiro L. Atypical congenital haemolytic anemia, *Quart J Med* 22:79, 1953.

Kaplan E, and Zuelzer W W. Familial nonspherocytic hemolytic anemia, *Blood* 5:811, 1950.

\*Motulsky, A G, Crosby, W H, and Rappaport H. Hereditary nonspherocytic hemolytic disease, *Blood* 9:749, 1954.

- \_\_\_\_\_, Gibson II W, Burkhardt J and Furch C A. Erythrocyte carbohydrate metabolism in hereditary hemolytic anemias. *Am J Med* 19: 291 1955.
- Rankerd T A J. Inborn errors of metabolism in red cells of congenital hemolytic anemias. *Am J Med* 22: 724 1957.
- Wiley R K, Dempsey H, Villeneuve P and Campbell J S. Atypical familial hemolytic anemia. *Blood* 11: 324 1956.

of the erythrocytes although they tend to be more fragile after incubation for 24 hours. Electrophoretic studies show that the predominant hemoglobin is Type A with a slight increase of Hgb F.

Patients with hereditary nonspherocytic hemolytic anemia are not greatly handicapped by the disease and lead relatively normal lives.

**HEREDITY**—The condition has been reported in about a dozen families; it has been seen in both Europe and the United States. Undoubtedly many more affected persons exist but have not been reported because clinically they appear to be so similar to persons with other hematological conditions.

Although genetic studies in the reported families are as yet incomplete, the condition appears to be transmitted as an autosomal dominant. However, there seems to be a variable degree of penetrance and expressivity—usually incomplete.

Several workers have suggested that this group of patients is not homogeneous. For instance, in some families autohemolysis is not increased but the addition of glucose does not reduce the amount of hemolysis to the degree that it does in a normal control. In other families there is an increased degree of autohemolysis which is not prevented by the addition of glucose.

**PATHOGENESIS**—At the present time at least two separate forms of hereditary nonspherocytic hemolytic anemia are known to exist: (1) in some patients there is a normal rate of glycolysis and  $P^{32}$ -orthophosphate exchange but increased intracellular contents of 2,3 diphosphoglucose and (2) in others there is a low content of ATP, deficient glucose consumption and decreased  $P^{32}$ -orthophosphate exchange. Further studies are needed to decide whether we are dealing with a single disease or with two or more separate diseases.

**DIAGNOSIS**—Hereditary nonspherocytic hemolytic anemia can be differentiated: (1) from hereditary spherocytosis by the absence of spherocytes and essentially normal fragility tests; (2) from thalassemia by the clinical course, fetal hemoglobin content and peripheral smear; (3) from the abnormal hemoglobins by electrophoretic and solubility studies; and (4) from erythroblastosis fetalis by blood grouping studies.

**TREATMENT**—None is required. Splenectomy is probably not helpful and transfusions only serve to increase the degree of hemosiderosis.

Dacie J V, Mollison P L, Richardson N, Selwyn J G and Shapiro L. Atypical congenital haemolytic anemia. *Quart J Med* 22:79 1953.  
Kaplan E. and Zuelzer W W. Familial nonspherocytic hemolytic anemia. *Blood* 5:811 1950.

\*Motulsky A G, Crosby W H and Rappaport H. Hereditary nonspherocytic hemolytic disease. *Blood* 9:749 1954.




FIG 35—Biosynthetic pathway of thyroid hormone (postulated). A block at site I results in cretinism from failure of organic iodine to form at site II in cretinism from failure of iodotyrosines to couple, and at site III in cretinism from failure of iodotyrosine to deiodinate.

## 1. CRETINISM FROM FAILURE OF ORGANIC IODINE TO FORM

**CLINICAL FEATURES**—In 1950, Stanbury and Hedge reported on a 15-year-old girl who had both cretinism and goiter and who had lived on the seacoast of Massachusetts all of her life. In going over her history, they found that she had developed normally until about 6 months of age and thereafter had shown marked retardation. She had never walked, and she could not speak or feed herself at the time of the examination.

Signs of cretinism were noted at the age of 1 year. Skin was dry, cool, and coarse, with a spongy elasticity. The hair was slightly coarse. The bridge of the nose was depressed, and the lips were thick and protuberant.

At the age of 7 years she was noted to have a mass in the neck, which had slowly increased in size. Pathological examination of the gland showed intense compensatory hyperplasia, which was followed by degeneration and fibrous tissue replacement.

**HEREDITY**—In this girl's family, the first three children were nor-



## Disturbances in Endocrine Metabolism

**DISTURBANCES IN ENDOCRINE METABOLISM** may be divided into two groups thyroid and adrenal

### **FAMILIAL CRETINISM WITH GOITER**

The biosynthesis of thyroid hormone takes place through a series of separate steps (Fig 35) (1) Iodide and various forms of iodine enter the body through the intestinal tract and are distributed throughout the extracellular compartment of the body (2) Some of the iodide is excreted through the kidneys, but most of it is trapped within the thyroid gland and oxidized to elemental, or free, iodine. The trapping process requires oxygen and is undoubtedly enzymatically controlled. A defect in this step results in *cretinism from a failure of organic iodine to form* (3) The free iodine then reacts with tyrosyl residues to form moniodotyrosine and diiodotyrosine (4) Some of the iodinated tyrosyl residues condense to form iodinated thyronines—namely, thyroxine and triiodothyronine which are the active hormonal products of the thyroid gland. This coupling process is probably also enzymatically controlled. A defect in this step results in *cretinism from a failure of iodotyrosines to couple* (5) The remainder of the iodinated tyrosyl residues are dehalogenated by the enzyme “iodotyrosine deshalogenase” and returned to the thyroid iodide pool. This step is necessary for the proper conservation of iodine in the body. A defect in this system results in *cretinism from a failure of iodotyrosines to deiodinate*.


\*Stanbury, J. B. and McGarr, E. M. Sporadic or non-endemic familial cretinism with goiter, *Am J Med* 22:712, 1957

Since it is known that the latter drugs inhibit the transfer of iodide to tyrosyl residues through an enzymatically controlled oxidative step, one may assume that this form of cretinism with goiter represents a metabolic block at this step. As a result, the thyroid gland contains iodide but is unable to convert it to iodine.

This defect causes a complete deficiency of thyroid hormone pro-

CHART 34

CRETINISM FROM FAILURE OF ORGANIC  
IODINE TO FORM



duction. The gland tries to compensate for the deficiency by hypertrophy and hyperplasia, but this is largely unsuccessful and cretinism results (Chart 34).

**DIAGNOSIS**—The diagnosis of cretinism from failure of organic iodine in form is established by the uptake and release of  $I^{131}$  in the thyroid gland and the typical response to KSCN (see Procedure 42).

**TREATMENT**—Therapy with thyroid hormone early in life may help in preventing cretinism and mental retardation.

mal and the next four were all cretins. The parents were normal but were first cousins. In another family, 4 out of 13 children were found to be cretins. Since the condition affects individuals of both sexes, this would imply that the condition is transmitted as an autosomal recessive.

**PATHOGENESIS**—Stanbury showed that, when labeled iodine ( $I^{131}$ ) was given orally, a large fraction of it was accumulated rapidly in the thy-




FIG. 36—Radioactive iodine accumulation and discharge in a patient with cretinism from failure of organic iodine to form. At zero time a tracer dose of 100  $\mu$ c of  $I^{131}$  was given. The open circles are net counts per minute over the thyroid gland. When this of 2 Gm of potassium thiocyanate is labeled iodine from the gland. dy of a family of goitrous cretins.


roid gland. When this had reached a plateau in 4 hours, an oral dose of 2.0 Gm of KSCN caused a striking and rapid disappearance of the labeled iodine from the gland (Fig. 36). The same effect was not observed among controls.

The changes observed appeared to be identical with changes in patients who had received antithyroid drugs of the thiocarbamide group.

Since it is known that the latter drugs inhibit the transfer of iodide to tyrosyl residues through an enzymatically controlled oxidative step, one may assume that this form of cretinism with goiter represents a metabolic block at this step. As a result, the thyroid gland contains iodide but is unable to convert it to iodine.

This defect causes a complete deficiency of thyroid hormone pro-

CHART 34  
CRETINISM FROM FAILURE OF ORGANIC  
IODINE TO FORM



duction. The gland tries to compensate for the deficiency by hypertrophy and hyperplasia, but this is largely unsuccessful and cretinism results (Chart 34).

**DIAGNOSIS**—The diagnosis of cretinism from failure of organic iodine to form is established by the uptake and release of  $I^{131}$  in the thyroid gland and the typical response to KSCN (see Procedure 42).

**TREATMENT**—Therapy with thyroid hormone early in life may help in preventing cretinism and mental retardation.


- Schultz A Flink E W Kennedy B J and Zieve L. Exchangeable character of accumulated  $I^{131}$  in the thyroid gland of a goitrous cretin J Clin Endocrinol 17 441 1957
- Stanbury J B Cretinism with goiter A case report J Clin Endocrinol 11 740 1951
- and Hedge A N A study of a family of goitrous cretins J Clin Endocrinol 10 1471 1950

## 2 CRETINISM FROM FAILURE OF IODOTYROSINES TO COUPLE

CLINICAL FEATURES — In 1955, Stanbury, Ohela, and Pitt Rivers described a 25 year-old woman who showed retarded development and

CHART 35

CRETINISM ARISING FROM FAILURE OF  
IODOTYROSINES TO COUPLE



goiter. Past history revealed that she had started talking at the age of 1 year and had started walking at 2½ years. Evidence of cretinism appeared at about the age of 4, with retarded growth and a thick and dry skin. She was sensitive to cold and was constipated. These symptoms seemed to improve upon the administration of thyroid.

At the time of her admission, the thyroid gland was enlarging rapidly. Pathological examination of the goiter showed marked hyperplasia with no colloid formation within the follicles.

**HEREDITY**—A sister of the patient also showed evidence of cretinism with goiter. Both of the parents were normal and unrelated. Up until the present time, this is the only family with this type of cretinism which has been reported.

**PATHOGENESIS**—Stanbury and his co-workers found that, although there was a rapid uptake of  $I^{131}$  by the thyroid, the administration of KSCN failed to discharge any of the retained labeled iodine. Direct analysis demonstrated labeled thyroxine and triiodothyronine in the blood but only a trace of thyroxine in the gland. On the other hand, labeled mono- and diiodotyrosine were found in the gland in abundance.

By measuring the rate of disappearance of labeled iodine from the gland and the urinary content of labeled and stable iodine before and during the administration of methimazole, a drug which blocks the incorporation of iodide with organic compounds, these investigators showed that more stable iodine was leaving the gland than could be accounted for by thyroxine and triiodothyronine production. They concluded that this represented a primary failure in the enzymatic coupling of iodotyrosines. This in turn caused a deficiency of thyroid hormone and a compensatory thyroid hyperplasia (Chart 35).

**DIAGNOSIS**—The diagnosis is established by the kinetics of iodine metabolism with  $I^{131}$  administration before and during the administration of methimazole (see Procedure 43).

**TREATMENT**—The administration of thyroid hormone may be of value in preventing the development of cretinism.

Stanbury J B, Ohels K and Pitt Rivers R. The metabolism of iodine in 2 goitrous cretins compared with that in 2 patients receiving methimazole, *J Clin Endocrinol* 15:54, 1955.

### 3 CRETINISM FROM FAILURE OF IODOTYROSINE TO DEIODINATE

**CLINICAL FEATURES**—This condition was described first by Sir William Osler in 1897. Patients with this disease develop myxedema or goiter before the age of 3 years, and the physical changes are quite striking. In addition to a striking family likeness, most patients have the coarse, rather ugly facies of myxedema, as well as the supraclavicular pads, scanty eyebrows, and dry, lusterless hair. Most of the patients are markedly retarded in both physical and mental development, and usually they are unable to talk and are not toilet trained by adulthood. Their mental status is only slightly improved by thyroid therapy.

The pathological changes within the thyroid gland are highly variable. Some areas are characteristic of colloidal goiter, while other areas show

little or no colloid formation, still other areas are filled with fibrous tissue. The changes suggest that, although there is an abundance of thyroid tissue and an adequate supply of iodine, there is an insufficient supply of thyroid hormone going to the tissues in the body.

**HEREDITY**—Congenital hypothyroidism with goiter resulting from failure of iodotyrosine to deiodinate appears to be transmitted by an autosomal recessive gene. Consanguinity is a frequent occurrence and the condition usually occurs among several of the siblings without the parents or other near relatives being involved.

Stanbury has recently shown that the near relatives of known patients show a decreased ability to deiodinate diiodotyrosine, and that a larger fraction of the  $I^{131}$  that is injected is excreted unchanged in the urine compared with normal individuals. It would appear therefore that the heterozygous carriers of the abnormal gene can be detected in this manner.


**PATHOGENESIS**—The biosynthesis of thyroid hormone appears to take place by a series of separate steps: (1) the oxidation of iodide to iodine, (2) the iodination of tyrosine radicals within the thyroglobulin molecule to form mono- and diiodotyrosine, and (3) the coupling of two molecules of diiodotyrosine to give one molecule of thyroxine. Roche and his associates have shown that not all of the iodotyrosines formed in step 2 go to step 3. Instead, the unused portions are dehalogenated by a specific enzyme, iodotyrosine deshalogenase. This step is necessary for the proper conservation of iodine in the body and explains why mono- and diiodotyrosines are not found in the blood.

In 1955, Stanbury and his co-workers demonstrated the presence of both mono- and diiodotyrosine in the blood of a patient who had congenital hypothyroidism with goiter. They showed that intravenously administered mono- and diiodotyrosine were excreted in the urine either unchanged or as unidentified substances. There was no evidence of deiodination taking place. More recently they have shown that the enzyme iodotyrosine deshalogenase was actually absent in the thyroid tissue of a patient with familial goitrous cretinism.

The effects of the enzyme deficiency are shown in Chart 36. The deficiency of iodotyrosine deshalogenase results in the accumulation of mono- and diiodotyrosine within the blood and its loss through urinary excretion. The loss of iodine resulting from continuous excretion might be sufficient to prevent the formation of thyroid hormone in adequate

CHART 36

### CRETINISM RESULTING FROM FAILURE OF IODOTYROSINE TO DEIODINATE



956

ODOTYROS NE DESHALOGENASE

odbojnost —————> odboj

### Accumulation of mono and diiodotyrosine in blood

Exc e p n of m o o and d o d o y o s n e n u n e

nodecup e fo ma on pf hy o d ho mone

Compensatory type poses  
of thyroid gland  
(goiter)

**Hypothesis 1**

Coarse  
skin and ho

Men o and phys co  
e a da on

**DIAGNOSIS**—Congenital hypothyroidism with goiter is diagnosed by the presence of labeled mono- and diiodotyrosines in the blood following the administration of a tracer dose of  $I^{131}$  (see Procedure 44)

**TREATMENT**—Early therapy with thyroid hormone may be helpful in preventing cretinism and mental retardation.

Lutch *son* J II and McG *rr* E M Sporadic non-endemic goitrous cretinism

Hereditary transmission *Lancet* 2 906 1956

Quendo A Stanbury J B Kassenaar A A II and Meyer J W A The



metabolism of iodotyrosines III - Di iodotyrosine deshalogenating activity of human thyroid tissue *J Clin Endocrinol* 16 1096 1956

Roche J Michel O Michel R, Gorbman A, and Lissitzky S Sur la déshalogenation enzymatique des iodotyrosines par le corps thyroïde et sur son rôle physiologique II *Biochim et biophys Acta* 12 570 1953

Stanbury J B, Meijer J W A, and Kassenaar A A II The metabolism of iodo-tyrosines II The metabolism of mono and di iodotyrosines in certain patients with familial goiter, *J Clin Endocrinol* 16 848 1956

## THE ADRENOGENITAL SYNDROME

The adrenogenital syndrome is an over all term which can be applied to three separate conditions (1) *adrenal hyperplasia with virilism only*, (2) *adrenal hyperplasia with hypertension* and (3) *adrenal hyperplasia with electrolyte disturbances*. Although the three types appear to be clinically quite similar, genetic studies have shown that only one of the types is found among the affected members of a given family. Biochemical studies have shown that the first two types represent metabolic blocks at different sites in the normal pathway of compound F synthesis as shown in Figure 37

### 4 TYPE I, ADRENAL HYPERPLASIA WITH VIRILISM ONLY

**CLINICAL FEATURES** —The picture differs depending on the sex of the patient

In the female pseudohermaphrodite, the disorder begins in embryonic life and the sexual abnormalities are present at birth (Fig 38). The characteristic findings are a hypertrophied phallus, which resembles a hypospadiac penis, and a persistent urogenital sinus which communicates anteriorly with the urethra and posteriorly with the vagina, uterus, and tubes. The condition may occasionally be confused with true genetic intersexes, who may have testes, ovotestes, or ovaries. However the latter do not show the marked increase of 17 ketosteroids in the urine.

In the male, there are no abnormalities of embryonic sex differentiation. However, *macrogenitosomia praecox* develops early in life. This is not true sexual precocity, since the testes remain small and immature. The Leydig cells do not appear, and the tubules do not show spermatogenesis. The elevation of urinary 17 ketosteroids differentiates the condition from sexual precocity.

In both sexes, there is a marked acceleration of both height and bone age during early childhood. However, because of the early closure of epiphyses, the final stature is usually less than average. There is also premature appearance of pubic, axillary, and facial hair. Because of the

- I Adrenal hyperplasia with virilism only  
 II Adrenal hyperplasia with hypertension




FIG 37—Biosynthetic pathway of compound F and sites of metabolic blocks in adrenogenital syndrome (After Bongiovanni, A M, and Eberlein, W R. *Clinical and metabolic variations in the adrenogenital syndrome* Pediatrics 16 628 1958)

marked androgenic effects, female sexual development does not occur at the usual time in female pseudohermaphrodites

The histological changes of the adrenal cortex consist of hyperplasia of the zona reticularis the presumed site of androgen production

Patients who have adrenal hyperplasia with virilism only do not develop hypertension or electrolyte disturbances, which is an important point in differential diagnosis in the adrenogenital syndrome



FIG 38 —A female pseudohermaphrodite with marked increase in the size of the clitoris

HEREDITY —Adrenal hyperplasia with virilism only appears to be transmitted by a single recessive gene Childs and his co-workers have been studying several families in which they attribute this in part to a recessive gene. They are to the more striking and the clinical picture is estimated to be of the order of 1 in 7 000 and 1 in 128 in some cases.

Attempts have been made to detect the effects of a possible gene in the parents, who are presumed to be heterozygotes. This was done by measuring pregnanetriol in the urine after the administration of 60-80 units of ACTH. The parents of known patients appear to excrete somewhat more of that compound than do the normal controls, the difference being significant at the 2-5% level.

**PATHOGENESIS**—This has been clarified as a result of three fundamental discoveries. (1) in 1950, Wilkins and his associates showed that both the clinical manifestations and the excessive secretion of androgens can be effectively controlled by the administration of cortisone, (2) the following year, Bartter and his co-workers showed that adrenal hyperplasia probably represents a failure in the synthesis of compound F, and (3) in 1953, Bongiovanni and his fellow workers showed that patients with adrenal hyperplasia routinely excreted an excessive amount of pregnanetriol (3 $\alpha$ ,17 $\alpha$ ,20 $\alpha$ -pregnanetriol).

Bartter, in 1951, first postulated the normal pathway for the synthesis of compound F from cholesterol, as shown in Figure 37. The deficiency of compound F together with the excess of pregnanetriol indicates that the block must occur between 17-hydroxyprogesterone and compound S. It has been postulated that this block occurs as a result of a deficiency of an enzyme which hydroxylates carbon-21 to yield compound F, which might be referred to as "21-hydroxylase." The identity and characteristics of such an enzyme have just been demonstrated.


The effects of a deficiency of such an enzyme are shown in Chart 37. First, its absence would result in the accumulation of 17-hydroxyprogesterone, which in turn would be converted to pregnanetriol and excreted. This would also lead to a deficiency of compound F. The pituitary gland attempts to compensate for this deficiency by overproducing ACTH, and this results in the excessive production of androgens and the excessive excretion of 17-ketosteroids. The effects of the excessive androgens on the male are shown on the left side of the chart, precocious hair growth, accelerated stature, and macrogenitosomia praecox are prominent features. In the female, in addition to enlargement of the clitoris and early growth of hair and stature, there is a suppression of the female sex characteristics at puberty.

**DIAGNOSIS**—The diagnosis of adrenal hyperplasia with virilism only is established by (1) the absence of hypertension and electrolyte disturbances, (2) the presence of pregnanetriol in the urine (see Procedure 45); and (3) increased 17-ketosteroids in the urine (see Procedure 46).

**TREATMENT**.—Wilkins and his co-workers have shown that small doses of cortisone (initial dosage of 50-100 mg daily, followed by 50 mg

every 2 or 3 days) are effective in reducing the 17 ketosteroid excretion to normal levels. In female pseudohermaphrodites, this is effective in bringing about breast development and vaginal smears showing estrogen

CHART 37

ADRENAL HYPERPLASIA WITH VIRILISM ONLY (TYPE I)

ic activity. In about half of the cases, normal menstruation will occur. In the older patients, there is no change in somatic growth because of early closure of the epiphyses. In some of the males there is an enlargement of the testes, suggesting that normal maturation is occurring.

Replacement therapy with cortisone should be started at an early age in order to insure proper somatic growth and development as well as normal sexual development.

- Bartter, F. C., Albright, F., Forbes, A. F., Leaf, A., Dempsey, E.; and Carroll, E. The effects of adrenocorticotrophic hormone and cortisone in the adrenogenital syndrome associated with congenital adrenal hyperplasia, *J Clin Invest.* 30 237, 1951
- Bongiovanni, A. M. In vitro hydroxylation of steroids by whole adrenal homogenates of beef, normal man and patients with the adrenogenital syndrome, *J Clin Invest.* 37 1342, 1958
- Childs, B., Grumbach, M. M., and Van Wyk, J. J. Virilizing adrenal hyperplasia: A genetic and hormonal study, *J Clin Invest* 35 213, 1956
- Eberlein, W. R., and Bongiovanni, A. M. Partial characterization of urinary adrenocortical steroids in adrenal hyperplasia, *J Clin Invest.* 34 1337, 1955
- \*Wilkins, L. The diagnosis of the adrenogenital syndrome and its treatment with cortisone, *J Pediatr* 41 860 1952
- , Crigler, J. F., Jr., Silverman, S. H., Gardner, L. I., and Migeon, C. J. Further studies on the treatment of congenital hyperplasia with cortisone. III The control of hypertension with cortisone, with a discussion of variations in the type of congenital adrenal hyperplasia and report of a case with probable defect of carbohydrate regulating hormones, *J Clin Endocrinol* 12 1015, 1952

## 5 TYPE II, ADRENAL HYPERPLASIA WITH HYPERTENSION


**CLINICAL FEATURES**—In this type of adrenal hyperplasia, all patients show a persistent hypertension, which usually starts in the first few years of life and averages about 180 mm Hg systolic and 140 mm Hg diastolic without therapy. Occasionally the persistent hypertension will result in cardiac decompensation and cerebral vascular accident.

**HEREDITY**—Childs has shown that two siblings of patients with this form of adrenal hyperplasia also showed the same condition. It is not clear whether this segregation in particular families is the result of different genes occurring as a system of alleles at one locus, or of different genes at different loci.

**PATHOGENESIS**—Eberlein and Bongiovanni have shown that the principal metabolite excreted in the urine is a tetrahydro-S (pregnane-3 $\alpha$ ,17 $\alpha$ ,20-triol,20-one). There was a complete absence of the normal 11-oxygenated C-21 and 17-ketosteroids. Pregnanetriol was present, but in reduced quantities as compared with the first type. These investigators suggested that this hypertensive form of adrenal hyperplasia represented a metabolic block between compound S and compound F, resulting in the accumulation of both compound S and tetrahydro-S, as shown in Figure 37. These changes could be due to a deficiency of an adrenal enzyme concerned with the introduction of a hydroxyl group into the steroid molecule at C-11, and this could, therefore, be called the deficiency of "11-B-hydroxylase."

The results of this enzyme deficiency are shown in Chart 38, which essentially represents the same pedigree of causes as for adrenal hyper-

## CHART 38

ADRENAL HYPERPLASIA WITH HYPERTENSION (TYPE II)

plasia with virilism only. The hypertension may be due to the secretion of desoxycorticosterone by the adrenal cortex since metabolites of this substance have been partially identified in the urine of a patient with this condition.

**DIAGNOSIS**—Adrenal hyperplasia with hypertension can be diagnosed by the presence of (1) persistent hypertension and (2) tetrahydro S in the urine (see Procedure 47).

**TREATMENT**—Cortisone in moderate doses will bring the blood

pressure down to normal levels and completely abolish the abnormal steroids in the urine

- Bongiovanni, A M, and Eberlein W R Clinical and metabolic variations in the adrenogenital syndrome, *Pediatrics* 18 628, 1955
- Eberlein W R, and Bongiovanni, A M Congenital adrenal hyperplasia with hypertension Unusual steroid pattern in blood and urine *J Clin Endocrinol* 15 1531, 1955
- \*Wilkins L The diagnosis of the adrenogenital syndrome and its treatment with cortisone, *J Pediat* 41 860 1952
- , Crigler, J F Jr, Silverman S H, Gardner L I, and Migeon C J Further studies on the treatment of congenital adrenal hyperplasia with cortisone III The control of hypertension with cortisone with a discussion of variations in the type of congenital adrenal hyperplasia and report of a case with probable defect of carbohydrate regulating hormones, *J Clin Endocrinol* 12 1015 1952

## 6. TYPE III, ADRENAL HYPERPLASIA WITH ELECTROLYTE DISTURBANCES

**CLINICAL FEATURES**—Certain infants with congenital adrenal hyperplasia develop serious disturbances in electrolyte metabolism Characteristically, without treatment they become apprehensive and irritable and lose their appetite Soon vomiting and weight loss occur The serum electrolytes will show a sodium level of less than 120 mEq/L, a potassium level of more than 6 mEq/L, and a  $\text{CO}_2$  level of less than 20 mEq/L The changes in the serum chloride levels are more variable If treatment is not promptly instituted, the infant will die from sodium loss and dehydration or from cardiac arrest due to hyperkalemia


Pathological studies have shown that in some cases the zona glomerulosa of the adrenal is absent This suggests that the Na retaining hormone might be lacking, since it is believed to be secreted in that area

**HEREDITY**—The condition appears to be transmitted by a rare recessive gene Childs has shown that all 11 siblings of 10 index patients with this form of adrenal hyperplasia were salt losers Also, they found that, unlike Type I, there is less of a disproportion of females to males, possibly because the symptoms in these patients are much more striking and the infants are more likely to come to the attention of physicians

**PATHOGENESIS**—The metabolic block for adrenal hyperplasia with electrolyte disturbances has not been completely worked out At the present time, there appear to be two types of deficiencies, which may be in some way related (1) there is the usual deficiency of compound F, which is responsible for the virilization, the excess of 17-ketosteroids, and pregnanetriol, and (2) there is a deficiency of the Na-retaining hormone, which could be aldosterone The latter deficiency is responsible



## CHART 39

ADRENAL HYPERPLASIA WITH ELECTROLYTE DISTURBANCES  
(TYPE III)

for the loss of sodium and for hyperkalemia and acidosis, which are characteristic of this condition (Chart 39). Recently, Eberlein and Bongiovanni have shown that an essentially complete failure of hydrocortisone synthesis due to lack of 21-hydroxylase may be responsible for these marked changes.

**DIAGNOSIS**—The diagnosis can be established by the disturbances of electrolyte metabolism in a patient with virilizing adrenal hyperplasia.

**TREATMENT**—Prior to the advent of the corticotrophins, the administration of NaCl together with large doses of corticosteroids controlled

the electrolyte disturbances but did not check the progressive virilization. Wilkins and his co-workers have found that, if cortisone is administered in sufficient amounts to suppress the excretion of 17-ketosteroids, less DOCA and NaCl are required. The exact amounts of steroids and salt to be given must be adjusted on an individual basis.

Butler, A. M., Ross, R. A., and Talbot, N. B.: Probable adrenal insufficiency in infant, *J. Pediatr.* 15: 831, 1939.

Crigler, J. F., Jr., Silverman, S. H., and Wilkins, L.: Further studies on the treatment of congenital adrenal hyperplasia with cortisone. IV. Effect of cortisone and compound B in infants with disturbed electrolyte metabolism, *Pediatrics* 10: 397, 1952.

Eberlein, W. R., and Bongiovanni, A. M.: Steroid metabolism in the "salt losing" form of congenital adrenal hyperplasia. *J. Clin. Invest.* 37: 889, 1958.

Wilkins, L.: The diagnosis of the adrenogenital syndrome and its treatment with cortisone. *J. Pediatr.* 41: 860, 1952.

## Disturbances in Pigment Metabolism

### THE METHEMOGLOBINEMIAS

**METHEMOGLOBINEMIA** IS A condition in which a substantial proportion of the intracellular hemoglobin exists as methemoglobin the ferrous form of hemoglobin iron which is incapable of transporting oxygen. When certain drugs such as acetanilide, antipyrine, and phenacetin are administered to normal people, a transient methemoglobinemia may result. The condition can also occur as a result of an inborn error of hemoglobin metabolism.

At least three types of congenital methemoglobinemia have been recognized as described below.

#### I CONGENITAL METHEMOGLOBINEMIA TYPE I

**CLINICAL FEATURES**—In Type I the most common type methemoglobinemia is present at birth and persists unchanged throughout life unless reversed by some special form of treatment. Most individuals with this condition appear to suffer no physical disability and lead normal active lives without specific treatment. A few show marked cyanosis and develop dyspnea on exertion and sometimes a compensatory polycythemia. Occasionally more serious disabilities such as dwarfing and mental deficiency are found in association with the defect.

One of the striking features is the fact that the abnormal pigment can be rapidly removed from the patient's blood after the administration of methylene blue and somewhat more slowly by ascorbic acid and other oxidizing agents.

**HEREDITY**—This type of congenital methemoglobinemia is transmitted as a rare recessive. In the pedigree described by Gibson and Harrison 5 out of 9 brothers and sisters were definitely affected although the par-

ents and all near relatives did not appear to be. The family lived on a small farm in a remote and mountainous part of Ireland, and since the families of both parents had lived in the same village for generations, consanguinity was likely to have occurred to some degree. The heterozygous carriers of this gene have not been detected by chemical means.

The incidence of this type of congenital methemoglobinemia is not known. The condition is probably quite rare, since only about 50 families have been reported from all over the world.

**PATHOGENESIS**—It is generally accepted that in normal blood there is a slow but continuous oxidation of hemoglobin to methemoglobin and that the reducing systems in the erythrocytes are sufficiently active so that




FIG. 39.—Oxygen dissociation curve of blood in Type I methemoglobinemia. *A* with blood containing 4.2 Gm of methemoglobin per 100 ml of blood; *B* with blood after removal of methemoglobin with methylene blue (From Gibson, O. H. and Harrison, E. C. Familial idiopathic methemoglobinemia. *Lancet* 2: 941, 1947.)

only about 0.4% of the erythrocytes consists of methemoglobin. In congenital methemoglobinemia, there is a defect in the reducing system within the erythrocytes, so that 20–50% of the red-cell pigment is present in the form of methemoglobin, as shown in Figure 39. The amount of methemoglobin does not continue to increase in the blood of affected persons to an unlimited extent because, as the concentration of methemoglobin rises, its rate of reduction with the nonspecific reducing agents in the blood also rises and an equilibrium becomes established. It is probable that, in this respect, ascorbic acid and glutathione are the most important reducing agents in the blood.

In the normal individual, methemoglobin is reduced as shown in Figure 40, pathway *A*. The conversion of glucose to lactate reduces coen-

zyme I (diphosphopyridine nucleotide), and the reduced coenzyme I together with a flavoprotein, diaphorase I, acts as a carrier in the conversion of methemoglobin to hemoglobin. Under normal circumstances pathway *B* is of no importance because coenzyme II dehydrogenases do






FIG 40—Reactions in the reduction of methemoglobin in erythrocytes. *A* main normal pathway (blocked in idiopathic methemoglobinemia by deficiency of diaphorase I) *B* effective alternative pathway in presence of catalyst methylene blue (After Gibson)

not play a significant part in the reduction of methemoglobin probably because diaphorase II does not react with methemoglobin.

Gibson and his co-workers have demonstrated that in congenital methemoglobinemia there is a significant deficiency of diaphorase I, and that this results in the metabolic block of the conversion of methemoglobin to hemoglobin and in the accumulation of methemoglobin in the blood cells (Chart 40). When methylene blue is administered this substance is capable of reacting rapidly with both diaphorase I and II and methemoglobin and the reduction of the latter compound occurs as a result of both an

## CHART 40

CONGENITAL METHEMOGLOBINEMIA TYPE I

acceleration of pathway A and an opening-up of the new pathway B, using coenzyme II dehydrogenases

**DIAGNOSIS**—Congenital methemoglobinemia (Types I, II, and III) may be diagnosed by the presence of excessive amounts of methemoglobin in the erythrocytes (see Procedure 48). Type I may be differentiated by the absence or reduction of diaphorase I activity in the blood (see Procedure 49), and by an abnormal oxygen dissociation curve (Procedure 50)

**TREATMENT**—Normally, no specific treatment is required. In a

crisis, 50 mg of methylene blue will quickly convert the methemoglobin to normal hemoglobin. This form of therapy is of interest because it represents the first example of overcoming the defect by an alternative pathway of metabolism.

Darlington R C and Roughton F J W. The effect of methemoglobin on the equilibrium between oxygen and hemoglobin. *Am J Physiol* 137:56, 1942.


Gibson, Q H. The reduction of methemoglobin in red blood cells and studies on the cause of idiopathic methemoglobinemia. *Biochem J* 42:13, 1948.

— and Harrison D C. Familial idiopathic methemoglobinemia. *Lancet* 2:941, 1947.

Waisman H A, Bain J A, Richmond J B, and Munsey, F A. Laboratory and clinical studies in congenital methemoglobinemia. *Pediatrics* 10:293, 1952.

## 2 CONGENITAL METHEMOGLOBINEMIA TYPE II

In 1948, Horlem and Weber reported a second type of congenital methemoglobinemia, which was distinct in a number of ways. Patients with this type of disease had some 15-20% of the red-cell pigment in the form of methemoglobinemia. This did not bother them, and they led normal lives. However, unlike the first type, the condition was transmitted



from parent to child for four generations, which suggested that the affected individuals were heterozygous for the condition and that it was transmitted as a dominant.

The methemoglobin curve from these patients (Fig. 41) protein into its


t spectral absorption. Weber split this the com

ponents with fractions obtained from normal blood, and showed that the abnormality lay in the globulin component


Finally, the administration of methylene blue or ascorbic acid failed to convert the pigment back to normal hemoglobin

Gerald and his co-workers have reported on another family with the

CHART 41

CONGENITAL METHEMOGLOBINEMIA TYPE II

I H o e n B. Webb 348



same spectral abnormality. They were able to separate the abnormal hemoglobin from normal adult hemoglobin electrophoretically, and they demonstrated that in the affected individuals both forms of hemoglobin were present. Because the defect lies in the globulin component, this abnormal hemoglobin has been included among the abnormal hemoglobins and designated hemoglobin M. More recent work from Gerald's laboratory indicates that hemoglobin M should probably be subdivided into several varieties depending on the absorption spectra



crisis, 50 mg of methylene blue will quickly convert the methemoglobin to normal hemoglobin. This form of therapy is of interest because it represents the first example of overcoming the defect by an alternative pathway of metabolism.

Darlington R. C., and Roughton F. J. W. The effect of methemoglobin on the equilibrium between oxygen and hemoglobin. *Am J Physiol* 137:56, 1942.


Gibson Q. H. The reduction of methemoglobin in red blood cells and studies on the cause of idiopathic methemoglobinemia. *Biochem J* 42:13, 1948.

——— and Harrison D. C. Familial idiopathic methemoglobinemia. *Lancet* 2:941, 1947.

Waisman H. A., Bain J. A., Richmond J. B., and Munsey F. A. Laboratory and clinical studies in congenital methemoglobinemia. *Pediatrics* 10:293, 1952.

## II CONGENITAL METHEMOGLOBINEMIA TYPE II

In 1948, Horlein and Weber reported a second type of congenital methemoglobinemia, which was distinct in a number of ways. Patients with this type of disease had some 15-20% of the red-cell pigment in the form of methemoglobin. This did not bother them and they led normal lives. However, unlike the first type, the condition was transmitted



mitted as a dominant

The methemoglobin in these patients had a different spectral absorption curve from that of Type I (Fig. 41). Horlein and Weber split the protein into its heme and globulin components and recombined the com-

remission when the patient is completely free of symptoms. During attacks the symptoms vary a great deal. In some cases they are entirely abdominal, in others, nervous, but in most instances, both types of symptoms occur.

**CLINICAL FEATURES**—Abdominal pain is often very severe, it takes the form of colic, and may involve all of the abdomen or may be highly localized. The condition has been mistaken for appendicitis, bowel obstruction, renal or biliary colic, perforated ulcer, and pancreatitis. Often there are no bowel movements for days on end.

The nervous manifestations may take four forms: (1) peripheral neuropathy, (2) bulbar symptoms, (3) psychic changes, and (4) autonomic involvement.

The peripheral neuropathy is characterized by pain in the limbs, especially in the legs, weakness, or marked flaccid paralysis. The latter comes on suddenly and may involve many parts of the body all at once, with an irregular distribution. For instance, some patients may show an ankle clonus without patellar reflexes in the same leg. Paralysis of the abdominal or other trunk muscles occurs less frequently, and the sensory system is never affected except for pain.

Bulbar signs are seen in the more severe cases. There is difficulty in swallowing, regurgitation, and aspiration. There may be vocal cord paresis, with a weak, hoarse, high pitched voice. Tachycardia may be quite marked because of vagal nuclear involvement.

Among the psychic changes, a pseudohysteria is the most common finding. The patients are noted to be excessively "nervous" for years before the first attack. In some instances, acute porphyria has been wrongly diagnosed as schizophrenia or as a neurotic or depressed state.

It is difficult to determine exactly the autonomic nervous system involvement. A pigment is deposited in the autonomic ganglia, and the abdominal pain may be due to this rather than to a direct effect of porphyrin or porphobilinogen on the intestinal wall, as has been suggested. Hypertension is usually marked. In some cases, fatal relapses occur in association with pregnancy. In such instances the infant may show a "passive" porphyria, where the urine is port-wine colored and contains uroporphyrin and excessive coproporphyrin. This symptom persists for a few days and then disappears, suggesting that these substances were transferred across the placental barrier.

The characteristic biochemical finding in acute porphyria is the presence of abnormal quantities of porphobilinogen. There appears to be also an increased excretion of  $\delta$ -aminolevulinic acid. However, most of the

These have been subclassified into the "Boston type" (Hgb M<sub>B</sub>), "Saskatoon type" (Hgb M<sub>S</sub>), and "Milwaukee type" (Hgb M<sub>M</sub>)

Although the exact cause for this type of methemoglobinemia is not fully understood, the disturbance in the globulin structure may be similar to that of the abnormal hemoglobins (Chart 41)

Gerald, J. S. The electrophoretic and spectroscopic characterization of Hgb M Blood 13 936, 1958

———, Cook, C. D., and Diamond L. K. Hemoglobin M Science 126 300 1957

Horlein, H., and Weber, G. Über chronische familiäre methämoglobinämie und eine neue Modifikation des Methämoglobins Deutsche med Wchnschr 73 476, 1948

Kiese, M., Karz, H., and Schneider, C. Chronische Hamoglobinämie durch pathologischen Blutfarbstoff, Klin Wchnschr 34 957, 1956

### 3 CONGENITAL METHEMOGLOBINEMIA TYPE III

In 1949, Eder, Finch, and McKee reported a third type of congenital methemoglobinemia. The only known patient was a 23 year-old man who had been blue ever since early infancy. He had a methemoglobin level of 40% and a compensatory polycythemia but no evidence of excessive blood destruction. He was otherwise well and was able to lead a normal life. The family history revealed no similar cases among near relatives.

Unlike the other forms of methemoglobinemia, here the erythrocytes did not show the typical alteration by means of an oxygen dissociation curve. Also, the methemoglobin was quickly removed by both methylene blue and ascorbic acid. Preliminary studies suggest that the diaphorase I system in the erythrocytes of this patient was functioning satisfactorily. The pathogenesis is, therefore, not known.

Eder, H. A., Finch, C., and McKee, R. W. Congenital methemoglobinemia. A clinical and biochemical study of a case, J Clin Invest 28 265 1949

## OTHER PIGMENT DISTURBANCES

### 4 HEPATIC PORPHYRIA


Hepatic porphyria may occur in three forms: intermittent acute porphyria, chronic cutaneous porphyria, and mixed porphyria, with both acute and chronic porphyria seen in the same family. The three conditions should probably be considered together.

#### INTERMITTENT ACUTE PORPHYRIA

As implied by the name, intermittent acute porphyria is characterized by individual attacks of longer or shorter duration with periods


CHART 42

## HEPATIC PORPHYRIA



(Weinstein 1956)

## POSSIBLE BLOCK III

 $\delta$ -Amino-levulinic Acid  $\rightarrow$  Porphobilinogen  $\rightarrow$  Porphyrins


adult, porphyria does not develop. However, when it is administered to patients with porphyria, it is converted to urinary porphobilinogen to a much greater degree. Also, Granick has reported the presence of rather large quantities of  $\delta$ -amino-levulinic acid in the urine of a patient with acute porphyria during a clinical remission. This would suggest that a partial block above the porphobilinogen step might be responsible for porphyria (Chart 42). More recently, experimental porphyria has been produced in animals through the use of compounds with a chemical structure such as that shown on page 182.


free porphyrins which at various times have been reported in the urine of such patients were probably mainly formed secondarily from excreted porphobilinogen

**HEREDITY**—The genetics of acute porphyria have been extensively studied by Waldenstrom in Sweden. The condition appears to be transmitted as an autosomal dominant. Penetrance is incomplete, partly because the age of onset is highly variable, onset seldom occurring before puberty. Acute porphyria has been seen in both members of a pair of concordant uniovular twins. The incidence of consanguinity is not increased. For some unexplained reason, the ratio of affected males to females is about 2 to 3.

Waldenstrom has shown that the incidence of acute porphyria is 1.4 per 100,000 in Sweden but increases to 1 in 100 in Lapland in the northern part of the country.

**PATHOGENESIS**—Studies by Shemin, Rumington, Granick, and others indicate that the conversion of precursor pyrrole to porphyrins occurs as a result of the following steps (Fig. 42). (1) Two molecules of  $\delta$ -aminolevulinic acid condense in the presence of a dehydrase to give the monopyrrole "porphobilinogen." (2) Porphobilinogen is then acted upon anaerobically by two enzymes. One enzyme is a deaminase, which condenses porphobilinogen to uroporphyrinogen I, which in turn is converted by auto oxidation to uroporphyrin I. (3) A second enzyme is an isomerase, which, acting together with the deaminase, converts porphobilinogen to uroporphyrinogen III, which in turn is converted to uroporphyrin III. (4) Finally, a third enzyme fraction, a decarboxylase, converts uroporphyrinogen III to coproporphyrinogen III, which then is converted to coproporphyrin III.

Two pieces of evidence have been presented regarding the possible metabolic error in acute porphyria. Neuberger and his co-workers have shown that, when  $\delta$ -aminolevulinic acid is administered orally to a normal



Although these chemical studies are very promising, they do not, unfortunately, help to explain the peculiar abdominal and central nervous system symptoms of porphyria. Explanations for these symptoms are yet to be determined.

**DIAGNOSIS**—Acute porphyria can be diagnosed by the characteristic clinical picture and the presence in the urine (1) of porphobilinogen (see Procedure 51) and of  $\delta$  amino levulinic acid and (2) lesser quantities of zinc complexes of uroporphyrin I and III (see Procedure 52) and coproporphyrin III (Procedure 53). The bone marrow in this form of porphyria is not affected.

**TREATMENT**—Supportive and symptomatic treatment is all that can be given. Patients should also avoid alcohol, barbiturates, and hepatotoxins, which are likely to precipitate attacks. Death, when it occurs, is usually the result of a rapidly ascending paralysis which finally affects the medullary centers.

\*Ciba Symposium on Porphyrin Biosynthesis and Metabolism (London: J & A Churchill Ltd., 1955).

\*Granick, S. et al. *Metabolism and Function of Iron*. Report of the Nineteenth Ross Pediatric Research Conference (Columbus, Ohio: Ross Laboratories, 1955).



in Sweden Acta genet et stat med 6 122, 1956

—Studien über Porphyria, Acta med scandinav supp 82 1937

### CHRONIC CUTANEOUS PORPHYRIA

Chronic cutaneous porphyria usually appears in middle aged adults. The patients often present a chronic eczematoid dermatitis and a lesser degree of the typical *hydra aestivale* seen in porphyria erythropoietica (p 67). The abdominal and nervous system symptoms are milder although cirrhosis of the liver sometimes develops late in the course of the disease.

This type of porphyria is also familial and is transmitted as an autosomal dominant with incomplete penetrance.

The main chemical difference between this form of porphyria and the acute form is that porphobilinogen is absent from the urine in this form, whereas uroporphyrins I and III and coproporphyrin III are present and increased, just as in the acute form.

In clinical remission, there is a marked increase of protoporphyrin and coproporphyrin in the feces. This would suggest that this condition





FIG. 42.—Conversion of pyrrole to porphyrins

tion tests are negative, however, there is a marked inability of the patient to handle bilirubin, as shown by the bilirubin excretion test (see Procedure 54)

**HEREDITY**—The condition has been seen in only two families (1) in the large kindred in western Maryland and (2) in a single child of Italian ancestry. In both instances, consanguinity was noted. Congenital nonhemolytic jaundice with kernicterus is probably transmitted by a single autosomal recessive gene, which is expressed only in homozygous individuals.

Childs has recently demonstrated that the parents of such individuals show a decreased ability to form glucuronides following the administration of salicylates and other metabolites. This would suggest that they are heterozygous carriers of the abnormal gene.

**PATHOGENESIS**—Schmid and his associates have shown that "indirect" bilirubin is converted to "direct" bilirubin by the following reaction:



This reaction is catalyzed by an enzyme system in the microsomes of mammalian liver which appears to be the same system that conjugates such substances as *o*-aminophenol or phenolphthalein with glucuronic acid.

The bilirubin from the serum of patients with congenital nonhemolytic jaundice with kernicterus has been crystallized by ammonium sulfate fractionation and found to be of the unconjugated type. Also, bilirubinuria is absent, and the bile in these patients is colorless and contains only traces of unconjugated bilirubin. Finally, the glucuronide formation of menthol, of salicylate, and of the metabolites of hydrocortisone is markedly depressed, which indicates that this condition represents a metabolic block at the stage of bilirubin conjugation and probably is due to a specific enzyme defect (Chart 43).

Extensive studies *in vitro* and *in vivo* have shown that a relationship exists between the elevation of "indirect" bilirubin in the serum and the kernicterus in erythroblastosis fetalis, premature infants, and those suffering from syngavit (menadiol) toxicity. The elevation of the bilirubin in this form is probably responsible for the brain damage in this disease. The reason for some infants getting kernicterus while others escape this complication is not known.

**DIAGNOSIS**—Congenital familial nonhemolytic jaundice with kernicterus must be differentiated (1) from familial nonhemolytic jaundice



represents a disturbance in porphyrin metabolism which is quite unlike that found in congenital or acute porphyria. The nature of this disorder however, is quite obscure.

Brunsting L. A., Mason H. L., and Aldrich H. A. Adult form of chronic porphyria with cutaneous manifestations. *J. A. M. A.* 146: 1207, 1951.

Schmid R., Schwartz S., and Watson C. J. Porphyrin content of bone marrow and liver in the various forms of porphyria. *Arch. Int. Med.* 93: 167, 1954.

### MIXED PORPHYRIA

The term 'mixed porphyria' applies to patients presenting both abdominal and nervous system symptoms in association with porphobilinogen in the urine during the course of chronic cutaneous porphyria. Several instances have been reported where both chronic cutaneous porphyria and intermittent acute porphyria are known to exist in the same family.

Brunsting L. A., Mason H. L., and Aldrich R. A. Adult form of chronic porphyria with cutaneous manifestations. *J. A. M. A.* 146: 1207, 1951.

Dean G. and Barnes H. D. Porphyria. *Brit. M. J.* 1: 298, 1958.

Wells Q. C. and Rumington C. Studies on a case of porphyria cutanea tarda. *Brit. J. Dermat.* 65: 337, 1953.

### 5 CONGENITAL NONHEMOLYTIC JAUNDICE WITH KERNICTERUS

In 1952, Crigler and Najjar reported on a group of infants with a previously undescribed congenital abnormality characterized by the elevation of 'indirect' bilirubin. All of these patients were from a large kindred in western Maryland, where there had been close inbreeding for several generations. Since extrapyramidal tract involvement is a prominent feature of the disease, the condition was named 'congenital nonhemolytic jaundice with kernicterus'.

**CLINICAL FEATURES**—Infants with this condition develop jaundice early, frequently on the second day of life. The increase in bilirubin is limited to the 'indirect' fraction which gradually rises to levels of between 25 and 45 mg/100 ml. Opisthotonus, spasticity, and rigidity soon become apparent, and many of the infants with kernicterus die in the first year of life.

At postmortem, staining of the basal ganglia is a characteristic finding. Surprisingly, the liver shows no real abnormalities except for the presence of bile thrombi in the hepatic canaliculi.

Most of the laboratory tests are not remarkable. Blood grouping studies reveal no incompatibilities. Fragility tests, bone marrow examinations, and reticulocyte counts are usually within normal limits. The liver func-

(Gilbert's disease) by the difference in age of onset and prognosis (2) from chronic idiopathic jaundice with hepatic pigmentation (Dubin-Johnson syndrome) by the liver changes microscopically and (3) from erythroblastosis fetalis by blood grouping studies. The diagnosis is ultimately established by the ability of the liver to conjugate bilirubin (see Procedure 55).

**TREATMENT**—Exchange transfusions temporarily lower the serum bilirubin levels and may be helpful during the first weeks of life, when the brain is presumably most susceptible to damage.

- Billing B H and Lathe G H The excretion of bilirubin as an ester glucuronide giving the direct van den Bergh reaction *Biochem J* 63 6P 1956
- Childs B The nature of direct bilirubin *Bull Johns Hopkins Hosp* 97 333 1955
- and Najjar V A Familial nonhemolytic jaundice with kernicterus *Pediatrics* 18 369 1956
- Crigler J F Jr and Najjar V A Congenital familial nonhemolytic jaundice with kernicterus *Pediatrics* 10 169 1952
- Rosenthal I M Zimmerman H J and Hardy N Congenital nonhemolytic jaundice with normal red blood cells and normal liver function tests *Arch Biochem* 70 255 1957

#### 6 FAMILIAL NONHEMOLYTIC JAUNDICE (Gilbert's disease)


Early in this century, Gilbert and his co-workers in France called attention to a nonhemolytic acholuric icterus which was familial in nature. Subsequent workers felt that Gilbert and his associates were describing hereditary spherocytosis, a condition which was becoming known at that time, and little attention was paid to the condition 'familial nonhemolytic jaundice' for many years. In the past decade interest in this condition has been renewed, and some 350 cases are now recorded in the literature.

**CLINICAL FEATURES**—The age of onset is not known. Most of the patients who come to the attention of physicians are between 15 and 25 years of age but one might well assume that the symptoms have been present, although undetected, for some years previously.


Most patients with familial nonhemolytic jaundice are not aware that they are abnormal. They will frequently complain of weakness and lack of energy, but they attribute this state to overindulgence in alcohol, lack of sleep, overwork, excitement or intercurrent infection. The jaundice appears only intermittently, and even then is usually mild in nature. The elevation of serum bilirubin is limited to the indirect fraction.

# CHART 43

## CONGENITAL NONHEMOLYTIC JAUNDICE WITH KERNICTERUS



(Childs & Naylor 1956)



**PATHOGENESIS**—The etiology of this disturbance is far less well understood than in that of congenital familial nonhemolytic jaundice with kernicterus. Dameshek and Singer have postulated that the disturbance may also represent a congenital inability to convert 'indirect' bilirubin to 'direct' bilirubin (Chart 44). Recently Arias and London have shown that a deficiency of bilirubin glucuronyl transferase exists in a patient with Gilbert's disease. This raises the serious question of whether congenital familial nonhemolytic jaundice with kernicterus and Gilbert's disease are one and the same condition. If so, some explanation must be found for the marked differences in clinical symptoms and the mode of genetic transmission.

**DIAGNOSIS**—For the present, familial nonhemolytic jaundice should be differentiated (1) from congenital familial nonhemolytic jaundice with kernicterus by the age of onset and severity of bilirubinemia, (2) from chronic idiopathic jaundice with hepatic pigmentation (Dubin-Johnson syndrome), where the diagnosis is made on the basis of liver biopsy and negative family history, (3) from hereditary spherocytosis by the absence of spherocytes and hemolysis, and (4) from jaundice due to liver disease by liver function tests.

**TREATMENT**—None is required.

Alwall N, Laurell C B and Nilsby I. Studies on heredity in cases of non hemolytic bilirubinemia without van den Bergh reaction (hereditary non hemolytic bilirubinemia). *Acta med scand nav* 124:114, 1946.

Arias I M and London J M. Bilirubin glucuronide formation in vitro: demonstration of a defect in Gilbert's disease. *Science* 126:563, 1957.



Dameshek W and Singer L. Familial nonhemolytic jaundice: Constitutional hepatic dysfunction with indirect van den Bergh reaction. *Arch Int Med* 67:259, 1941.

Gilbert A, Lereboullet P and Herscher M. Les trois choleemies congenitales. *Bull et mém Soc méd hôp Paris* 24:1203, 1907.

Meulengracht E. A review of chronic intermittent juvenile jaundice. *Quart J Med* 16:83, 1947.

Other laboratory tests are within normal limits. There is no macrocytosis or spherocytosis, the osmotic and mechanical fragility of erythrocytes is not altered, and the bone marrow is normal. Quantitative measurements of the urobilinogen in the stools have shown no evidence of blood destruction. The reactions of the liver function tests are consistently negative, and biopsies of the liver show only a slight fatty infiltration of the liver cells. As in congenital familial nonhemolytic jaundice with

## CHART 44

FAMILIAL NONHEMOLYTIC JAUNDICE

kernicterus, there is delayed excretion of bilirubin, as shown by the bilirubin excretion test.

**HEREDITY**—Familial nonhemolytic jaundice is probably transmitted as a dominant trait with incomplete penetrance. This is suggested in one study where half of the siblings and a quarter of the parents showed bilirubin levels in excess of 1.3 mg/100 ml. The exact hereditary pattern is difficult to determine because some affected individuals do not show consistent hyperbilirubinemia and other, normal, persons show slight icterus with fatigue or excessive intake of alcohol.

bones, ribs, jaws, and teeth. There are focal symmetrical defects in the metaphyses of the long bones. The spongiosa appears to be reduced, and the architecture of the cortex is coarse. There is a distinct brush border at the distal ends of the radius, tibia, and fibula.

At postmortem, many of the skeletal changes are found to be similar to those of rickets. The long bones are considerably shorter than the long bones of the normal infant of similar age. There is evidence of a deficiency of calcification, with the cartilaginous epiphyses separated from the diaphysis by a zone consisting mainly of osteoid tissue. Only vestiges of a zone of provisional calcification are present, and in most places the cartilage gives way to osteoid tissue without any calcification. There is also marked irregularity of the endochondral ossification, with islands and tongues of degenerate cartilage commonly present in the disorderly metaphyseal zones. Alkaline phosphatase is usually diminished or absent in the serum, tissues, and bone sections examined.

If the bone changes are marked, the affected infant may die in the neonatal period. If they are moderate, the infant will survive for a few years and die early in childhood, from either intercurrent infection or the complications of the bony deformities. A few individuals survive to adult life and are not greatly incapacitated by the defect.

**HEREDITY**—Hypophosphatasia appears to be transmitted as an autosomal recessive. The condition is usually seen among siblings, and not in different generations. A history of consanguinity has been noted in some of the affected families.

The heterozygous carriers of the abnormal gene can be detected in two ways: (1) the known parents of affected children frequently, although not always, show a decrease of alkaline phosphatase in the serum, and (2) these same individuals usually show an increased excretion of phosphoethanolamine, an abnormal metabolite in the urine.

The frequency of hypophosphatasia in the population is not known. The condition is probably not rare, however, since some 20 affected families have been described in England and at least an equal number in the United States.

**PATHOGENESIS**—The primary metabolic defect in hypophosphatasia appears to be a deficiency or absence of alkaline phosphatase, a disturbance which is genetically determined. This defect appears to be responsible for the principal bone changes in this disease: (1) deficient calcification, (2) excess of osteoid tissue, and (3) irregularity of endochondral ossification (Fig. 43).

In 1955, McCance, Morrison, and Dent in England, and Fraser, Yendt, and Christie in Canada, simultaneously observed that phos-

## Other Probable Enzyme Disturbances

The present chapter covers four miscellaneous enzyme disturbances. Two of these are fully expressed and the other two become apparent only under unusual circumstances. Those in the former group are *hypophosphatasia*, which is caused by a deficiency of alkaline phosphatase and *cystic fibrosis of the pancreas*, which is a generalized disease involving all of the exocrine glands. Those in the latter group are *deficiency of glucose 6  $PO_4$  dehydrogenase*, which appears only when the individual has been exposed to naphthalene, fava bean, or primaquine and *deficiency of pseudocholinesterase*, which can be demonstrated only when the patient has been given suxamethonium or procaine.


### I HYPOPHOSPHATASIA

In 1948, Rathbun reported on a 3 week-old infant with rachitic bone lesions and a diminution of alkaline phosphatase activity despite adequate doses of vitamin D. He felt that this represented a new developmental anomaly, and suggested that the condition be called 'hypophosphatasia.'


**CLINICAL FEATURES**—Patients with this condition show marked changes in the bones and teeth. The skeletal abnormalities include marked knock knees, bowing of the femurs and tibias, enlarged wrists, Hansen's groove, and a protuberant abdomen. These changes are frequently present at birth, and sometimes, by x ray studies, they can be shown to be present in utero. Spontaneous shedding of teeth prematurely is also a common feature of the disease.

Roentgenographic studies show poor mineralization of the long

## CHART 45

HYPOPHOSPHATASIA

(McConce et al 1956)



\*Fraser H Hypophosphatasia Am J Med 22 730 1957

Yendt, E. R., and Christie F H E Metabolic abnormalities in hypophosphatasia Lancet 1 286, 1955

McConce H A Fairweather H V I Barrett A M and Morrison A B Genetic, clinical, biochemical and pathological features of hypophosphatasia Quart J Med 25 523 1956

Morrison A B and Dent C E The excretion of phosphoethanolamine and hypophosphatasia Lancet 1 131, 1955

Rathbun J C Hypophosphatasia Am J Dis Child 75 822 1948

Sobel L H, Clark L C Jr Fox R M and Robinson M Rickets deficiency of "alkaline" phosphatase activity and premature loss of teeth in childhood, Pediatrics 11 309 1953



phosphoethanolamine was present in the urine of all patients with hypophosphatasia. More recently Pranker<sup>1</sup> has shown in a preliminary way that adenosinemonophosphate may also be in the urine of these patients.

At the present time it is difficult to postulate how these three biochemical defects are interrelated. There appears to be no real disturbance in



FIG. 43—Pelvis and extremities in hypophosphatasia. There is poor ossification at the metaphysal ends of the bones with slight irregularity of the epiphysal metaphysal junctions; also spotty areas of incompletely ossified bone in the tibias.

the handling of phosphoethanolamine. One current view is that the deficiency of bone alkaline phosphatase results in the accumulation of the natural substrate for that enzyme, which may well be phosphoethanolamine (Chart 45).

**DIAGNOSIS**—Hypophosphatasia may be diagnosed by a decrease of alkaline phosphatase in the serum (see Procedure 56) and the presence of phosphoethanolamine in increased amounts in the urine (see Procedure 57).

**TREATMENT**—The treatment is mainly supportive. There is no indication that vitamin D has any therapeutic value in this disease.

times that of normal controls. Similar changes were observed in the secretions of the salivary glands. In 1955, Sant Agnese reported a fourth defect, that of mucoproteins in the duodenal fluid. Precipitates of these mucoproteins by an ethanol benzene mixture are not readily soluble in



FIG. 44—Anteroposterior views of patient with cystic fibrosis of pancreas. *A* some pneumatic infiltrate in right midlung field with bilateral emphysema and a small amount of pulmonary fibrosis. *B* 1½ years later diffuse pulmonary fibrosis and emphysema progressing. *C* 1½ years later heart slightly enlarged marked progression of the pulmonary fibrosis and pneumonic consolidation in the right lower lobe.

water, whereas the precipitates from normal individuals are water soluble. These observations have led to the conclusion that fibrocystic disease of the pancreas represents a generalized disturbance of many—and perhaps all—of the exocrine glands.

Infants with this disease show marked retardation in physical growth, signs of vitamin deficiencies due to poor absorption of fats, bronchiectasis, and cor pulmonale. Cirrhosis of the liver is also a compli-

## 2 CYSTIC FIBROSIS OF THE PANCREAS

Cystic fibrosis of the pancreas is a congenital defect in which the clinical evidences of the celiac syndrome, resulting from pancreatic exocrine insufficiency, are combined with severe pulmonary disease and disturbances in the secretion of the sweat and salivary glands

**CLINICAL FEATURES**—The earliest and most severe manifestation of fibrocystic disease is *meconium ileus* in the newborn infant. In this condition the meconium fails to liquefy because of a marked deficiency or absence of pancreatic enzymes. The thick, tenacious meconium forms plugs causing intestinal obstruction, and the terminal ileum becomes greatly distended and hypertrophied. Failure to correct this condition soon after birth results in intestinal perforation and meconium peritonitis. On the other hand, after surgical correction prognosis in such children is similar to that in other children with cystic fibrosis of the pancreas. About 15% of all affected children develop meconium ileus at birth.


If the deficiency of pancreatic enzyme is not complete, the infants do not develop meconium ileus, but the initial symptoms result from poor intestinal digestion or respiratory tract infections. These infants appear to be normal at birth but soon fail to gain weight despite adequate food intake. In fact, many show an increased appetite. Also, the parents notice that the infant passes foul smelling bulky stools, a symptom which becomes worse following the addition of cereal or starchy foods.

The respiratory symptoms start off first as a severe nonproductive cough, which later becomes spasmodic and productive and at times is followed by vomiting. Because of these symptoms many of the infants are believed to be suffering from pertussis. The absence of the thin, watery secretions of mucus, which normally lubricate the cilia of the bronchial epithelium, causes the ciliary movement to be abolished. This results in the formation of thick, tenacious mucus within the trachea and bronchi and the child coughs to try to expel the material. The lack of ciliary action also permits secondary bacterial invasion of the lungs by *Staphylococcus aureus* of comparatively low virulence. The pulmonary infiltration gives a characteristic x ray picture which is diagnostic of the disease (Fig. 44).

In 1951, Kessler and Andersen reported that a number of infants with fibrocystic disease suffered from heat prostration during a heat wave in New York City. Two years later, Sant'Agnes and his co-workers showed that such prostration is caused by a depletion of salt. The concentration of sodium and chloride in the sweat of these infants was from 2 to 4


# CHART 46

## CYSTIC FIBROSIS OF THE PANCREAS



(D. Sant Agnese 1955)

? DEFICIENCY OF ENZYME COENZYME OR SUBSTRATE  
(IN SECRETORY CELLS)



cation. Death usually occurs in the first year or two of life, but life expectancy has been greatly prolonged through the combined use of high protein diets, pancreatin preparations, and wide spectrum chemotherapeutic agents.

During the past few years a number of reports have appeared showing the existence of partial pancreatic insufficiency. The affected individuals frequently show only one of the several manifestations usually seen in fibrocystic disease of the pancreas. Some individuals develop a progressive decrease of pancreatic enzymes without pulmonary symptoms. Others show changes in sweat electrolytes. These cases appear to be examples of a partial manifestation of cystic fibrosis, and the affected individuals are not thought to represent heterozygous carriers of the abnormal gene.

**HEREDITY**—Cystic fibrosis of the pancreas is transmitted as an autosomal recessive trait. Several large studies in both England and the United States suggest that the condition is fully penetrant. The disease affects siblings but not parents or collateral relatives. Since the gene is so common in the population, one does not find an increased incidence of consanguinity.

The heterozygous carriers of the abnormal trait are detectable in two ways: (1) many of the parents of affected children show an intermediate elevation of sweat electrolyte levels, and (2) some of them also demonstrate a decrease in duodenal enzymes. The former change appears with much greater regularity.

Population surveys have shown that the incidence of cystic fibrosis is between 0.7 and 1.0 cases per 1,000 live births. This means that 1 out of every 16.20 persons are carriers for the abnormal gene, a surprisingly common one. Since the homozygotes for cystic fibrosis always die before the age of reproductivity, geneticists have raised the question: How is this high gene frequency maintained? Two theories have been proposed: either (1) the heterozygotes have greater survival value or reproductive fitness, or both, compared with the general population, or (2) there is a high mutation rate for this gene. Since there is no specific evidence to support the former, we have to assume that the latter is the case.

**PATHOGENESIS**—Gochberg and Cooke have postulated the mechanism responsible for fibrocystic disease. They feel that it may be caused by a genetically determined deficiency of an enzyme, coenzyme, or substrate, with a consequent alteration in the release of energy. As a result the composition of secretion is abnormal. This may be reflected by the decrease of free-water clearance in this disease.

In any event, the generalized disturbance of exocrine gland function

- Pryles C V, and Gross, R E Meconium ileus, *AMA J Dis Child* 91 223, 1956
- Smoller M and Hsia D Y Y Studies on the genetic mechanism in cystic fibrosis of the pancreas *AMA J Dis Child* 98 277 1959

### 3 DEFICIENCY OF GLUCOSE 6- $\text{PO}_4$ DEHYDROGENASE

**CLINICAL FEATURES**—In 1952, Hockwald and his co-workers reported that when primaquine (8 [4-amino-1-methylbutylamino] 6-methoxyquinoline), an antimalarial agent, is given to patients, it induces intravascular hemolysis in about 10% of Negroes but rarely in Caucasians. This hemolytic cycle consists of three phases (1) *an acute hemolytic phase*, characterized by a marked fall in hemoglobin from about 15 Gm/100 ml to 10 Gm/100 ml in about a week, a rise of reticulocytes to 8% or higher, and a darkening of the urine due to massive hemolysis (radioactive tracer studies indicate that about half of the original red-cell population is destroyed during this time), (2) *a recovery phase*, which starts when the hemoglobin concentration begins to rise and later the reticulocyte count begins to fall (this phase lasts from 3 to 4 weeks), and (3) *an equilibrium phase* which is followed by the maintenance of normal hemoglobin levels and a reticulocyte count which is within normal limits. Laboratory studies have shown that the hemolysis is due to a defect of the red blood cells themselves and that there is no extracorporeal defect. Individuals with this condition have an increased tendency to Heinz body formation and their erythrocytes have been shown to have reduced amounts of glutathione.

Recently Zinkham and Childs have shown that hemolytic crises following the ingestion of fava beans and naphthalene moth balls occur because of the same mechanism. They showed that glutathione levels are markedly reduced when the erythrocytes of susceptible individuals are incubated with alpha and beta naphthol and with alpha- and beta naphthoquinone. The same hemolytic process can also be induced by the ingestion of acetanilide, sulfanilamide, Promizole®, phenylhydrazine, and menadione sodium bisulfite (Hykinone®).

**HEREDITY**—Zinkham and Childs have shown that the susceptibility to naphthalene moth ball poisoning is transmitted as a sex linked recessive from parent to child. This is presumptive evidence that all forms of deficiency of glucose 6- $\text{PO}_4$  dehydrogenase are transmitted by the same mechanism. The condition appears to be present in about 10% of Negroes but has been seen among Caucasians in only a few instances.

It should be emphasized that a relative deficiency of glucose-6- $\text{PO}_4$  dehydrogenase exists in normal newborn infants which makes them un-

appears to be responsible for all of the signs and symptoms of the disease (Chart 46). The changes in the electrolyte content of the sweat cause heat prostration. The lack of pancreatic enzymes causes meconium ileus in the young infant and poor absorption and utilization of food in the older child. This exocrine disturbance is also probably responsible for the changes in mucoproteins. The lack of mucous gland secretions accounts for the pulmonary changes and, in turn, cor pulmonale.

From these facts one can conclude that deficiencies of trypsin and amylase are not the fundamental enzyme defects in this disease but that they merely reflect a more basic process.

**DIAGNOSIS**—Although many tests are available for establishing the diagnosis of fibrocystic disease, probably the most valuable ones are those showing (1) abnormal composition of sweat electrolytes (see Procedure 58), (2) decrease of duodenal enzymes (this can be screened by the stool gelatin test [see Procedure 59] and more accurately ascertained by duodenal intubation [see Procedure 60]), and (3) changes in mucoprotein characteristics (Procedure 61).

**TREATMENT**—Early diagnosis, together with proper therapy, can frequently prolong the life expectancy greatly. In meconium ileus surgical intervention is indicated. When the condition appears in infancy the following regimen is recommended: (1) normal diet with avoidance of excessive fat, (2) twice the recommended dose of water miscible vitamins, (3) viokase powder,  $\frac{1}{4}$ – $\frac{1}{2}$  teaspoonful with each meal, (4) Aureomycin® or Achromycin® 5–15 mg per kilogram body weight daily, (5) in advanced cases, aerosol consisting of 100,000 units of aqueous penicillin and 250 mg streptomycin in 4 cc saline or detergent three times daily.

\*Bodian M. *Fibrocystic Disease of the Pancreas* (New York: Grune & Stratton Inc. 1953).

\**Fibrocystic Disease of the Pancreas*. Eighteenth Ross Pediatric Research Conference (Columbus, Ohio: Ross Laboratories 1955).

Gochberg S. H. and Cooke R. E. Physiology of the sweat gland in cystic

D: - - - - - pancreas with normal or

- - - - - E. Abnormal electrolyte

- - - - - chemical differences of

- - - - - the fibrosis of the pan

I - - - - - in fibrocystic disease of

\* - - - - - adosis, *Advances Pediat*

- Przyet, C. V., and Gross, R. E. Meconium ileus, *A.M.A. J. Dis. Child* 91 223, 1956
- Smoller, M., and Hsia D. Y. Y. Studies on the genetic mechanism in cystic fibrosis of the pancreas, *A.M.A. J. Dis. Child* 98 277, 1959

### 3. DEFICIENCY OF GLUCOSE-6- $\text{PO}_4$ DEHYDROGENASE

**CLINICAL FEATURES**—In 1952, Hockwald and his co-workers reported that when primaquine (8 [4-amino-1-methylbutylamino]-6-methoxyquinoline), an antimalarial agent, is given to patients, it induces intravascular hemolysis in about 10% of Negroes but rarely in Caucasians. This hemolytic cycle consists of three phases: (1) an *acute hemolytic phase*, characterized by a marked fall in hemoglobin from about 15 Gm/100 ml to 10 Gm/100 ml in about a week, a rise of reticulocytes to 8% or higher, and a darkening of the urine due to massive hemolysis (radioactive tracer studies indicate that about half of the original red-cell population is destroyed during this time), (2) a *recovery phase*, which starts when the hemoglobin concentration begins to rise and later the reticulocyte count begins to fall (this phase lasts from 3 to 4 weeks), and (3) an *equilibrium phase*, which is followed by the maintenance of normal hemoglobin levels and a reticulocyte count which is within normal limits. Laboratory studies have shown that the hemolysis is due to a defect of the red blood cells themselves and that there is no extracorporeal defect. Individuals with this condition have an increased tendency to Heinz body formation, and their erythrocytes have been shown to have reduced amounts of glutathione.

Recently, Zinkham and Childs have shown that hemolytic crises following the ingestion of fava beans and naphthalene moth balls occur because of the same mechanism. They showed that glutathione levels are markedly reduced when the erythrocytes of susceptible individuals are incubated with alpha- and beta-naphthol and with alpha- and beta-naphthoquinone. The same hemolytic process can also be induced by the ingestion of acetanilide, sulfanilamide, Promizole®, phenylhydrazine, and menadione sodium bisulfite (Hykinone®).

**HEREDITY**—Zinkham and Childs have shown that the susceptibility to naphthalene moth ball poisoning is transmitted as a sex-linked recessive from parent to child. This is presumptive evidence that all forms of deficiency of glucose-6- $\text{PO}_4$  dehydrogenase are transmitted by the same mechanism. The condition appears to be present in about 10% of Negroes but has been seen among Caucasians in only a few instances.

It should be emphasized that a relative deficiency of glucose-6- $\text{PO}_4$  dehydrogenase exists in normal newborn infants which makes them un-



appears to be responsible for all of the signs and symptoms of the disease (Chart 46). The changes in the electrolyte content of the sweat cause heat prostration. The lack of pancreatic enzymes causes meconium ileus in the young infant and poor absorption and utilization of food in the older child. This exocrine disturbance is also probably responsible for the changes in mucoproteins. The lack of mucous gland secretions accounts for the pulmonary changes and, in turn, *cor pulmonale*.

From these facts one can conclude that deficiencies of trypsin and amylase are not the fundamental enzyme defects in this disease but that they merely reflect a more basic process.

**DIAGNOSIS**—Although many tests are available for establishing the diagnosis of fibrocystic disease, probably the most valuable ones are those showing (1) abnormal composition of sweat electrolytes (see Procedure 58), (2) decrease of duodenal enzymes (this can be screened by the stool gelatin test [see Procedure 59] and more accurately ascertained by duodenal intubation [see Procedure 60]), and (3) changes in mucoprotein characteristics (Procedure 61).

**TREATMENT**—Early diagnosis, together with proper therapy, can frequently prolong the life expectancy greatly. In meconium ileus surgical intervention is indicated. When the condition appears in infancy the following regimen is recommended: (1) normal diet with avoidance of excessive fat, (2) twice the recommended dose of water miscible vitamins, (3) viokase powder,  $\frac{1}{4}$ - $\frac{1}{2}$  teaspoonful with each meal, (4) Aureomycin® or Achromycin® 5-15 mg per kilogram body weight daily, (5) in advanced cases, aerosol consisting of 100,000 units of aqueous penicillin and 250 mg streptomycin in 4 cc saline or detergent three times daily.

\*Bodian, M. *Fibrocystic Disease of the Pancreas* (New York: Grune & Stratton, Inc., 1953).

\**Fibrocystic Disease of the Pancreas*: Eighteenth Ross Pediatric Research Conference (Columbus, Ohio: Ross Laboratories, 1955).

Gochberg, S. H. and Cooke, R. E. Physiology of the sweat gland in cystic fibrosis of the pancreas. *Pediatrics* 18: 701, 1956.

Di Sant'Agnes, F. A. Fibrocystic disease of the pancreas with normal or partial pancreatic function. *Pediatrics* 15: 683, 1955.

———, Darling, R. C., Perera, G. A. and Shea, E. Abnormal electrolyte composition of sweat in cystic fibrosis of pancreas. *Pediatrics* 12: 549, 1953.

———, Dische, M. and Danilchenko, A. Physicochemical differences of mucoproteins in duodenal fluid of patients with cystic fibrosis of the pancreas and controls. *Pediatrics* 19: 252, 1957.


Kessler, W. R. and Andersen, D. H. Heat prostration in fibrocystic disease of pancreas and other conditions. *Pediatrics* 8: 648, 1951.

\*Shwachman, H., Leubner, H. and Catzel, P. Mucoviscidosis. *Advances Pediat.* 7: 249, 1955.


usually susceptible to naphthalene or primaquine. However, as the infant gets older, the enzyme becomes present in normal quantities, and this deficiency should not be confused with a genetically determined deficiency.

**PATHOGENESIS**—Carson and his associates have worked out the met-

CHART 47

GLUCOSE-6- $\text{PO}_4$  DEHYDROGENASE DEFICIENCY

[Childe et al. 1958]

DEFICIENCY OF GLUCOSE-6- $\text{PO}_4$  DEHYDROGENASE

abolic defect in primaquine sensitivity. In normal persons, glutathione is reduced in the manner shown in Figure 45. Taking erythrocytes from sensitized and normal individuals, these investigators were able to show that the first and third of these reactions were the same but that there was a deficiency of glucose-6- $\text{PO}_4$  dehydrogenase in the sensitized individuals.


The deficiency of glucose-6- $\text{PO}_4$  dehydrogenase results in an abnormality in the direct oxidation of glucose in the erythrocytes of these individuals. The ingestion of primaquine or naphthalene causes Heinz-body




FIG 45—Site of metabolic block in primaquine sensitivity of erythrocytes

- 1 Individuals with a dibucaine number of between 71 and 85 (which is a measure of the degree of inhibition of serum cholinesterase obtained with dibucaine under standard diet conditions and is expressed as a percentage) who are normal
- 2 Another group with a dibucaine number of between 58 and 66—individuals who most probably are heterozygotes for this abnormality

CHART 48  
SUSCEPTIBILITY TO SUXAMETHONIUM



(Lehmann & Ryan 1956)



- 3 Those with dibucaine numbers of 55 or less, who are probably homozygotes for this condition

On the basis of family studies, it would appear that this trait is transmitted as an autosomal recessive with about 1 in 5,000 individuals in the general population being homozygotes for the abnormality

**PATHOGENESIS**—Low pseudocholinesterase levels provide another example of an enzyme defect which would not be important or detectable under ordinary circumstances. However, when a specific chemical

formation and massive hemolysis accompanied by anemia, reticulocytosis and hemoglobinuria. The deficiency of glucose 6 PO<sub>4</sub> dehydrogenase also results in a failure to reduce oxidized glutathione, and this in turn is responsible for the low glutathione levels in such individuals (Chart 47).

**DIAGNOSIS**—The defect can be diagnosed by the deficiency of glucose 6 PO<sub>4</sub> dehydrogenase in the red cells (Procedure 61A) and the glutathione stability test (Procedure 61B).

**TREATMENT**—Hemolysis can be prevented by avoiding naphthalene, primaquine and other aniline derivative drugs.

Beutler E, Dern R J, Flanagan C L and Alving A S. The hemolytic effect of primaquine. VII. Biochemical studies of drug sensitive erythrocytes. *J Lab & Clin Med* 45:286 1955.

Carson P E, Flanagan C L, Ickes C M and Alving A S. Enzymatic deficiency in primaquine sensitive erythrocytes. *Science* 174:484 1956.

Childs B, Zinkham W, Browne E A, Kimbro E L and Torbert J V. A genetic study of a defect in glutathione metabolism of the erythrocyte. *Bull. Johns Hopkins Hosp* 102:21 1958.

Dern R J, Beutler E and Alving A S. The hemolytic effect of primaquine. II. The natural course of the hemolytic anemia and the mechanism of its self limited character. *J Lab & Clin Med* 44:171 1954.

Hockwald R S, Arnold J, Clayman C B and Alving A S. Status of primaquine. 4. Toxicity of primaquine in Negroes. *J.A.M.A.* 149:1569 1952.

Szeinberg A, Asher Y and Sheba, C. Studies on glutathione stability in erythrocytes of cases with past history of favism or sulphadiazine induced hemolysis. *Blood* 13:348 1958.

Zinkham W H and Childs B. Effect of naphthalene derivatives on glutathione metabolism of erythrocytes from patients with naphthalene hemolytic anemia. *J Clin Invest* 36:938 1957.

———, Lenhard R E and Childs B. A deficiency of glucose 6-phosphate dehydrogenase activity in erythrocytes from patients with favism. *Bull. Johns Hopkins Hosp* 102:169 1958.

#### 4 DEFICIENCY OF PSEUDOCHOLINESTERASE

**CLINICAL FEATURES**—Suxamethonium (succinylcholine) is a chemical compound used by anesthetists to induce relaxation of the muscles. The duration of its action is relatively short because it is soon destroyed by the pseudocholinesterase in the plasma. However, if the patient happens to have a low pseudocholinesterase level, he is likely to develop prolonged apnea following its use.

**HEREDITY**—Low concentrations of pseudocholinesterase can be caused by liver damage from malnutrition. However, Lehmann and Ryan have recently shown that idiopathic low pseudocholinesterase levels may be familial. The genetic transmission of this trait has been worked out by Kalow and his co-workers. They have shown that the human population may be divided into three types:

## PART IV

# Disturbances in Renal Transport Mechanisms

A NUMBER OF hereditary diseases arise because of defects in specific renal transport mechanisms. Before describing these disturbances in detail, it might be useful to review briefly how the mechanisms work in normal persons.

Urine is formed by two separate processes within the kidney. (1) A protein-like ultrafiltrate of plasma is prepared within the glomeruli; this appears to be a purely physical process and does not require any specialized transport mechanisms. (2) All but a minute fraction of this ultrafiltrate is reabsorbed in the proximal convoluted tubules; the remainder is excreted as urine. The process of reabsorption takes place because of specific renal transport mechanisms across the cell membranes. It has been shown that a number of distinct transport mechanisms are present in the tubular epithelium and that each of these operates more or less independently. For example, certain substances, such as water and electrolytes, are reabsorbed in sufficient proportions to maintain isotonicity with the extracellular fluid. Other substances, like glucose and the amino acids, must work against concentration gradients of a hundredfold or more.

At the present time, it is not entirely clear how these renal transport mechanisms function. Presumably, each one is governed

compound (suxamethonium) is administered, these individuals show prolonged apnea, and this could lead to death if not corrected immediately (Chart 48). Kalow and his co-workers have also expressed the view that the unusual dibucaine numbers in suxamethonium sensitive individuals is part of a typical pattern of substrate passivity and inhibition characteristics of serum cholinesterase which is present, and they suggest that this is due to the synthesis of an enzyme protein differing structurally in some way from that synthesized in some people. Thus, the peculiarity which gives rise to suxamethonium sensitivity is attributed not to the formation of normal cholinesterase in smaller amounts than normal but to the formation of a distinct enzyme protein with rather different catalytic properties from that of its normal counterpart.

**DIAGNOSIS**—Susceptibility to suxamethonium can be diagnosed by measuring pseudocholinesterase levels in the plasma (see Procedure 62).

**TREATMENT**—Individuals with this defect should avoid contact with suxamethonium and other anticholinesterases.

Kalow W. and Staron N. On distribution and inheritance of atypical forms of human serum cholinesterase as indicated by dibucaine numbers. *Canad J Biochem & Physiol* 35:1305, 1957.

Lehmann H., and Ryan E. The familial incidence of low pseudocholinesterase level, *Lancet* 2:124, 1956.

## Renal Transport Defects

### SINGLE DEFECTS IN RENAL TRANSPORT MECHANISMS

#### I. NEPHROGENIC DIABETES INSIPIDUS

In nephrogenic diabetes insipidus there is a congenital failure of the renal tubules to reabsorb water, a condition which does not respond to antidiuretic hormone. The disease was first described by Waring, Kadji, and Tappan in 1945.

**CLINICAL FEATURES**—The disease becomes apparent in early infancy, when it is characterized by a failure of the infant to thrive and develop normally and by attacks of unexplained fever, vomiting, and constipation. Polyuria may not be so noticeable as in an older child, although the mother may remember, in retrospect, that the baby's diaper always seemed to be wet. Thirst, too, is not an easily recognizable symptom in a young infant, although water, if offered between feedings, may be taken avidly.

There is a continual excretion of a large volume of dilute urine, as well as excessive thirst, and if sufficient water is not consumed, the patient will rapidly become dehydrated and feverish. During hot weather, infants may occasionally die from dehydration.

**HEREDITY**—The condition is transmitted as a sex linked recessive. All of the reported cases except one have been in males. The single affected girl was born out of wedlock, and the possibility that this child may be the offspring of a union that was consanguineous should be kept in mind.

It has always been noted that the mothers of known patients, who are presumed to be carriers, have suffered from excessive thirst and



by a separate gene which synthesizes either a special enzyme or an enzyme like substance, which in turn controls the reabsorption of a particular substance. However, no such enzymes have yet been isolated, and this may prove to be too simple an explanation. On the other hand, we are aware of at least six inborn errors of metabolism which result from a defect in one or another of the renal transport mechanisms, as shown in Table 3. The first four represent defects of a single mechanism, the last two involve several such mechanisms. The latter suggest that the genes for these renal transport mech-

TABLE 3.—RENAL TRANSPORT DEFECTS

CLINICAL CONDITIONS	RENAL TRANSPORT MECHANISMS					
	H <sub>2</sub> O	Glucose	Amino Acids		P	K
			Diabasic	Others		
1 Nephrogenic diabetes insipidus	+					
2 Renal glycosuria		+				
3 Resistant rickets					+	
4 Cystinuria			+			
5 Fanconi syndrome	(+)	+	+	+	+	(+)
6 Cystinosis	(+)	+	+	+	+	(+)

+ Mechanism involved (+) Mechanism sometimes involved

anisms may be located close to one another, or may even represent multiple alleles at the same locus. With the passage of time and the improvement of techniques for study, additional defects will undoubtedly be described.

These primary defects of renal transport mechanisms should not be confused with secondary renal disturbances. For example, the aminoaciduria in Wilson's disease and galactosemia are secondary manifestations of a more basic defect elsewhere. In these cases the disturbances in renal transport are usually not present at birth and can frequently be abolished upon correcting the primary metabolic error.

- Carter, O. C., and Simpkins, M. The "carrier" state in nephrogenic diabetes insipidus, *Lancet* 2 1069, 1956
- Waring, A. J., Kadju, L., and Tappan, V. A congenital defect of water metabolism, *Am. J. Dis. Child* 69 323, 1945
- Williams, R. H., and Henry, C. Nephrogenic diabetes insipidus Transmitted by females and appearing during infancy in males, *Ann. Int. Med.* 27 84, 1947

## 2. RENAL GLYCOSURIA


Renal glycosuria is a benign condition characterized by the excretion of glucose in the urine when the blood sugar is normal

**CLINICAL FEATURES**—Patients with this condition are completely well and remain free of symptoms. Some of the individuals with renal glycosuria have been followed for many years, and none have developed diabetes mellitus or any of the other complications attributable to the sugar in the urine. The condition is important only as a point of differential diagnosis in diabetes mellitus.

**HEREDITY**—The condition is transmitted as an autosomal dominant

CHART 50

### RENAL GLYCOSURIA



(Hjelle, 1927)

DEFECT IN RENAL TRANSPORT FOR GLUCOSE




GLYCOSURIA


polyuria Recently, Carter and Simpkins investigated four families having the disease, and they found that the administration of Pitressin® did not reduce the polyuria or affect the specific gravity of the urine. However, simple measurements of urine concentration after withholding fluid intake for 12 hours gave reasonably good discrimination between normal individuals and presumed heterozygotes.

**PATHOGENESIS**—All of the signs and symptoms can be attributed to

CHART 49

NEPHROGENIC DIABETES INSIPIDUS

(Carter &amp; Simpkins 1956)

DEFICIENCY OF RENAL TRANSPORT MECHANISM FOR  $H_2O$ 

■ specific defect of the renal tubules which renders them unable to reabsorb water (Chart 49). The patients also fail to respond to antidiuretic hormone.

**DIAGNOSIS**—The diagnosis is suggested by the large urine volume and the failure to concentrate above pH 1.004. The patient should be given the Pitressin® test (see Procedure 63). A failure to concentrate after Pitressin® indicates nephrogenic diabetes insipidus.

**TREATMENT**—Adequate fluid intake is necessary to maintain life.

Carter, O. C., and Simpkins, M. The "carrier" state in nephrogenic diabetes insipidus, *Lancet* 2: 1069, 1956

Waring, A. J., Kadu, L.; and Yappan, V. A congenital defect of water metabolism, *Am J Dis Child* 69: 323, 1945

Williams, R. H., and Henry, C. Nephrogenic diabetes insipidus. Transmitted by females and appearing during infancy in males, *Ann. Int. Med.* 27: 84, 1947

## 2. RENAL GLYCOSURIA


Renal glycosuria is a benign condition characterized by the excretion of glucose in the urine when the blood sugar is normal.

**CLINICAL FEATURES**—Patients with this condition are completely well and remain free of symptoms. Some of the individuals with renal glycosuria have been followed for many years, and none have developed diabetes mellitus or any of the other complications attributable to the sugar in the urine. The condition is important only as a point of differential diagnosis in diabetes mellitus.

**HEREDITY**—The condition is transmitted as an autosomal dominant.

CHART 50

### RENAL GLYCOSURIA



(H. Stone, 1927)

DEFECT IN RENAL TRANSPORT FOR GLUCOSE



GLYCOSURIA

In a survey based on one large family over several generations, Hjarne found that 34 out of 199 blood relatives were affected

Renal glycosuria is a rare disorder. Only about 0.3% of all cases of melituria can be attributed to it.

**PATHOGENESIS**—The condition is believed to represent a congenital defect of the renal transport mechanism for glucose (Chart 50). Normally, glucose passes freely into the glomerular filtrate and is almost completely reabsorbed by the proximal convoluted tubules. In renal glycosuria, however, this mechanism appears to be in some way inefficient, and the glucose passes into the urine. Some years ago, Friedman showed that, when the blood sugar was in the normal range of 100-200 mg/100 ml, these patients spilled glucose into the urine. More recently, Reubi has measured the ratio of  $Tm_G/C_T$  (maximal reabsorptive capacity for glucose divided by glomerular filtration rate). In the normal individual this equals  $2.41 \pm 0.35$ . In patients with renal glycosuria on a hereditary basis it is reduced to between 1.2 and 1.7 and remains low with increasing glucose loads of up to 600 mg/minute (Fig. 46). This finding is in distinct contrast to the findings in other nonfamilial types of renal glycosuria, in which the ratio rises with increased loads. The transport defect is limited to glucose alone, other clearance tests are perfectly normal in such individuals.

Recent evidence suggests that the transport mechanism for glucose involves the stepwise phosphorylation and dephosphorylation of glucose in the cells of the proximal convoluted tubule. This would involve (1) the utilization of phosphate bond energy, (2) the interaction of the transport compound and the cellular element involving carboxyl mechanism and (3) certain interdigitations with acetate metabolism, which should be apparent. If this is actually the case, a deficiency of one of the tissue phosphatases in the kidney could well account for the metabolic defect in renal glycosuria.

**DIAGNOSIS**—The proper diagnosis of renal glycosuria requires (1) that glucose be present in appreciable quantities in the urine on several occasions, both when fasting and postprandially, (2) that blood sugar levels and glucose tolerance curves be consistently normal, (3) that moderate doses of insulin exert little or no effect upon the glycosuria, and (4) that both carbohydrate and fat utilization be normal.

**TREATMENT**—None is required.

Friedman, M., Selzer, A., Sugannan, J., and Sokolov, M. Renal blood flow glomerular filtration rate and degree of tubular reabsorption of glucose in renal glycosuria, *Am J Med Sci* 204:22, 1942.





FIG 46—*Top*, ratio of  $T_0/C_r$  to glucose load  $C_T P_g$  in six renal glycosuric patients. The ratio remains far below the normal range of  $2.41 \pm 0.35$  even for high values of filtered glucose. *Bottom*, ratio of  $T_0/C_r$  to glucose load  $C_T P_g$  in three other glycosuric patients. The ratio is below normal range for low values of filtered glucose  $C_T P_g$  but increases rapidly and almost linearly when the amount of filtered glucose is raised, becoming normal at high levels of blood glucose.

I  
 CP 20 433 1949  
 21 1 2

*Ciba Foundation Symposium on the Kidney* (Boston: Little Brown & Company, 1954) p. 65

### 3 RESISTANT RICKETS (refractory rickets, raised late rickets, resistance to vitamin D, essential hypophosphatasia rickets)

The term 'resistant rickets' describes a clinical condition which is distinguishable from ordinary rickets except that the signs occur despite an adequate intake of vitamin D in the diet. Resistant rickets is believed to occur because of a defect in the renal transport mechanism for phosphorus.

**CLINICAL FEATURES**—While ordinary rickets is uncommon in patients beyond the eighteenth month, refractory rickets persists or may



FIG. 47.—Pelvis of patient with resistant rickets. Note the lateral slipped femoral heads. The width of the epiphyseal metaphyseal junction is increased because the osteoid failed to convert to bone.

even manifest itself for the first time in childhood. The clinical findings are those of florid rickets, with bossing of the frontal bones, beading of the ribs, narrow flaring chest, prominent abdomen, swelling of the epiphyses of the wrists and ankles, and bowing of the legs and pronation of the feet. Progression of the defect in mineralization will lead to retarded growth and skeletal deformities (Fig. 47). Adults with this condition are

usually in good general health but may suffer from bone pains especially in the lower back region. There may be a severe muscular weakness, which sometimes causes confusion with muscular dystrophy. Tetany, however, never occurs.

The primary feature of the disease is its refractoriness to treatment with ordinary doses of vitamin D.

**HEREDITY**—The condition is usually transmitted as a sex linked dominant. In the past, geneticists thought that the dominance was incomplete in its manifestations since quite a few cases seemed to occur in families in which both parents appeared to be perfectly healthy and normal. It was felt that these cases could not all be caused by fresh mutations. Recently, Graham has clarified the situation in some studies on a large kindred in North Carolina. He found that a low serum phosphorus level was transmitted as a dominant with complete manifestation but that not all of the affected individuals showed clinical signs of rickets.

No figures are available on the incidence of resistant rickets in the population. The disease is probably quite rare, since less than 100 cases have been reported from all over the world.

**PATHOGENESIS**—Resistant rickets represents a congenital defect in the renal transport mechanism for phosphorus (Chart 51). The lack of reabsorption of phosphorus has the effect of keeping the plasma phosphate concentration at a permanently low level, usually in the order of 2 mg/100 ml. This in turn leads to a failure of normal bone development, manifested by most of the classical features of rickets.

The action of vitamin D on this condition is the subject of considerable dispute. Albright and his co-workers have expressed the view that in normal individuals the rising phosphorus level following the administration of vitamin D should be attributed to a decreased parathyroid activity resulting from the rise in serum calcium. They visualize the following sequence of events occurring after the administration of vitamin D: in-


... feels that vitamin D in massive doses exerts its effects directly on the renal tubules. Simultaneous determinations of the rates of glomerular filtration and of phosphorus clearance before treatment and when healing was well advanced have shown that the rise of serum inorganic phosphorus coincides with an increased efficiency of the tubular epithelium in reabsorbing phosphorus from the glomerular filtrate.

**DIAGNOSIS**—The diagnosis can be established by the finding of a



216      **DISTURBANCES IN RENAL TRANSPORT MECHANISMS**  
 persistently low serum phosphorus level (2 mg/100 ml) despite adequate vitamin D therapy

**TREATMENT** —Very large doses of vitamin D are required. As a rule daily dosages of 200,000-400,000 units of oral calciferol are needed to cure the radiological signs and to prevent recurrence. It should be careful



ly noted that the toxic dose, the therapeutic dose, the only to its not to find the

D may not be resistance to not to 1 5 mg/

than this It is of to raise

calcium to no more than 11.5 mg/100 ml and the urine calcium to no more than 400 mg/24 hours.

Albright, F., Burnett, C. H., Parson, W., Reifenstein, E. C., Jr., and Roos, A.: Osteomalacia and late rickets, *Medicine* 25: 399, 1946.

Robertson, B. R., Harris, H. C., and McCune, D. J.: Refractory rickets. Mechanism of therapeutic action of calciferol, *Am J Dis Child* 64: 948, 1942.

\*Winters, H. W., Graham, J. B., Williams, T. F., McFalls, V. W., and Burnett, C. H.: A genetic study of familial hypophosphatemia and vitamin D resistant rickets, with a review of the literature. *Medicine* 37: 97, 1958.

#### 4. CYSTINURIA

A congenital defect in the reabsorption of the dibasic amino acids in the renal tubules appears to be responsible for the clinical condition known as "cystinuria." This disease is of historic interest because it is one of the original four inborn errors of metabolism described by Sir Archibald Garrod.

**CLINICAL FEATURES**—The first case of cystinuria was probably described by Wollaston in the *Philosophic Transactions* of the Royal Society in 1810. However, it was not until over a century later that it became known that renal calculi are composed almost entirely of cystine. More recently, Dent and Rose have shown that the abnormality in the urine is not limited to cystine alone but that three other dibasic amino acids—lysine, arginine, and ornithine—are also involved. On the average, a patient with cystinuria will, in the course of a day, excrete 0.73 Gm of cystine, 1.8 Gm of lysine, 0.83 Gm of arginine, and 0.37 Gm of ornithine, and these amounts persist throughout his life relatively uninfluenced by dietary intake. Stone formation occurs in such patients because cystine is one of the least soluble of the amino acids. In urine of pH 5-7, cystine is soluble only to the extent of 300-400 mg/L. It can be seen that when the urine volume decreases, particularly at night, this amino acid is likely to come out of solution, and renal calculi may form. Since lysine, arginine, and ornithine are freely soluble, they do not become incorporated in stone.

Harris and his associates have recently suggested that patients with cystinuria may be divided into two phenotypes: (a) those who show a greatly increased excretion of cystine, lysine, arginine, and ornithine in their urine and who often develop cystine stones, and (b) those who

show only a moderate increase of cystine and lysine but no increase of arginine in the urine and who never develop cystine stones

**HEREDITY**—Family studies indicate that cystinuria occurs in two separate genotypes. In Type I, which is transmitted by an autosomal recessive gene, the mode of inheritance is suggested (1) by the fact that abnormal individuals are found only in a single sibship in each family with the parents, children, and other near relatives being normal, and (2) by the increased incidence of consanguinity among the parents. The individuals who are homozygous for the cystinuric gene belong to phenotype (a) and have large increases of all four amino acids in the urine and have cystine stones. No urinary abnormalities may be demonstrated among the heterozygous carriers of this abnormal gene. In Type II, which is also transmitted by an autosomal recessive gene, the individuals who are homozygous again belong to phenotype (a) and frequently have cystine stones. However, the heterozygotes of this type show changes in the urine which are characteristic of phenotype (b), and they can clearly be differentiated from individuals who are completely normal.


It would appear that these two types represent the effects of separate genes rather than those of a single gene affected by modifiers. The absence of any instances of a child with a group (a) pattern being derived from normal parents or from a parent with (b) pattern is rather in favor of the genes being located at two different loci.

In the past, it was felt that cystinuria was a comparatively rare metabolic disorder. Garrod stated that Simon encountered only one instance of cystine sediment in 15,000 urines examined. In 1932, Lewis threw a completely new light on the situation. By using reliable chemical tests for cystine, he was able to demonstrate that gross cystinuria could occur in individuals without either the appearance of cystine crystals or formation of cystine stones. In a systematic experiment involving over 10,000 students, he found that 18 gave positive reactions to chemical tests for cystine but that only 4 showed cystine crystals in the urine. He estimated that approximately 1 in 600 of the general population excreted abnormally large quantities of cystine, even though it is not clear at present how many of the affected individuals are homozygotes and how many are heterozygotes.

**PATHOGENESIS**—Although early workers have suggested that cystinuria occurs as a result of some kind of block in the intermediary metabolism of cystine or methionine, Dent and his associates have clearly demonstrated that the primary defect is at the site of renal excretion of cystine and lysine. They

**CHART 52**

## CYSTINURIA

DEFICIENCY IN RENAL TRANSPORT MECHANISM FOR  
DIBASIC AMINO ACIDS

increased excretion  
in case of



Cyst no

Lyb. 00

**Are you**

On the one

### Formation of Cystine calculi

have shown that in cystinurias the cystine levels in plasma and other body fluids are comparable to or even lower than the levels in normal controls. There is no excessive accumulation of cystine in the cystine rich tissues such as hair and nails. The feeding of large amounts of cystine, methionine and cysteine to these patients and to normal individuals produced no differences in the intermediary metabolism of these substances. Finally, they have shown that the clearance of cystine in cystinurias is often more than 30 times that found in normal individuals and thus in

about the same as the expected rate of glomerular filtration. It seems probable that cystinuria can be explained on the basis that little or no renal tubular reabsorption of cystine takes place in these patients. Presumably, the same difficulties in reabsorption apply to lysine, arginine and ornithine.

**DIAGNOSIS**—Cystinuria can be diagnosed by the presence of excessive amounts of cystine in the urine (see Procedure 64). The condition can be differentiated from cystinosis in two ways: (1) by determining the type of aminoaciduria and (2) by the clinical pattern. By the use of paper partition chromatography (see Procedure 65), it is possible to demonstrate that in cystinuria the aminoaciduria is limited to the four dibasic amino acids, with the other amino acids being excreted in normal quantities, while in cystinosis the aminoaciduria is a generalized one. Clinically, cystinosis is a systemic disease with deposits of cystine in the eyes, liver, kidneys, and long bones, and rickets is a common finding. None of these phenomena are present in cystinuria.

**TREATMENT**—Therapy should be directed toward reducing the formation of cystine stones in the kidneys. This can be done by greatly increasing the fluid intake, especially at night, and by making the urine alkaline with sodium bicarbonate or lactate.

Dent

I

col

20 205 1951

and Senior, B. Studies in the treatment of cystinuria. *Brit J Urol* 27 317 1955

Harris, H. Mittwoch, U., Robson, E. B. and Warren, F. L. Phenotypes and geno-

20 57 1045

74 1957

I

young men and women

Stein, W. H. Excretion of amino acids in cystinuria. *Proc Soc Exper Biol & Med* 78 705 1951

## MULTIPLE DEFECTS IN RENAL TRANSPORT MECHANISMS

Although many variants of defects in the reabsorption of phosphates, glucose, amino acids, and sometimes potassium and water have appeared in the literature, the defects can usually be classified into two general groups: (1) those with renal tubular dysfunction but without cystine deposits, usually called 'Fanconi syndrome', and (2) those with both renal tubular dysfunction and cystine deposits, known as 'Lignac's disease'. At the present time, there is considerable controversy as to whether the Fanconi syndrome and Lignac's disease are one and the same condi-

tion We feel that deposits of cystine in the body tissues are sufficiently unique to require that they be considered as a separate condition

## 5 FANCONI SYNDROME

In 1931, Professor Fanconi in Zurich briefly described finding rickets and stunted growth in a child with albuminuria and glycosuria Two years later, de Toni in Italy reported on a dwarfed child who had vitamin D resistant rickets and spontaneous fractures and who showed a low level of serum phosphorus, acidosis, pronounced glycosuria, and albuminuria A little later, Debre reported a similar case from France In 1936, Fanconi collected all these cases, added two more of his own, and established a new syndrome, which he called "nephrotic glycosuric dwarfism with hypophosphatemic rickets" The third feature of this condition, aminoaciduria, was described by Dent in England and the Fanconi syndrome became a definite clinical entity

**CLINICAL FEATURES**—The Fanconi syndrome can clinically be divided into two types *infantile* and *adult* Although physiologically and pathologically these types appear to be identical, they may represent different gene mutations

In the *infantile* type, the infant grows and develops normally during the first 6-8 months of life The parents then note his refusal of feed ings other than liquids, the development of polyuria, and a cessation of growth The infant may be brought into the hospital in a crisis, with fever, dehydration, and acidosis In older children the bone deformities due to rickets are often striking and there is a marked shortening of stature Physical examination may disclose florid rickets which develops despite adequate vitamin D prophylaxis, and there may be severe malnutrition, variable fever associated with dehydration, and occasional enlargement of the liver, as well as dwarfism The skeletal musculature may be very flabby and hypotonic The blood pressure is usually normal initially but may rise as the renal disease progresses

In contrast, in the *adult* type the patients seldom show any manifestations until the second or third decade of life The initial complaints are severe pain in the back, shoulder, ribs, and thighs and spontaneous fractures Laboratory studies usually show glycosuria and aminoaciduria Whether or not the renal changes have been present since birth is not known, but the possibility that the disease develops in later life is very real Death usually occurs after a crisis characterized by hypokalemia and uremia

The only consistent changes noted at postmortem are in the kidneys

The epithelial cells lining the tubules are, in many places, extremely large, practically blocking the lumen, but this is not a cloudy, swollen type of enlargement, and there is no evidence of degeneration.

**HEREDITY**—The condition is probably transmitted by an autosomal recessive gene. The affected individuals are usually found in a single sibship, with parents, offspring, and near relatives being unaffected. There is sometimes a history of consanguinity, and at least one example of involvement in both members of a pair of identical twins has been reported to date.


mal genes may be involved. It is interesting to speculate whether these genes are at different loci or are alleles. If the latter is the case then the underlying biochemical disturbances leading to the clinical syndrome would be qualitatively very similar, although different in degree.

**PATHOGENESIS**—All of the clinical signs and symptoms can be explained on the basis of a defect in the proximal convoluted tubules. This is shown first by the fact that the functions classically relegated to the distal portions of the nephrons—namely, production of ammonia and acid—are relatively well preserved in the majority of cases. Secondly, Clay and his co-workers have shown that, if the nephron is dissected free throughout its entire length, the glomeruli appear to be uniform and normal throughout but that there is a "swan neck" appearance of the first portion of the tubule. There is also a shortening of the proximal convoluted tubules, including their narrow portion. It is not clear whether this is a developmental defect in the morphological sense or whether it represents secondary changes due to a chemical defect. However, there appears little doubt that the proximal portion of the convoluted tubule is disturbed. Finally, Stowers and Dent, and Cooke and his associates have shown, by Gomori's stain, a complete absence of phosphatase in the proximal convoluted tubules, and this may represent the genetically determined enzyme defect responsible for this condition.


Regardless of the cause, the primary defects lie in the renal transport mechanisms for glucose, phosphates, amino acids and, to a less marked extent, for water and potassium. The pedigree of causes for the Fanconi syndrome is shown in Chart 53. The loss of phosphates is responsible for the rickets and bony changes, the loss of amino acids, probably for the cirrhosis and fatty infiltration of the liver, and the loss of water and potassium, in the terminal hypokalemia.

**DIAGNOSIS**—The diagnosis of the Fanconi syndrome is difficult be

CHART 53  
FANCONI SYNDROME



(De & Ho 1956)



cause no one change is specific for the condition. Some of the laboratory findings which are characteristic of the condition are:

acidosis

Renal function tests may not be remarkable during the early part of the disease

TREATMENT —The adult form of the disease responds quite well to



doses of potassium or sodium bicarbonate and vitamin D. The infantile form shows some response to this treatment, but the ultimate outlook is poor because most of the patients succumb eventually to renal failure.

Clay, H. B., Darmady, E. M., and Hawkins, M. The nature of the renal lesion in the Fanconi syndrome. *J. Path. & Bact.* 65: 551, 1953.

Cooke, W. T., Barclay, J. A., Govan, A. D. T., and Nagley, L. Osteoporosis associated with lowered serum phosphorus and renal glycosuria. *Arch. Int. Med.* 80: 147, 1947.

Dent, C. E. The amino-aciduria in Fanconi syndrome. *Biochem. J.* 41: 240, 1947.

— and Harris, H. Hereditary forms of rickets and osteomalacia, *J. Bone & Joint Surg.* 38B: 204, 1956.

— and C. E. Dent. The nature of the renal lesion in the Fanconi syndrome. *J. Path. & Bact.* 65: 551, 1953.

*Quart. J. Med.* 16: 275, 1947.

## 6 CYSTINOSIS (Lignoc's disease)

In 1903, Abderhalden reported on some chemical examinations carried out on tissues from a 21-month old Swiss infant dying of "marasmus." He found that the white flecks on the liver and spleen, which were hexagonal or round, were deposits of cystine. Since two other siblings had died of identical complaints, he tested the urine sediments of all members of the immediate family and found that all showed cystine. He there-

growth, severe rickets, "severe renal disease," and progressive dwarfism. At autopsy, widespread cystine deposits were found in all three cases. Subsequently, one of Fanconi's cases of "nephrotic glycosuric dwarfism with hypophosphatemic rickets" was also found to have cystine deposits, and so the clinical entity of cystinosis was established.

**CLINICAL FEATURES**—Clinically the patients have all of the manifestations described in the de Toni-Fanconi-Debre syndrome. Dwarfism, wasting, rickets, osteoporosis, polydipsia, polyuria, dehydration, and acidosis are prominent findings. In addition, photophobia is usually noted. Cystine crystals may be interstitial, but usually they are accumulated in the large phagocytic reticuloendothelial cells, primarily in the liver, spleen, kidneys, lymph nodes, and bone marrow (Fig. 48).

**HEREDITY**—Bickel and Harris have postulated that the condition is transmitted as an autosomal recessive. This is suggested by these facts

it has never been known to occur in different generations, there is often a history of consanguinity, and only siblings are involved in any given family. The heterozygotes cannot be detected by chemical means, not even by the newly developed lysine tolerance test (see Procedure 66).

Cystinosis is not genetically related to either cystinuria or the de Toni-Fanconi-Debre syndrome. Considerable confusion has arisen





FIG 48.—Photomicrograph of liver section from a patient with cystinosis. Deposits of cystine crystals occupy Kupffer's cells and hepatic cells; seen here in foamy groups of cells especially prominent adjacent to a venule. The hepatic cells also show coarse cytoplasmic vacuoles, indicative of fatty metamorphosis.

over the fact that Abderhalden described the heterozygotes of his original pedigree as being cystinurics. This does not seem to be likely, because (1) no cases of cystinosis have since been found among pedigrees of cystinuria and (2) no examples of cystinuria with characteristic urinary amino acid patterns have ever been found among families with cystinosis.

The frequency of cystinosis in the general population is estimated to be roughly 1 in 40 000, with a gene frequency of 1 in 200.


**PATHOGENESIS**—The pathogenesis of the rickets, renal changes, and electrolyte disturbances is identical to that of the de Toni-Fanconi-Debre syndrome. The etiology for the cystine deposits is completely unknown.

# CHART 54 CYSTINOSIS



{ Dent & Morris 1956 }

(Chart 54) At least three theories have been proposed (1) that there is a failure of oxidative degradation of cysteine to sulfate along the metabolic pathway proposed by Brand and his associates (Fig 49), which results in its increased oxidation to cystine, (2) that there is a defect in the utilization of amino acids in the kidneys which results in cystine storage, and (3) that there is a defect in the intracellular metabolism of amino acids within the reticuloendothelial system, resulting in cystine deposits. No proof has come forth for any of these theories, and we are



serum in normal amounts, that cystine is excreted through the urine in slightly greater amounts, but no more so than any of the other amino acids, and that something has happened to the cystine in transit.

**DIAGNOSIS**—The diagnosis can be established by identifying cystine (see Procedure 67) in the urine.

**DIAGNOSIS**—The diagnosis can be established by identifying cystine (see Procedure 67) in the bone marrow, liver, or kidney. Clinically, cystine can easily be seen in the eyes with the aid of a slit lamp.

**TREATMENT**—Patients are helped by treatment with sodium citrate, and moderately

**TREATMENT**—Patients are helped by treatment with citric acid, sodium citrate, and moderately high doses of vitamin D. Potassium chloride

should be added also, to prevent hypokalemia. The prognosis is universally poor in children.

Abderhalden, E. Familiäre Cystinurie. *Ztschr physiol Chem* 111:557, 1903.

\*Worthington, H. G. Cystinuria: a review of the clinical and laboratory features.

" " " " " "

" " " " " "

71:1016, 1924.

Robson, M. H., and Rose, G. A. The effect of intravenous lysine on the renal clearances of cystine, arginine, and ornithine in normal subjects, in patients with cystinuria, in Fanconi syndrome, and in their relatives, *Clin Sc* 16:75, 1957.

\*Worthington, H. G., and Good, R. A. The de Toni-Fanconi syndrome with cystinosis, *AMA J Dis Child* 95:653, 1958.

## PART V

# Disturbances in Which the Etiology is Unknown

WE SHALL NOW CONSIDER some of the hereditary diseases about whose primary gene effect we know relatively little. These diseases will, therefore, be grouped according to the presenting symptoms, with the thought that their classification will be changed when more is known about the chemical defects responsible for each of these in-born errors of metabolism.

These disturbances will be arbitrarily divided into (1) disturbances in lipid metabolism, (2) the muscular dystrophies, and (3) miscellaneous metabolic disorders.

## Disturbances in Lipid Metabolism

IN THIS CHAPTER, we shall take up the disturbances involving lipid metabolism. These include (1) *idiopathic hyperlipemia*, (2) *primary hypercholesteremia*, (3) *Gaucher's disease*, (4) *Niemann-Pick disease*, (5) *amaurotic familial idiocy*, and (6) *lipochondrodystrophy*.

\*Crocker, A. C. Skin xanthomas in childhood. *Pediatrics* 8: 573, 1951.

\*Herdon, C. N. Genetics of the lipidoses. *Proc. A. Res. Nerv. & Ment. Dis.* 33: 239, 1954.

### 1. IDIOPATHIC HYPERLIPEMIA (Buerger-Grütz disease)

In 1932, Buerger and Grütz described a new clinical syndrome in children which was characterized by the following triad: (1) sporadic attacks of acute abdominal pain, (2) a xanthomatous type of skin lesion, and (3) a fasting serum which is milky white. About 40 such cases have been reported from all over the world. Since the condition is frequently familial, it is customarily included among the inborn errors of metabolism.

**CLINICAL FEATURES**—Affected children usually first come to the attention of the physician because of peculiar attacks of abdominal pain characterized by extreme tenderness, boardlike rigidity, and sometimes collapse. Such an attack is accompanied by fever, polymorphonuclear leukocytosis, and anorexia, and it is sometimes mistaken for a surgical emergency. It lasts from 1 to 4 days and then terminates spontaneously with a decrease of the serum lipid levels.

Another prominent feature is the presence of cutaneous xanthomas (Fig. 50). These consist of soft yellow papules and nodules, commonly located in the extensor aspects of the knees and elbows, on the buttocks and thighs, and also on the trunk, face, hands, and feet. Xanthelasmata (of the eyelids) does not seem to occur in such patients. When the blood



FIG 50—Cutaneous xanthomas in patient with idiopathic hyperlipemia (From Boggs, J D, Hsia, H Y Y, Mann, R, and Bigler J A. The genetic mechanism of idiopathic hyperlipemia. *New England J Med* 257 (10): 1957.)



FIG 51—Heart in a patient with idiopathic hyperlipemia opened to expose the left ventricular endocardium and base of aorta. Endocardial and myocardial fibrosis is apparent and left ventricular myocardium shows hypertrophy.







FIG 52 —Photomicrographs of sections of heart shown in Figure 51 *Top* left coronary artery Advanced atherosclerosis has reduced the vascular lumen to a narrow slit Focal calcification is seen in the atheroma *Bottom* margin of the myocardial infarct Young still moderately vascular scar tissue has replaced a portion of the myocardium

lipid levels rise excessively, *lipemia retinalis* can be seen easily. Episodes of relapsing pancreatitis and atherosclerosis are the principal complications, and many affected individuals suffer from angina pectoris or myocardial infarction in the teens or twenties (Figs 51 and 52).

**HEREDITY**—Idiopathic hyperlipemia is transmitted by an autosomal recessive gene. The condition has been noted among siblings in at least eight different families, and consanguinity has been reported once. Some of the asymptomatic relatives, who are presumably heterozygous carriers

CHART 55



of the abnormal gene, have been found to have slight, but definite, increases in serum lipid levels.

The condition has been reported among both whites and Negroes and has been seen in different parts of the world. Although the exact incidence of this disease is not known, the condition probably occurs fairly rarely. In this era of frequent blood tests, it is unlikely that many cases are missed, because of the striking appearance of the serum.

**PATHOGENESIS**—Some unknown defect in fat metabolism is responsible for idiopathic hyperlipemia (Chart 55). Thannhauser and Stanley have shown that when  $P^{32}$  labeled neutral fat is administered to affect-

ed individuals, the disappearance of iodine from the blood serum is considerably prolonged, as compared with normal subjects. In 1940, Goodman made the interesting observation that the blood from one such patient would not cause a splitting of olive oil, suggesting an absence of lipase in the blood.

The cause of the recurrent episodes of abdominal pain is also not known. Ahrens has postulated that they occur as a result of temporary obstructions of the thoracic duct with chylous fluid, and of exudation of chyle into retroperitoneal tissues and the mesenteric root. Distention of these tissues would probably produce pain and occasionally vascular collapse. Ahrens has shown that the attacks are not related to the blood lipid levels as such. Rather, the anorexia accompanying such an attack is frequently responsible for significant falls in the level of serum lipids.

**DIAGNOSIS**—The diagnosis of idiopathic hyperlipemia is suggested by the milky white appearance of the serum (see Procedure 68) and the increase of total lipids (see Procedure 69). Laboratory tests reveal the following changes in the serum lipids:

	NORMAL RANGE* (mg/100 ml)	IDIOPATHIC HYPERLIPEMIA* (mg/100 ml)
Turbidity (units)	19-45	26
Total fatty acids	190-300	2,696
Neutral fat	0-400	2,116
Total cholesterol (see Procedure 70)	160-290	614
Free cholesterol	50-100	273
Esterified cholesterol	120-220	377
Phospholipids (see Procedure 71)	160-310	575

\*Based on the figures of Lever, W. F., Smith, P. A. J., and Hurley, N. A. Idiopathic hyperlipemic and primary hypercholesteremic xanthomatosis. I. Clinical data and analysis of the plasma lipids, *J. Invest. Dermat.* 22:33, 1954.

Electrophoretic analyses of the plasma show that either the alpha 2 peak alone or both the beta-1 and alpha-2 peaks are elevated. High-speed centrifugation at 18,000 rpm at  $-5^{\circ}\text{C}$  induces partial or complete clearing of the plasma, with an accumulation of a creamy layer of lipid material on the top, a decrease in the size of previously elevated alpha 2 and beta 1 peaks, and a considerable decrease of neutral fat, cholesterol, and phospholipids.

The condition can easily be differentiated from primary hypercholesteremia by the milky appearance of the serum.

**TREATMENT**—The reduction of fat in the diet causes some reduction in the plasma levels, but not sufficient to bring them down to normal. Lever has shown that the intravenous injection of 50-100 mg of heparin causes a change in the appearance of the electrophoretic pattern and will, if the injections are continued for long periods, result in considerable

decrease of turbidity and of lipid values in the serum. In time the cutaneous xanthomas will also disappear. This form of therapy is indicated if the patient has a predisposition to atherosclerosis.

Boggs J D, Hsia, D Y Y, Mass R. and Bigler J A. The genetic mechanism of idiopathic hyperlipemia. *New England J Med* 257 1101, 1957.

Buerger, M., and Grütz, O. Über hepatosplenomegale Lipendose mit xanthomatösen Veränderungen in Haut und Schleimhaut, *Arch. Dermat.* ■ Syph 166 542, 1932.

Holt, L. E., Jr., Aylward F X. and Timbrea, H. G. Idiopathic familial lipemia, *Bull. Johns Hopkins Hosp.* 64 279 1939.

Lever W F., Herbst, F S M., and Hurley, N A. Idiopathic hyperlipemia and primary hypercholesteremic xanthomatosis. IV Effects of prolonged administration of heparin on serum lipids in idiopathic hyperlipemia, *A.M.A. Arch. Dermat.* 71 150, 1955.

———, Smith, P A J., and Hurley, ■ A. Idiopathic hyperlipemic and primary hypercholesteremic xanthomatosis. I Clinical data and analysis of the plasma lipids, *J. Invest. Dermat.* 22 33, 1954.

Thannhauser, S J., and Stanley, M M. Serum fat curves following oral administration of  $^{131}$  labelled neutral fat to normal subjects and those with idiopathic hyperlipemia, *Tr. A. Am. Physicians* 62 245, 1949.

## 2. PRIMARY HYPERCHOLESTEREMIA (essential hypercholesteremic xanthomatosis)

Primary hypercholesteremia is characterized by an increase in the total cholesterol in the serum, frequently associated with the formation of xanthomas in various tissues.

**CLINICAL FEATURES**—The condition can be differentiated from idiopathic hyperlipemia by the following characteristics: (1) the fasting serum is always clear, (2) the distribution of the xanthomas tends to be different (xanthelasma is present in about a quarter of all affected individuals, while xanthoma tuberosum lesions are not quite so frequently seen on the extensor surfaces), (3) the tendons are frequently involved, with xanthomas being frequently seen in the Achilles tendon, the extensor tendons of the hand, and the patellar tendon, (4) the atheromatous changes take place early in life, and death from xanthomatous infiltrations of the aortic valve and coronary arteries frequently occur during childhood, and (5) the genetic factor seems to be much more prominent, with many of the close relatives of affected persons also showing the same elevations of serum cholesterol levels.

The pathology of the xanthoma tuberosum lesion has been described by Pollitzer and Wise, who sampled skin lesions at various stages of maturity in a single patient. The earliest changes appear in the adventitial connective-tissue cells of the smallest blood vessels. When lipid is present in excess in the blood, these cells pick it up, proliferate, and increase

berosum aortic stenosis coronary sclerosis and angina pectoris Am J Dis Child 73 326 1947

Fliegelman, M T, Wilkinson C F, and Hand E A Genetics of xanthoma tuberosum multiplex, Arch Dermat & Syph 58 409 1948

\*Herndon, C N Genetics of the lipidoses, Proc A Res Nerv & Ment Dis 33 239 1954

Pollitzer, S, and Wile, U J Xanthoma tuberosum multiplex J Cut Dis 30 235 1912

Schaefer, I E, Drachman, S R, Steinberg, A G, and Adlersberg D Genetic studies on hypercholesteremia Frequency in a hospital population and in families of hypercholesteremic index patients Am. Heart J 46 99, 1953

### 3 GAUCHER'S DISEASE

This disease was first described in 1882 by Philippe Charles Ernest Gaucher, a French dermatologist In a thesis submitted to the Faculty of Medicine in Paris, entitled *De l'epithelioma primitif de la rate*, he reported on a patient in whom the splenic pulp had been entirely replaced by large, pale cells At first he attributed this condition to a primary epithelioma of the spleen, but later he recognized it as a systematized storage disease of the reticuloendothelial system

**CLINICAL FEATURES**—Gaucher's disease tends to occur in two forms (1) an acute, or *infantile*, type, and (2) a chronic, or *adult*, type

The *adult* type, the more common form, becomes evident at any age Classically, the patients have moderate to marked splenomegaly, anemia, and other evidences of hypersplenism, as well as patchy brown pigmentation of the skin, especially over the anterior surfaces of the legs and the malar region Pingueculas of the conjunctivas are often seen in adults

The bones show changes characteristic of failure of tubulation There is a flaring of the ends of the femurs (so-called 'Erlenmeyer flask appearance') with thinning of the cortex There is also a widening of the medullary cavities, and osteoporosis may occur in the vertebrae, pelvis, tibiae, and humeri, which may lead to pathological fractures and severe deformities Many of the patients also suffer from epistaxis, anemia, and purpura which are frequently relieved by splenectomy The prognosis is variable, but many affected individuals lead long, nearly unhandicapped lives, especially after splenectomy

In contrast, the *infantile* type pursues a rapid and malignant course The infant, who is usually normal at birth, soon exhibits apathy together with progressive physical and developmental retardation The abdomen becomes enlarged, with first the spleen and later the liver increasing in size Subsequently, neurological symptoms begin to appear, and these become quite marked, with hypertonia and opisthotonus Dysphagia, choking spells, severe cough, and intermittent cyanosis are frequently

present and are aggravated by increasing pulmonary infiltrations with Gaucher cells. Cachexia becomes marked, and death usually occurs during the first year of life.

**HEREDITY**—Gaucher's disease is usually transmitted by an autosomal recessive gene, with the homozygote being affected. The condition has been noted among siblings in a number of families, and at least one instance of consanguinity has been reported. We have recently found that when one affected individual has central nervous system involvement, all affected siblings in that family would be similarly involved.

In 1948, Groen demonstrated that the asymptomatic father of one of the patients showed Gaucher-like cells in the sternal marrow, and he suggested that this factor might represent a carrier state for the disease. This finding requires confirmation.


**PATHOGENESIS**—Laboratory studies show that in Gaucher's disease the serum lipid and cholesterol levels are normal. Fat absorption studies show that there is no alteration by the usual laboratory tests. Furthermore, no measurable quantities of cerebroside have been found in the serum of these patients.

On the other hand, at least three substances have been isolated in abnormal quantities within the tissues containing Gaucher cells (Chart 57): (1) a galactosiderocerebroside (kerasin), which is composed of lignoceric acid, sphingosine, and galactose, (2) a glucosiderocerebroside, in which the hexose is present in the form of glucose instead of galactose, and (3) a water soluble glycolipid, which is made up of long-chain saturated fatty acids, sphingosine, or a sphingosine like base, and one or more hexose residues. This last type of compound has been named a "polycerebroside."


Two explanations have been suggested for these changes. Pick has felt that this condition represents a primary disturbance of the intermediary lipid metabolism, which expresses itself in an accumulation of cerebroside in the serum and leads secondarily to a storage of this abnormal substance in the reticulum cells of the affected organs. Thannhauser, on the other hand, feels that there is a dysfunction of the reticular cells themselves as a result of an enzymatic disturbance within the cell, which leads to an increased synthesis of cerebroside and simultaneously to a storage of these substances within the cell.

Normally, ceramide (lignoceric sphingosine) combines with cholinophosphoric ester under the influence of phosphorylcholinesterase to form sphingomyelin. Also, ceramide combines with galactose or glucose to

# CHART 57 GAUCHER'S DISEASE



(Green, 1948)



form cerebroside (Fig 53) Thannhauser believes that in Gaucher's disease the balance of enzymes which leads to cerebroside formation or cerebroside disintegration is disturbed, with the result that cerebroside accumulates in the organs involved. He has suggested that this may represent a perpetuation of a fetal mechanism after birth.

Uzman has shown that there is much less of the water soluble glycolipid in the spleens of older patients with Gaucher's disease than in those




FIG 53—Postulated breakdown of ceramide

of younger patients, although histologically both show heavy engorgement with Gaucher cells. He wonders if this compound represents a transitional stage which finally results in kerosin formation, since in Tay-Sachs disease there is great abundance of gangliosides in the central nervous system and since there is great similarity between gangliosides and polycerebroside. This may help to explain the neurological changes in infantile Gaucher's disease.

Finally, Tuchman and his co-workers have shown an increase of acid



phosphatase in the serum of patients with Gaucher's disease. The significance of this finding remains to be clarified.

**DIAGNOSIS** —A positive diagnosis is established by demonstrating the characteristic accumulation of a pale, poorly staining material in large, often multinucleated cells with wrinkled cytoplasm (Fig. 54). Aspiration of the bone marrow is the safest and most frequently used method for finding the abnormal cells.

**TREATMENT** —Splenectomy is sometimes helpful in relieving the ane-




FIG. 54 —Photomicrograph of spleen in Gaucher's disease. Many large, pale, foamy cells occupy the pulp; a portion of a malpighian body occupies one margin.

mia and thrombocytopenia associated with hypersplenism. There is no treatment available for the basic defect.

Bigler J. A., Naylor J. S. and Hsia D. Y. Y. Gaucher's disease: report of a father-son transmission. *New England J. Med.* 261: 164, 1959.

Gaucher P. C. E. *De l'epithelioma primitif de la rate. Hypertrophie idopathique*

8  
Negro

atbo-

ase in

181

1953

#### 4 NIEMANN-PICK DISEASE (lipid histiocytosis)

In 1914 Niemann described a new clinical syndrome which had many clinical features in common with Gaucher's disease but which

appeared to spread more diffusely through all the organs. A few years later, Pick presented the characteristic pathological features, and hence it is now generally given the combined name "Niemann-Pick disease." About 80 such cases have been reported from all over the world.

**CLINICAL FEATURES**—The clinical changes usually begin early in life. Although the infant may appear to be normal at birth, he soon begins to show both physical and mental retardation. Gradually, increasing debility and neurological deterioration, wasting of the extremities, and marked protuberance of the abdomen become noticeable. Spleen and liver are both markedly enlarged, with the hepatomegaly being more prominent than in Gaucher's disease. The skin is usually clear, but occasionally it has been observed to have extensive brownish, molelike pigmented areas, or vague, irregular, bluish or brownish discoloration, or, rarely, eruptive xanthomas. A cherry-red spot is present in the macula lutea in somewhat less than half of the patients. Anemia is often marked, and vacuolization in the agranulocytes in the peripheral blood smear can sometimes be found. Before long, the infant becomes apathetic and dull, and the clinical pattern can be defined as that of an anemic and emaciated idiot with an enlarged abdomen. Death occurs after the child is 6 months old, seldom do children with this condition live beyond 5 years.

During recent years a few cases of an adult, or chronic, type of Niemann-Pick disease have been described. The patients have the characteristic Niemann-Pick cells in the liver, lungs, and lymph nodes but show none of the clinical signs and symptoms described above.

Pathologically, there is an extremely generalized distribution of large pale cells (Fig. 55) with foamy appearing vacuolated cytoplasm which stains in varying degree with the Smith Dietrich myelin stain. The liver, spleen, lung, lymph nodes, and bone marrow are primarily involved, but almost no organ escapes infiltration. Degenerative changes in the ganglion cells with swelling are found in the central nervous system and elsewhere. The great similarity in the involvement of the central nervous system in both Niemann-Pick and Tay-Sachs disease has led to speculation on a possible common etiology of the two conditions.

**HEREDITY**—Niemann-Pick disease has been described in Europe, the United States, Japan, and Australia. The condition is thought to appear with somewhat greater frequency among Jews.

The disease is probably transmitted by an autosomal recessive gene. There are many reports of the condition occurring among siblings, and it has appeared in a pair of identical twins. The heterozygous carrier is not detectable. Pfandier has suggested that the infant with the malignant form may represent the homozygote for the trait and that the adult, or

chronic, form may represent the heterozygote. This has not been confirmed to date.

**PATHOGENESIS**—A slight increase in some of the serum lipids has occasionally been seen in Niemann-Pick disease, but this is not a characteristic or consistent feature of the disease. On the other hand, there is an




FIG 55—Photomicrograph of spleen in Niemann-Pick disease. The characteristic lipid-filled cells occupy most of the pulp. The lipid material and sphingomyelin distends the cytoplasm and displaces the nucleus peripherally.


immense intracellular accumulation of lipids, particularly sphingomyelin, in the tissues (Chart 58).

Thannhauser has postulated that in this disease the mechanism of conversion from ceramide to sphingomyelin is intact but the mechanism for reversing that step is defective (Fig 53). As a result, sphingomyelin accumulates in the various tissues, and this results in hepatosplenomegaly, mental deterioration, and changes in the ganglion cells.

**DIAGNOSIS**—The demonstration of the characteristic foam cells in the bone marrow or in a biopsy specimen of the spleen, liver, or lymph nodes is diagnostic of Niemann-Pick disease (Fig 55).

**TREATMENT**—None is of any avail.

## CHART 58

NIEMANN-PICK DISEASE

## 5 AMAUROTIC FAMILIAL IDIOCY

Amaretic familial idiocy is an over all term applied to several distinct but probably interrelated disturbances in lipid metabolism. Generally these are divided into the following types: (1) the infantile form (Tay Sachs disease), (2) the late infantile form (Bielchowsky Jansky disease), (3) the juvenile form (Spielmeyer Vogt disease), and the late juvenile form (Kufs disease).

chronic, form may represent the heterozygote. This has not been confirmed to date.

**PATHOGENESIS**—A slight increase in some of the serum lipids has occasionally been seen in Niemann-Pick disease, but this is not a characteristic or consistent feature of the disease. On the other hand, there is an




FIG. 55—Photomicrograph of spleen in Niemann-Pick disease. The characteristic lipid-filled cells occupy most of the pulp. The lipid material and sphingomyelin distends the cytoplasm and displaces the nucleus peripherally.

immense intracellular accumulation of lipids, particularly sphingomyelin in the tissues (Chart 58).

Thannhauser has postulated that in this disease the mechanism of conversion from ceramide to sphingomyelin is intact but the mechanism for reversing that step is defective (Fig. 53). As a result, sphingomyelin accumulates in the various tissues, and this results in hepatosplenomegaly, mental deterioration, and changes in the ganglion cells.

**DIAGNOSIS**—The demonstration of the characteristic foam cells in the bone marrow or in a biopsy specimen of the spleen, liver, or lymph nodes is diagnostic of Niemann-Pick disease (Fig. 55).

**TREATMENT**—None is of any avail.

\*Crocker, A. Niemann-Pick disease, *Medicine* 37:1, 1958.



Niemann, A. Ein unbekanntes Krankheitsbild. *Jahrb. f. Kinderh.* 79:1, 1914.

Pick, L., and Bielschowsky, M. Über lipoidzellige Splenomegalie (Typus Niemann-Pick) und amaurotische Idiotie. *Klin. Wchnschr.* 1631, 1927.

\*T

... of

NIEMANN-PICK DISEASE



**5 AMAUROTIC FAMILIAL IDIOCY**

"Amaurotic familial idiocy" is an over-all term applied to several distinct, but probably interrelated, disturbances in lipid metabolism. Generally, these are divided into the following types (1) the infantile form (Tay-Sachs disease), (2) the late infantile form (Bartschowsky disease), (3) the juvenile form (Spielmeyer-Vogt disease), and (4) the late juvenile form (Kufs's disease).

chronic form may represent the heterozygote. This has not been confirmed to date.

**PATHOGENESIS**—A slight increase in some of the serum lipids has occasionally been seen in Niemann Pick disease but this is not a characteristic or consistent feature of the disease. On the other hand there is an




FIG. 55.—Photomicrograph of spleen in Niemann Pick disease. The characteristic lipid-filled cells occupy most of the pulp. The lipid material and sphingomyelin displace the cytoplasm and displace the nucleus peripherally.

immense intracellular accumulation of lipids, particularly sphingomyelin in the tissues (Chart 58).

Thannhauser has postulated that in this disease the mechanism of conversion from ceramide to sphingomyelin is intact but the mechanism for reversing that step is defective (Fig. 53). As a result sphingomyelin accumulates in the various tissues, and this results in hepatosplenomegaly, mental deterioration, and changes in the ganglion cells.

**DIAGNOSIS**—The demonstration of the characteristic foam cells in the bone marrow or in a biopsy specimen of the spleen, liver, or lymph nodes is diagnostic of Niemann-Pick disease (Fig. 55).

**TREATMENT**—None is of any avail.



Cock, A. B. — *N. Engl. J. Med.* 194 1914 (Typus Net)

\*Thannhauser, S. J. Diseases of the nervous system associated with disturbances of lipid metabolism. *Proc. A. Res. Nerv. & Ment. Dis.* 32: 238, 1953.  
Videback, A. Niemann-Pick disease. Acute or chronic type? *Acta paediat.* 37: 95, 1949.

non Jewish child was thought to be either the result of racial mixing many generations ago or a matter of misdiagnosis. Experience with greater numbers of cases now indicates that about 10% of all Tay-Sachs patients are non Jewish.

The disease appears to be transmitted by a rare recessive gene. Apart

CHART 59

TAY-SACHS DISEASE

from an increased incidence among siblings, the condition has been described in two sets of monozygotic twins with both members of each pair being affected. Consanguinity is present in about 10% of the cases, the incidence being notably higher among non Jews. This would seem to suggest that this rare recessive gene is present predominantly among Jewish people but that over the years it has spread slightly to the non Jewish population through intermarriage. In agreement with this assumption, the homozygous form of the disease appears relatively frequently in ran-



### INFANTILE AMAUROTIC FAMILIAL IDIOCY (Tay Sachs Disease)

In 1881, Tay described a familial disease of infants in which there appears in the maculae of both retinas during the first year of life a cherry-red spot which is surrounded by a fairly well defined white area. A few years later, Sachs described autopsy findings and called the condition "amaurotic idiocy." It has subsequently been referred to as "Tay-Sachs disease," and over 100 cases of the condition have been reported in the world's literature.

**CLINICAL FEATURES**—Affected children appear to be essentially normal up to the age of 4-6 months. The first noticeable changes are hyperacusis, irritability, and a plateauing of development. There is a progressive loss of muscle strength until the infant becomes completely helpless. Also, he no longer notices or recognizes the mother, the eyes cease to fix on objects, and gradually it becomes apparent that he sees badly, and he becomes blind later in the course of the disease. These symptoms are always accompanied by striking hyperacusis and sometimes by bursts of explosive laughter. Eventually the process advances to a state of complete idiocy. Early in the course of the disease, muscular spasticity and hyperflexion usually appear, with muscular twitchings and convulsions, this is followed by weight loss and emaciation, and, terminally, the infants have repeated respiratory infections with accumulation of secretions in the respiratory passages. There is also an increase of head size late in the disease which is not due to hydrocephalus. Most of the affected children die at about 2½-3½ years of age.

The ganglion cells of the retina are seriously affected by the degenerative process, which leads to an enlargement of the small red spot and allows more of the choroidal coat to show through, and the excess lipid in the ganglion cells produces the opaque whitish appearance of the zone surrounding the red spot, the color of the zone varying according to the intensity of the process. The brain is always firm and is frequently hard or leathery in consistency. The ganglion cells throughout the central nervous system are swollen, and the cytoplasm appears finely granular and sometimes vacuolated. Special stains demonstrate that the swelling and distortion of cells is due to the accumulation of lipid droplets. Defective primary myelination is noted together with cell destruction, and the microglia and astrocytes undergo proliferation and distention.

**HEREDITY**—At one time, Tay-Sachs disease was believed to be limited to those of Hebrew ancestry. The occasional case that occurred in a

taxia and other cerebellar signs. The cherry red spot in the macula is not found, but there is optic atrophy and pigmentation of the retina. There is some question whether the changes in the cases in this form are distinctive, this condition may merely be a variant of the infantile or the juvenile type.

**HEREDITY**—The genetics of this form is not known. The type is not found predominantly in Jews.

**PATHOGENESIS**—Unknown.

**TREATMENT**—None is available.

Bielschowsky M. Über spät infantile familiäre amaurotische Idiotie mit Kleinhirnsymptomen. *Deutsch Ztschr f Nerv* 50:7, 1914.

Janáček J. Über einen bisher nicht publizierten Fall von familiärer amaurotischer Idiotie kompliziert mit Hypoplasie des Kleinhirns. *Rev de méd Tchéque* Prague 1:58, 1908.

### JUVENILE AMAUROTIC FAMILIAL IDIOCY (Spielmeyer-Vogt Disease)

In 1903 Batten drew attention to the occurrence of "cerebral degeneration with symmetrical changes in the maculae in two members of a family." One patient developed symptoms at the age of 6 years, and his sister at the age of 5. The retinas showed generalized peppered pigmentary changes, and at each macula there was an irregular reddish black spot, with the region immediately surrounding the spot being paler. Shortly after Vogt and Spielmeyer reported further, with more detailed description of cases, and the condition has now become known as Spielmeyer-Vogt disease.

**CLINICAL FEATURES**—The clinical course of Spielmeyer-Vogt disease is similar to that of Tay-Sachs disease but is distinguished by later onset and slower progression. The onset usually occurs between 3 and 10 years of age. Loss of vision is usually the first sign, and this is the only sign for about 2 years. It is followed by tonic and clonic convulsions and certain changes in mentality, including loss of emotional control, irritability, and alterations in personality. Definite mental deterioration follows, with progression to dementia. Muscle rigidity and signs of tremor start to appear, and paralysis follows. Sometimes athetosis is a prominent feature. Death occurs at about 15 years of age, following either convulsions or intercurrent infections.

The retinal lesions are often more diffuse than in Tay-Sachs disease, and there is often a dark brown pigmentation which can be mistaken for retinitis pigmentosa. There is also a secondary atrophy of the optic nerves with a rapid loss of vision.



ataxia and other cerebellar signs. The cherry red spot in the macula is not found, but there is optic atrophy and pigmentation of the retina. There is some question whether the changes in the cases in this form are distinctive, this condition may merely be a variant of the infantile or the juvenile type.

**HEREDITY**—The genetics of this form is not known. The type is not found predominantly in Jews.

**PATHOGENESIS**—Unknown.

**TREATMENT**—None is available.

Belschowsky M. Über spät infantile familiäre amaurotische Idiotie mit Kleinhirn Symptomen. Deutsch. Ztschr. f. Nerv. 50:7, 1914.

Jansky J. Über einen bisher nicht publizierten Fall von familiärer amaurotischer Idiotie kompliziert mit Hypoplasie des Kleinhirns. Rev. de med. Tchèque. Prague 1:111, 1908.

### JUVENILE AMAUROTIC FAMILIAL IDIOTCY (Spielmeyer-Vogt Disease)

In 1903, Batten drew attention to the occurrence of "cerebral degeneration with symmetrical changes in the maculae in two members of a family." One patient developed symptoms at the age of 8 years, and his sister at the age of 5. The retinas showed generalized peppered pigmentary changes, and at each macula there was an irregular reddish black spot, with the region immediately surrounding the spot being paler. Shortly Vogt and Spielmeyer reported further, with more detailed description of cases, and the condition has now become known as Spielmeyer-Vogt disease.

**CLINICAL FEATURES**—The clinical course of Spielmeyer-Vogt disease is similar to that of Tay-Sachs disease but is distinguished by later onset and slower progression. The onset usually occurs between 3 and 10 years of age. Loss of vision is usually the first sign, and this is the only sign for about 2 years. It is followed by tonic and clonic convulsions and certain changes in mentality, including loss of emotional control, irritability, and alterations in personality. Definite mental deterioration follows, with progression to dementia. Muscle rigidity and signs of tremor start to appear, and paralysis follows. Sometimes athetosis is a prominent feature. Death occurs at about 15 years of age, following either convulsions or intercurrent infections.

The retinal lesions are often more diffuse than in Tay-Sachs disease, and there is often a dark brown pigmentation which can be mistaken for retinitis pigmentosa. There is also a secondary atrophy of the optic nerves with a rapid loss of vision.



protracted clinical course. However, by such an arbitrary grouping one can differentiate the types with greater ease.

#### 6 GARGOYLISM (Hurler's syndrome, lipochondrodystrophy)

This is a generalized disease process characterized by defects in the construction of the collagenous tissues within the body. The skeletal defects were first described by Hunter, an Englishman, in 1917, and the



FIG. 56—A typical gargoyle. Note the facies, the appearance of the hands and the markings denoting the enlargement of the liver and spleen.

mental retardation and clouding of the cornea were noted by Hurler in Germany 2 years later. Over 250 cases of gargoylism have been described from all over the world.

**CLINICAL FEATURES**—Patients with Hurler's syndrome can best be described by the term 'grotesque' (Fig. 56). Changes are present in almost every part of the body.

The head is always enlarged and can be described as scaphocephalic. The lips are thick, and the teeth appear to be poorly formed and wide apart. The distance between the orbits is great. Many of the patients








FIG 57—Deformities in gargoylism. *Left* gross deformity of the right humerus radius and ulna with gross irregular development of the epiphyses. The metacarpals and phalanges are bizarre in shape and show loss of modeling. The hands are broad and the bones shortened and thickened. *Right* lower thoracic ribs—narrow at the vertebral border and broader toward the periphery. Marked chondrodysplastic changes around the hip joints consist of incompletely developed acetabula and femoral heads and irregularity of the epiphyseal metaphyseal junction.  $\Pi$  lateral coxa valga and enlarged liver and spleen are present.

pears to be made up of two distinct chemical entities (Chart 60). Brante has identified one of them as a mucopolysaccharide which is similar to or identical with chondroitin (or Mucotin®) sulfuric acid. This component appears to be made up of 3.9% sulfur, 27% hexosamine, and 26% glucuronic acid. It was found to be soluble in water but insoluble in ethanol and other organic solvents.  $\Pi$  shows metachromasia with toluidine blue, which is characteristic of the storage substance in this condition. Recently Dorfman and his associates have identified a similar mucopolysaccharide in the urine of patients with lipochondrodystrophy.

In 1955 Uzman identified a second storage substance in these tissues—a water-soluble glycolipid. This compound is soluble in ethanol but insol-



## CHART 60

GARGOYLISM (HURLER'S SYNDROME)

uble in other organic solvents. It is electrophoretically homogeneous at pH 8.6 and 7.0 but unhomogeneous at lower levels of pH. The chief constituents of this fraction appear to be fatty acids, sphingosine, neuraminic acid, hexuronic acid, hexosamines, glucose, and galactose.

Uzman has defined the mucopolysaccharide substance as fraction P and the glycolipid as fraction S. It is generally felt that the accumulation of fraction P is the primary metabolic defect and that fraction S is present as a consequence of the interference of normal function in involved cells resulting from the deposition of the first. This defect in the metabolism of



a structural polysaccharide in proportion to protein growth and differentiation leads to morphological anomalies in tissues normally rich in polysaccharides, resulting in the formation of abnormal connective tissue, reticular tissue, cartilage, valvular tissues of the heart, and Bowman's layer of the cornea, which are the principal manifestations of gargoylism.

**DIAGNOSIS**—The condition can usually be diagnosed by the typical grotesque facies and appearance. The diagnosis can be confirmed by the characteristic history and changes in the connective tissues.

**TREATMENT**—None is of any avail.

- Brante, ■ Gargoylism. A mucopolysaccharidosis, *Scandinav J Clin & Lab Invest* 4 43, 1952.
- Dorfman, A., and Lorincz, A. E. Occurrence of urinary acid mucopolysaccharides in the Hurler's syndrome. *Proc Nat. Acad. Sc* 43 443, 1957.
- Hunter, C. A rare disease in two brothers, *Proc Roy Soc Med* 10 104, 1917.
- Hurler, ■ Über einen Typ multipler Arbartungen vorwiegend am Skelet system, *Ztschr Kinderh* 24 220, 1919.
- Jervis, G. A. Gargoylism (lipochoondrodystrophy). A study of 10 cases with emphasis on the formes frustes of the disease, *Arch Neurol & Psychiat* ■ 681, 1950.
- Nja, A. A sex linked type of gargoylism, *Acta paediat* 33 267, 1945.
- Uzman, L. L. Chemical nature of the storage substance in gargoylism. *A M A Arch Path.* 60 308 1955.

## CHART 60

GARGOYLISM (HURLER'S SYNDROME)

uble in other organic solvents. It is electrophoretically homogeneous at pH 8.6 and 7.0 but unhomogeneous at lower levels of pH. The chief constituents of this fraction appear to be fatty acids, sphingosine, neuraminic acid, hexuronic acid, hexosamines, glucose, and galactose.

Uzman has defined the mucopolysaccharide substance as fraction P and the glycolipid as fraction S. It is generally felt that the accumulation of fraction P is the primary metabolic defect and that fraction S is present as a consequence of the interference of normal function in involved cells resulting from the deposition of the first. This defect in the metabolism of

a structural polysaccharide in proportion to protein growth and differentiation leads to morphological anomalies in tissues normally rich in polysaccharides, resulting in the formation of abnormal connective tissue, reticular tissue, cartilage, valvular tissues of the heart, and Bowman's layer of the cornea, which are the principal manifestations of gargoyism

**DIAGNOSIS**—The condition can usually be diagnosed by the typical grotesque facies and appearance. The diagnosis can be confirmed by the characteristic history and changes in the connective tissues

**TREATMENT**—None is of any avail

Brante G. Gargoyism. A mucopolysaccharidosis. *Scandinav J Clin & Lab Invest.* 4:43, 1952

Jervis G. A. Gargoyism (hypochoondrodystrophy). A study of 10 cases with emphasis on the former frustes of the disease. *Arch Neurol & Psychiat.* 63:681, 1950

Nja A. A sex linked type of gargoyism. *Acta paediat* 33:267, 1945

Uzman, L. L. Chemical nature of the storage substance in gargoyism. *A M A Arch Path* 60:308, 1955

## The Muscular Dystrophies

THE MUSCULAR DYSTROPHIES consist of a group of hereditary conditions characterized by a primary degenerative process within the skeletal muscles themselves. Unlike many of the neural and spinal muscular atrophies, there is no defect in the innervation of the affected muscles. In fact, one is frequently surprised to find pathologically that the muscular nerves and nerve endings are intact despite severe degeneration of the muscle fibers all around them. Clinically, the muscular atrophy is symmetrical in distribution, and the ability to respond to faradic excitability is retained in proportion to the remaining power of contraction. There are no sensory changes, and the cutaneous reflexes are preserved in this disease.

Although workers have described many separate and distinct types of muscular dystrophy, we shall limit the discussion to the following main groups: (1) *severe generalized familial muscular dystrophy*, (2) *mild restricted muscular dystrophy*, (3) *progressive dystrophia ophthalmoplegia*, and (4) *myotonia dystrophia*.

\*Adams, R. C., Denny Brown, D., and Pearson, C. M.: *Diseases of Muscle* (New York: Paul B. Hoeber, Inc., 1953), pp. 239-254.

### I SEVERE GENERALIZED FAMILIAL MUSCULAR DYSTROPHY (Duchenne's pseudohypertrophic muscular dystrophy)

The severe generalized familial muscular dystrophy is the most common form of muscular dystrophy. The condition usually begins early in childhood and follows a rapidly progressive course. The patients may or may not show pseudohypertrophy, but the outcome and prognosis are about the same.

**CLINICAL FEATURES**—The two outstanding clinical findings in pseudohypertrophic muscular dystrophy are a progressive alteration in the

size of the muscles and weakness. Attention is called to the former because of an unusual enlargement of the calf muscles, which is followed by enlargement of the infraspinatus and deltoid muscles. Eventually, most of the muscles in the body become affected. As the disease progresses, the hypertrophy tends to turn to atrophy, and terminally, the patients may give the appearance of wasting away.

Evidence of weakness is usually apparent for several years before the disease is recognized. The weakness may be suggested by an inability to walk or run at the usual age, or a tendency to fall easily. As the condition progresses, there is a bilateral weakness of the extensors of the hip and knee joints which interferes with such activities as arising from the floor or from a chair and climbing stairs. Ultimately, marked deformities and scoliosis may develop from the weakness.

Death usually occurs either because of persistent pulmonary infections or from cardiac hypertrophy and failure. Patients with this disease seldom survive past 20 years of age.

**HEREDITY**—Pseudohypertrophic muscular dystrophy occurs 6 times as frequently in males as in females. The disease can also be transmitted by unaffected females. Because of this, it is generally agreed that the condition is transmitted as a sex-linked recessive.

The most extensive genetic studies on the disease were made by Julia Bell, who analyzed 1,228 cases from the literature and the files of the National Hospital in Queen's Square, London. The reader is referred to her excellent monographs on how a disease should properly be studied from the genetic standpoint.


**PATHOGENESIS**—Numerous attempts have been made to discover a fundamental biochemical abnormality in progressive muscular dystrophy. So far, this research has led to several pieces of isolated information which may or may not prove to be important in the etiology of this disease (Chart 61).

First, most patients with progressive muscular dystrophy show an increase in the excretion of creatine and a decrease in the excretion of creatinine in the urine during the acute phase of the disease. In advanced dystrophy, the content of both the creatine and the creatinine in the urine decreases to below that of normal. Some investigators have also found an increase of creatine in the plasma while the creatinine remains within normal limits. It is believed that these abnormalities reflect changes in muscle mass and have little to do with the energy mechanisms in muscle contraction.


Second, Milhorat and others have shown that a deficiency of *l*-tocopherol (vitamin E) in rabbits causes a pathological condition not un-

# CHART 61

## SEVERE GENERALIZED FAMILIAL MUSCULAR DYSTROPHY



(Kosakow, 1937)



like that of muscular dystrophy. However, the administration of vitamin E to patients with the disease does not in any way alter the muscular weakness or atrophy.

Third, chemical analyses of dystrophic muscles have shown that there is less creatine, phosphocreatine, and adenosinetriphosphate present than in normal muscle. More recently, Dreyfus and his associates have shown that in such muscle there is also a decrease in the activity of phosphorylase and aldolase. On the other hand, aldolase and glutamic oxalacetic transaminase are greatly increased in the serum of dystrophic patients.

Fourth, Minot and his co-workers have demonstrated the presence of a pentose in the urine (see Procedure 72) of the majority of patients with progressive muscular dystrophy.

Finally, Horvath and his associates have shown that there is an actual decrease of potassium in the muscles of such patients as compared with normal controls.

While it is still too early to speculate on the possible mechanisms responsible for this disease of skeletal muscle, these preliminary findings suggest that it represents a defect in either glycolysis or energy transfer possibly at the membrane level.

**DIAGNOSIS**—The diagnosis can be established on clinical grounds and confirmed by muscle biopsy.

**TREATMENT**—Symptomatic therapy to prevent pulmonary and cardiac complications is needed late in the course of the disease.

\*Bell J. On pseudohypertrophic and allied types of progressive muscular dystrophy in *The Treasury of Human Inheritance* (London: Cambridge University Press 1943) vol 4 pp 283-342.

Dreyfus J C, Schapira G and Schapira F. Biochemical study of muscle in progressive muscular dystrophy. *J Clin Invest* 33: 794, 1954.

Duchenne G B. *De l'électrisation localisée et son application à la pathologie et à la thérapeutique* (Paris: J B Baillière et fils 1855).

Gowers W R. *Pseudo Hypertrophic Muscular Paralysis. A Clinical Lecture* (London: J & A Churchill Ltd 1879).

Horvath B, Berg L, Cummings D J and Shy G M. Muscular dystrophy. Blood content of dystrophic muscles. *J Appl Physiol* 8: 22, 1955.

Kostakow S and Derix F. Familienforschung in einer muskeldystrophischen Sippe und die Erbprognose ihrer Mitglieder. *Deutsches Arch klin Med* 180: 585, 1937.

Minot A S, Frank H and Dziewiatkowski D. Occurrence of pentose and phosphorus-containing complexes in the urine of patients with progressive mus-

\* C. M. Serum enzymes in muscular dystrophy and certain other muscular and neuromuscular diseases. *J Serum glutamic oxalacetic transaminase*. *New England J Med* 256: 1069, 1957.

*Proceedings of the 1st and 2nd Medical Conferences of the Muscular Dystrophy*



*Association, Inc., Held = New York April 14 15 1951, and May 17-18 1952 (ed by A. T. Milhorat) (New York Muscular Dystrophy Association of America, Inc., 1953)*

\*Shank, R. H., Giler, H., and Hoagland, L. Studies on diseases of muscle I Progressive muscular dystrophy, a clinical review of 40 cases, *Arch Neurol & Psychiat* 52 431, 1944

## 2. MILD RESTRICTED MUSCULAR DYSTROPHY (facioscapulohumeral dystrophy of Landouzy and Déjerine)

Unlike the severe generalized familial muscular dystrophy, mild restricted muscular dystrophy is slow in progression, with long remissions and often complete arrest. It involves primarily the musculature of the shoulder and often of the face.

**CLINICAL FEATURES**—The first symptoms of this condition are usually noted between the ages of 7 and 20 years. The most common initial complaint is the loss of ability to raise the arms above the head or to hold them in that position. Some patients note abnormal posture without noting this symptom.


As the disease progresses, there is atrophy and weakness of the facial muscles, resulting in an inability to pucker the lips and whistle and an in-co-ordination of the remainder of the facial muscles. The shoulder muscles also become involved, with the pectoralis major, rhomboids, and deltoids being most seriously affected. However, the weakness progresses very slowly, and most of the patients have a normal life span with only minor disability.

**HEREDITY**—Mild restricted muscular dystrophy has been extensively studied by Tyler and Stephens in a Mormon family in which 159 out of 1,249 members are affected with the facioscapulohumeral type of dystrophy. They have concluded that the condition is transmitted as a simple autosomal dominant with complete penetrance but variable expression.


This form of muscular dystrophy, however, can also sometimes be transmitted as a recessive trait, as reported in a small restricted community in Switzerland by Minkowski and Sidler. Probably the term "mild restricted muscular dystrophy" should be applied to a variety of nearly similar muscular dystrophies, each caused by a separate gene abnormality, and thus, each would be expected to show a different mode of inheritance.

**PATHOGENESIS**—It is not clear at present whether this type of muscular dystrophy has a common etiology with the type described in the preceding section. If so, much of the discussion above would be applicable here (Chart 62).

## CHART 62

MILD RESTRICTED MUSCULAR DYSTROPHY

(Tyler &amp; Stephens 1950)



**DIAGNOSIS** —The clinical signs and course are characteristic, and the diagnosis can be confirmed by muscle biopsy

**TREATMENT** —Usually, none is required

Landouzy, L., and Dejerine, J. De la myopathie atrophique progressive (myopathie hereditaire) debutant dans l'enfance, par la face sans alteration du systeme nerveux, *Compt. rend Acad sc* 98 53, 1884

Minkowski M., and Sadler, A. Zur Kenntnis der dystrophia musculorum progressiva und ihrer Vererbung, *Schweiz. med Wchnschr* 9 1005, 1928

Tyler, F H., and Stephens F E. Studies in disorders of muscle II Clinical manifestations and inheritance of facioscapulohumeral dystrophy in a large family, *Ann Int. Med* 32 640, 1950



### 3. PROGRESSIVE DYSTROPHIA OPHTHALMOPLÉGIA

Progressive dystrophia ophthalmoplegia can develop at any age. The onset is usually insidious and the course progresses slowly

**CLINICAL FEATURES** —As a rule, ptosis of the eyelids is noted first

This is followed by a progressive weakness of the lateral and vertical movements of the eyes. In the advanced stage of the disease, all movements are paralyzed and the eyes remain slightly divergent. Myotonia cataracts, and other endocrine disturbances have not been observed (Chart 63)

**HEREDITY**—The condition occurs with about equal frequency in



males and females. In about half of the families a history of ptosis or ophthalmoplegia can be elicited.

The disease is usually transmitted as an autosomal dominant trait, but instances of recessive inheritance have also been described.

**PATHOGENESIS**—Nothing is known.

**DIAGNOSIS**—The clinical course is usually quite typical.

**TREATMENT**—As a rule, none is required.

Bradburne A. A. Hereditary ophthalmoplegia in five generations. *Tr. Ophth. Soc. U. Kingdom* 32: 142, 1912.

Faulkner H. Familial ptosis with ophthalmoplegia externa starting in adult life. *Brit. M. J.* 854, 1939.

Gates R. R. *Human Genetics* (New York: The MacMillan Company, 1936) vol. II, pp. 955-1009.

#### 4 MYOTONIA DYSTROPHIA

Myotonia dystrophica is a familial disorder characterized by myotonia, atrophy of the distal muscle compartments, cataracts, frontal baldness, and various endocrinopathies

**CLINICAL FEATURES**—In most patients the myotonia precedes the muscular atrophy by 2 or 3 years. The prolonged contraction of skeletal muscles can be caused by external factors such as electrical or mechanical stimulation, or it can represent a delay in relaxation after a strong voluntary contraction. The latter state tends to be aggravated by cold and is more marked after the muscles have been at rest for some time.

The muscle atrophy follows a characteristic pattern and eventually involves the abduction of the thumb, the muscles of the forearm, the sternocleidomastoids, the facial muscles, the quadriceps, and the dorsiflexors of the feet. One is frequently impressed by the thinness and lack of expression in the face, and there is a wasting-away of the masseters and sternocleidomastoids.


Myotonia dystrophica differs from the other forms of muscular dystrophy with regard to the endocrine glands. The most common disturbance is testicular insufficiency, characterized by atrophy of the seminiferous tubules, an absence of spermatogenic and Sertoli's cells, and normal-appearing Leydig cells. This results in either reduced libido or impotence in a considerable proportion of the reported cases, and most patients with myotonia dystrophica fail to reproduce. Other endocrine disturbances include deficiencies of the thyroid, adrenal, and pituitary glands. Frontal baldness and cataracts are also frequently seen.

**HEREDITY**—The condition seems to be transmitted as an autosomal dominant. However, in some instances, both parents appear to be normal.


Fleischer and others believe that the disease may frequently occur at an earlier age, and in a more severe form, in each succeeding generation. They point out that in a given family the dominant inheritance may manifest itself in the first generation by a very slight sign, such as senile cataracts, in the next generation, by earlier onset of cataracts, in the next generation, by the full syndrome of myotonia dystrophica, and that sterility excludes the continued propagation of that trait. On the other hand, Penrose feels that the degree of manifestation of the main gene for myotonia dystrophica does not depend on this, but on the allelic gene which accompanies it.

**PATHOGENESIS**—This is completely unknown at the present time. Some preliminary studies suggest that the endocrinopathy does not in any

## CHART 64

MYOTONIA DYSTROPHIA

(Holland &amp; Hill 1956)



way appear to be related to the muscular defect in the patients (Chart 64)

**DIAGNOSIS**—The clinical course usually suggests the diagnosis. Muscle and testicular biopsies may be helpful.

**TREATMENT**—None is of any avail.

Fleischer, B. Über myotonische Dystrophie mit Katarakt. Eine hereditäre familiäre Degeneration. Arch. Ophth. 96:91, 1918.

Holland, C. M., and Hill, E. R. Myotonia dystrophica. Report of six cases in one family with an analysis of the metabolic defects. Ann. Int. Med. 44:738, 1956.

Penrose, L. S. The problem of anticipation in pedigrees of dystrophia myotonica. Ann. Eugenics 14:125, 1948.

\*Ravin, A. Myotonia. Medicine 18:443, 1939.

## Miscellaneous Metabolic Disorders

WE SHALL NOW take up the disturbances which have not so far been classified into specific groups. The first three (*idiopathic spontaneous hypoglycemia*, *pituitary diabetes insipidus*, and *diabetes mellitus*) represent endocrine disorders, the last three (*gout*, *hereditary periodic paralysis*, and *congenital pancytopenia with multiple congenital anomalies*), disturbances in purine, electrolyte, and possibly peroxidase metabolism.

### 1. IDIOPATHIC SPONTANEOUS HYPOGLYCEMIA

In the 1954 presidential address before the American Pediatric Society, Dr. Irvine McQuarrie reported on 25 children with signs and symptoms which might best be described as those of "idiopathic spontaneous hypoglycemia." In many instances the condition appears to be familial in nature, and it should probably be included among the inborn errors of metabolism.


**CLINICAL FEATURES**—Children with this condition suffer from fatigue, weakness, flushing, sweating, speech disturbances, and visual disturbances. There are also neurological manifestations, such as in-coordination, tremor, syncope, convulsions, and coma. In milder cases the changes may be confined to irritability, negativism, and behavior changes. There may also be hypothermia.

Idiopathic spontaneous hypoglycemia usually appears before the age of 2 years, and the symptoms tend to become milder as the child grows older. If the condition goes unrecognized—and this can easily be the case—permanent brain damage may be the result, characterized by epileptic seizures and mental retardation, complications which are irreversible.

**HEREDITY**—Idiopathic spontaneous hypoglycemia appears to be

familial, since 11 of the 25 children studied by McQuarrie had brothers or sisters with the same complaint. The condition is probably transmitted as an autosomal recessive with incomplete manifestation. Some of the milder cases probably go unrecognized because of the difficulties of being absolutely certain of the diagnosis. Anderson has reported that some of the parents of the children

CHART 65

IDIOPATHIC SPONTANEOUS HYPOGLYCEMIA

spontaneous hypoglycemia is not well understood (Chart 65). When corticotropin (plain ACTH) is given intramuscularly, the fasting blood glucose level rises, the patient no longer suffers from hypoglycemia or convulsions, and normal mental development becomes possible. This would suggest that the hypoglycemia is in some way related to an adrenal deficiency, which can be corrected by stimulation with pituitary hormone.

**DIAGNOSIS**—The oral glucose tolerance test (using 1.75 Gm of glucose per kilogram of body weight, given by mouth in a fasting state) shows either a flat response or a diabetic type of curve, which eventually drops to hypoglycemic levels with a true glucose value of less than 50

mg/100 ml There is also unusual sensitivity to small doses of insulin On the other hand, the blood sugar will show a characteristic response to adrenalin, since there are adequate stores of glycogen

Idiopathic spontaneous hypoglycemia should be differentiated from (1) true hyperinsulinism, which is caused by an adenoma, malignant tumor, or hyperplasia of the beta cells of the islets of Langerhans, (2) other specific causes, such as adrenal insufficiency, panhypopituitarism, hypothyroidism, and von Gierke's disease, and (3) functional disturbances of carbohydrate metabolism, such as the "dumping" syndrome

**TREATMENT**—ACTH, 5-10 mg every 2 or 3 days, appears to be the treatment of choice Partial pancreatectomy or the production of diabetes mellitus by alloxan used to be tried as a means of controlling hypoglycemia, but since the introduction of the corticotropins, such therapy is no longer necessary

- Anderson, R C, Wright W S, Bauer E G, and McQuarrie, I Familial hypoglycemia of probable genetic origin, *Am J Human Genet* 2 264, 1950  
 McQuarrie, I Idiopathic spontaneously occurring hypoglycemia in infants, *AMA Am J Dis Child* 87 399 1954  
 —, Bauer, E G, Ziegler, M R, and Wright, W S Effect of pituitary adreno corticotropic hormone in children with non Addisonian hypoglycemia, *Proc Soc Exper Biol & Med* 71 555, 1949

## 2. PITUITARY DIABETES INSIPIDUS

Pituitary diabetes insipidus is a rare genetic condition characterized by an increase of thirst and the passage of large quantities of urine low in specific gravity The symptoms can be relieved quickly by the administration of antidiuretic hormone preparations

**CLINICAL FEATURES**—Polydipsia and polyuria are the principal symptoms During early infancy the child cries excessively and can only be quieted by being given large amounts of fluids to drink If unrelieved, the infant quickly becomes dehydrated, and fever usually develops In older children, nocturnal and diurnal polyuria is the rule, and enuresis is not an uncommon complaint Thirst is accompanied by epigastric pain, hunger, and a sensation of a rise in temperature developing in the afternoon, with the lips developing the "sensation of fever blisters"


**HEREDITY**—Several large pedigrees of families afflicted with this disease have been reported In most instances, pituitary diabetes insipidus is transmitted as an autosomal dominant However, Forssman has reported on two pedigrees in which this form of diabetes insipidus has been inherited as sex linked recessive The heterozygous carriers of this abnormality have not been detected by laboratory tests




Pituitary diabetes insipidus is a rare disease In 1914, Fitz collected the material from four hospitals and found 79 cases out of 553,007 patients, or 14.5 per 100,000 From the Mayo Clinic, Rowntree has noted 56 cases out of 428,000 patients

**PATHOGENESIS**—In 1913, von der Velden and Farmit, working separately, showed that the extracts of the posterior lobe of the pituitary have

CHART 66  
DIABETES INSIPIDUS



(Levy and Escamilla 1955)



an antidiuretic effect on patients with pituitary diabetes insipidus (Chart 66) This active substance was later identified as vasopressin

The production of vasopressin depends on a complex functional unit which consists of the posterior lobe of the pituitary gland, part of the

fundibular stalk, the nucleus paraventricularis, the nucleus supraopticus of the hypothalamus, and the nerve tracts connecting them. Damage to any part of this functional unit may cause a deficiency in the excretion of vasopressin, and diabetes insipidus may be expected to develop. Presumably, some disturbance in this basic mechanism is responsible for the hereditary form of pituitary diabetes insipidus.

The antidiuretic principle of the posterior lobe of the pituitary acts on the kidney tubules. A deficiency of this causes either a failure to reabsorb water preferentially or to avoid reabsorption of salt, or both (Chart 66).

**DIAGNOSIS**—The diagnosis of pituitary diabetes insipidus is suggested by a failure to concentrate urine above a specific gravity of 1.008 despite withholding fluids to the point of discomfort in the patient. The condition must be differentiated from the following: psychogenic polydipsia, nephrogenic diabetes insipidus, and secondary pituitary diabetes insipidus. (1) Psychogenic polydipsia can be determined by observing the effect of an intravenous infusion of hypertonic saline solution on urine flow. The patient with true diabetes insipidus will not show the characteristic increased urinary output of the normal individual (see Procedure 63). (2) A patient with pituitary diabetes insipidus will show a cessation of diuresis and an increase of urine specific gravity after the administration of a 30 mg lozenge of posterior pituitary extract, while the patient with nephrogenic diabetes insipidus will show no such response (see Procedure 63). (3) Secondary pituitary diabetes insipidus is usually due to a specific cause, such as a pituitary tumor, encephalitis, Hand-Schüller-Christian disease, trauma, etc., and has no familial basis.

**TREATMENT**—For the sake of convenience, lozenges of posterior pituitary, 30 mg each, are effective when taken every 4 hours. Patients will also respond to vasopressin tannate in oil or to posterior pituitary powder used as snuff.

- Cannon J. F. Diabetes insipidus. *A.M.A. Arch. Int. Med.* 96:215, 1955.  
 Farini A. Diabete insipido ed optoterapia ipfisana. *Gaz. d. opp.* 34:1135, 1913.  
 Forsman H. On hereditary diabetes insipidus. *Acta med. Scandinav. suppl.* 159:1945.  
 Langer E. L. and Escamilla R. F. Hereditary diabetes insipidus. *J. Clin. Endocrinol.* 15:547, 1955.  
 Von der Velden R. Die Nierenwirkung von Hypophysenextrakten beim Menschen. *Berlin klin. Wchnschr.* 50:2083, 1913.

### 3. DIABETES MELLITUS

In a book of this size, it is obviously impossible to give an adequate discussion on the diagnosis, pathogenesis, and treatment of diabetes mel

litus Instead we shall take up only the genetic aspects of this inborn error of metabolism

**HEREDITY**—It is universally agreed that there is a large hereditary component in the causation of diabetes mellitus In fact, in the preamble to Chapter 3 of *The Treatment of Diabetes Mellitus* Joslin states that heredity is the basis of diabetes Disagreement arises, however, when an attempt is made to describe the exact nature of this component

The first extensive studies on the hereditary nature of diabetes mellitus were done by Pincus and White in 1934 They presented the following evidence to support the hypothesis that the disease has a genetic origin (1) the almost simultaneous occurrence of diabetes mellitus in both members of pairs of similar twins, (2) the greater incidence of diabetes mellitus in blood relatives of diabetics than in a controlled population, (3) the demonstration that Mendelian ratios of the recessive type are found in a large series of cases selected at random, (4) the demonstration of expected ratios in presumably latent cases, and (5) the observation, from genealogies that diabetics behave as a recessive trait

In the years that followed, there was considerable controversy over the mode of inheritance of diabetes mellitus Opinions varied all the way from regarding the condition as a dominant with a penetrance of about 10%, to regarding it as an autosomal recessive, to considering it a sex-linked tendency in familial diabetes in a significant proportion of the families In 1950 Harris suggested that many of the late-onset cases may be heterozygous for a gene which in homozygous form may give rise to the severe, early-onset type of case

The recent studies of Steinberg and Wilder suggest that diabetes mellitus is transmitted by a single autosomal recessive gene,  $d$  Individuals who are genetically liable to develop the disease are  $dd$ , and those who are not genetically liable to develop it are  $Dd$  or  $DD$  These investigators have estimated that about 5% of the population of the United States belongs to  $dd$  However, because of the variable age of onset and the difficulty of making the diagnosis clinically, only about 1% of the population is recognized as being diabetic

Using this type of nomenclature, it is possible to calculate the probability of genetic susceptibility to diabetes mellitus in any given family When  $Dd$  mates  $Dd$ , it is expected that 25% of the offspring will be  $dd$  When  $Dd$  mates  $dd$ , where one parent is genetically liable to develop diabetes mellitus 50% of the offspring will be  $dd$  Finally when  $dd$  mates  $dd$ , 100% of the offspring will be  $dd$  also On this same assumption, it is possible to calculate the probability of any one individual in a

given family being *dd* if one knows that certain other relatives in the same family have diabetes mellitus or may be *dd*

We are still left with the problems of how to determine (1) which asymptomatic individuals are *dd* and (2) when they are likely to show symptoms of diabetes mellitus. Fajans and Conn have made progress toward answering the first question by devising a combined cortisone-glucose tolerance test. They found that 19% of 152 relatives of known diabetics showed an abnormality of the usual glucose tolerance test. However, if 50 mg of cortisone was administered 8 hours before, the incidence was increased to 24%. In contrast, only 1 of 50 control subjects with no history of diabetes mellitus in the family demonstrated an abnormality with the usual glucose tolerance test, and 1 of 37 control subjects demonstrated blood sugar changes by the cortisone-glucose tolerance test.

Woodyatt and Spetz have suggested that the onset of diabetes mellitus becomes earlier with each affected generation. Thus, if the grandfather developed diabetes mellitus at the age of 50, the father may develop symptoms at 30, and the offspring at 10. More recent studies suggest that, although such a trend may sometimes be present, there is no evidence of such a consistent relationship between parent and child, and the term "anticipation" should not be used.

In summary, present thinking indicates that diabetes mellitus is probably transmitted by a simple autosomal recessive gene. Individuals who are homozygous for this gene (*dd*) are liable to develop diabetes, but the age of onset is highly variable.

Fajans, S. S., and Conn, J. W. An approach to the prediction of diabetes by modification of the glucose tolerance test with cortisone, *Diabetes* 3: 296, 1954.

Woodyatt, R. T., and Spetz, M. A study of the relatives of diabetics. *Am J Med* 1: 100, 1946.

Further analysis of

Steinberg, A. G., and Wilder, R. M. An analysis of the phenomenon of "anticipation" in diabetes mellitus. *Ann Int Med* 36: 1285, 1952.

Woodyatt, R. T., and Spetz, M. Anticipation in the inheritance of diabetes, *JAMA* 120: 602, 1942.

#### 4. GOUT

Gout is a hereditary constitutional disorder of purine metabolism characterized by increased amounts of uric acid in the blood and recurrent attacks of acute arthritis. If the articular inflammation becomes chronic, tophaceous deposits of sodium urate take place in many of the tissues.

The history of gout is a long and distinguished one. The early writings of Aretaeus of Cappadocia and Caelius Aurelianus indicate that the

physicians of Greece and Rome had an intimate knowledge of its varied features. For instance, Aretaeus mentions that during the asymptomatic periods, a gouty subject was capable of winning in the Olympic games. Throughout the ages, members of the nobility seem to have been especially prone to develop the disease, and few royal lines appear to have escaped. Writers of fiction and biography have made classical descriptions of its dramatic appearance, the ensuing pathos, and the rapid recovery with or without treatment. Victims of gout were also the favored subjects of many caricatures during the nineteenth century.

**CLINICAL FEATURES**—The best clinical description of an acute attack of gout was given in 1696 by Dr. Thomas Sydenham, himself a victim of the disease for 34 years. Since this account has not been improved upon, we shall quote from him directly.

He goes to bed and sleeps well but about two a Clock in the Morning is waked by the Pain seizing either his great Toe the Heel the Calf of the Leg or the Ankle this Pain is like that of dislocated Bones with the Sense as it were of Water almost cold poured upon the membranes of the Part affected presently shivering and shaking follow with a feverish Disposition the Pain is first gentle but increases by degrees sometimes resembling a violent stretching or tearing those Ligaments sometimes the gnawing of a Dog and sometimes a weight moreover the part affected has such a quick and exquisite Pain that it is not able to bear the weight of the Cloths upon it nor

hither  
in ease  
eing in

been out of order

Recurrent attacks of acute arthritis are followed by remissions during which the patient experiences no arthritic symptoms. These periods become progressively shorter until acute episodes occur regularly once or twice a year. As the disease continues, more of the joints become affected. In addition to the first metatarsophalangeal joint, which is usually the first to become affected, other joints in the feet, hands, ankles, and wrists become involved. The infiltration of urates into periarthicular and bursal tissues produces subcutaneous tophi, which are the cause of the knobby

deformities of the knuckles and interphalangeal joints.

crystals be precipitated by

1 excessive alcoholic intake

HEREDITY—The exact incidence of gout is not known because statistics reported for various sections of the United States and other countries require interpretation. For instance, only a small fraction of 1% of the meat eating people of the British Isles are afflicted while 70% of natives in India, who are largely vegetarians, are afflicted.

The

1

b

because the patients do not

c

characteristic features of chronic gout

From the beginning, medical writers have believed that gout is a hereditary disease, but the mode of transmission was not well understood. In 1948, Smyth and his co-workers showed that asymptomatic hyperuricemia is caused by a single autosomal recessive gene. The fraction of the

gout T

in disease in women in the

following

was estimated that the statistical upper limit of normal

serum uric acid level in women is about 1 mg/100 ml lower than in men. As a result, levels of 5-6 mg/100 ml represent hyperuricemia among female relatives of gouty patients. These slight increases are sufficient to equalize the distribution of hyperuricemia between the sexes but are usually not sufficient to cause precipitation of urates in tissues and the symptoms of gout clinically.

At present there is no way of determining which of the individuals with hyperuricemia will develop gout.

PATHOGENESIS—Various theories have been advanced to explain the complex features of gout, but, unfortunately, none are compatible with all of the known facts about the disease (Chart 67). It should be mentioned that in most mammals uric acid is converted by means of an enzyme, uricase, to the more readily soluble allantoin. However, New World monkeys, the anthropoid apes, and men lack this uncoupling enzyme. As a result, uric acid either has to be disposed of through the urine, bile, saliva, or sweat or, in healthy individuals, these routes are

excrete sufficient uric acid via the


, when the uric acid begins to

accumulate in the blood stream and becomes deposited in the various tissues.

Gutman and Yu have suggested that four mechanisms may be re-

sponsible for the deposition of urates in gout (1) uricolysis may occur in lesser degree in the gouty than in the normal subject, thus permitting retention of urate, (2) urate production may be within the normal range or even low, but the capacity for disposal may be so reduced that urate is nevertheless retained, (3) the overproduction of urate may be so great


CHART 67

GOUT

(Smith, Collerman &amp; Freyberg 1948)

## DISTURBANCE IN PURINE METABOLISM

(Overproduction or underexcretion or both)



that, even if the disposal routes are of normal capacity, or indeed respond to the need by increasing their capacity, they are inadequate to the load, and excess urate therefore persists in the body, and (4) there may be both overproduction and reduced excretion of urate

Considering these mechanisms in the order cited, we find, first, little to suggest that the oxidation of urate occurs at a rate less than normal in

out. At the most, such oxidation could represent only a minor accessory factor in the causation of chronic tophaceous gout.

Second, the evidence for a primary renal defect is also not very satisfactory. Some gouty individuals have been found to show albuminuria and impairment of renal function, especially of the glomerular filtration rate. However, this is by no means a consistent finding. Furthermore, studies on the clearance of uric acid itself reveal little or no significant difference between gouty and nongouty subjects. The renal changes could simply be due to secondary changes following urate retention and perhaps the disabilities of the tophaceous form of the disease.

Third, there is also controversy over the theory that hyperuricemia is the result of an overproduction of uric acid in the body. Some workers have pointed out that frequently the urinary urate excretion in gouty individuals is within, or even below, the normal range, and also that the inorganic phosphates in the urine show no evidence of being increased, a finding one would expect with an accelerated nucleoprotein breakdown. Benedict and his associates have argued that there is actually an overproduction of uric acid in these patients. In one experiment they injected  $^{14}\text{C}$ -labeled glycine, a precursor of uric acid. There was initially a greater rise and subsequently a more rapid fall in isotope concentration of uric acid than normal. They interpreted this as indicating that a portion of the uric acid excreted by this subject was formed from dietary glycine by a more rapid, and possibly more direct, process. This means that some of the glycine nitrogen was diverted from metabolic pathways ordinarily culminating in urea formation to other pathways leading to urate formation, and this action might represent the primary metabolic defect in gout.

Finally, it is possible that both the overproduction of urate and its reduced excretion may play a role in the pathogenesis of gout.

**DIAGNOSIS**—Gout can be diagnosed by a constant elevation of serum uric acid levels (see Procedure 74) to 6 mg/100 ml or higher.

**TREATMENT**.—Attacks of acute gouty arthritis can be prevented by a diet low in purines and by restraint of alcohol consumption. Drugs that have been found helpful in reducing discomfort during acute attacks are colchicine, salicylates, and, more recently, the corticotropins.

Benedict J. D., Roche, M., Yu, T. F., Bien, E. J., Gutman A. B., and Stetten, D. Incorporation of glycine nitrogen into uric acid in normal and gouty man. *Metabolism* 1:3, 1952.

\*Gutman A. B., and Yu, T. F. Gout, a derangement of purine metabolism, *Advances Int. Med.* 5:227, 1952.

\_\_\_\_\_ and \_\_\_\_\_. Current principles of management in gout. *Am J Med* 13:744, 1952.



- Smyth C J, Cotterman C W, and Freyberg R H The genetics of gout and hyperuricemia—an analysis of 19 families *J Clin Invest.* 27 749 1948
- Sydenham T Tractatus de podagra et hydrope in *The Works of That Excellent Physician Dr Thomas Sydenham* (tr by John Pechy) (London R. Wellington 1696)
- Talbott, J H and Coombs F S Metabolic studies on patients with gout, *J.A.M.A.* 110 1977, 1938

## 5 HEREDITARY PERIODIC PARALYSIS

Hereditary periodic paralysis is a rare clinical entity characterized by intermittent attacks of flaccid paralysis of the muscles of the extremities and loss of the deep tendon reflexes. These changes usually occur in association with a decrease in the concentration of potassium in the se




FIG 58—Arterial and venous plasma potassium concentrations during attack

rum. The condition was probably first described by Musgrave in 1727 although contemporary literature usually attributes its first description to Cavere, a French clinician of the nineteenth century.

**CLINICAL FEATURES**—Patients with hereditary periodic paralysis suffer from acute attacks of paralysis (Fig 58). The attacks are frequently preceded by a prodromal period when the patients feel tired or irritable or sometimes have a sense of apprehension for several hours before the

actual attack In the typical case, paralysis begins peripherally in the legs and progresses centrally until the patient becomes completely helpless and unable to move The deep reflexes of the involved parts are greatly diminished or absent during these episodes, but there are no accompanying sensory or psychic disturbances beyond mild apprehension At its height, electrical or mechanical excitability of the involved muscles is either absent or markedly impaired In some instances, paralysis of the respiratory muscles leads to suffocation and death

After a few hours the muscles begin to recover gradually, starting with the central muscles, which were the last to become affected, and followed by the more peripheral ones Some residual stiffness or soreness may persist for a few days after an attack

Episodes of paralysis may occur as often as several times weekly, or even daily in some affected individuals, while occurring infrequently or not at all in others In some well-documented familial cases there have been only one or two spontaneous attacks during a long lifetime Most commonly, the attacks occur during the early morning hours or in the forenoon, and then disappear later in the day An attack can sometimes be induced following strenuous exercise, the ingestion of a high carbohydrate meal, or by the injection of epinephrine

HEREDITY —The condition appears to be transmitted as an autosomal dominant, and it sometimes skips a generation Also, it tends to affect males more frequently than females This suggests that the penetrance is not complete

More than 400 cases of hereditary periodic paralysis have been reported from various parts of the world In most instances, symptoms appear about the time of puberty Very few examples are reported as beginning during early infancy or childhood

PATHOGENESIS —According to Talbott and to Gass and his co-workers, hereditary periodic paralysis is caused by an unknown defect in the metabolism of potassium which causes its mobilization beyond normal limits This defect could be due to (a) a natural deficiency of potassium in the liver or other tissues, (b) an unexplained increased requirement for potassium in certain aspects of metabolism or (c) a change in cellular permeability to potassium or other cations In any event, when glucose is increased in the liver from the ingestion of carbohydrates or from the injection of epinephrine, three types of changes occur (1) a decrease of potassium in the serum and urine, (2) a decrease of phosphorus in the serum and urine, which may be related to the disturbance of potassium metabolism, and (3) a decrease of potassium in the muscle, which is accompanied by paralysis of the peripheral muscles, cardiac arrhythmia,



and electrocardiographic changes (Chart 68) All of these symptoms can be reversed upon the administration of potassium

**DIAGNOSIS**—Clinically, the condition can be diagnosed by flaccid paralysis, loss of reflexes, and loss of electrical excitability Laboratory studies show a low serum potassium level during an attack

**TREATMENT**—The oral administration of 2-10 Gm of potassium chloride is effective in stopping an acute attack The episodes can also be prevented by taking frequent low carbohydrate meals and prophylactically administering KCl at regular intervals

fasting and of various types of diet on occurrence of paralytic attacks *Metabolism* 1 129 1952

Schmidt, A K E Die paroxysmale Lahmung *Monograph der Ges Neurol u Psychiat*, 11 18 1919

\*Talbot, J H Periodic paralysis *Medicine* 20 85 1941

## 6 CONGENITAL PANCYTOPENIA WITH MULTIPLE CONGENITAL ANOMALIES (Fanconi type)

In 1926, Fanconi described three siblings who presented a syndrome consisting of multiple congenital anomalies, pancytopenia, and hypoplasia of the bone marrow Nearly 30 examples of this condition have now been reported from all over the world

**CLINICAL FEATURES**—Patients with Fanconi's syndrome have a wide range of congenital anomalies The most common finding is a patchy brown pigmentation of the skin, which has been shown to be due to a deposit of melanin Other morphological changes include dwarfism, microcephaly, hypogenitalism, strabismus, anomalies of thumbs, absence of the radius and renal malformations Mental retardation is also a common manifestation

Laboratory studies show a pancytopenia characterized by marked anemia, leukopenia with the white cell count of less than  $4,000/\text{mm}^3$ , and a decrease of platelets to below  $100,000/\text{mm}^3$  The bone marrow is hypoplastic, and there is no evidence of reticulocytes or regeneration The erythrocytes show a normal life span by the Ashby technique



The disease is fatal in about two thirds of the cases Death usually occurs as a result of hemorrhage into either the brain or the gastrointestinal tract

**HEREDITY**—Fanconi's syndrome appears to be transmitted by an

autosomal recessive gene with variable penetrance. The condition usually occurs in siblings and does not affect parents or other relatives. Consanguinity has been reported in at least two instances. No attempt has been made to detect the condition among heterozygotes.

**PATHOGENESIS**—In 1953, Higashi and his associates made observations on the peroxidase activity of the erythrocytes in a patient with this condition and found a decrease of nuclear peroxidase in the normoblasts,

CHART 69  
FANCONI'S ANEMIA



which they interpreted as reflecting some constitutional defect in the red cell precursors (Chart 69).

Fanconi's syndrome is of particular interest because it is one of the few inborn errors of metabolism in which a defect in metabolism is presumably present early in utero and is responsible for the morphological malformations. This same metabolic error appears to persist after birth and is reflected by changes in erythrocyte peroxidase activity.

**DIAGNOSIS**—The diagnosis is suggested by a combination of pancytopenia and multiple congenital anomalies.

**TREATMENT**—Multiple transfusions are useful in the control of anemia, and antibiotic therapy is indicated during periods of infection.

Some patients show a nonspecific improvement following splenectomy

- \*Dawson J P Congenital pancytopenia associated with multiple congenital anomalies, *Pediatrics* 15 325, 1955  
Fanconi, H Familial infantile perniatocytic Anemie (perniatocytoses Blutbild und Konstitution), *Jahrb f Kinderh* 117 257, 1927  
Higashi O, Koseki E, and Higuchi M A study of perniatocytosis  
Reinh  
pop  
791



## PART VI

# Extension of the Concept of "Inborn Errors of Metabo- lism" to Clinical Medicine

IN THIS BOOK only those conditions which may clearly be regarded as *inborn errors of metabolism* have been discussed. However, as one thinks about disease processes in the broader sense, it becomes apparent that this concept may eventually be extended to cover much of clinical medicine.



## The Future of Biochemical Genetics

IT WOULD BE interesting to speculate on the future of hereditary diseases as they relate to clinical medicine. First one might consider the group of hereditary conditions which are primarily morphological in nature (Table 4). It appears probable that the structural abnormalities in these diseases are the sequelae of a genetically induced chemical abnor-

TABLE 4—PARTIAL LIST OF GENETIC CONDITIONS FOR WHICH THERE HAS SO FAR BEEN FOUND LITTLE EVIDENCE OF A BASIC CHEMICAL CAUSE

- 1 Acephaly
- 2 Aniridia
- 3 Arachnodactyly (Marfan's syndrome)
- 4 Arcus juvenalis
- 5 Arthro-onychodysplasia
- 6 Brachydactyly
- 7 Calvé Legg Perthes disease
- 8 Cataracts
- 9 Chondrodystrophy
- 10 Chondroectodermal dystrophy (Ellis van Creveld syndrome)
- 11 Choroideremia
- 12 Cleft lip
- 13 Cleft palate
- 14 Clubfoot
- 15 Coloboma iridis
- 16 Congenital dislocation of hip
- 17 Craniofacial dysostosis (Crouzon's disease)
- 18 Disseminated sclerosis
- 19 Endocardial sclerosis
- 20 Epidermolysis bullosa
- 21 Epiloia (tuberous sclerosis)
- 22 Friedreich's ataxia
- 23 Hemiatrophy
- 24 Hemorrhagic telangiectasia (Osler's disease)
- 25 Hereditary spastic paraplegia

- 26 Huntington's chorea
- 27 Hydrocephalus
- 28 Hyperelastosis cutis (Ehlers Danlos syndrome)
- 29 Hypertelorism
- 30 Hypertrophic neuritis
- 31 Ichthyosis
- 32 Intestinal polyposis (Jegher Peutz syndrome)
- 33 Lindsau's disease
- 34 Lobster-claw defect of hands and feet
- 35 Marines (cerebellar) ataxia
- 36 Mandibulofacial dysostosis (Treacher-Collins syndrome)
- 37 Merzbacher Pelizaeus cerebral sclerosis
- 38 Microcephaly
- 39 Microphthalmia
- 40 Multiple exostoses
- 41 Nadelung's deformity
- 42 Neurofibromatosis (Recklinghausen's disease)
- 43 Optic atrophy
- 44 Osteochondrodystrophy (Morquio's disease)
- 45 Osteogenesis imperfecta (Lobstein's disease)
- 46 Osteopetrosis (marble bones, Albers-Schonberg disease)
- 47 Otosclerosis
- 48 Pectus excavatum
- 49 Peroneal muscular atrophy (Charcot Marie Tooth disease)
- 50 Pleonosteosis
- 51 Polycystic kidneys
- 52 Polydactyly
- 53 Polyostotic fibrous dysplasia
- 54 Progressive lipodystrophy
- 55 Pseudohemophilia (von Willebrand's disease)
- 56 Psoriasis
- 57 Pterygium syndrome (Bonnieville Ulrich syndrome)
- 58 Reticular pigmentosa
- 59 Retinoblastoma (gloma retinae)
- 60 Schilder's disease
- 61 Situs inversus viscerum (Kartagener's syndrome)
- 62 Spina bifida aperta
- 63 Sprengel's deformity
- 64 Sturge Weber Dimstrin disease
- 65 Syndactyly
- 66 Torticollis
- 67 Xeroderma pigmentosum

malty during the early stages of embryonic development. As a result of this insult, the individual is left with a deformity of bone, eye, or muscle. The chemical abnormality is no longer detectable after birth, and we cannot classify such conditions as inborn errors of metabolism in the strict sense. Yet, in their way, these conditions represent a hereditary condition resulting from a chemical abnormality.

At the present stage of our thinking, we cannot be too rigid in defining the lines that separate the morphological disturbances from the function

al For instance, there is increasing evidence that there may be a chemical basis for some of the muscular atrophies. As we learn more about the fundamental processes of transport across cell membranes and the energy mechanisms responsible for the processes, this group of conditions may turn out to be similar to some definitely known chemical disturbances, such as cystic fibrosis of the pancreas. Likewise, in conditions like Fanconi's anemia, the primary disturbance may be morphological, and the present evidence indicating a biochemical lesion may turn out to be incorrect.

Next, we might consider the group of biochemical disturbances in which genetics may play an etiological role (Table 5). On the basis of the presently available information, these disturbances cannot be classi-

TABLE 5—PARTIAL LIST OF CONDITIONS WHICH MAY BE GENETICALLY DETERMINED

1 Acatasia	19 Laurence-Moon Biedl syndrome
2 $\beta$ -Amino-adipic-aciduria	20 Milroy's disease
3 Angioneurotic edema	21 Mongolism
4 Celiac disease	22 Myasthenia gravis
5 Cretinism	23 Otosclerosis
6 Epilepsy	24 Oxaluria
7 Ethanolaminuria	25 Primary amyloidosis
8 Familial cirrhosis	26 Psychosis
9 Familial eosinophilia	27 Rickets
10 Familial hemophagocytic reticulocytosis	28 Secretors and nonsecretors of blood group substances
11 Familial hypoplastic anemia	29 Sexual precocity
12 Familial nephrosis	30 Succosuria
13 Familial neutropenia	31 Taste sensitivity to thiourea
14 Histidinuria in pregnancy	32 Thrombocytopenic purpura
15 Hydroxyphenuria	33 Urobilinuria
16 Hypochromic microcytic anemia	34 Xanthinuria
17 Idiopathic hypoparathyroidism	35 Xanthurenic aciduria
18 Idiopathic hypoproteinemia	

fied among the hereditary diseases in the classical sense. For instance, only about 5% of the brothers and sisters of children who have vitamin D deficient rickets develop this complication. Yet, it does occur in such families with greater regularity than in other families where the diet is equally deficient in that vitamin. In such instances, it is difficult to decide to what extent the rickets occurs because of inadequate vitamin intake and to what degree it is due to familial tendencies. Similar examples may be found in such conditions as cretinism, familial nephrosis, and idiopathic hypoproteinemia. It appears probable that genetic factors play a role in such diseases, and they can, therefore, be regarded as inborn errors of metabolism in the broader sense.

One can carry this reasoning one stage farther. The ability of the individual to respond to certain situations may be genetically determined. In an earlier section (p. 201), we have discussed the disturbance in hemolysis which follows the ingestion of primaquine or fava beans and which is due to a hereditary deficiency of glucose-6 PO<sub>4</sub> dehydrogenase. Many other similar deficiencies must occur in the human race and such individuals can only be detected when placed in certain environments or stresses. Eventually it may be possible to show that the individual response to such things as the common cold or an overdose of alcohol may in part be genetically determined.

Finally, we should bear in mind the large amount of work being done by Williams and others in "biochemical individuality." They have found that any given person tends to remain the same from a biochemical point of view, throughout his life. He will tend to put out the same amount of lysine in his urine, show the same glucose tolerance curve, and have the same uric acid level from day to day regardless of the diet he is on or the type of work he is doing. These characteristics distinguish him from another person who may be of the same age, eating the same food, and working in the same office as the first man. Preliminary studies suggest that the biochemical individuality of a person may in part also be genetically determined. If so, this represents another approach to our thinking concerning the inborn errors of metabolism in man.

It is apparent that all of the problems regarding the inborn errors of metabolism are far from solved. In fact, we are just beginning to make an intelligent study of this vast and virgin field of medicine. We hope that this book has served its purpose in arousing interest in this area and that all physicians will henceforth think, not only about the specific patient he is treating, but also about the family background which produced the disease process.



# Appendix

*(The symbol ► indicates that the procedure has been checked and found to be satisfactory in our own laboratory)*

## Chapter 2

### SICKLE CELL ANEMIA AND THE OTHER ABNORMAL HEMOGLOBINS

#### ► 1 TEST FOR SICKLING

REFERENCE Hanno H A and Margolies M P Science 112 109 1950

PROCEDURE From 5 to 10 ml of venous blood is collected in an oxalated tube. The blood is transferred to an Erlenmeyer flask and a stream of pure CO<sub>2</sub> is directed into the neck of the flask for 10-15 seconds. The flask is then immediately stoppered and the blood gently swirled for a few seconds. After the flask has remained stoppered for 5 minutes the cork is removed and a drop of blood is quickly transferred by means of a pipette to a clean cover glass. A petrolatum sealed preparation is immediately made on a slide and the cells are examined under a microscope.

#### 2 SOLUBILITY OF HEMOGLOBIN SOLUTIONS

REFERENCE Hano H Arch Biochem 47 148 1953

##### REAGENTS

1. Blood specimens are obtained in citrate or oxalate. The erythrocytes are separated from the plasma and washed with 0.15 M NaCl. Following lysis of the erythrocytes with water a one third volume of toluene is added and shaken. The toluene and stromal layer are then removed by centrifugation.

2 The precipitating solution is prepared by dissolving anhydrous  $\text{KH}_2\text{PO}_4$  crystals and  $\text{K}_2\text{HPO}_4$  powder of reagent grade in water, it contains 1.62 M  $\text{K}_2\text{HPO}_4$  and 1.18 M  $\text{KH}_2\text{PO}_4$  per liter. Insoluble material is removed by filtering this solution through a sintered glass funnel. Anhydrous  $\text{Na}_2\text{S}_2\text{O}_4$  powder is used to maintain the reduced state of the ferrohemoglobin during the solubility determinations.

**PROCEDURE** The concentration of the original hemoglobin solution is determined at 540 m $\mu$  in the Beckman Model B spectrophotometer. A slit width of 0.15 m $\mu$  is used.

The solubility is then tested in 2.24 M phosphate. Into a 10 ml volumetric flask 100 mg of  $\text{Na}_2\text{S}_2\text{O}_4$  is weighed. Eight ml of the phosphate solution is delivered to the flask from a burette and the contents are agitated until the  $\text{Na}_2\text{S}_2\text{O}_4$  goes into solution. One ml of water is layered over this solution. A volume of hemoglobin solution containing 50 mg of hemoglobin is then added with a measuring pipette into the superficial water layer. Care is taken at this stage to avoid the precipitation of hemoglobin. The flask is immersed in a water bath at 25° C. Finally water is added to the 10 ml mark and the contents are completely mixed by inversion several times.

If a solid phase appears, the mixture is transferred and centrifuged at  $17,000 \times g$  for 20 minutes at 25° C. Following centrifugation, a long hypodermic needle is inserted through the superficial layer and 3-4 ml of the solution phase is removed and the hemoglobin determined spectrophotometrically.

If precipitation does not occur in the flask following 8 ml of phosphate solution the procedure is repeated with 9.2 ml of solution.

**INTERPRETATION** The solubility of the hemoglobin present can be calculated from the difference between the original hemoglobin solution and the amount of hemoglobin left in solution after precipitation.

### 3 PAPER ELECTROPHORESIS

**REFERENCE** Chernoff A. New England J Med 253:322, 1955.

#### REAGENTS

1 From 2 to 3 ml of unclotted venous blood is prepared and diluted to 5 Gm/100 ml of hemoglobin.

2 0.06 M Tris buffer, pH 8.6, is prepared by dissolving 6.06 g of Tris base in 100 ml of water.

3 To prepare a 0.06 ionic strength solution this is diluted with 1 part buffer and 3 parts water.

**ELECTROPHORESIS APPARATUS** A sheet of filter paper is inserted between two glass plates. Silicized glass plates, 9-15/16 × 14 × 1/4 inch, are suspended between two buffer chambers made of Plexiglas. Each buffer chamber is divided by a partition into two sections, which are connected by a series of glass agar bridges. Carbon or platinum electrodes are placed in the outer receptacles, and the paper dips into the inner containers. Direct current of 300-400 volts is used to supply the necessary power.

**PROCEDURE** Veronal® buffer is placed in each of the four compartments and equalized. The smooth side of a sheet of Whatman No. 3 MM paper is soaked in the buffer solution and blotted almost dry. From 0.002 to 0.005 ml of the hemoglobin solution is applied at the cross mark, and approximately 350 volts of direct current is applied. With a paper width of 9 1/2 inches, 14-16 milliamperes of current will be drawn. The electrophoretic run is permitted to proceed for 6-8 hours. The paper is then dried rapidly. For a permanent record, the paper may be stained with bromophenol blue.

## Chapter 3

### OTHER "STRUCTURAL" DISTURBANCES

#### THALASSEMIA

#### 4. DETERMINATION OF BLOOD PLASMA IRON

**REFERENCE** Kitzes, G., Elvehjem, C. A. and Schuette, H. A. J. Biol. Chem. 155: 653, 1944.

##### REAGENTS

Trichloroacetic acid, 25% solution in water. Redistill if not free from iron.

Hydrochloric acid, 6 N, redistilled.

Ammonium hydroxide, approx. 6 N.

Buffer solution, pH 4.58, 27.2 ml of C.P. glacial acetic acid and 33.4 Gm of C.P. sodium acetate (anhydrous) dissolved in water and made to a volume of 250 ml.

Thioglycolic acid, Eastman's practical grade.

p-Nitrophenol, 0.1% solution in water.

α-Bipyridine, 0.2% solution in 5% acetic acid. Dissolve 0.2 Gm of the reagent in 5 ml of C.P. glacial acetic acid and dilute to 100 ml with water.



**Standard iron solution** Dissolve iron wire (99.8%) in a mixture of nitric acid and hydrochloric acid and dilute with water to give a concentration of 1 mg per ml. From this stock solution standard solutions are made of 100 and 1  $\gamma$  per ml.

**Iron free water** Distilled water should be redistilled from glass. All equipment should be thoroughly cleaned and rinsed with iron free water.

Plasma iron may be determined with a maximum error of  $\pm 10\%$  for blood plasma containing 30-90% iron with a maximum error of  $\pm 5\%$  for blood plasma containing 100-200  $\gamma$  per 100 ml of iron.

**PROCEDURE** From 3 to 5 ml of blood plasma containing about 3-9  $\gamma$  of inorganic iron is pipetted into an ungraduated Pyrex 15 ml conical centrifuge tube. Three ml of redistilled water is added and mixed with the plasma.

A blank consisting of all the reagents used is also prepared.

Place the tubes in boiling water for 2-3 minutes or until the solution becomes opaque. Cool the tubes in cold water.

Add 2 ml of 25% trichloroacetic acid solution and stir thoroughly so that the acid is intimately mixed with the plasma. Use a small blunt end stirring rod in order not to break through the bottom of the tubes.

Place the tubes in a water bath at 90°-95° C for 3 minutes stirring the solution once or twice.

Remove from the bath and cool in cold water. Centrifuge at 2,000-3,000 rpm and decant the supernatant liquid into a 15 ml graduated centrifuge tube.

Add 4 ml of water to the sediment and 1.0 ml of 25% trichloroacetic acid. Mix. Place in water bath and centrifuge. Combine with first supernatant.

Add 1 drop of 0.1% *p*-nitrophenol indicator solution and add  $\text{NH}_4\text{OH}$  drop by drop until the solution becomes yellow.

Add 1 ml of the buffer solution and enough water to make 15 ml. Mix.

Pipette an aliquot 10 ml containing 2-3  $\gamma$  of iron into an Evelyn tube and add 2 drops of thioglycolic acid and mix.

Determine the center setting (100% transmission on the galvanometer scale) for each solution in the colorimeter. Filter is 520.

Add 1 ml of 0.2%  $\alpha\alpha'$ -bipyridine reagent and mix by gentle shaking or tapping of the tube. Read each tube in the colorimeter with the respective center setting previously determined. The galvanometer reading is recorded to the nearest 0.1 of a scale division if the Evelyn colorimeter is used.

**CALCULATIONS** Calculate the amount of iron in the solution in each

tube by reference to a standard curve or use the following formula after calculating the  $L$  values from the  $G$  readings (where  $L = 2 - \log G$ )

$$\frac{\text{Micrograms iron}}{\text{Aliquot}} = 40.6 \times L \text{ aliquot} - L \text{ reagent blank}$$

## 5 IRON BINDING CAPACITY

REFERENCE Rath C E and Finch C A J Clin Invest 28 79 1949

### REAGENTS

0.9% NaCl

Iron standard solution Prepared by diluting 14 mg of ferrous ammonium sulfate plus 0.5 ml of 1 N acetic acid to a total volume of 100 ml This represents 20% of iron per ml of standard solution Each standard solution is checked by direct iron analysis Each addition of from 0.05 to 2 ml of plasma represents an increment of 50% / 100 ml serum

PROCEDURE Fasting venous blood is withdrawn without hemolysis into a syringe coated with mineral oil The clotted blood is centrifuged at 2 000 rpm for 15 minutes and the serum obtained is centrifuged again to remove all red cells A Coleman spectrophotometer Model 11 and cuvettes of 1 cm depth are used One cuvette is filled with 5 ml of 0.9% NaCl while the other is filled with 2 ml of serum and 3 ml of 0.9% NaCl Iron standard solution is added in 0.05 ml lots to both cuvettes and a glass stirring rod used to mix the contents Readings of light transmission at 525 m $\mu$  are made 2-3 minutes after each mixing The iron solution is added until there is no change in the per cent transmission after three successive readings

The data are plotted and the point of intersection of the two slopes is taken as the amount of iron necessary to saturate the iron binding protein

INTERPRETATION In normal individuals the serum iron comprises about a third of the total binding capacity

## ELLIPTOCYTOSIS

### 6 MEASUREMENT OF DIAMETER OF ERYTHROCYTES

REFERENCE Details of this technique are described in Larsen G Acta med scand nav vol 132 supp 220 1948

INTERPRETATION It is generally agreed that any individual with more than 25% elliptical erythrocytes can be regarded as a carrier and anyone with less than 10% elliptical erythrocytes can be regarded as normal

## ERYTHROPOIETIC PORPHYRIA

## 7 FLUORESCENCE MICROSCOPY

REFERENCE Schmid R, Schwartz S, and Sundberg R D Blood 10 416 1955

PROCEDURE Unstained bone marrow slides are prepared from material aspirated from the sternal marrow For fluorescence microscopy a specially constructed microspectrometer, an essential part of which is a Steinheil microanalytic spectrocope is used As light source a modified Bal water cooled high pressure GE AH 6 mercury vapor lamp is employed with a primary Corning filter No 5 58 (5113) to isolate the 405 m $\mu$  line An orange Corning filter No 3 67 (3482) is placed between the objective and the eyepiece of the microscope

After studying and photographing the unstained bone marrow slides in the fluorescence microscope the areas of the smear so examined are marked with a Zeiss slide marker and subsequently stained with Wright's stain for detailed morphological study of the individual cells

## 8 TOTAL UROPORPHYRINS

REFERENCE Lockwood W H Australian J Exper Biol & Med Sc 31 453 1953 based on method of Sveinsson S L Rimington C and Barnes H D Scandinv J Clin & Lab Invest 12 1949

PROCEDURE One ml of glacial acetic acid is added to 10 ml of urine and the coproporphyrin is removed by extraction with 20 ml of ether The ether is washed twice with a total of 5 ml of water and the washings are added to the main aqueous layer To this is added 0.5 ml of saturated CaCl<sub>2</sub> solution and then 40% NaOH 1.5 ml being added after the first permanent precipitate The calcium salts are then spun down washed once with methanol to remove water, and dissolved in methanolic HCl The solution is allowed to stand for at least an hour and is then passed into saturated sodium acetate overlaid with ether The ether is washed with H<sub>2</sub>O Na<sub>2</sub>CO<sub>3</sub> and extracted three times with a total of approximately 4 ml of 3 N HCl The optical densities are then read in a 1 cm cuvette at 425 m $\mu$ , 407 m $\mu$ , and 390 m $\mu$  and compared with known standards

INTERPRETATION The normal range of uroporphyrin excretion is between 15 and 30 mg/24 hours The isomers for uroporphyrins (I and III) may be separated by the methods described by Rimington C, and Miles, P A Biochem J 50 202 1951 and

Watson C J Schwartz S and Hawkinson V J Biol Chem  
157 345 1945

## 9 TOTAL URINARY COPROPORPHYRIN

REFERENCE Schwartz S, Zieve L and Watson C J J Lab & Clin Med 37 843 1951

COLLECTION OF URINE A 24 hour urine collection is made in a bottle containing 5 Gm of Na CO<sub>3</sub>

EXTRACTION OF SAMPLE To 5 ml of the well mixed urine in a separatory funnel add 5 ml of buffered acetic acid solution (prepared by adding four volumes of glacial acetic acid to one volume of saturated aqueous sodium acetate solution) 75-100 ml of ethyl acetate and 15-20 ml of distilled water This is shaken well The aqueous phase is discarded The ethyl acetate is washed twice with 20-30 ml portions of 1% sodium acetate and once with 0.005% aqueous iodine (prepared fresh by diluting with water from a refrigerated stock 1% solution of iodine in alcohol)

The porphyrin is then extracted from the ethyl acetate with four portions of about 5 ml each of 1.5 N HCl If the fourth extract still has any reddish orange fluorescence when irradiated in the dark with near ultraviolet light the HCl extracts are continued till no fluorescence shows

The combined HCl extracts are diluted with 1.5 N HCl to 25 ml or some other convenient volume and the fluorescence intensity is measured in a sensitive fluorimeter

The sample is read in a fluorimeter employing a photomultiplier tube (manufactured by Callectron Inc 2444 Beverly Road St Paul 4 Minn) and compared with coproporphyrin standards

INTERPRETATION The normal values for children are given by Hsia D Y Y and Page M Proc Soc Exper Biol & Med 85 86 1954 and for adults by Schwartz *et al* J Lab & Clin Med 37 843 1951

The ratio of urinary coproporphyrin isomers (I and III) can be determined by a fluorescence quenching technique described by Schwartz S Hawkinson V Cohen S and Watson C J J Biol Chem 168 133, 1947

## 10 PORPHOBILINOGEN

REFERENCES Modification of method by Watson C J and Schwartz S Proc Soc Exper Biol & Med 47 393 1941 A more detailed technique is described by Westall R G Nature 170 614 1952

REAGENT Ehrlich's reagent (2% dimethyl amino benzaldehyde in 60 N HCl)

PROCEDURE Into a 10 ml volumetric flask place 0.1 ml of urine 4.9

0.5 ml of pyrophosphate, and 0.2 ml of carbamate is prepared and the optical density (D3) determined

The  $\mu\text{g}$  of direct reacting copper per 100 ml of plasma is calculated from the following formula

$$D2 - (D1f + D3) \times K \times 100$$

where  $f$  is 0.952 and  $K$  is constant derived from the standard curve

**INTERPRETATION** Normal range, 0.20  $\mu\text{g}/100$  ml in Wilson's disease 20-40  $\mu\text{g}/100$  ml

#### 14 PLASMA COAGULATION (QUALITATIVE)

**REFERENCE** Frick, P. G., and McQuarrie, I. J. : *Pediatrics* 13:44, 1954

**PROCEDURE** Plasma is mixed with equal volumes of any of the following reagents

$\text{CaCl}_2$  ( $1/4$ - $1/80$  M)

$\text{CaCl}_2$  ( $1/4$ - $1/80$  M) plus rabbit brain thromboplastin

Bovine thrombin (conc 15,000 units/cc)

With normal plasma, a fibrin clot will form. With plasma from a patient with congenital afibrinogenemia no clot will form

#### 15 PLASMA FIBRINOGEN LEVEL

**REFERENCE** Cullen, G. E., and Van Slyke D. D. : *J Biol Chem* 41:587, 1920

##### REAGENTS

0.8% NaCl

$\text{CaCl}_2$  solution made up by dissolving 2.5 Gm of anhydrous  $\text{CaCl}_2$  in 100 ml of water

Conc  $\text{H}_2\text{SO}_4$

$\text{K}_2\text{SO}_4$

Copper sulfate

**PROCEDURE** Blood is collected in a tube containing 0.5% potassium oxalate, and the plasma is separated by centrifugation. Five ml of plasma is added to 150 ml of 0.8% NaCl and 5 ml of the  $\text{CaCl}_2$  solution. This is allowed to stand for 10-15 minutes until complete coagulation takes place. The solution is filtered with filter paper and washed with 0.8% NaCl five times, allowing each washing to remain in contact with the fibrin for 10 minutes by clamping the outlet of the funnel for that period.

The filter paper containing the fibrin clot is transferred to a Kjeldahl flask. Add 20 ml of concentrated  $\text{H}_2\text{SO}_4$ . 12 Gm of  $\text{H}_2\text{SO}_4$  and a crystal of copper sulfate are added. The nitrogen of the fibrin is determined in the usual way. The plasma fibrinogen level can be calculated from the nitrogen content of the fibrin clot

**INTERPRETATION** Normal range, 200-400 mg/100 ml Patients with afibrinogenemia show no detectable fibrinogen

## Chapter 5

### DEFICIENCIES OF CLOTTING FACTORS

#### PREPARATIONS

*Oxalated plasma*—Fresh whole blood, 4.5 ml, is mixed with 0.5 ml of 0.1 M sodium oxalate solution. The blood is centrifuged at 1,000 rpm for 5 minutes. The supernatant is taken off as oxalated plasma. The blood must be fresh.

*Serum*—Freshly drawn blood is permitted to clot. Several hours later, the clot is centrifuged and the serum removed. The sample is kept for 24 hours at room temperature and then decalcified with one-fifth volume of 0.1 M sodium oxalate.

*Aged plasma*—Oxalated plasma is kept in the refrigerator for a month and then used, provided that the one-stage prothrombin time is over 180 seconds.

*Adsorbed plasma*—A suspension of 50 mg of BaSO<sub>4</sub> powder is added to each ml of freshly oxalated plasma. After mixing for 10 minutes and centrifuged, the clear supernatant plasma is prothrombin free. This must be freshly prepared for use.

#### TESTS

#### ► 16 CLOTTING TIME

**REFERENCE** Lee, R. I., and White, P. D. *Am J M Sc* 145:495, 1913

**PROCEDURE** One ml of blood is withdrawn from an arm vein and the time is noted. The needle is removed, and the contents of the syringe are transferred into a small glass tube (about 3 mm in diameter) which has previously been rinsed out with normal saline solution. The tube is rotated endwise every 30 seconds, and that point at which the rotated blood no longer flows from its position but maintains its surface contour when inverted is taken as the end point.

**INTERPRETATION** The normal range for clotting time by this method is 5-8 minutes.

► 17. PLASMA CLOTTING OR RECALCIFICATION TIME

**PROCEDURE** Oxalated plasma, 0.2 ml, is mixed with 0.2 ml of 0.01 M  $\text{CaCl}_2$  solution and the stop watch is started. The tube is dipped in and out of a water bath at 37° C until a fibrin clot appears. The test is done in triplicate, and the results are averaged.

**INTERPRETATION** The normal range for plasma clotting time is 100-200 seconds.

► 18. PROTHROMBIN COMPLEX TIME (ONE STAGE)

**REFERENCE** Quick, A. J. *Am J Clin Path* 15:560, 1945

**REAGENTS**

Thromboplastin (acetone dried rabbit brain). Each day, a fresh solution is prepared by dissolving 0.2 Gm of the material in 5 ml of normal saline solution and incubating for 15-20 minutes at 50° C. The solution should then be kept in a 37° C water bath until used.

$\text{CaCl}_2$  0.02 M solution

**PROCEDURE** The determination is carried out in a small Pyrex tube placed in a 37° C water bath. To 0.1 ml of oxalated plasma, 0.1 ml of thromboplastin is added.  $\text{CaCl}_2$ , 0.1 ml, is blown forcibly into the mixture and the stop watch started. The tube is shaken lightly in the water bath to within a few seconds of the expected clotting time. For the accurate timing of the end point, it is essential to tilt the tube very gently.

**INTERPRETATION** Normal prothrombin time is 12 seconds.

► 19. TWO STAGE PROTHROMBIN DETERMINATION

**REFERENCE** Details of the method are given in Ware, A. B., and Seegers, W. H. *Am J Clin Path* 19:471, 1944.

► 20. ANTIHEMOPHILIC FACTOR (AHF)

**REFERENCE** Langdell, R. D., Wagner, R. H., and Brinkhous K. M. *J Lab & Clin Med* 41:637, 1953.

**REAGENTS**

Citrated hemophilic plasma as substrate  
 stock solution  
 mixing 7 parts of 0.11  
 72, and 5 parts 0.9%  
 NaCl

**PROCEDURE** The oxalated control or plasma is treated with  $\text{BaSO}_4$  and then with oxalate 1, 2.5, 5, and 10%, respectively. During the treatment, the mixture is kept in a 28° C

water bath except for the hemophilic plasma substrate, which is kept in an ice bath

For each clotting test, the following are added, *in the order listed*, to a 10 × 75 mm dry glass tube: 0.1 ml citrated hemophilic plasma, 0.1 ml diluted control or test plasma, 0.1 ml cephalin, and 0.1 ml calcium imidazole solution. Clotting times for each dilution of plasma are determined in triplicate and the mean determined. The mean clotting times are plotted against the per cent of the test or control plasma used, the latter being indicated on a log scale. By interpolation, the dilution of the test plasma which could give the same clotting times as 1, 2.5, and 5% control plasmas are determined and the AHF activity determined.

$$\frac{\% \text{ control plasma}}{\% \text{ test plasma}} \times 100 = \% \text{ AHF activity in test plasma}$$

**INTERPRETATION:** In classical hemophilia, the AHF activity is markedly decreased to below 10%.

## ► 21 PROTHROMBIN UTILIZATION TEST

**REFERENCE:** Details of this method are given in Langdell, R. H., Graham, J. H., and Brinkhous, K. M. *Proc Soc Exper Biol & Med* 74:424, 1950.

## 22 PARTIAL THROMBOPLASTIN TIME

**REFERENCES:** Langdell, R. D., Wagner, R. H., and Brinkhous, K. M. *J Lab & Clin Med* 41:637, 1953; Brinkhous, K. M. *et al*, *J.A.M.A.* 154:481, 1954.

**PROCEDURE:** The partial thromboplastin time is performed at 37° C by mixing, in this order: 0.1 ml of oxalated plasma, 0.1 ml of partial thromboplastin (either crude cephalin or Asolectin), and 0.1 ml of 0.02 M CaCl<sub>2</sub>. The concentration of partial thromboplastin is adjusted by dilution to give a clotting time in the range of 40-80 seconds. A 0.3% suspension is usually satisfactory.

## ► 23 THROMBOPLASTIN GENERATION TEST

**REFERENCE:** Biggs, R., and Douglas, A. S. *J Clin Path* 12:23, 1953.

**PREPARATION OF SAMPLE:** Venous blood is collected from a normal subject and from the patient. Part of each sample is citrated by adding 1 part of 3.8% sodium citrate to 9 parts of blood. The plasma is separated after centrifugation at 2,000 rpm for 15 minutes. An additional 3 ml of whole venous blood is placed in a tube with three beads. The tube is stoppered and inverted repeatedly until clotting occurs. This process encourages the conversion of prothrombin to thrombin during coagulation. When coagulation



is complete, the blood is allowed to stand at 37° C for 2 hours. The serum is then separated and diluted 1/10 with normal saline for use in the test.

# REAGENTS

Normal plasma

Normal plasma is

The mixture

Normal plasma is sep

parated by centrifugation. The plasma is diluted 1/5 with normal saline.

**Platelets and substrate.** Normal blood, 20 ml, is collected in two silicone treated 10 ml graduated centrifuge tubes each containing 1 ml of 3.8% sodium citrate. The blood is centrifuged at 1,500 rpm for 10 minutes and the plasma separated and put into silicone treated tubes and centrifuged again for 15 minutes at 3,000 rpm. The platelets are deposited and the clear supernatant plasma is separated and reserved as substrate for the test. The platelets are washed twice with saline solution, the platelet mass being fragmented with a wooden applicator stick and re-deposited on each occasion by centrifugation. After the second washing the platelets are resuspended in a volume of normal saline solution equal to one third of the volume of original plasma from which they were derived.

**PROCEDURE.** Into each of six small tubes of uniform diameter placed in a water bath at 37° C, 0.1 ml of substrate plasma is pipetted. In an additional tube in the water bath is placed 0.3 ml of alumina plasma diluted 1/5, 0.3 ml of platelet suspension and 0.3 ml of serum diluted 1/10. To this is added 0.3 ml of M/40 CaCl<sub>2</sub> and a stop watch is started. At intervals of 1 minute 0.1 ml of the mixture is withdrawn into a graduated Pasteur pipette and using the other hand, 0.1 ml of M/40 CaCl<sub>2</sub> is withdrawn with a second pipette. The contents of the two pipettes are then discharged simultaneously into one of the tubes containing 0.1 ml of substrate. The clotting times of the substrate samples are recorded. This can be represented in terms of thromboplastin concentration, using a thromboplastin dilution curve.

**INTERPRETATION.** The results of this test in the hemophilias are given in the following table.

## DIFFERENTIATION OF THE HEMOPHILIAS WITH THE THROMBOPLASTIN GENERATION TEST

SOURCE OF TEST REAGENTS			RESULTS OF TGT IN VARIOUS HEMOPHILIAS		
Al(OH) <sub>3</sub> or BaSO <sub>4</sub> Plasma	Serum	Platelets	AHG	PTC	PTA
Patient	Patient	Normal	Abnormal	Abnormal	Abnormal
Patient	Normal	Normal	Abnormal	Normal	Normal
Normal	Patient	Normal	Normal	Abnormal	Normal

## 24 TEST FOR AC GLOBULIN

REFERENCE Quick A J, and Stefamini, M J Lab & Clin Med 33 819, 1948

## REAGENTS

Plasma, stored for 14 days

Tricalcium phosphate suspension Prepared by dissolving 158 Gm of trisodium phosphate in 1 liter of water Separately, 66.6 Gm of anhydrous  $\text{CaCl}_2$  are dissolved in 1 L of water The  $\text{CaCl}_2$  solution is poured into the trisodium phosphate with thorough stirring The pH is adjusted to 7 The precipitated tricalcium phosphate is washed repeatedly by decantation until the  $\text{NaCl}$  is removed The volume is brought to 1 L, making a 0.2 M solution A 0.008 M solution is prepared by adding 4 ml from the stock solution to 96 ml of distilled water

PROCEDURE Nine volumes of fresh blood is collected with one volume of 0.1 M sodium oxalate The plasma is deprothrombinized by treatment with tricalcium phosphate suspension as follows 1 ml of 0.008 M suspension is transferred to a small tube and centrifuged The supernatant water is poured off and drained One ml of plasma is mixed with the packed tricalcium phosphate After 10 minutes at room temperature the adsorbent is separated by centrifugation On adding the treated plasma to stored human plasma, the prothrombin time by the Quick method can be reduced from 60-70 seconds to 10-11 seconds

INTERPRETATION The absence of this ability to reduce prothrombin time suggests Ac globulin deficiency

## 25 SPCA

REFERENCE DeVries A, Alexander B and Goldstein R Blood 4 247, 1949

PROCEDURE Normal oxalated plasma 0.05 ml is mixed with 0.9 ml of  $\text{BaSO}_4$  treated plasma and the prothrombin activity (expressed as per cent from a graph) is determined The patient's serum prothrombin activity is then estimated and 0.05 ml of this serum is added to the diluted plasma and the prothrombin time determined on 1 ml of the mixture

The SPCA is calculated by subtracting the algebraic sum of the individual prothrombin activities of the serum and plasma components from the observed prothrombin activity of the mixture The value thus obtained divided by the algebraic sum gives the percentage enhancement of prothrombin activity

INTERPRETATION The failure of enhancement of prothrombin activity would suggest SPCA deficiency

## Chapter 6

### DISTURBANCES IN AMINO ACID METABOLISM

#### PHENYLKETONURIA

#### 26 PHENILPYRUVIC ACID

##### ► (a) QUALITATIVE METHOD

###### REAGENTS

1 N HCl

10% ferric chloride

**PROCEDURE** A few drops of 10% ferric chloride are added to a specimen of urine previously acidified with a few drops of 1 N HCl. If phenylpyruvic acid is present the urine will turn an intense green color.

**COMMENT** Although this test is simple and serves as an excellent screening device the presence of large quantities of urates or phosphates may interfere with its sensitivity.

##### ► (b) QUANTITATIVE METHOD

**REFERENCE** Kropp A. and Lang A. *Klin Wchnschr* 33 482 1955

###### REAGENTS

10% ferric citrate

10% citric acid

**PROCEDURE** A 1:10 dilution is made of urine. To 5 ml of the diluted urine 0.5 ml of 10% ferric citrate and 0.5 ml of 10% citric acid are added. The color reaction is read in 3 minutes in a photoelectric colorimeter at 630 mμ. The unknowns can be compared with standard solutions of phenylpyruvic acid treated in the same manner.

**INTERPRETATION** Normal range 0 mg/24 hours in phenylketonuria  
500-1000 mg/24 hours

#### ► 27 DETERMINATION of L PHENYLALANINE

**REFERENCE** Modification of method by Udenfriend ■ and Cooper J R. *J Biol Chem* 203 953 1953

###### REAGENTS

Acetone-dried powder of *Streptococcus faecalis* (R)

0.7 M citrate buffer pH 5.5

10 N NaOH

## 0.001 M / phenylalanine standard

Chloroform containing 3.3% isoamyl alcohol. The solvents are washed successively with 1 N NaOH, 1 N HCl, and twice with water before mixing.

Methyl orange reagent. Methyl orange, 500 mg, is dissolved in 100 ml of warm water. The resulting solution is washed several times with an equal volume of chloroform. The methyl orange reagent is made by diluting this solution with an equal volume of saturated boric acid solution.

**PROCEDURE** To prepare the filtrate, 0.2 ml of 1 N HCl is mixed with 2.0 ml of plasma and placed in a 100° C water bath for 3 minutes. The solution is then neutralized with 0.2 ml of 1 N NaOH, and the supernatant is separated by centrifugation.

The following reagents are placed in a stoppered glass tube of 15 ml capacity:

0.2 ml of 0.7 M citrate buffer, pH 5.5

0.2 ml of Strep faecalis suspension (This is prepared by mixing 8.25 mg of powder with 0.2 ml of water for each tube depending on activity of enzyme.)

0.2 ml of standard or filtrate of unknown (0.03-0.3  $\mu$ M / phenylalanine)

0.9 ml of water

The tubes are incubated for 2 hours in a 37° C water bath with occasional shaking.

After cooling 0.2 ml of 10 N NaOH and 5 ml of chloroform-isoamyl alcohol reagent are added into each tube. The solutions are shaken vigorously for 5 minutes and centrifuged for 2 minutes.

The aqueous phase is removed by aspiration with a fine-tipped pipette.

Two ml of chloroform extract is transferred to a 2 ml volumetric tube which has a glass stopper. Methyl orange reagent, 0.2 ml, is added and the mixture shaken up and centrifuged.

The tubes are warmed in a beaker of water (to remove clouding) and are read directly in a Coleman Junior colorimeter at 430 $\mu$ .

## CALCULATIONS

$$\text{I Phenylalanine } (\mu\text{M/ml}) = \frac{\text{Reading unknown}}{\text{Reading 0.1 } \mu\text{M/ml standard}} \times \frac{1.2}{10} \times \frac{1}{0.2}$$

**INTERPRETATION** Normal range, 0.02-0.14  $\mu$ M/ml, in phenylketonuria, 1.2-2.4  $\mu$ M/ml

## TYROSINOSIS

28 *p* HYDROXYPHENYLPYRUVATE

## ► (a) MILLON REACTION

REFERENCE Folin O., and Ciocalteu V J Biol Chem 73 627, 1927

## REAGENTS

15%  $\text{HgSO}_4$  in 6 N  $\text{H}_2\text{SO}_4$

2 N  $\text{H}_2\text{SO}_4$

2%  $\text{NaNO}_2$

PROCEDURE Into a 15 ml centrifuge tube place 2.5 ml of urine and 2 ml of 15%  $\text{HgSO}_4$  in 6 N  $\text{H}_2\text{SO}_4$ . This mixture is allowed to stand for 1 hour and then centrifuged. The supernatant liquid is poured into a 50 ml centrifuge tube the original tube being drained carefully and its sides washed with a few drops of distilled water. A standard solution is prepared in the same manner.

Ten ml of 2 N  $\text{H}_2\text{SO}_4$  is added. The mixture is then boiled for 15 minutes. A second portion of 10 ml of 2 N  $\text{H}_2\text{SO}_4$  is added. The liquid is allowed to stand for 30 minutes. If a slight cloudiness appears, the tubes should be centrifuged again. The contents are then poured into a 50 ml volumetric flask. One ml of 2%  $\text{NaNO}_2$  is added, and the contents are diluted to volume. This is then read at once in a colorimeter.

INTERPRETATION This reaction measures both tyrosine and tyrosine derivatives but is not specific for *p* hydroxyphenylpyruvate. However, it is useful as a screening device for tyrosinosis.

## ► (b) ALPHA KETO ACID TEST

REFERENCES Bucher, T., and Kirberger, E. *Biochim et biophys acta* 8 401, 1952. Knox W. E., and Pitt, B. M. J Biol Chem 225 675, 1957.

## REAGENTS

2 N sodium arsenate pH 6

2 N sodium arsenate with borate pH 6

PROCEDURE Urine 0.1 ml is added to each of two cells one of which contains 2 ml of sodium arsenate and the other 2 ml of sodium arsenate borate. The cells are read 5 minutes later in a Beckman DU spectrophotometer, with the first acting as a blank. *p*-Hydroxyphenylpyruvate gives a characteristic peak at 310 $\mu$ .

INTERPRETATION This test is useful in measuring both phenylpyruvic and *p* hydroxyphenylpyruvic acid. The former can be ruled out by the ferric chloride test. *p* Hydroxyphenylpyruvic acid is not a significant component of normal urine.

## ALKAPTONURIA

## 29. HOMOGENETISIC ACID

## ➤ (a) QUALITATIVE SCREENING TESTS

1 Alkalinizing the urine with NaOH or ammonia will turn the urine either dark brown or black

2 Homogentisic acid will reduce Benedict's solution, giving rise to a yellow or orange precipitate and a brown or black supernatant. To differentiate homogentisic acid from glucose homogentisic acid will not ferment yeast or rotate a beam of polarized light, while glucose will

3 When ferric chloride is added dropwise to the urine, an evanescent blue color appears. When strong alkali is added and the specimen is shaken, the solution promptly turns dark

## (b) QUANTITATIVE TESTS

REFERENCE Lanyar, F., and Lieb, H. *Ztschr physiol Chem* 203 135, 1931

INTERPRETATION Homogentisic acid is not present in normal urine

## MAPLE SUGAR URINE DISEASE AND II DISEASE

## 30. AMINO ACID METHODS

## ➤ (a) MEASUREMENT OF TOTAL FREE ALPHA AMINO NITROGEN

REFERENCES Van Slyke, D. D., et al. *J Biol Chem* 141 627, 1941, Hamilton, P. B., and Van Slyke, D. D. *J Biol Chem* 150 231, 1943, Van Slyke, D. D., MacFadyen, D. A., and Hamilton, P. B. *J Biol Chem* 150 251, 1943

BACKGROUND The method depends on the fact that alpha amino acids, when boiled in water with an excess of ninhydrin at low pH's, evolve CO<sub>2</sub> of their carboxyl groups quantitatively in a few minutes, in the following manner



(Proline and hydroxyproline yield their carboxyl CO<sub>2</sub> in the same manner as the amino acids with primary NH<sub>2</sub> in the alpha position)

## PROCEDURE

## 1 Preparation of sample

(a) Plasma—Two ml of plasma is precipitated in 10 ml of 1% picric acid solution. The precipitate is removed by both

centrifuging and filtration. The supernatant is used for testing.

(b) *Urine*—Two ml of urine (preserved with thymol) is placed in a ninhydrin reaction vessel, and the pH adjusted to a little over 6. A crystal of thymol and 0.2 ml of 1% urease solution are added, and the vessel is left overnight for removal of urea. The pH is then brought down to about 3 the next day and the sample is used for testing.

2 *Reaction with ninhydrin*—The picric acid filtrate of plasma or the urease treated urine is placed in a ninhydrin reaction vessel, the excess  $\text{CO}_2$  is removed by boiling over a microburner, and the solution is chilled in an ice bath. Next 100 mg of ninhydrin is added, the vessel is closed and evacuated, and it is then immersed completely in boiling water and allowed to remain for 20 minutes, with the water boiling vigorously all the time. The vessel is then removed from the water and cooled to room temperature.

3 *Measurement of  $\text{CO}_2$* —The  $\text{CO}_2$  is measured in a Van Slyke-Neill manometer by absorption in 0.5 N NaOH and by release of the gas on the addition of 2 N lactic acid.

4 *Calculation*—The pressure  $p\text{CO}_2$  from amino acid groups is calculated as follows:

$$p\text{CO}_2 = p_1 - p_2 - c$$

where  $p_1$  represents the initial pressure after release of  $\text{CO}_2$ ,  $p_2$  represents the final pressure after the gas has been reabsorbed by 6 N NaOH and  $c$  represents the ninhydrin blank.

The alpha amino N is calculated as follows:

$$\text{Mg alpha amino N/100 cc} = p\text{CO}_2 \times \text{Factor} \times V$$

where  $V$  is cc of filtrate equivalent to 100 cc, which for plasma is 120 and urine is 50.

#### INTERPRETATION

*Plasma*—Normal range 3.4–5.5 mg/100 ml (Hamilton, P. B. and Van Slyke, D. D. *J. Biol. Chem.* 150:231, 1943).

*Serum*—Normal range 4.9–7.0 mg/100 ml (MacFadyen, D. A. *J. Biol. Chem.* 145:387, 1942).

*Urine*—Normal range 0.75–0.95 mg/lb/24 hours (Hsia, D. Y. Y., and Gellis, S. S. *J. Clin. Invest.* 33:1603, 1954).

#### ► (b) DETERMINATION OF SPECIFIC AMINO ACIDS BY PAPER CHROMATOGRAPHY

Re

... .. A J P

*et al* *Paper chromatography A laboratory manual* (New York Academic Press Inc 1954) Smith E L and Tuller E F Arch Biochem 54 114 1955

**BACKGROUND** The resolution of mixtures of solutes on filter paper may depend on surface absorption on ion exchange or on partition between solvents. Substances absorbed to filter paper were separated by passing through the paper or solvent which would preferentially elute each substance in the mixture and on this basis paper partition chromatography was conceived.

#### APPARATUS

Chromatographic chamber  
Desalting apparatus  
Equipment for evaporation in vacuo  
Micropipettes  
Drying oven  
Spraying equipment

#### PROCEDURE

##### 1 *Preparation of sample*

###### (a) *Urine*

**Desalting**—Approximately 10 ml of urine (preserved with thymol) is desalted. This can be done by shaking with resins or with a desalting apparatus by electrolysis. Such an apparatus can be made in the laboratory (see Consden, Gordon, and Martin) or purchased commercially. (Although some authors feel that this step can be omitted, our experience indicates that the interference of the salt effect causes so much distortion and blurring that it makes identification of the amino acid spots very difficult.)

**Evaporation in vacuo**—The desalted urine is then evaporated to dryness at low boiling temperatures using suction and dry ice. The precipitate is redissolved in water to one fourth of the original volume and is used for spotting on paper.

###### (b) *Plasma*

**Deproteinization**—The plasma is deproteinized by a solution of sodium tungstate and N ethylmethylamine. The supernatant is then desalted and evaporated in vacuo as above.

- 2 *Application of sample to paper*—Between 15 and 50  $\mu$ l of the sample is spotted in the lower right hand corner of the paper. The sample should be accurately measured with a self filling micropipette (manufactured by Microchemical Specialties Co) and not more than 5  $\mu$ l should be applied at one time. The paper should be thoroughly dried before another sample is



applied. A hair dryer or heat lamp will greatly accelerate the drying process.

- 3 *Running of chromatogram*—The chromatogram may be run by a variety of methods depending on the type of problem and personal preference. The following variables may be used:
  - Method: ascending, descending, ascending-descending
  - Chambers: one way, two way, fish tank
  - Dimensions: one or two dimensions
  - Solvents: phenol, butanol, acetic, collidine, lutidine, etc.
  - Paper: Whatman No. 1 or 4, S & S others

In our laboratory, we have employed two-dimensional ascending chromatography, using a metal rack in a fish tank. The chromatograms have been made with Whatman No. 4 paper using phenol-water in one direction for 12 hours and butanol-acetic in the other direction for 18 hours.

- 4 *Analysis of data*—The data may be analyzed by one of the following methods:

(a) *Densitometer*—The photoelectric densitometer made by Photovolt is excellent for one-dimensional work but is difficult to use and interpret with two-dimensional data.

(b) *Direct analysis of ninhydrin spray*—The papers are sprayed with ninhydrin, dried in an oven, and analyzed immediately. Each of the amino acids is identified by superimposing using  $R_f$  values, and the results are tabulated semiquantitatively by grading against an arbitrary standard judged under constant lighting conditions.

(c) The spots can be cut out and diluted after identification on a duplicate sheet, and the solution measured by addition of ninhydrin on a photoelectric colorimeter.

#### INTERPRETATION

*Plasma*—Normally, between 19 and 21 amino acids can be identified in the plasma with paper chromatography.

*Urine*—Normally, alanine, glutamine, glycine, histidine, and serine are present in measurable quantities. The appearance of other amino acids in excessive quantities is abnormal.

#### (c) DETERMINATION OF SPECIFIC AMINO ACIDS BY COLUMN CHROMATOGRAPHY

**REFERENCES** Stein, W. H. and Moore, S. Cold Spring Harbor Symposium Quant. Biol. 14: 179, 1950; Stein, W. H. J. Biol. Chem. 201: 45, 1953; Stein, W. H., and Moore, S. J. Biol. Chem. 211: 915, 1954; Huisman, T. H. J. Pediatrics 14: 245, 1954.

**PROCEDURE** A few ml of specially prepared amino acids from urine or plasma are added to the top of a starch column. The sample

■ allowed to drain with the starch and fresh solvent containing no amino acids is added and run through under slight pressure. The packed column ■ mounted over an automatic fraction collector which has been designed to collect continuously small fractions of specific volume. The amino acid concentration in each of the tubes is determined by a simple photometric ninhydrin method. The data obtained permit the construction of effluent curves which reveal the detailed behavior and full resolving power of the column.

(d) DETERMINATION OF SPECIFIC AMINO ACIDS  
BY CHEMICAL OR MICROBIOLOGICAL METHODS

REFERENCES

<i>Amino Acid</i>	<i>References (see below)</i>
Glutamine	1 2 4 5 17
Alanine	3 7 14 19
Lysine	11 13 14 15 19
Valine	11 13 14 15 19
Cysteine-cystine	10
Glycine	3 6 11 14 19
Proline	14 19
Leucine	11 13 14 15 19
Arginine	8 12 13 14 15
Histidine	11 13 14 15
Threonine	11 12 13 14 15 19
Isoleucine	11 13 14 15 19
Phenylalanine	14 15 19
Tryptophane	11 14 15 19
Serine	19
Tyrosine	9 11 14 15 19
Glutamic acid	4 5 17
Methionine	13 14 16 19
Aspartic acid	14 19

- 1 Archibald R M J Biol Chem 154 643 1944
- 2 Hamilton P B J Biol Chem 158 375 1945
- 3 Christensen H M *et al* J Biol Chem 168 191 1947
- 4 Krebs H A Eggleston L V and Hems R Biochem J 44 159 1949
- 5 Waelsch H Advances Prot Chem 6 305 1951
- 6 Alexander B, Landwehr G and Seligman A M J Biol Chem 159 9 1945
- 7 Alexander B and Seligman A M J Biol Chem 159 9 1945
- 8 Huberman H D J Biol Chem 167 721 1947
- 9 Bernhart F W and Schneider H W Am J M Sc 205 636 1943
- 10 Hutchins M E, *et al* J Biol Chem 185 839 1950

- 11 Hofstatter, L., Ackermann, P. G., and Kountz, W. B. *J. Lab & Clin. Med.* 36:259, 1950
- 12 Henderson, L. M., and Snell, E. E. *J. Biol. Chem.* 172:15, 1948
- 13 Kirsner, J. B., Sceffner, A. L., and Palmer, W. L. *J. Clin. Invest.* 28:716, 1949
- 14 Steele, B. F., Reynolds, M. S., and Baumann, C. A. *J. Nutrition* 40:145, 1950
- 15 Hier, S. W., and Bergain, O. *J. Biol. Chem.* 163:129, 1946
- 16 Harper, H. A., Kinsell, L. W., and Barton, H. D. *Science* 106:319, 1947
- 17 Harper, H. A. *Arch. Biochem.* 15:433, 1947
- 18 Horn, M. J., *et al.* *J. Biol. Chem.* 169:739, 1947
- 19 Steele, B. F., *et al.* *J. Biol. Chem.* 177:533, 1949

## Chapter 7

# DISTURBANCES IN CARBOHYDRATE METABOLISM

## PENTOSURIA

### 31 / XYLULOSE

#### (a) QUALITATIVE SCREENING TEST

One ml of urine is added to 5 ml of Benedict's qualitative reagent, mixed and placed in a test tube in a water bath at 55° C for 10 minutes. The appearance of a yellow precipitate under these conditions is very suggestive of xylulose.

#### (b) PAPER CHROMATOGRAPHY

This may be performed using a 3:2:1:5 mixture of *n*-butanol, pyridine, water, solvent (Horrocks, R. H., and Manning, G. B. *Lancet* 1:1042, 1949). The sugar spots show up with the *p*-phenylenediamine reagent of Flynn (Flynn, P. V., Harper, C., and DeMayo, P. *Lancet* 2:698, 1953).

#### (c) OSAZONE FORMATION

**REFERENCE** Enklewitz, M., and Lasker, M. *J. Biol. Chem.* 110:443, 1935

**PROCEDURE** Recrystallized phenylhydrazine and sodium acetate are added directly to the urine in the proportion of 4 Gm:6 Gm:1

Gm of total reducing bodies This is heated for 1¼ hours in a boiling water bath and then cooled in air In urine which contains a large amount of xylulose, a precipitate, osazone, begins to form in the hot solution This is filtered off as soon as the solution is cold

The osazone is allowed to stand overnight and is then dried and recrystallized several times The phenylhydrazine is identified as *l* xylosazone by (1) its gross and microscopic appearance and its solubility, (2) its melting point at 162° C (3) the formation of *dl* xylosazone, (4) its optical activity, and (5) its nitrogen content

INTERPRETATION *l* Xylulose is not a component of normal urine

## FRUCTOSURIA

### 32 FRUCTOSE

PROCEDURE Fructose may be identified in the urine by the following methods

- 1 In an acid urine, the reducing sugar must be present and active at room temperature
- 2 The urine must ferment with ordinary yeast
- 3 The urine must be levorotatory, and the levorotation must disappear upon fermentation
- 4 The Selivanoff test must be positive

Reagent—Selivanoff's reagent is prepared by dissolving 0.05 Gm of resorcinol in 100 ml of dilute 1:2 hydrochloric acid

Method—A few drops of urine are added to 5 ml of Selivanoff's reagent and heated to boiling The presence of fructose is indicated by the production of a red color, which may or may not lead ultimately to the separation of a red precipitate The latter is dissolved in alcohol to impart a striking red color

- 5 Preparation of methylphenyllosazone—This is prepared by adding urine to 4 Gm of methylphenylhydrazine and enough alcohol to clarify the solution Four ml of 50% acetic acid is added, and the mixture is heated for 5-10 minutes in a boiling water bath When the mixture has stood for 15 minutes at room temperature, crystallization begins, and is completed in 2 hours The crystals have a melting point of 153° C The osazone can be compared with that prepared from fructose by paper chromatography

- 6 Paper chromatography—Fructose can be identified by paper

*chromatography, using butanol ethanol ammonia as solvents and aniline phthalate as developer*

**INTERPRETATION** Fructose is not a component of normal urine

### 33 FRUCTOSE TOLERANCE TEST

This test is performed by giving 50 Gm of fructose by mouth after an 18 hour fast. Samples of blood are taken both before the test and at 30, 60, 90, 120, and 240 minutes after ingestion. Fructose is determined by the method described by Roe (J Biol Chem 107 15, 1934)

#### REAGENTS

0.1% alcohol resorcinol solution

30% HCl

**PROCEDURE** The blood is precipitated with zinc sulfate and NaOH, and the filtrate is added to tubes containing 2 ml of 0.1% alcohol resorcinol solution and 6 ml of 30% HCl. The tubes are shaken vigorously and kept in a water bath at 80° C for 8 minutes. The color is compared colorimetrically with known standards.

**INTERPRETATION** Levels of fructose in excess of 40 mg/100 ml are suggestive of fructosuria. The presence of fructose in the urine after the test is also highly suggestive of the diagnosis.

## GALACTOSEMIA

### ► 34 GALACTOSE IN URINE

**PROCEDURE** Galactose may be identified in the urine by the following methods:

1. **Mucic acid test**—Urine, 50 ml, and concentrated nitric acid, 12 ml, are heated in a water bath and cooled overnight. A fine white precipitate of mucic acid will form if lactose or galactose is present. These crystals can be identified under the microscope and by their melting point (217°-218° C).
2. **Osazone test**—Clarified and concentrated urine, 25 ml, is mixed with phenylhydrazine hydrochloride and sodium acetate and heated in a water bath for 45 minutes. The crystals that appear can be compared with the osazone prepared from pure galactose. After three recrystallizations the crystals should melt constantly at 182° C, and when mixed with a known specimen containing galactosazone, there should be no depression of the melting point. The osazone can also be compared with that prepared from galactose by paper chromatography.
3. **Paper chromatography**—Galactose can be identified in the urine by using one-dimensional chromatograms with butanol-

ethanol ammonia as solvent and aniline phthalate as developer and comparing the unknown with known galactose standards

**INTERPRETATION** Galactose is not a component of normal urine

### 35 GALACTOSE TOLERANCE TESTS

The galactose tolerance can be determined by two different methods: the oral and intravenous

1 For the oral galactose tolerance test 1.75 Gm/kg body weight of galactose is given by mouth on a fasting stomach. Duplicate 0.2 ml capillary blood samples are collected both prior to feeding and at 30, 60, 90, 120, and 240 minutes after feeding

2 For the intravenous galactose tolerance test, 1.2 Gm/kg body weight of galactose is injected intravenously and duplicate blood samples are taken both before injection and at 15, 30, 45, 60, and 75 minutes after injection

#### BLOOD GALACTOSE DETERMINATION

**REFERENCES** Hartmann, A. *J. Pediat.* 43:1, 1953; Somogyi, M. *J. Biol. Chem.* 117:771, 1937

#### REAGENTS

Fresh baker's yeast

Copper reagent, made up of 25 Gm of  $\text{Na}_2\text{CO}_3$ , 25 Gm of Rochelle salt, 4 Gm of  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ , 20 Gm of  $\text{NaHCO}_3$ , 200 Gm of  $\text{Na}_2\text{SO}_4$  (anhydrous, analytic grade), 1.5 Gm of  $\text{KI}$ , and 6 ml of 1 N  $\text{KIO}_3$  diluted to 1 L

Iodide and iodate solution, prepared by adding 2 Gm of  $\text{Na}_2\text{CO}_3$  dissolved in 50 ml of 0.1 N  $\text{K}_2\text{CO}_3$  and diluted to 1 L

1 N  $\text{H}_2\text{SO}_4$

0.05 N thiosulfate solution

1% starch solution

**PROCEDURE** One of the duplicate samples is precipitated with zinc sulfate and sodium hydroxide. The other sample is first treated with fresh baker's yeast (0.2 ml of blood is added to 5.8 ml of 10% suspension of washed fresh yeast), allowed to stand 5 minutes, then precipitated with zinc sulfate and  $\text{NaOH}$  in the same manner

Five ml of filtrate is placed into a Pyrex tube containing 5 ml of the copper reagent. The tube is stoppered with a glass bulb and placed in a boiling water bath for 20 minutes and cooled. If the solution to be tested contains more than 0.50 mg of glucose, then 5 ml of iodide and iodate solution is added (This is equivalent to an additional 0.50 mg of glucose)

Five ml of 1 N  $\text{H}_2\text{SO}_4$  is then added. After standing 5-10 minutes with occasional agitation, the solution is rinsed and titrated with

0.005 N thiosulfate solution One ml of 1% starch solution is added toward the end point

The amount of sugar present is calculated from the amount of thiosulfate solution added minus the amount added to the blank tube made with water. If titration is less than 1 ml of thiosulfate, the result is doubtful because of the reagent's approach to capacity. The difference between the yeast treated tube and the untreated tube represents the galactose level in the blood.

**INTERPRETATION** Galactose levels in excess of 50 mg/100 ml by either test are abnormal.

### ► 35a GALACTOSE 1- $\text{PO}_4$ URIDYL TRANSFERASE ACTIVITY

**REFERENCES** Anderson, E. P., Kalckar, H. M., Kurahashi, K., and Isselbacher, K. J. *J. Lab. & Clin. Med.* 50:469, 1957, and Tentative Technical Bulletin No. 600, Sigma Chemical Co., St. Louis 18, Missouri.

#### REAGENTS\*

0.9% NaCl

Uridine diphosphoglucose (UDPG), 5  $\mu\text{M}$ /ml

Galactose 1- $\text{PO}_4$ , 7.5  $\mu\text{M}$ /ml (barium free)

Tris glycine buffer, 0.2 M, pH 8.1

UDPG dehydrogenase, 800 units/ml

**PROCEDURE** Approximately 5 ml of blood is collected in heparinized tubes. The red cells are washed twice with a double volume of 0.9% NaCl and hemolyzed by the addition of an equal volume of cold distilled water. The hemolysate (0.25 ml) is then incubated with UDPG, galactose 1- $\text{PO}_4$ , and tris glycine buffer for 30 minutes at 37° C. For each sample a control is run where no galactose 1- $\text{PO}_4$  is added to the substrate. After incubation, UDPG is determined in heat inactivated hemolysates by means of UDPG dehydrogenase. The difference between the measurements of UDPG in the sample and the control represents the amount of UDPG consumed through the activity of Gal 1 P-uridyl transferase. Uridine diphosphoglucose pyrophosphorylase activity is also determined to assure that the blood sample and the hemolysate are properly handled.

**INTERPRETATION** The means of Gal 1 P-uridyl transferase activity were found to be 4.5 ( $\pm 0.47$ ) and 0.5 ( $\pm 0.04$ )/Gm Hgb for the normal and galactosemic patients, respectively.

\*All reagents may be obtained from Sigma Chemical Company, St. Louis 18, Missouri.

## GLYCOGEN STORAGE DISEASE

## 36 EPINEPHRINE RESPONSE

An injection of 0.1-0.2 ml of epinephrine should normally cause a rise of 40-70 mg/100 ml in the blood sugar at the end of 1 hour. This rise does not occur in patients with glycogen storage disease Type I (of the liver and kidneys) and is reduced in Types III and IVa.

## ▶ 37. GLUCOSE-6-PHOSPHATASE OF THE LIVER

REFERENCE. Technique is described in Cori, G. T., and Cori, C. F. J Biol Chem 199:661, 1952.

PROCEDURE. The obtained livers are frozen within 4 hours. Samples were not allowed to thaw before use. Small pieces (0.3-4 mg) are chiseled off the frozen livers, weighed, and homogenized immediately in ice-cold water in a cold stainless steel homogenizer, or ground in a cold mortar without sand. For 1 part of liver, 2 parts of water is used.

The homogenates are filtered through gauze to remove small amounts of fibrous tissue, yielding a filtrate which can be pipetted without difficulty.

Several dilutions of the same homogenate are incubated with glucose-6- $\text{PO}_4$  in order to test proportionality to enzyme concentration.

The samples are deproteinized with trichloroacetic acid and the filtrates analyzed for inorganic phosphate, by the method of Fiske and Subbarow.

Each experiment includes samples incubated without the addition of glucose-6- $\text{PO}_4$ . The amount of inorganic phosphate formed after incubation without substrate is deducted from that formed in the presence of substrate. In all instances only small amounts of phosphate were formed on incubation without substrate.

The reaction mixture consists of

0.3 ml	0.1 M potassium citrate, pH 6.8
0.5 ml	0.01 M potassium-glucose-6- $\text{PO}_4$ , pH 6.8 (or 0.5 ml $\text{H}_2\text{O}$ for blanks)
0.2 ml	homogenate (equivalent to 4.33 mg of liver)
<hr/>	
1.0 ml	Total volume

The reaction mixture is incubated for 1 hour at 30° C and removed at the end of 1 hour and placed in ice. It is deproteinized with 1 ml of 10% TCA (ice cold), and the inorganic phosphate on 1 ml of the filtrate is determined.



## 38 CHARACTER OF GLYCOGEN

REFERENCES Technique as described in Illingworth, H. Larnier, J. and Cori G. T. *J Biol Chem* 199 631, 1952, and in Larnier, J., Illingworth, B., Cori G. T., and Cori, C. F. *J Biol Chem* 199 641, 1952

## HEREDITARY SPHEROCYTOSIS

## ► 39 OSMOTIC FRAGILITY

REFERENCE Shen, S. C., and Ham, T. H. *New England J Med* 229 701, 1943

PROCEDURE Accurately measured 0.1 ml samples of blood are pipetted into a series of tubes containing 1.0 ml amounts of the following solutions: hypertonic NaCl (2.0, 1.5, and 1.0%), isotonic NaCl (0.85%), and hypotonic NaCl (0.801%) and distilled water. The samples are mixed and centrifuged. The supernatant fluid is poured into a separate set of clean tubes and 0.5 ml of the supernatant solutions are diluted to 1.0 ml with distilled water in Evelyn colorimetric tubes. One drop of  $\text{NH}_4\text{OH}$  is added to each tube, and the samples are read and the hemoglobin determined in an Evelyn colorimeter, using a 540 m $\mu$  filter. The colorimetric values observed in the hypertonic salt mixtures are averaged as the 'blank' and subtracted from each value obtained in the hypotonic range to give a corrected figure for hemolysis.

The per cent hemolysis of each salt concentration is then calculated by dividing the corrected figure for the hemolysis by the corrected figure for complete hemolysis produced in distilled water. The results can then be plotted with the hemolysis in per cent as the ordinate and tonicity of the hypotonic mixture as the abscissa.

## ► 40 MECHANICAL FRAGILITY

REFERENCE Shen, S. C., Castle, W. B., and Fleming, E. M. *Science* 100 387, 1944

PROCEDURE Defibrination is performed under aseptic conditions in 50 ml Erlenmeyer flasks containing glass beads. The fibrin clot is then removed with sterile applicators. The hematocrit of the specimen is adjusted to 35% by adding or removing serum and 0.5 ml of the corrected specimen is placed in a 50 ml Erlenmeyer flask with 8 glass beads and rotated for 60 minutes at 100 rpm in a

rotator with the center of the flask 3.25 cm from the center of the wheel

Of the remaining portion of the corrected specimen 0.1 ml is added to 1.0 ml of distilled water (complete osmotic lysis) in a centrifuge tube, another 0.1 ml is added to 1 ml of 1.25% NaCl (no osmotic lysis) in a second tube. The amounts of free hemoglobin in the supernatant of these tubes are determined in an Evelyn photoelectric colorimeter, and the results are designated *H* (complete lysis) and *O* (no lysis) respectively.

Two 0.1 ml samples from the rotated samples are added to each of two tubes containing 1 ml of 1.25% NaCl solution. These are similarly centrifuged and the free hemoglobin in the supernatants is determined. Results are designated as *S*<sub>1</sub> and *S*<sub>2</sub> respectively.

The mechanical fragility of the sample is then determined by the use of the following formula

$$MF = \frac{S - O}{H - O}$$

and expressed as a percentage value where *S* is the average of *S*<sub>1</sub> and *S*<sub>2</sub>.

**INTERPRETATION** Values above 6% are abnormal in adults and in children after the age of 1 week.

#### ▶ 41 INCUBATED OSMOTIC AND MECHANICAL FRAGILITY

**PROCEDURE** Procedures 40 and 41 are repeated on sterile blood which has been incubated for 24 hours at 37° C.

## Chapter 8

### DISTURBANCES IN ENDOCRINE METABOLISM

#### CONGENITAL HYPOTHYROIDISM WITH GOITER

#### 42 RADIOACTIVE IODINE UPTAKE AND KSCN EFFECT

**REFERENCE** Techniques are outlined in Stanbury, J. B., and Hedge, A. N. *J Clin Endocrinol* 10:1471, 1950.

#### ■ EFFECT OF METHIMAZOLE

**REFERENCE** The methods are described in Stanbury, J. B., Ohela, K., and Pitt Rivers, R. *J Clin Endocrinol* 15:54, 1955.

44 <sup>131</sup>I LABELED MONO- AND DIODOTYROSINE  
IN BLOOD AND URINE

REFERENCE Technique is described in detail in Stanbury, J B, Kassenaar, A A H, and Meijer, J W A *J Clin Endocrinol* 16 735, 1956

## ► 45 PREGNANETRIOL IN URINE

REFERENCE Bongiovanni, A M, and Clayton G W, Jr *Bull Johns Hopkins Hosp* 94 180 1954

PROCEDURE A 50 ml aliquot of a freshly collected 24 hour urine specimen is incubated at 37° C with 15,000 units of glucuronidase (obtained from Warner Institute, New York City) and 10 ml of 0.5 M acetate buffer, pH 4.5, for 24 hours. When high levels of steroid metabolites are expected, only 5 ml of urine with proportionately less enzyme and buffer is employed.

The urine is then extracted three times with one third volume of benzene. The urine is then discarded. The benzene is washed three times with 15 ml of 1.0 N NaOH and three times with water. The benzene is now evaporated on a steam bath with a gentle air blast.

A column is prepared (11.0 mm diameter) with 12 Gm of alumina (Harshaw Chemical Co., Elyria, Ohio) and benzene. The urine residue is dissolved in 5-10 ml benzene with the aid of gentle heat and applied to the column. Two extra washings of the residue with 3-4 ml of benzene are performed to insure quantitative transfer.

A simple three fraction elution with the following solutions is employed: (a) 100 ml of 0.05% ethanol in benzene (this may be discarded), (b), 150 ml of 2.0% ethanol in benzene, and (c) 100 ml of 10% ethanol in benzene. The second fraction contains the pregnanediol and the third pregnanetriol. A 50 ml aliquot of the second and third fraction is evaporated in a flask with air to dryness. To the dry flask is added 5.0 ml of ethanol, which is then evaporated to insure complete removal of benzene. To each of the dry flasks is added 10 ml of concentrated H<sub>2</sub>SO<sub>4</sub> with swirling and the resultant chromogens are read in 20 minutes with the Beckman DU spectrophotometer at 325, 390, 425, 440 and 460 mμ.

The results are corrected and calculated as follows:

$$\text{Corrected reading at 425 m}\mu = \text{OD at 425} - \frac{\text{OD 390} + \text{OD 460}}{2}$$

INTERPRETATION Normal range of pregnanetriol 0-2.0 mg/24 hours  
Patients with adrenal hyperplasia excrete 10-40 mg/24 hours

## 46 17 KETOSTEROIDS IN URINE

**REFERENCE** Slightly modified from Drecker I J, Pearson S, Bartczak, E, and McGavack T II J Clin Endocrinol 7 795 1947

**PRINCIPLE** A 24 hour urine specimen is collected. An aliquot of the urine is hydrolyzed with HCl and extracted with ether and then washed with NaOH to remove the phenolic compounds. The solvent is evaporated, and the dried residue taken up in alcohol. The resulting color is produced by the coupling of the ketone group at position 17 with *m*-dinitrobenzene in the presence of a strong alkali.

### REAGENTS

Conc HCl

5 N KOH (carbonate free)

Absolute ethyl alcohol aldehyde free

2% *m*-dinitrobenzene. The *m*-dinitrobenzene should be purified according to the method of Callow *et al*. Dissolve 20 Gm of *m*-dinitrobenzene in 750 ml of 95% alcohol warm to 40° C to dissolve, and add 100 ml of 2 N NaOH. After 5 minutes cool the solution and add 2 500 ml of water. Collect the precipitated *m*-dinitrobenzene on a Buchner funnel wash with large amounts of water, and suck dry. Recrystallize twice in succession from 120 ml and 80 ml of absolute alcohol. The material should be obtained as colorless needles.

From this make the 2% *m*-dinitrobenzene solution in alcohol.

It may be preserved in a dark bottle and kept for about 2 weeks. Standard solution of dehydroisoandrosterone or androsterone containing 50 mg/100 ml in absolute alcohol.

Working standard. 1 ml of the stock standard solution is diluted to 10 cc with absolute alcohol (0.2 ml equals 0.01 mg).

10% NaOH

Ether

**COLLECTION** A 24 hour urine specimen is collected in a bottle containing 5 ml of concentrated HCl.

**HYDROLYSIS** To 5 ml of concentrated HCl in a 50 ml glass stoppered Erlenmeyer flask, add 20 ml of urine. Place the flask in a water bath at 80° C for 15 minutes and then cool it. This solution may be left for 24 hours in the refrigerator.

**EXTRACTION** In a 125 ml separatory funnel put 10 ml of the hydrolyzed urine. Add 20 ml of ether and shake for 1 minute. Remove the aqueous layer. Add 10 ml of 10% NaOH and shake. Remove the aqueous layer. Add 10 ml of distilled water and shake. Remove the aqueous layer. Into a 50 ml glass stoppered centrifuge

tube put the washed ether layer and centrifuge slowly for about 1 minute

**EVAPORATION** Into three test tubes place 5 ml of the ether extract. Evaporate in a water bath at 56° C until all the ether has completely disappeared (The stored residue may be stored in a desiccator indefinitely)

**COLOR REACTION (Zimmerman reaction)** Tubes 1, 2, and 3 are used for duplicate unknowns and a pigment blank. Additional tubes (4 and 5) are used for standard and reagent blank. The arrangement of the tubes is as follows

UNKNOWN (TUBES 1 AND 2)	PIGMENT BLANK (TUBE 3)	STANDARD (TUBE 4)	REAGENT BLANK (TUBE 5)
0.2 alcohol	0.4 ml alcohol	0.2 ml diluted standard	0.2 ml alcohol
0.2 <i>m</i> -dinitrobenzene		0.2 ml <i>m</i> -dinitrobenzene	0.2 ml <i>m</i> -dinitrobenzene
0.2 ml 5 N KOH	0.2 ml 5 N KOH	0.2 ml 5 N KOH	0.2 ml 5 N KOH

Place all tubes in a 25° C water bath for 60 minutes. Immediately add 10 ml of 80% ethyl alcohol and read in a photoelectric colorimeter within 10 minutes using filter 540 mμ.

Ten ml of 80% alcohol is used as the colorimeter blank.

#### CALCULATIONS Corrected

$$\frac{\text{Optical density of unknown}}{\text{Optical density of standard}} \times 0.01 \times \frac{1}{2} \times 24 \text{ hr urine volume} = \text{Mgm 17 ketosteroids/24 hour specimen}$$

To correct optical density of unknown subtract optical density of reagent blank plus optical density of pigment blank from optical density of unknown

To correct optical density of standard subtract optical density of reagent blank from optical density of standard

#### NORMAL RANGE

Male adults 10-20 mg/24 hours

Adult females 5-15 mg/24 hours

In children from birth to 8 years the values are near 0 or less than 1 mg/24 hours. At the age of 12 they are 1-5 mg and then they gradually increase to adult levels at about the age of 16. There is no marked sex difference until the age of 16 years.

There is a moderate day and night variation.

#### 47 TETRAHYDRO S IN URINE

**REFERENCE** Technique is described in detail in Eberlein W, and Bongiovanni A M. J Clin Endocrinol 15:1531, 1955

## Chapter 9

### DISTURBANCES IN PIGMENT METABOLISM

#### CONGENITAL METHEMOGLOBINEMIA

##### ► 48 METHEMOGLOBIN

REFERENCE Evelyn, H T, and Malloy, K A J Biol Chem 126 655, 1938

###### REAGENTS

0.1 M phosphate buffer, pH 6.9

Sodium cyanide or sodium hydrosulfite solution, dilute

PROCEDURE To 16 ml of distilled water, 0.6 ml of blood is added. After the solution has stood for 10 minutes, 8 ml of 0.1 M phosphate buffer is added and the solution centrifuged.

The solution is put into two similar 1 cm Beckman glass cells and first read against a water blank in a Beckman spectrophotometer. The absorption band at 633 m $\mu$  is characteristic of methemoglobin. A small amount of sodium cyanide or sodium hydrosulfite is then added to one of the cells, resulting in the disappearance of the band. The differences between the two cells represents the methemoglobin content of the solution.

INTERPRETATION Methemoglobin levels in excess of 1% of total hemoglobin are abnormal.

##### 49 DIAPHORASE I

REFERENCE Technique is described in detail in Gibson, Q H Biochem J 42 13, 1948

##### 50 OXYGEN DISSOCIATION CURVE

REFERENCE Technique is described in detail in Darlington, R C, and Roughton, F J W Am J Physiol 137 56 1942

#### HEPATIC PORPHYRIA

##### 51 PORPHOBILINOGEN

See Procedure 10

##### 52 UROPORPHYRIN

See Procedure 8

## ► 53 COPROPORPHYRIN

See Procedure 9

CONGENITAL FAMILIAL NONHEMOLYTIC JAUNDICE  
WITH KERNICTERUS

## ► 54 BILIRUBIN EXCRETION TEST

**PROCEDURE** Commercial bilirubin, 5 mg/kg, is dissolved in 11 M sterile  $\text{Na}_2\text{CO}_3$  and injected intravenously. The serum bilirubin is determined at 30 minutes, 1, 2½, 4, and 6 hours after injection. A retention of more than 10% after 6 hours is abnormal.

► 55 BILIRUBIN CONJUGATION WITH GLUCURONIDE  
BY TISSUE HOMOGENATES

**REFERENCE** Grodsky, G. M., and Carbone, J. V. *J Biol Chem* 226:449, 1957

**REACTANTS**

**Bilirubin solution**—Stock solution consists of 10 mg of bilirubin (Eastman 2101) dissolved in 100 ml of chloroform. Immediately before each experiment, a 10 ml aliquot is extracted by shaking with 5 ml of 0.3% of bovine albumin solution made alkaline by the addition of 0.15 ml of 2.5%  $\text{NH}_4\text{OH}$ , extraction is repeated and the extracts are pooled. The pH is adjusted to 7.4, using N HCl. The final concentration of bilirubin in this solution is approximately 40  $\gamma$ /ml.

**Boiled liver extract**—Three Gm of fresh liver tissue is quickly disrupted in an all glass homogenizer in 2.5 ml of 0.5% KCl; the contents are poured into a large test tube containing 7.5 ml of the KCl solution and boiled for 10 minutes. The volume is readjusted with water, and the supernatant fluid is stored at 6° C during the preparation of the homogenate.

**Tissue homogenate**—One Gm of fresh liver or other test tissue is ground in a homogenizer with 10 ml of ice-cold, alkaline KCl (prepared by adding  $32 \times 10^{-3}$   $\text{KHCO}_3$  to 0.154 M KCl).

**PROCEDURE** One ml each of the above three reactants are added to 25 ml flasks containing 0.3 ml of 0.5 M  $\text{K}_3\text{PO}_4$  (pH 7.4) and 0.1 ml of 0.3 M  $\text{MgCl}_2$ . Incubation is carried out in air at 37° C. for 30-45 minutes with shaking. After this period, the flasks are removed quickly, <sup>and</sup> ice bath, and their contents are removed and <sup>all centri</sup> for 5 minutes. Three ml of the <sup>diluted</sup> water addition <sup>in</sup> <sup>ately</sup>

**BILIRUBIN ASSAY** The 1 minute bilirubin is used as a measure of conjugation of bilirubin to direct bilirubin. The 10 ml samples are divided into two 5 ml portions. To one is added 1 ml of fresh diazo reagent (10 ml of 3% sulfanilic acid in 0.1 N HCl plus 0.3 ml of 0.5% sodium nitrite) to the other 1 ml of blank solution (0.1 N HCl) is added. After one minute the tubes are read in a spectrophotometer at 535 $\mu$ . To determine total bilirubin 6 ml of ethanol is added to each tube and the color is read after 30 minutes.

**INTERPRETATION** A 4 to 5 fold increase in direct bilirubin over that observed in the controls indicates an intact bilirubin glucuronide conjugating enzyme system in the test tissue.

## Chapter 10

### OTHER PROBABLE ENZYME DISTURBANCES

#### HYPOPHOSPHATASIA

##### ▶ 56 SERUM ALKALINE PHOSPHATASE ACTIVITY

**REFERENCE** Kaplan A and Narahara A. J Lab & Clin Med 41:819 1953

**PRINCIPLE** The phosphatase of the serum liberates phenol from a substrate of disodium phenylphosphate. Therefore the phosphatase activity is defined as that activity which liberates 1 micromol of phenol per milliliter of serum per hour at 37° C.

#### REAGENTS

**Substrate** 0.05 M disodium phenylphosphate. Purify by extracting 15 Gm with 25 ml portions of hot alcohol. Filter with suction and dry in air. Place 1.09 Gm in a 100 ml volumetric flask and make up to 100 ml volume with water.

**Borate buffer** pH 9.8. Dissolve 9.5 Gm of sodium borate in 950 ml of water and add 35-40 ml of N NaOH until the pH of 9.8 is reached as measured with a pH meter. Make up to 1 L.

20% MgCl<sub>2</sub>

**Buffered substrate** To 10 ml of substrate solution add 1 ml of 20% MgCl<sub>2</sub> and make up to 100 ml with borate buffer.

1.5 M formaldehyde

**Saturated alcoholic borax solution** To 150 ml of 95% ethyl alcohol add 850 ml of water and 35 Gm of sodium borate and shake well. Let the undissolved residue remain in the bottle.

**Diazo reagent** Place 100 ml of water in an ice bath and cool be



low 5° C Dissolve 0.125 Gm of Red II salt in the cold water and filter Add 1 ml of cold, approximately 18 N H<sub>2</sub>SO<sub>4</sub> and store in the refrigerator

**Standard phenol solution** Dissolve 0.940 Gm of anhydrous phenol crystals in water and make up to 100 ml Phenol concentration is 100 µM/L.

**Working phenol standard, 0.05 µM/ml** Dilute 1 ml of standard phenol solution to 100 ml volume Transfer 5 ml of this diluted standard to a 100 ml volumetric flask and make up to volume with water Prepare the working standard on the same day as used

**PROCEDURE** Make a 1:100 dilution of serum Place 2 ml of buffered substrate in a test tube and allow it to come to equilibrium in a 37° C water bath Add 1 ml of the diluted serum mix, and let stand in the 37° C water bath for 30 minutes At the end of this time, stop the reaction by adding 2 ml of 1.5 M formaldehyde solution and remove from the bath

A blank is run for each serum Two ml of substrate are heated at 37° C for 30 minutes Add 2 ml of 1.5 M formaldehyde solution, followed by 1 ml of serum

**COLOR DEVELOPMENT** To both test solution and blank, add 4 ml of saturated alcoholic borax solution and 1 ml of diazo reagent Mix well immediately This is important, for otherwise the coupling of the phenol with the diazotized salt will be incomplete After 5 minutes read in a photoelectric colorimeter at a transmission of 490 mµ

**PREPARATION OF STANDARD CURVE** Place 0.5, 1.0, 2.0, 3.0, and 4.0 ml of phenol working standard containing 0.025, 0.05, 0.100, 0.150, and 0.200 µM, respectively, of phenol in a series of test tubes Add 1 ml of borate buffer and sufficient water to each to make a total volume of 5 ml Develop and measure the color of the phenyl dye, as described above, by the addition of alcoholic borax solution and diazo reagent Plot the optical densities against 200 times the concentration of phenol expressed as micromoles Thus the serum alkaline phosphatase is obtained directly in units when the time of the reaction is 30 minutes and 1 ml of a 1:100 dilution of serum is used

**INTERPRETATION** Normal range, 0.8-4.5 µM, with an average of 2.3 µM

## ► 57 PHOSPHOETHANOLAMINE

**PROCEDURE** Urine is subjected to two-dimensional chromatography, and the color is developed with ninhydrin as described in Procedure 30 (p. 307) The phosphoethanolamine appears as a large

blue spot whose  $R_f$  can be compared with a known sample of phosphoethanolamine

**INTERPRETATION** Phosphoethanolamine is not usually detectable in normal urine

## CYSTIC FIBROSIS OF THE PANCREAS

### ▶ 58 SWEAT ELECTROLYTES

**REFERENCE** Shwachman, H, and Leubner, H. *Advances Pediatr* 7 297, 1955

**PROCEDURE** No special preparation of the patient is necessary. The back is washed with distilled water and dried. A 3 in square of gauze is weighed in a container and then placed on the back, care being taken not to touch the area or the gauze with the fingers. A slightly larger square of plastic sheeting is placed over the gauze and taped to the skin. Then the patient is placed in a plastic suit, which is secured about his neck and wrapped in blankets. At the end of 30-90 minutes, depending on the rate of sweating, he is removed from the bag, the plastic sheeting is removed and the sweat soaked gauze is placed in its original container, again taking care not to touch it with the fingers. The container and gauze are weighed, giving the weight of sweat by difference. Forty ml of distilled water is added to the container to elute the sweat. Five ml of the solution is then diluted to 50 ml and the sodium concentration is determined, using the flame photometer.

**INTERPRETATION** A sodium value of more than 60 mEq/L is diagnostic of cystic fibrosis of the pancreas.

### ▶ 59 STOOL TRYPSIN TEST

**REFERENCE** Shwachman H, Patterson P, and Laguna, J. *Pediatrics* 4 222, 1949

**PROCEDURE** A 1:1,000 dilution of stool is made, placed on the gelatin surface of an x-ray film, and incubated for 1 hour at 38°C.

**INTERPRETATION** Three negative results for stool trypsin in the 1:5 or 1:10 dilution should be considered sufficient evidence to justify a tentative diagnosis of cystic fibrosis of the pancreas in a child.

### 60 DUODENAL FLUID

Duodenal fluid is obtained by intubation following an 8-hour fast. The position of the tube may be checked by x-ray. The specimen should be alkaline.

## (a) VISCOSITY

REFERENCE Shwachman, H., and Leubner, H. *Advances Ped* 7 283, 1955

PROCEDURE Using an Ostwald viscosimeter, viscosity is measured immediately after collection of the specimen without centrifugation or filtration

INTERPRETATION Viscosity time, in minutes, exceeds 3 minutes 87% of the patients with cystic fibrosis and complete pancreatic sufficiency, and in 70% of the patients with cystic fibrosis a partial pancreatic insufficiency

## ► (b) TRYPSIN

REFERENCE Shwachman, H., and Leubner, H. *Advances Ped* 7 286, 1955

PROCEDURE Serial dilutions of duodenal fluid with phosphate buffer (pH 8.4) are incubated at 37° C with 2 ml of 7.5% solution Knox gelatin, in a final volume of 4 ml. After 1 hour the tubes are chilled, and the end point is read as the last tube in which the gelatin remained liquid. The result is given as the number of ml duodenal fluid present in this tube.

INTERPRETATION Normally, the minimal volume of duodenal juice which gives a positive trypsin result is 0.0025-0.04 ml. An alternate end point consists of determining the reduction in viscosity of gelatin-enzyme mixture, incubated as above. A unit of trypsin is defined as the amount of enzyme required to reduce the initial viscosity of the mixture to 1/2 of the initial viscosity. The result is expressed as the number of units per ml of duodenal juice contains by the former per ml by the sufficiency.

## ► (c) AMYLASE

REFERENCE Lawrence, G. (to be published)

PRINCIPLE Amylase activity is a measure of the ability of the enzyme to reduce a carbohydrate. The results are expressed as the amount of reducing substances formed from a buffered substrate under controlled conditions of pH, temperature, and time.

REAGENTS Starch or glycogen substrates may be used which are made up with a buffer.

Phosphate chloride buffer Dissolve 2.7312 Gm of potassium acid phosphate and 4.3 Gm of NaCl in 300 ml of distilled water. Add approximately 10 ml of 1 N NaOH and check the pH. Add

just pH 7.0 Make up to a volume of 500 ml with distilled water

**Starch substrate** Mix 1.0 Gm of soluble starch with a little cold distilled water. Add this slowly to a boiling solution of phosphate chloride buffer and continue heating until the mixture is clear (about 1-5 minutes). Make up the solution to a volume of 100 ml with phosphate chloride buffer.

**Glycogen substrate** Add 0.5 Gm of glycogen to 70 ml of phosphate chloride buffer. Mix and make to a volume of 100 ml with phosphate chloride buffer.

**NaOH, 0.3 N**

**ZnSO<sub>4</sub>, 5%** These two reagents should be titrated against each other so that 10 ml of ZnSO<sub>4</sub> equals 10 ml of 0.3 N NaOH.

**Glucose standard** One ml equals 0.05 ml of glucose.

**Alkaline copper reagent** Dissolve 14 Gm of anhydrous disodium phosphate and 20 Gm of Rochelle salt in about 350 ml of distilled water. Add 50 cc of 1 N NaOH. With constant shaking add 40 ml of 10% CuSO<sub>4</sub> (• 5 H<sub>2</sub>O). Add 90 Gm of anhydrous Na<sub>2</sub>SO<sub>4</sub>. When this has dissolved, dilute to 500 ml with distilled water.

**Arsenomolybdate color reagent** Dissolve 25 Gm of ammonium molybdate in 450 ml of distilled water, add 21 ml of concentrated H<sub>2</sub>SO<sub>4</sub>, mix, and add 3 Gm of sodium arsenate which has been dissolved in 25 ml of distilled water. Mix and place in an incubator at 37° C for 24-48 hours.

**METHOD** Make a 1:250 dilution of the duodenal contents with phosphate chloride buffer solution. This should be done just prior to use. Into two small tubes, marked 1' and 2', put 3 ml of substrate and warm to 37° C for 5 minutes.

Take a few ml of diluted duodenal contents and put into a boiling water bath for 15 minutes and cool.

To tube 1, add 0.2 ml of diluted duodenal contents and incubate at 37° C for 15 minutes.

At the end of the incubation period, immediately add 0.4 ml of 0.3 N NaOH to tubes 1 and 2.

To tube 2, add 0.2 ml of boiled duodenal contents. (This tube represents a blank duodenal tube which has no enzymatic activity, only other reducing substances.)

To both tubes, add 0.4 ml of 5% ZnSO<sub>4</sub>, shake, and then centrifuge.

In the meantime, prepare a blank for the glucose standard as follows: 3.2 ml of distilled water, 0.4 ml of 0.3 N NaOH, and 0.4 ml of 5% ZnSO<sub>4</sub>. (If a glucose curve or factor has been established, this step is not necessary.)

Into 25 ml calibrated sugar tubes add the following reagents

	TUBE 1	TUBE 2	STANDARD BLANK	STANDARD (1 ml-0.5 mg GLUCOSE)
Filtrate	0.5 ml	0.5 ml	2 ml	2 ml
Water	1.5 ml	1.5 ml		
Alkaline copper reagent	2 ml	2 ml	2 ml	2 ml

Cover tubes and place in a boiling water bath for 10 minutes  
Cool in ice bath for 5 minutes

To all tubes, add 1 ml of color reagent (arsenomolybdate reagent) Mix well and dilute to a volume of 25 ml with distilled water Read in a colorimeter at 515 mμ.

A distilled water blank is used to set the galvanometer at 100% transmission or zero optical density, and all the tubes are read against a water blank

#### CALCULATIONS

- 1 Optical density of standard minus optical density of blank equals corrected optical density of standard
- 2 Optical density of tube 1 minus optical density of tube 2 equals corrected optical density of unknown
- 3 The results are calculated as follows

$$\frac{\text{Optical density of unknown}}{\text{Optical density of standard}} \times 0.1 \times \frac{20}{0.5} \times 250 = \text{Mg of reducing substances liberated at } 37^{\circ} \text{ C for 15 minutes}$$

INTERPRETATION Normal range of amylase activity for glycogen substrate 0.19-0.65 Gm/cc of reducing substances, starch substrate 0.026-0.90 Gm/cc of reducing substance at 37° C and 15 minutes' incubation

#### ► (d) LIPASE

REFERENCE Shwachman H, Farber, S, and Maddock, L L  
Am J Dis Child 66 418, 1943

PROCEDURE Duodenal juice is diluted 1:10 with phosphate buffer  
and 1 ml of 1% egg albumin is added

egg albumin (3%), and 10 ml of diluted duodenal juice is added well, incubate at 37° C for 1 hour and then add 36 ml of an alcohol ether mixture (4 parts of 95% ethanol to 1 part of ether) Titrate liberated fatty acids against 0.1 N alcohol KOH, with thymol blue as indicator Titrate a similar mixture in which enzyme

has been inhibited by adding alcohol ether immediately after adding duodenal juice. Subtract latter number of ml of KOH from number used in titration of incubated sample.

**INTERPRETATION** A lipase unit is the amount which splits 24% of 2.5 Gm of olive oil under these conditions.

$$\text{Units/100 ml juice} = \frac{\text{ml } 0.1 \text{ N KOH} \times 100}{20.7}$$

Values of 0-10 units are typical of pancreatic cystic fibrosis.

## ► 61 MUCOPROTEINS

**REFERENCE** Di Sant'Agnese P *et al* *Pediatrics* 19:252 1957

**PROCEDURE** One ml of duodenal fluid (or more) is centrifuged to remove any particles not in solution. To the supernatant fluid is added nine volumes of ethanol benzene (equal parts of absolute alcohol and petroleum benzene). The mixture is left at 4° C for 2 hours, then centrifuged, supernatant decanted, and precipitate washed twice with ethanol. Distilled water, twice the original volume of duodenal fluid, is added to the precipitate. If solution is not complete, the tube is reexamined after 1 hour at room temperature.

**INTERPRETATION:** Precipitates from normal persons dissolve easily in water. Considerable insoluble residue remains in cases of cystic fibrosis, dissolving only in 1 N NaOH after heating. Water-insoluble mucoproteins are present in 100% of patients with cystic fibrosis and complete pancreatic achylia, in 58% (8/14) of patients with cystic fibrosis and partial pancreatic achylia, and in an occasional person without cystic fibrosis.

## DEFICIENCY OF GLUCOSE 6 PO<sub>4</sub> DEHYDROGENASE

### ► 61a DETERMINATION OF GLUCOSE 6 PO<sub>4</sub> DEHYDROGENASE

**REFERENCE** Zinkham W H, Lenhard R E Jr and Childs B  
*Bull Johns Hopkins Hosp* 102:169 1958

#### REAGENTS

0.14 M NaCl

0.3 M MgCl<sub>2</sub> pH 7.0

0.19 M tris (hydroxymethyl aminomethane) buffer pH 8.0

0.02 M dipotassium glucose 6-PO<sub>4</sub> pH 7.0

0.002 M TPN (triphosphopyridine nucleotide), pH 6.8

**PROCEDURE** Five ml of venous blood is collected in a test tube containing 10 mg of sodium heparin. The specimen is immediately centrifuged in the cold at 3,000 rpm for 10 minutes. The supernatant plasma, white-cell layer, and a small portion of the red cells are

aspirated and the remaining red cells are washed three times in the cold with chilled 0.14 M NaCl. Most of the saline is removed after the last washing, and 0.2 ml of packed red cells is added to 3.8 ml of distilled water. A hematocrit is done on the remainder of the red-cell sediment. The red cell and water mixture is left standing at 26° C for 10 minutes and the solution is vigorously shaken before and after the period of incubation. The resulting hemolysate is centrifuged in the cold at 3 000 rpm for 10 minutes and the supernatant is withdrawn.

An assay for glucose 6-PO<sub>4</sub> dehydrogenase activity is done in the 1 cm cell of the model DU Beckman spectrophotometer at 340μ. The assay system consists of 0.1 ml of hemolysate, 0.1 ml of MgCl<sub>2</sub>, 1.0 ml of tris buffer, 0.1 ml of glucose 6-PO<sub>4</sub>, 0.2 ml of TPN, and 1.5 ml of water. The blank solution contains all these reagents but TPN and glucose 6-PO<sub>4</sub>. The reaction is started by addition of TPN and optical density readings are made at 1 minute intervals from 5 to 20 minutes after starting the reaction.

**CALCULATIONS** The glucose 6-PO<sub>4</sub> dehydrogenase activity is calculated as follows:

$$\frac{\text{Change of OD/Min}}{2.07} \times 20 \times \frac{100}{\text{Hct}} \times 1000 \\ = \text{Units of glucose 6-PO}_4 \text{ dehydrogenase/100 ml RBC}$$

**INTERPRETATION** Normal adults show a range of 150-215 units/100 ml RBC. Patients with glucose-6-PO<sub>4</sub> dehydrogenase deficiency show less than 10 units/100 ml RBC.

## ► 61b GLUTATHIONE STABILITY TEST

**REFERENCE** Beutler, E. J. Lab & Clin Med 49:84, 1957

### REAGENTS

3.0% metaphosphoric acid solution. Prepared by dissolving 3.0 Gm of reagent acid phosphoric meta (Merck) (35% HPO<sub>3</sub>) in 100 ml of water.

2% sodium nitroprusside solution. Prepared fresh daily.

Sodium cyanide-sodium carbonate solution. Prepared by adding 328 mg of sodium cyanide and 15.9 Gm of sodium carbonate to 100 ml of water.

Glutathione (GSH) standard

Acetylphenylhydrazine

**PROCEDURE** 1 ml of whole blood is added to 2 ml of distilled water. After a few minutes, 5 ml of a 3.0% metaphosphoric acid solution is added during constant agitation of the hemolysate with a stirring rod. Approximately 3 Gm of NaCl is added and the test tube sealed with parafilm. Then the mixture is shaken for 10 min-

utes in a Burrell wrist action shaker, Model BB, set at the maximum amplitude. The suspension is filtered through paper (Whatman No. 2 and S & S No. 595 have both been satisfactory). These manipulations are all carried out at room temperature. Two ml of the filtrate is added to a 25 mm Coleman Junior spectrophotometer cuvette containing 6 ml of saturated NaCl solution. The mixture is allowed to equilibrate for 10-20 minutes at 21-23° C in a water bath. One ml of the sodium nitroprusside is layered over the filtrate, and 1 ml of the sodium cyanide-sodium carbonate mixture is added immediately. The contents of the cuvette are mixed and measured in a Coleman Junior spectrophotometer against a reagent blank containing 6 ml of saturated NaCl solution, 1 ml of the sodium nitroprusside, and 1 ml of the sodium cyanide-sodium carbonate mixture. The glutathione content is compared with a glutathione standard run simultaneously. The GSH content is calculated according to the linear relationship that exists between optical density of the GSH nitroprusside complex and the GSH concentration. The GSH content of the red cells equals the whole blood GSH divided by the hematocrit of the sample.

The stability of the red-cell GSH to acetylphenylhydrazine is determined as follows. Heparinized venous blood samples are used within 3 hours of the time they are drawn. The blood is mixed and oxygenated by shaking vigorously in 24 mm screw-cap vials. After the red-cell glutathione level is determined in the usual manner, 1 ml aliquots of whole blood are added to test tubes containing 5 mg of acetylphenylhydrazine. A glass stirring rod is used to aid in the suspension of the acetylphenylhydrazine and the tube is agitated by vigorously tapping its bottom against the palm of the hand to assure solution of the acetylphenylhydrazine and adequate oxygenation of the red cells. The tube is incubated at 37° C. The agitation is repeated at the end of 1 hour and at the end of 2 hours the GSH determinations are made in the usual manner.

**INTERPRETATION** A striking fall of GSH content of whole blood after incubation with acetylphenylhydrazine as compared with before incubation, indicates deficiency of glucose 6-PO<sub>4</sub> dehydrogenase.

## SUSCEPTIBILITY TO SUXAMETHONIUM

### 62 DETERMINATION OF PSEUDOCHELINESTERASE

**REFERENCE** Kalow, W., and Genest, K. *Canad J Biochem & Physiol* 35 339, 1957

**PROCEDURE**, Human serum or plasma is diluted 1:100. As a solvent, 1/15 M phosphate buffer, pH 7.4, should always be used. Crystalline benzylcholine chloride (Hoffmann-LaRoche) is stored in a



vacuum desiccator over  $H_2SO_4$ . For the stock solution of substrate, the concentration is  $2 \times 10^{-4}$  M. The stock solution of inhibitor is  $4 \times 10^{-5}$  M dibucaine (Nupercaine®, Ciba).

The spectrophotometric measurements are performed at 240 m $\mu$ . Esterase stock solution diluted with equal parts of the buffer is used as the optical blank. For measuring reaction rates the solutions of benzylcaine and of dibucaine are mixed in equal proportions, and 2 ml of this mixture is added to 2 ml of the stock solution of esterase. The procedure is then repeated, using buffer instead of the solution of dibucaine. Both reactions are recorded for 3 minutes as timed by a stop watch. Because of the absorbence of dibucaine the recordings of the inhibited and the uninhibited reaction begins at different levels of absorbence.

Immediately after completion of each recording while the sample is still in the cell compartment the temperature is measured by dipping a Thermistor into the solution. If there is a difference of temperature between the inhibited and the uninhibited reaction, the following formula should be used to correct the observed reaction rates to agree with the rate at 26° C.

$$\text{Reaction rate at } 26^\circ \text{ C} = \text{Observed rate} \times \text{antilog} \\ [0.0283 \times (26^\circ \text{ C} - \text{Measured degrees C})]$$

The results are calculated by the following equation

$$\text{Dibucaine number} = \text{Per cent inhibition} \\ = 100 \times 1 - \left( \frac{\text{Decrease of absorbence in presence of dibucaine}}{\text{Uninhibited decrease of absorbence}} \right)$$

INTERPRETATION A dibucaine number under 70 is probably abnormal.

## Chapter 11

### RENAL TRANSPORT DEFECTS

#### NEPHROGENIC DIABETES INSIPIDUS

#### ▶ 63 TESTS FOR DIABETES INSIPIDUS

REFERENCE Carter, A. C., and Robbins, J. J. Clin. Endocrinol. 7:753, 1947.

PROCEDURE All antidiuretic therapy is stopped and fluids are withheld for 8 hours preceding the test. The subjects are hydrated with water, 20 ml/kg of body weight by mouth over a period of 1 hour. Thirty minutes after the hydration is begun an indwelling

catheter is inserted. Urine specimens are collected in 15 minute periods, and urine flow is calculated in ml per minute.

After two control periods with an adequate urine flow (i.e., greater than 5 ml/minute), an infusion of 2.5% NaCl is begun. This is administered at the rate of 0.25 ml/kg/minute for 45 minutes. If no decrease in urine flow occurs during the first two post-infusion periods of 15 minutes each, 0.1 unit of Pitressin® is given intravenously and its effect on urine flow observed.

**INTERPRETATION** In normal individuals there should be a prompt and marked decrease in urine flow following the infusion of saline. Patients with pituitary diabetes insipidus show continued diuresis during and after the infusion. They will, however, show a decrease of urine flow following Pitressin®. Patients with nephrogenic diabetes insipidus will show no change after Pitressin®.

## CYSTINURIA

### 64. CYSTINE

REFERENCE: Lewis, H. B., *Ann. Int. Med.* 6:183, 1933.

#### (a) CYANIDE NITROPRUSSIDE TEST

##### REAGENTS

5% sodium cyanide solution, freshly prepared

5% sodium nitroprusside, freshly prepared

**PROCEDURE** To 5 ml of urine, 2 ml of a 5% sodium cyanide solution is added, and the reaction is allowed to proceed for 10 minutes. A few drops (usually 5 drops delivered from a serological pipette) of a 5% nitroprusside solution are added and thoroughly mixed. Normal urine shows a pale brown or occasionally a very faint flesh color, while urine containing cystine shows a rather stable magenta color.

#### (b) SULLIVAN REACTION

##### REAGENTS

5% aqueous solution of sodium cyanide

0.5% aqueous solution of 1,2-naphthoquinone-4-sodium sulfonate

10% solution of anhydrous sodium sulfite in 0.5 N NaOH

2% solution of  $\text{Na}_2\text{S}_2\text{O}_4$  in 0.5 N NaOH

**PROCEDURE** To 5 ml of urine, 2 ml of a freshly prepared aqueous solution of sodium cyanide is added. The solution is thoroughly mixed, and the reduction is allowed to proceed for 10 minutes at room temperature. One ml of 1,2-naphthoquinone-4-sodium sulfonate is added. The contents of the tubes are carefully mixed, and immediately 5 ml of a 10% solution of anhydrous sodium

## APPENDIX

sulfite in NaOH is added. The solutions are mixed and the reaction is allowed to proceed for 30 minutes at room temperature. After the addition of 1 ml of a 2% solution of  $\text{Na}_2\text{S O}_4$  in 0.5 N NaOH a pure red color is obtained if cystine is present.

## ▶ 65 AMINO ACIDS BY PAPER PARTITION CHROMATOGRAPHY

The techniques are discussed in detail in Procedure 30 b

## 66 LYSINE TOLERANCE TEST

REFERENCE Robson E and Rose G A Clin Sc 16 75 1957

PREPARATION OF AMINO ACID The monochloride of L lysine is dissolved in water which contains sufficient NaOH to give a solution of pH 7.4

METHOD OF ADMINISTRATION The test subject is first given 1 L of water and then 250 ml of water every 15 minutes thereafter

Four consecutive specimens of urine are collected as follows

- 1 After a control period of 40 minutes Immediately after this an amino acid solution containing 5 Gm of L lysine is given intravenously in 13 minutes using a 100 ml syringe connected to a polyethylene cannula which had previously been introduced into a suitable vein
- 2 After a study period of 15 minutes
- 3 After a study period of 30 minutes
- 4 After a final study period of 30 minutes

A venous blood sample is withdrawn from another vein at about the midpoint of each period of urine collection

PROCEDURE The plasma ultrafiltrate and urine are examined for amino acids by the standard paper chromatographic techniques described in Procedure 30 b

INTERPRETATION Lysine infusions into normal patients cause transient increases in the renal clearances of cystine arginine and ornithine. Similar infusions in cystinurics and in patients having Fanconi's syndrome cause little or no increase in renal excretion of cystine arginine and ornithine. Unaffected heterozygous carriers of recessive cystinuria and of Fanconi's syndrome behave as do normals following infusion

## CYSTINOSIS

## 67 CYSTINE CRYSTALS

## (a) WOLLASTON'S TEST

PROCEDURE After the specimen has been dried under alcohol strong hydrochloric acid will make the hexagonal crystals change into long needles grouped in bundles

*(b) POLARIZED LIGHT*

**PROCEDURE** The crystals are birefringent and react positively to the sulfur test with an alkaline lead acetate solution

*(c) SULLIVAN REACTION*

See Procedure 64 *b*

*(d) PAPER CHROMATOGRAPHY*

See Procedure 30 *b*

## Chapter 12

### DISTURBANCES IN LIPID METABOLISM

#### IDIOPATHIC HYPERLIPEMIA AND PRIMARY HYPERCHOLESTEREMIA

#### 32 TURBIDITY OF PLASMA

**REFERENCE** Geyer R F Mann G V and State F J J Lab & Clin Med 33 175 1948

#### REAGENTS

30% coconut oil emulsion

5% dextrose

Conc  $\text{NH}_4\text{OH}$

30%  $\text{H}_2\text{O}_2$

**PROCEDURE** By means of a hemoglobin pipette 20 mm<sup>3</sup> of blood is collected and discharged into 2 ml of 5% dextrose solution contained in a 13 × 100 mm Pyrex tube and the pipette is rinsed in the usual manner. The contents of the tube are well mixed by rotation and the tube is centrifuged at 1 300 rpm for 10 minutes. The supernatant is decanted into a Klett microtube care being taken to avoid carry-over of the sedimented cells and 0.05 ml of concentrated  $\text{NH}_4\text{OH}$  is added after mixing 0.05 ml of  $\text{H}_2\text{O}_2$  is added. The tubes are heated in a water bath at 60°–65° C for 4 minutes and then cooled to room temperature. Any moisture which has condensed on the sides of the tube is removed by gentle tapping. The turbidity is read in the colorimeter using filter No. 42.

A standard curve is obtained by making various dilutions of the emulsion using 5% dextrose solution as the diluent. Two ml quan

titles of each dilution are placed in the microtubes and delivered as above

## ► 69 TOTAL SERUM LIPIDS

**REFERENCE** Swahn, B *Scandinav J Clin & Lab Invest* vol 5, supp 9, 1953

**PRINCIPLE** The method consists of the application of 10-20  $\lambda$  of serum to filter paper and subsequent staining of the lipids with a solution of Sudan Black B in 50-55% aqueous ethanol. The dye dissolves physically in lipids, this being the staining mechanism. The coefficient of partition of the dye is enormously in favor of lipid in an aqueous ethanol lipid system. The concentration of ethanol is so low that its lipid-dissolving effect is minimal and can be disregarded.

### REAGENTS

**Saturated solution, Sudan Black B** To about 0.1 Gm of Sudan Black B, add 100 ml of 60% ethanol. Continuously stir the mixture and heat to boiling point. (Owing to evaporation during heating and subsequent filtration, the final ethanol concentration will be 50-55%.) Allow the solution to cool and then filter it (e.g., through Munktell No. 00 filter paper) at least twice to separate off any undissolved dye.

**Rinsing fluid, 50% ethanol**

**Eluent, 20 vol% glacial acetic acid in absolute ethanol**

**TE** . . . . .

on the method. Standard triolein solution\* (1,000 mg/100 ml solution in absolute ethanol), 0.02 ml, is applied to one of the fields. This is the reference standard.

The serum and triolein spots are allowed to dry at room temperature. When the spots are dry, the strip is immersed in a dye bath consisting of the dye in a 50-55% ethanol solution where it is allowed to remain for 3 hours. The paper is removed, and adhering dye solution is allowed to drain from the paper, which is then placed in a washing bath of 50-55% ethanol. This is twice repeated. The filter paper is allowed to dry after the third washing.

The lipid spots appear as blue to blue-black spots on a white to very pale blue-black background. The filter paper strip is cut into strips at the site of each incision. These segments are placed

\*Manufactured by California Company for Biochemical Research, Los Angeles 63, Calif.

in tubes containing 4.0 ml of acetic acid-ethanol eluent. Elution time = 30-60 minutes.

The extinction of the blue solution is read in a spectrophotometer at 590 m $\mu$ , using 1.0 cm cuvettes. The extinction of the blank is subtracted from that for the sera and the triolein standard. The amount of total lipids in the serum is given by the following formula:

$$\text{Total lipid} = \frac{\text{Lipid content of triolein standard (mg/100 ml)}}{\text{Extinction value for triolein standard}} \times \text{Extinction for serum}$$

## ► 70 TOTAL AND FREE CHOLESTEROL

**REFERENCES** Schoenheimer R. and Sperry W. M. J. Biol. Chem. 106:745, 1934; Sperry, W. M. and Webb W. J. Biol. Chem. 187:97, 1950.

**PRINCIPLE** Serum is treated with acetone-ethanol to remove the proteins and extract the lipids. To an aliquot of the extract digitonin is added, which precipitates free cholesterol as digitonide. For total cholesterol an aliquot is saponified with KOH and precipitated with digitonin. The precipitates are washed and dried and dissolved in glacial acetic acid. Acetic anhydride-H<sub>2</sub>SO<sub>4</sub> reagent (Liebermann-Burchardt reaction) is added and the tube read in a colorimeter at 625 m $\mu$ .

### REAGENTS

Mixture of 1 part acetone and 1 part absolute alcohol redistilled

Mixture of 1 part acetone and 2 parts ether

1% digitonin in 50% alcohol

50% KOH

10% acetic acid

Glacial acetic acid

Stock cholesterol: 100 mg in 100 ml of glacial acetic acid

Acetic anhydride-H<sub>2</sub>SO<sub>4</sub> reagent. This must be prepared immediately before use. Cool 10 ml of acetic anhydride in an ice bath. Add 1 ml of concentrated H<sub>2</sub>SO<sub>4</sub> with constant shaking. Put in ice bath for 10 minutes before using. If more than 10 ml of this reagent is used, make up in the ratio of 10:1. Be sure to use the reagent within 30 minutes after it has been made up—never later.

**PROCEDURE** If both total and free cholesterol are to be determined, use the following preparatory procedure for each.

Into a 10 ml volumetric flask put 5 ml of acetone-alcohol mixture. Add 0.5 ml of serum with constant shaking and warm in boiling water bath until solvent boils. Cool and make up to volume.

with acetone alcohol mixture. Filter the mixture through fat free cotton or filter paper.

#### *Total cholesterol*

**Extraction** (for total cholesterol or for a small amount of available serum) —Place 3 ml of acetone alcohol mixture into a graduated centrifuge tube. Add 0.2 ml of serum with constant shaking. Warm in water bath and cool. Make up to a volume of 5 ml with acetone-alcohol mixture. Cover with foil and centrifuge.

**Precipitation** —Put 1 ml of the extract into a graduated centrifuge tube. Add 1 drop of 50% KOH. Mix with a stirring rod and leave rod in tube. Place in a sand bath and incubate at 37°-40° C for 30 minutes. Raise stirring rod and add acetone alcohol mixture to the 2 ml mark. Add 1 drop of phenolphthalein. Titrate this with 10% acetic acid, about 4-6 drops and 1 drop in excess. Add 1 ml of digitonin to the solution and mix thoroughly. Place the mixture in a sand bath at room temperature for at least 3 hours or preferably overnight.

**Centrifugation** —Remove the stirring rod carefully so that there are no adherent particles. Then place the tubes in a wire rack corresponding to tube numbers and centrifuge for 15 minutes. Decant the supernatant fluid and remove the last drop by touching a paper towel or filter paper. Replace the stirring rod and wash down the sides of the tube with 2 ml of acetone-ether mixture. Remove the stirring rod and centrifuge the tube. Decant the supernatant fluid and repeat the washing using ether only. Centrifuge the tube, decant it and replace the rod in the tube.

**Color development** —See below.

#### *Free cholesterol*

**Extraction** —See above, under Total cholesterol.

**Precipitation** —Put 2 ml of the alcohol acetone extract into a 15 ml centrifuge tube. Add 1 ml of 1% digitonin solution. Mix with a stirring rod. Cover with aluminum foil and let stand in a dark place for 16 hours or overnight.

**Centrifugation** —Take out stirring rod and handle as for total cholesterol. Centrifuge. Decant filtrate and wash for total cholesterol, except wash one more time with ether (total of three washes).

**Color development for free and total cholesterol** —Add 0.5 ml of glacial acetic acid and warm in 60° C block until the precipitate has dissolved. *Be careful—too much heat destroys cholesterol.*

Add 3 ml of chloroform and 1 ml of acetic anhydride  $\text{H}_2\text{SO}_4$  reagent to all tubes, mix with a stirring rod, let stand for 25 minutes, and read in a Beckman DU spectrophotometer at 625 mμ wavelength and 0.04 slit width. The blank is prepared in the same manner except that 0.5 ml acetic acid is used in place of the unknown.

**CALCULATIONS** The calculations are based on using 1 ml of filtrate for total cholesterol and 2 ml of filtrate for free cholesterol

Total cholesterol, using 0.2 ml of serum to 5 ml of acetone-alcohol

$$\text{Optical density (of unknown)} \times \text{Factor} \times 25 \times 100 \\ = \text{Mg cholesterol/100 ml serum}$$

Free cholesterol, using 0.2 ml of serum to 5 ml of acetone-alcohol

$$\text{Optical density} \times \text{Factor} \times 12.5 \times 100 \\ = \text{Mg free cholesterol/100 ml serum}$$

**INTERPRETATION** Keys has reported that, in males, the average total serum cholesterol increases from an average of about 173 mg/100 ml at 19 years of age to 252 mg/100 ml at 52 years. Values for females are somewhat lower up to the age of menopause.

## 71. PHOSPHOLIPIDS

**PRINCIPLE** The lipids are extracted in an alcohol-ether mixture and digested with  $\text{H}_2\text{SO}_4$  and  $\text{H}_2\text{O}_2$ . The phospholipid is now present as phosphate and is determined colorimetrically by a method for inorganic phosphorus.

### REAGENTS

Alcohol-ether mixture, 3:1 Mix three volumes of ethyl alcohol with one volume of ether

10 N  $\text{H}_2\text{SO}_4$

30%  $\text{H}_2\text{O}_2$

2.5% ammonium molybdate Dissolve 2.5% ammonium molybdate in distilled water and make up to a volume of 100 ml. Discard when precipitate forms.

Aminonaphthol-sulfonic acid reagent (Fiske-Subbarow) In a 100 ml mixing cylinder place 97.5 ml of 15% sodium bisulfite and 2.5 ml of 20% sodium bisulfite. Add 250 mg of recrystallized 1-amino-2-naphthol-4-sulfonic acid. The fresh solution should always be colorless (on aging it acquires a yellow tinge); discard it when the reagent blank shows an appreciable increase.

**PROCEDURE** Into a 20 ml volumetric flask place 18 ml of alcohol-ether mixture. Add 1 ml of plasma or serum slowly, and with agitation, to the mixture. Heat in a boiling water bath until the contents of the flask boils. Cool to room temperature. Adjust to a volume of 20 ml. Mix and filter.

Into a 25 x 200 mm Pyrex test tube place 2 ml of the filtrate. Evaporate to dryness. Add 0.5 ml of 10 N  $\text{H}_2\text{SO}_4$ . Heat gently over a small flame. As soon as charring occurs or fumes appear, reduce the flame until the digest barely boils, and continue heat-



ing until no more charring occurs. Superheating must be avoided, and at no time should the flame touch the tube above the level of the fluid. Allow the tube to cool for 30 seconds and add 1 drop of 30%  $\text{H}_2\text{O}_2$ . If the digest does not become colorless, add another drop of 30%  $\text{H}_2\text{O}_2$  and heat again. Repeat this process until oxidation is complete. Add 2 ml of distilled water and heat to boiling for a few seconds. Cool to room temperature and transfer quantitatively to a 10 ml graduated test tube. (This represents the unknown.)

In another graduated test tube, place 0.5 ml of 10 N  $\text{H}_2\text{SO}_4$  and 5 ml of distilled water. (This represents the reagent blank.) To both unknown standard and reagent blank, first add 0.5 ml of 2.5% ammonium molybdate and mix, then to both unknown standard and reagent blank, add 0.5 ml of ammonaphthol sulfonic acid reagent and mix. Dilute all samples to 10 ml with distilled water, mix, and let stand in the dark for 10 minutes. Read in a photoelectric colorimeter at a wavelength of 660 m $\mu$ , setting the reagent blank at 100% transmission.

*Standard*—A standard may be prepared at the same time in which 5 ml of a solution contains 0.02 mg of phosphorus. Place 5 ml of the standard solution in a graduated tube and add 0.5 ml of 10 N  $\text{H}_2\text{SO}_4$ . Develop the color as for the unknown, starting with the last step.

**CALCULATION** Since 2 ml of filtrate represents 0.1 ml of serum and the standard contains 0.02 mg of phosphorus,

$$\frac{\text{Optical density of unknown}}{\text{Optical density of standard}} \times \frac{100}{0.1} \times 0.02 = \frac{\text{Mg phospholipid}}{\text{phosphorus/100 ml}}$$

To convert into phospholipids, multiply by 25.

**INTERPRETATION**—Normal values for plasma lipid phosphorus in the postabsorptive state are given as 6–11 mg/100 ml. Phospholipids increase in those conditions in which there is an increase in cholesterol, although the increase is usually smaller. About half of the phospholipid is lecithin.

## Chapter 13

### THE MUSCULAR DYSTROPHIES

#### SEVERE GENERALIZED FAMILIAL MUSCULAR DYSTROPHY

#### ► 72. PENTOSE (1-XYLULOSE) IN URINE

See Procedure 31

## Chapter 14

## MISCELLANEOUS METABOLIC DISORDERS

## DIABETES INSIPIDUS

## ▶ 73. RESPONSE TO SALINE AND PITRESSIN®

See Procedure 63

## ▶ 74. URIC ACID (IN PLASMA OR SERUM)

**PRINCIPLE** Uric acid, in a tungstic acid protein free filtrate, is treated with phosphotungstic acid in the presence of cyanide and urea, to produce a blue color

**SAMPLE**

Plasma or serum from blood withdrawn during postabsorptive state

Anticoagulant for plasma, lithium oxalate Avoid an excess

**REAGENTS**

- 1 Sulfuric acid, volumetric N/12. Add 2.5 ml of concentrated  $H_2SO_4$  (Grasselli, A.C.S.) to 1,000 ml of distilled water and mix well. Titrate against standard 0.1 N alkali, using phenolphthalein as indicator. Adjust accordingly and retitrate (20 ml of N/12 acid requires 16.7 ml of 0.1 N alkali)
- 2 Sodium tungstate, 10% aqueous. Dissolve 10 Gm of sodium tungstate ( $Na_2WO_4 \cdot 2H_2O$ —Mallinckrodt, Folin Special) in distilled water and dilute to 100 ml. The solution must be neutral or slightly alkaline to phenolphthalein, not more than 0.4 ml being required to neutralize 10 ml of 0.1 N HCl. Preserve in resistant glass bottle
- 3 Cyanide urea reagent (Newton). Just before use, dissolve 1 Gm of sodium cyanide ( $NaCN$ —Merck A.C.S.) in 20 ml of 20% urea (see below). Discard any excess.  
Urea 20% aqueous. Dissolve 20 Gm of urea ( $[NH_2]_2CO$ —Merck, reagent) in distilled water and dilute to 100 ml. If the solution is not crystal clear, allow it to stand for several days and filter through a Schleicher and Schuell No. 576 paper
- 4 Phosphotungstic acid reagent (Brown). Into a 1,000 ml Florence flask place 100 Gm of sodium tungstate ( $Na_2WO_4 \cdot 2H_2O$ —Mallinckrodt, Folin Special), 20 Gm of anhydrous dibasic sodium phosphate ( $Na_2HPO_4$ —Mallinckrodt, A.R.), and 150 ml of distilled water. Heat until solution is complete. Slowly, and with constant shaking, add 100 ml of warm 25%  $H_2SO_4$  (see

below) Reflux gently for 1 hour Cool under running tap water to room temperature Transfer to a 1,000 ml volumetric flask, thoroughly rinsing out the original flask with several portions of distilled water and transferring the washings to the volumetric flask Dilute to volume with distilled water and mix by inversion Reagent is stable indefinitely at room temperature

*Sulfuric acid 25% aqueous* Slowly add 25 ml of concentrated  $H_2SO_4$  (Grasselli, A C S) to 75 ml of distilled water and mix well This mixture should be prepared shortly before use and added as indicated above, while still warm

- 5 Uric acid stock standard Weigh out 100 mg of uric acid and transfer to a 1 L volumetric flask Dissolve 0.3 Gm of lithium carbonate in 100 ml of water and filter Heat the lithium carbonate solution to 60° C and pour onto the uric acid Shake until all the uric acid dissolves (the solution usually remains slightly turbid) Cool the flask under running water Add 20 ml of 40% formaldehyde (formalin) Dilute to about 500 ml and add 15 ml of normal  $H_2SO_4$  Mix, dilute to the mark and transfer to a cool, dark place (refrigerator) (Normal  $H_2SO_4$  is obtained by diluting concentrated acid 1:36)
- 6 Working standard (1 ml = 0.01 mg of uric acid) Dilute stock solution 1:10 ml in volumetric flask

**PROCEDURE** To 8 ml of 1/12 N  $H_2SO_4$  add 1 ml of serum and mix Add 1 ml of 10% sodium tungstate and shake vigorously Filter or centrifuge In a 25 ml graduated test tube (sample) place 2.5 ml of protein free filtrate and 2.5 ml of distilled water mix In a second 25 ml graduated test tube (reagent blank) place 5 ml of distilled water In a third 25 ml graduated test tube (standard) place 1 ml of standard uric acid solution (containing 0.01 mg) and 4 ml of distilled water To each tube add from a burette 3 ml of freshly prepared cyanide urea reagent (see 3, above), and mix Add 1 ml of phosphotungstic acid reagent (see 4, above), and mix Dilute to 15 ml with distilled water and mix by inversion Allow to stand at room temperature away from direct light for 60 minutes

Measure the transmittancy of the sample against the reagent blank set at 100% transmission at a wavelength of 700  $m\mu$  Obtain the value for uric acid from the calibration table or prepared standard

#### CALCULATION

$$\frac{\text{Optical density of unknown}}{\text{Optical density of standard}} \times 4 = \text{Mg of uric acid/100 ml}$$

# Index

[NOTE Asterisk (\*) indicates reference to page with illustration]

## A

### Abdominal pain

- with acute porphyria 181
- with idiopathic hyperlipemia 230  
234

### Acanthocytosis 65 ff

- clinical features 65 f
- diagnosis 67
- pathogenesis 67
- pedigree of causes 66\*
- transmission mode of 67
- treatment, 67

### Adrenal hyperplasia

- with electrolyte disturbances
  - clinical features 171
  - diagnosis 172
  - hormone deficiencies 171 f
  - pedigree of causes 172\*
  - transmission 171
  - treatment 173

### with hypertension 169

- diagnosis 170
- heredity 169
- metabolic block 165\* 169
- pedigree of causes 170\*
- treatment 171

### with virilism only

- clinical features 164 ff
- diagnosis 167
- incidence 166
- metabolic block 165\* 167
- pedigree of causes 168\*
- transmission 166
- treatment 167 f

### Adrenogenital syndrome

- clinical variations 164
- metabolic block 164 165\*
- mutation differences 18
- transmission 18

### Agammaglobulinemia congenital

- clinical signs 82
- diagnosis 83
- pedigree of causes 83\*
- primary defect 82 f
- tests for 298
- transmission 82
- treatment 81

### Agammaglobulinemia congenital 74

- clinical features 74 f
- diagnosis 76
- pedigree of causes 77\*
- primary defect 76
- test for 296
- transmission 75 f
- treatment, 76

### Albinism 15 105 116

- of eye 120
- partial 119 f
- pebald 119 f
- total 116 117\*
  - clinical features 116 f
  - diagnosis 119
  - incidence 117
  - pathogenesis 117 ff
  - pedigree of causes 118\*
  - transmission 117
  - treatment 119

### Alkaptonuria 15 105 114

- clinical signs 114
- diagnosis 116
- homogentisic acid test 307

- Alkaptonuria, (*cont*)  
 metabolic block, 116  
 mutation differences, 18, 115  
 pedigree of causes, 115\*  
 transmission, 114 f  
 treatment, 116
- Alpha keto acid test, 306
- late juvenile, 250 f  
 types, 245  
 differentiation of, 250 f
- Amino acids  
 determination  
 by chemical or microbiological  
 methods, 311 f  
 by column chromatography, 310 f  
 by paper chromatography, 308 ff  
 dibasic  
 renal reabsorption, defect in, 217,  
 218 ff  
 urinary excretion, with cystinuria,  
 217  
 in hemoglobin molecule, 41, 42\*  
 metabolism, disturbances in, 107 ff,  
 120 ff
- Aminoaciduria  
 with II disease, 123, 124 f  
 with Wilson's disease, 79, 80
- Amylase activity  
 lack of, in cystic fibrosis of pancreas,  
 200  
 test, 328 ff
- Anemia  
 Cooley's, *see* Thalassemia  
 Fanconi's, 279 f  
 hereditary nonspherocytic hemolytic,  
 152  
 clinical features, 152 ff  
 diagnosis, 154  
 forms of, 154  
 incidence, 154  
 pedigree of causes, 153\*  
 transmission, 154  
 treatment, 154  
 with hereditary spherocytosis, 149
- Mediterranean, *see* Thalassemia
- sickle cell  
 atypical, 50  
 clinical features, 38 f  
 course, 39  
 diagnosis, 43  
 erythrocyte levels, 39 f  
 gene expression, 24\*, 25  
 heredity, 40  
 molecular defect, 41, 42\*  
 pedigree of causes, 29, 30\*  
 primary gene effects, 17 f, 29  
 prognosis, 39  
 tests for, 289 ff  
 treatment, 43
- Antibodies development, with agammaglobulinemia, 74 f
- I Arabinosuria, 128
- Arthritis  
 with alkaptonuria, 114, 116  
 gouty, 272 ff  
 treatment, 275
- Autosomes, 23
- Bielschowsky Jansky disease, 248 f
- Bilirubin  
 assay, 325  
 conjugation, procedure, 324 f  
 excretion test, 324  
 "indirect," conversion to "direct,"  
 187  
 solution, preparation, 324
- Biochemical genetics and clinical medicine, 284 ff
- Blood  
 clot, formation of, 85 f  
 coagulation, fundamental concepts,  
 85 f  
 galactose levels, determination, 315 f  
 groups, molecular differences, 36  
 methemoglobin concentration, 175
- Boiled liver extract preparation, 324
- Bone changes  
 with Gaucher's disease, 238  
 with Hurler's syndrome, 252, 253\*  
 with hypophosphatemia, 192 f, 193,  
 194\*  
 with resistant rickets, 214
- Bone marrow  
 in erythropoietic porphyria, 68 ff  
 fluorescence microscopy, 294
- Brain pathology  
 with Hurler's syndrome, 252  
 with Spitzmeier Vogt disease, 250  
 with Tay-Sachs disease, 246  
 with Wilson's disease, 78, 80
- Buerger Grütz disease, *see* Hyperlipemia, idiopathic

## C

- Calciferol for resistant rickets 216 f
- Calculus cystine
  - formation 217
  - prevention 220
- Carbohydrate metabolism disturbances in 126 ff 149 ff
  - tests for 312 ff
- Celiac disease with acanthrocytosis 66 67
- Cells
  - ganglion in Tay Sachs disease 246
  - Gaucher components 239
  - Niemann Pick, 243
- Ceramide breakdown of 239 241\*
- Ceruloplasmin
  - deficiency effects 78 80
  - measurement
    - immunochemical method 297
    - serum copper enzyme method 297
    - spectrophotometric method 296 f
- Charts
  - explanation of 32
  - symbols used in 33\*
- Chickenpox pathogenesis hereditary and environmental factors 26\* 27
- Cholesterol
  - elevated serum 235 236
  - total and free determination 339 ff
- Christmas disease 91 f
- Chromatography
  - column 310 f
  - paper 309 f
- Chromosomes 17
  - sex 22 ff
- Cirrhosis hepatic with diffuse glycosinosis 144 ff
- Clotting factors 85 f
  - combined defects 103
  - congenital deficiencies of 86 f 103
  - test for 299 ff
- Clotting time test, 299
- Compound F
  - biosynthesis 165\* 167
  - deficiency effects 167 168\*
- Consanguinity effect on inheritance 21 f
- Copper
  - deposition 80
  - direct reacting fraction 79
  - test for 297
  - plasma forms of 79
- Coproporphyrin
  - biosynthesis 182
  - total urinary measurement 295
- Cornea
  - with Hurler's syndrome 252
  - with Wilson's disease 78 80
- Cough with cystic fibrosis of pancreas 196
- Crenation 67
- Cretinism goitrous 156
  - from failure of iodotyrosine to deiodinate see Hypothyroidism congenital with goiter
  - from failure of iodotyrosines to couple
    - clinical features 160
    - diagnosis 161
    - heredity 161
    - metabolic block, 156 157\* 161
    - pedigree of causes 160\*
    - treatment 161
  - from failure of organic iodine to form
    - clinical features 157
    - diagnosis 159
    - metabolic block 156 157\* 159
    - pedigree of causes 159\*
    - transmission 157 f
    - treatment, 159
- Cyanide nitroprusside test 335
- Cystic fibrosis of pancreas 196
  - clinical features 196 ff
  - diagnosis 200
  - enzyme deficiency 198 ff
  - heterozygous carriers detection 198
  - incidence 198
  - partial manifestation 198
  - pedigree of causes 199\*
  - tests 327 ff
  - transmission 198
  - treatment 200
- Cystine
  - clearance in cystinuria 219 f
  - crystals detection of 336 f
  - cyanide nitroprusside test for 335
  - deposits in Lignac's disease 224
  - etiology 225 ff
  - metabolic pathway 227\*
  - Sullivan reaction 335 f
  - urinary excretion 217 218
- Cystinosis 224
  - clinical features 224
  - diagnosis 220 227
  - incidence 225
  - pathogenesis 225 ff

Cystinosis (*cont*)

- pedigree of causes, 226\*
- tests for, 336 f
- transmission, 224 f
- treatment, 227 f

## Cystinuria, 15, 105, 217

- clinical features, 217 f.
- diagnosis, 220
- genotypes, 218
- incidence, 218
- mutation differences, 18
- pedigree of causes, 219\*
- phenotypes, 217 f
- renal transport defect, 218 ff
- tests for, 335 f.
- transmission, 218
- treatment, 220

## D

De Toni Fanconi Debre syndrome, *see* Fanconi syndrome

## Diabetes insipidus

- nephrogenic
  - clinical features, 209
  - diagnosis, 210
  - genetics 209 f, 210
  - pathogenesis, 209, 210
  - test for, 334 f
  - treatment 210
- pituitary, 267
  - clinical features, 267
  - diagnosis, 269
  - incidence, 268
  - pathogenesis, 268 f
  - saline and Pitressin® response, 269, 335
  - secondary, 269
  - transmission, 267
  - treatment, 269
- tests for, 334 f

## Diabetes mellitus

- gene expression, 25 f
- genetic susceptibility, 270 f
- hereditary nature, 270
- mode of inheritance, 270
- pathogenesis, hereditary and environmental influences, 26\*, 27
- transmission, 270, 271

## Diaphorase I activity, 176, 323

## Dibucaine numbers, 205, 334

## Diet

- for cystic fibrosis of pancreas, 200
- for galactosemia, 136
- low phenylalanine, 111 f

- in primary hypercholesterolemia, 237
- in von Gierke's disease, 140

## Dopa, 107

- conversion, 119

## Dubin Johnson syndrome, 189 191

## Duchenne's pseudohypertrophic muscular dystrophy, 256 ff

## Duodenal fluid

- amylase activity
  - normal range 330
  - test for, 328 ff
- lipase values, test, 330 f
- specimen, obtaining 327
- trypsin values, test, 328
- viscosity, measurement 328

## Dystrophia ophthalmoplegia progressive, 261 f

## E

## Electrolytes

- disturbances with congenital adrenal hyperplasia, 171
- sweat
  - in cystic fibrosis of pancreas, 196 f
  - sodium concentration procedure, 327

## Electrophoresis, paper, 290 f

## Elliptocytosis hereditary

- clinical types, 62 f
- diagnosis 64
- erythrocyte diameter, measurement 293
- hemoglobin disease, 55
- heredity, 63 f
- incidence, 62, 63
- pathogenesis, 64
- pedigree of causes, 64\*
- treatment, ■

## Endocrine glands with myotonia dystrophia, 263

## Endocrine metabolism . disturbances, 156

- tests, 319 ff

## Environment and pathogenesis of disease, 26 f

## Enzymes

- defects, causing hereditary disease, 105 f, 192
- in fructose metabolism, 129
- in galactose metabolism, 133, 134\*
- in glucuronic acid metabolism, 128
- in phenylalanine degradation, 107
- in tyrosine degradation, 107

Epilepsy pathogenesis heredity and environment in 26\* 27

Epinephrine response 317

Erythrocytes

in acanthrocytosis 65\* 66 67

crenation 67

diameter - measurement technique 293

in elliptocytosis 62 63\* 64

fragility

in hereditary spherocytosis 149 f 150 f

tests for 318 f

In sickle cell anemia 38 39\*

sickled description 41

in thalassemia 57 f 59 f

Excretion in hypophosphatemia 194\*

Eye

albinism of 120

In total albinism 116 f

## F

Facies with Hurler's syndrome 251\*

Facioscapulohumeral dystrophy 260 f

Factor

antithrombotic activity in plasma 300 f

fourth plasma thromboplastin component 95

Hageman 96 f

plasma thromboplastin component 91

SPCA

characteristics 100

deficiency test for 303

Stuart, 101 f

V deficiency 97 ff

X deficiency 103

Fanconi syndrome 221

See also Pancytopenia congenital

clinical features 221

laboratory findings diagnostic 223

pedigree of causes 222 223\*

transmission 222

treatment 223 f

types 221

Fava bean sensitivity to 201 ff

Fibrinogen congenital absence of see Afibrinogenemia congenital

Forelock white with white skin spotting 120

Fructose

metabolism 129 130\*

tolerance test 314

in urine methods of identification 313 f

Fructosuria

diagnosis 132

incidence 129

metabolic defect, 130

pathogenesis 129 ff

pedigree of causes 131\*

symptoms 129

tests for 313 f

transmission 129

treatment, 132

with unknown metabolic error 130 f

## G

Galactose

accumulation effects of 135 f

metabolism 133 134\*

$1\text{ PO}_4$  uridyl transferase activity, 316

tolerance curve 136

tolerance tests 315 f

in urine identification 314 f

Galactosemia 132

clinical features 132 133\*

diagnosis 136

incidence 132 f

metabolic defect 133

pedigree of causes 134\*

tests for 314 f

transmission 132 133\*

treatment 136

Gargoylism see Hurler's syndrome

Gaucher's disease 238

biochemical findings 239 ff

diagnosis 242

pedigree of causes 240\*

primary defect 239 ff

transmission 239

treatment 242

types 238

Genes 17

for abnormal hemoglobins 18

chemical structure 28

expression 24 f

mode of action 28 f

mutant, 17 f

expression 27 f

primary effects 29 31 f

secondary effects 29 ff

products primary 28

transmission 19 ff

template theory 28



Genotypes, 20, 21\*

cystinuria, 218

Gilbert's disease, 189 ff

Globulin

Ac

deficiency, 97 ff, 103

test for, 303

antihemophilic, deficiency, 88

with other clotting defects, 103

types of, 87 f

gamma

congenital absence, 74, 76

in serum, test for, 296

Glucose

conversion to glycogen, 137

renal transport mechanism, 212

tolerance test, in idiopathic spontaneous hypoglycemia, 266 f

Glucose 6 phosphatase

absence, effects of, 140

of liver, determination, 317

Glucose 6 PO<sub>4</sub> dehydrogenase

deficiency

diagnosis, 204

effects, 203 f

hemolytic crises in 201

in newborn, 201 f

pedigree of causes, 203\*

transmission, 201

treatment, 204

determination, procedure, 331 f

Glucuronic acid metabolism, 128

Glutathione

reduction, 202\*, 203

stability test, 332 f

Glycogen

abnormality, demonstration, 318

character

in diffuse glycogenosis with hepatic cirrhosis, 144, 145

in glycogen storage disease of liver, 147

in muscle, 148 f

conversion back to glucose, 137 f

metabolism, 137, 138\*

Glycogen storage disease, 137

of heart, 142 ff

with hepatic cirrhosis, *see* Glycogenosis

of liver, 146 f

enzyme defect, 137 f, 147

of liver and kidney, *see* von Gierke's disease

of skeletal muscle, 146, 147 ff

enzyme defect, 137 f, 149

tests for, 317

Glycogenosis with hepatic cirrhosis

clinical features, 144

diagnosis, 146

enzyme defect, 137, 145

pedigree of causes, 145\*

treatment, 146

Glycosuria, renal, 211 f

diagnosis, 212

incidence, 212

metabolic defect, 212

transmission, 19 f, 211

treatment, 212

Gout, 271 f

clinical features, 272 f

diagnosis, 275

gene expression, 25

hereditary nature, 273

incidence, 273

pathogenesis, 273 ff

treatment, 275

## H

H disease, 122 f

clinical symptoms, 123, 124\*

diagnosis, 125

pathogenesis, 123 ff

tests for, 307 ff

transmission, 123

treatment, 125

Hageman trait, 96 f

Hair

precocious growth, with adrenal hyperplasia, 164

in total albinism, 116, 117\*

Hands

with Hurler's syndrome, 251\*

with thalassemia, 57, 58\*

Heart

glycogen storage disease of 142 ff

with Hurler's syndrome, 252

with idiopathic hyperlipemia 231\*, 232\*, 233

xanthomatous infiltration, 235

Heat prostration with fibrocystic disease, 196 f

{ Hemarthrosis with hemophilia 87

Hematuria with sickle cell trait, 39

{ Hemoglobin

A

amino acid, 42\*

physical properties, 37, 41

- C**  
 amino acid 42\*  
 disease 45  
 with elliptocytosis 55 63  
 identification 44  
 physical properties 37 44 f  
 trait 45
- Q**  
 disease 46  
 identification 45  
 physical properties 37, 45  
 trait, 46
- R**  
 disease 47  
 identification 46  
 physical properties 37, 46  
 with thalassemia, 53  
 trait, 46 f
- F** physical properties 37
- G**  
 identification 47  
 physical properties, 37 47  
 with thalassemia 51 f, 54
- H**  
 identification 48  
 physical properties 37 48
- I**  
 identification 48  
 physical properties 37, 48
- J**  
 disease 49  
 identification 49  
 physical properties 37 49  
 trait, 49
- K** identification 49
- M** identification 179 f
- S**  
 amino acid 42\*  
 inheritance 17 f 38 40  
 physical properties 37 41  
 with thalassemia 52 f  
 trait, see Sickle cell trait
- abnormal**  
 identification of 37 43 f  
 physical characteristics 37  
 tests for 289 ff  
 unclassified 49 f
- amino acid content** 41 42\*
- diseases mixed heterozygous** 30 ff
- production**  
 loci for 37 f  
 in thalassemia 59
- in sickle cell anemia, physical characteristics** 29 37
- solutions solubility procedure**  
 289 f
- Hemophilia, 87**  
 A see classical  
 B 91 f  
 C 93 f  
 classical  
 antihemophilic factor activity 301  
 clinical signs 87  
 clotting characteristics 90  
 diagnosis ■■■  
 pathogenesis 16\* 27 ■■ 89\*  
 pedigree of causes 89\*  
 transmission 23 f 87 89\*  
 treatment, 90  
 differentiation with thromboplastin generation test 302  
 vascular 88
- Hemorrhage**  
 with congenital afibrinogenemia 82  
 with hemophilia 87  
 treatment 90  
 with SPCA deficiency 99
- Hepatolenticular degeneration** 78
- Hereditary diseases**  
 without basic chemical cause 284 ff  
 with biochemical disturbances 286
- Heterozygote** 20
- Histiocytosis lipid see Niemann Pick disease**
- Homogenetic acid**  
 converts on 107 115\* 116  
 tests for 307
- Homozygote** 20
- Hormones**  
 posterior pituitary deficiency 268 f  
 sodium retaining deficiency of 171  
 thyroid biosynthesis 156 157\* 162
- Huntington's chorea** 25
- Hurler's syndrome** 251  
 bone deformities in 252 253\*  
 clinical signs, 251 f  
 diagnosis 255  
 genetic types 252, 254\*  
 metabolic defect 254 f  
 pathological changes 252  
 storage substance 252 ff  
 treatment 255
- Hydroa aestivale ■■**
- Hydrocortisone synthesis failure of**  
 172
- p-Hydroxyphenylpyruvate tests for**  
 306

- Hypercholesterolemia, primary, 235**  
 diagnosis, 236 f  
*differentiation from hyperlipemia, 235*  
 genetics, 236, 237\*  
 metabolic disturbance, 236  
 tests for, 337 ff  
 treatment, 237
- Hyperlipemia, idiopathic, 230**  
 clinical signs, 230 ff, 233\*  
 diagnosis, 234  
 incidence, 233  
*pathogenesis, 233 f*  
 tests for, 337 ff  
 transmission, 233  
 treatment 234 f
- Hypertension**  
 with acute porphyria, 181  
 with congenital adrenal hyperplasia 169, 170 f
- Hypertrichosis in erythropoietic porphyria, 68**
- Hyperuricemia and gout, 273, 275**
- Hypoglycemia**  
 with fructose ingestion, 131 f  
 idiopathic spontaneous, 265 ff  
*differential diagnosis, 267*  
 treatment, 267
- Hypophosphatasia, 192**  
 clinical features 192 f  
 diagnosis, 194  
 genetics, 193  
 incidence, 193  
 metabolic defect, 193  
 pedigree of causes, 195\*  
 and resistant rickets, 214 ff  
 serum alkaline phosphatase determination, 325 f  
 treatment, 194
- Hypoprothrombinemia, congenital, 99, 103**
- Hypothrombinemia, idiopathic, 86 f**
- Hypothyroidism, congenital, with goiter**  
 clinical features, 161 f  
 diagnosis, 163  
 enzyme deficiency, 162  
 heredity, 162  
 metabolic block, 156, 157\*  
 pathogenesis, 162, 163\*  
 tests for, 319 f  
 treatment, 163
- I**
- Idiocy, see Amaurotic familial idiocy**
- Inborn errors of metabolism**  
 clinical similarities 18  
 common features, 15  
 expression, 27 ff  
 genetics, 17 ff  
 original four, 15  
 pathogenesis, concept of 15 ff  
 primary gene effects, 31 f  
 transmission, III ff
- Infections, resistance to**  
 with congenital agammaglobulinemia, 74 f  
 with Pelger Huet anomaly, 72
- Inheritance**  
 dominant mode, 19\* f  
   gene expression, 24  
   gene determination, 17  
 recessive mode, 20 f, 21\*  
   gene expression, 24 f  
   genetic findings, 21  
*sex linked mode, 23 f*
- Intelligence quotient with phenylketonuria, 109**
- Intersexes, genetic, 164**
- Iodine formation, 156**  
 block in, 158, 161  
 test for, 319
- Iodotyrosine**  
 coupling 156  
 deshalogenase, deficiency of, 162  
 I<sup>131</sup> labeled, in blood and urine, 320
- Iron binding capacity**  
 determination, 293  
 in thalassemia, 59, 60\*
- J**
- Jaundice**  
 congenital nonhemolytic with kernicterus 186  
 clinical features, 186  
 differential diagnosis, 187 ff  
 genetics, 187, 188\*  
 laboratory findings, 186 f  
 metabolic block, 187, 188\*  
 tests, 324 f  
 treatment, 189
- familial nonhemolytic 189**  
 clinical features, 189  
 differential diagnosis, 191  
 genetics, 190  
 laboratory findings, 190

Joints

- with alkaptonuria 114
- with gout 272 f
- with hemophilia 87

K

- Kayser Flescher rings 78 80
- Kernicterus 186 ff
- ketosteroids
  - determination procedure 321 f
  - normal range 322
- Kidney
  - copper deposition in Wilson's disease 80
  - with Fanconi syndrome 221 f
  - Kaufmann's disease 250 f

L

- Landouzy Dejerine dystrophy 260 f
- Lead poisoning
  - pathogenesis hereditary and environmental factors 26\* 27
- Leukocytes
  - Pelger's nuclear anomaly 70 71 f
- Lignac's disease *see* Cystinosis
- Lipase activity test 330 f
- Lipemia retinalis 233
- Lipid metabolism disturbances 230
  - diagnostic tests 337 ff
- Lipids
  - total serum determination 338 f
- Lipocholesterol dystrophy *see* Hurler's syndrome
- Liver
  - with cystinosis, 225\*
  - with diffuse glycogenesis 144
  - with galactosemia 132, 133\*
  - glucose-6 phosphatase 317
    - procedure
  - glycogen storage disease of 146 f
    - See also* von Gierke's disease
  - with Niemann Pick disease 243
  - with thalassemia 57
  - with von Gierke's disease 139\*
  - with Wilson's disease 78 79\*, 80
- Locus 17
  - for hemoglobin production 37 f
- Lungs
  - infiltration in fibrocystic disease 196 197\*
- Lysine tolerance test 336

M

- Macrogenitosisoma praecox 164
- Macula lutea
  - with Niemann Pick disease 243
  - with Tay Sachs disease 246
- Malaria
  - falciform and sickle cell disease 40
- Maple sugar urine disease 120
  - clinical symptoms 120 ff
  - diagnosis 122
  - pathogenesis 122
  - pedigree of causes 121\*
  - tests for 307 ff
  - transmission 122
  - treatment 122
- Marowitz theory of blood coagulation 86\*
- Meconium ileus 196
  - treatment 200
- Melanin 107
- Menorrhagia with parahemophilia 97
- Methemoglobin 174
  - measurement 323
  - reduction in erythrocytes 176 f
  - spectral absorption curve 178\*
- Methemoglobinemia congenital 174
  - diagnosis 177
  - mutation differences 18
  - tests for 323
  - treatment, 177 f
- Type I
  - clinical features 174
  - incidence 175
  - metabolic block 176 f
  - transmission 174 177\*
- Type II 178 ff
- Type III 180
- Methimazole effects 161 319
- Methionine metabolic pathway 227\*
- Microscopy
  - fluorescence of bone marrow 294
- Milton reaction 306
- Mucoproteins
  - duodenal
  - in cystic fibrosis of pancreas 197
  - solubility procedure 331
- Muscles
  - with facioscapulohumeral dystrophy 260
    - glycogen storage in 146 147 ff
  - with myotonia dystrophica 263
  - with pseudohypertrophic dystrophy 257
    - biochemical findings 259
- Muscular dystrophy 256

**Muscular dystrophy (cont.)**

- mild restricted, 260 f
- pseudohypertrophic
  - biochemical findings, 257 ff
  - clinical features, 256 f
  - diagnosis 259
  - genetic studies, 257
  - heredity, 257
  - pathogenesis 257 ff
  - treatment, 259
- severe generalized 256 ff
  - pedigree of causes, 258\*
  - test for, 342

Mutations, *see* Genes mutant

Myotonia dystrophica, 263 f

## N

Naphthalene sensitivity to, 201 ff  
 'Nephrotic glycosuric dwarfism with hypophosphatemic rickets,' 221, 224

**Nervous system changes**

- with acanthrocytosis, 66, 67
- with Gaucher's disease, 238 f
- with H disease, 123
- with hypoglycemia, idiopathic, 265
- with maple sugar urine disease, 120 ff
- with phenylketonuria, 109
- with porphyria, 181
- with Tay Sachs disease, 241, 246

Nicotinic acid utilization disturbance in, 124

**Niemann Pick disease, 242 f**

- adult type, 243
- biochemical defect, 244
- clinical signs and symptoms 243
- diagnosis, 244
- geographic distribution, 243
- interrelationship with Tay Sachs disease, 248
- pathological features, 243
- pedigree of causes, 245\*
- transmission 243
- treatment, 244

Ninhydrin reaction, 308

Nitrogen, alpha amino measurement of total free, 307 f

Normal, 20

## O

Ochronosis with alkaptonuria, 114, 116

Oligophrenia phenylpyruvic, *see* Phenylketonuria

Ophthalmoplegia, progressive, 261 f

Osazone formation, 312 f

Osteoporosis with Gaucher's disease, 238

Oxygen dissociation curve, 323

in Type I methemoglobinemia 175\*

## P

**Pancreas**

fibrocystic disease of *see* Cystic fibrosis of pancreas

partial insufficiency, 198

Pancytopenia, congenital, 279 ff

Paper electrophoresis, 290 ff

Parahemophilia, 97 ff

Paralysis, hereditary periodic, 276

clinical features, 276 f

diagnosis 279

incidence, 277

pathogenesis, 277 ff

transmission, 277

treatment, 279

Partial thromboplastin time, 301

Pathogenesis of disease hereditary and environmental factors in 26 f

Pelger Huet anomaly, 70 f

clinical features, 71 f

diagnosis 72

incidence, 72

pathogenesis, 71\*, 72

transmission 72

treatment, 72

Pentose test for, 342

Pentosuria, 15, 126

diagnosis, 128

incidence, 127

pathogenesis, 128

symptoms, 126 ff

transmission, 127 f

treatment, 128

Xylulose test, 312 f

Phenotypes 20 21\*

for cystinuria, 217 f

**Phenylalanine**

determination, 304 f

hydroxylase, deficiency, 107, 109

metabolism 107, 108\*

Phenylketonuria, 108

clinical features, 108 f

diagnosis, 111

gene expression, 24\*, 25

incidence, 109

- pathogenesis 107 109 ff  
   environmental influence 26\*, 27  
   pedigree of causes 110\*  
   secondary gene effects 29 ff 31\*  
   tests for 304 f  
   transmission 20 ff 109  
     effects of consanguinity 21 f  
   treatment 111 f  
 Phenylpyruvic acid tests for 304  
 Phosphatase alkaline  
   absence effects 193  
   test for 323 f  
 Phosphoethanolamine  
   in pathogenesis of hypophosphatasia 194  
   test for 326 f  
 Phospholipids determination 341 f  
 Phosphorus defect in renal transport effects 215 216\*  
 Pigment  
   absence *see* Albinism  
   metabolism disturbances in 174 ff 180 ff  
   tests for 323 ff  
 Pinguecula, conjunctival with Gauthier's disease 238  
 Pressor test 334 f  
 Pituitary hormone deficiency 268 f  
 Plasma  
   adsorbed preparation 299  
   aged preparation 299  
   alpha amino nitrogen normal 308  
   amino acids identification with paper chromatography 310  
   clotting time 300  
   coagulation qualitative measurement 298  
   copper 79  
   deproteinization 309  
   deprothrombinization of 302  
   fibrinogen  
     congenital deficiency 82 f  
     test for 298 f  
   fourth thromboplastin component deficiency 94 ff  
   iron measurement procedure 291 ff  
   isolated preparation 299  
   phospholipids determination 341 f  
   protein deficiencies in 73 74  
     tests for 296 ff  
   retalifiation time 300  
   thromboplastin antecedent deficiency 93 f  
     correction 90 94  
   thromboplastin component, deficiency 91 f  
     correction 90 92  
     with other clotting defects 103  
   turbidity test, 337 ff  
 Polycerebroside 239  
 Polydipsia, psychogenic 269  
 Porphobilinogen  
   biosynthesis 182  
   urinary test for 295 f  
 Porphyria  
   chronic cutaneous 185 f  
   erythropoietic 67  
   clinical features 67 f  
   diagnosis 70  
   incidence 68  
   pathogenesis 68 ff  
   tests for 294 ff  
   transmission 68  
   treatment 70  
   experimental 183  
   hepatic  
     forms of 180  
     pedigree of causes 183\*  
     tests 323 f  
   intermittent acute 180 f  
   biochemical findings 68 181 f  
   clinical features 181  
   diagnosis 70 183  
   genetics 18\*  
   incidence 182  
   metabolic block 182 f  
   treatment 185  
   mixed 186  
   passive in newborn 181  
 Potassium  
   concentrations with hereditary periodic paralysis 276\*  
   metabolic defect in 277 ff  
 Pregnancy acute porphyria during 181  
 Pregnenetriol excretion  
   in adrenal hyperplasia, 167 169  
   test, 320  
 Primaque sensitivity  
   intravascular hemolysis from 201  
   metabolic block 20\*\* 203 f  
 Primary gene products 28  
 Proteins  
   in blood coagulation 85  
   primary gene effects 31 f  
 Prothrombin  
   complex time (one-stage) 300  
   two-stage determination 300

## 356 INDEX

- Prothrombin (*cont*)  
 utilization test, 301  
 Pseudocholinesterase  
 deficiency, 204 ff  
 determination, procedure, 333 f  
 Pseudohermaphroditism, 164, 166\*  
 treatment, 167 f  
 Pseudohysteria with acute porphyria,  
 181  
 Pyrrole conversion to porphyrins,  
 182, 184\*

## R

- Renal transport mechanisms  
 action of, 207 f  
 defects in, 32  
 clinical conditions from, 208  
 diagnostic tests, 334 ff  
 multiple, 208, 220 ff  
 single, 208, 209 ff  
 with Wilson's disease, 80  
 Retina  
 with Bielschowsky Jansky disease,  
 249  
 with Spielmeier Vogt disease, 249  
 with Tay-Sachs disease, 246  
 Rickets, resistant, 214  
 clinical findings, 214 f  
 diagnosis, 215 f  
 with Fanconi syndrome, 221  
 genetics, 215, 216\*  
 incidence, 215  
 renal transport defect, 215  
 treatment, 216 f

## S

- Salt depletion in fibrocystic disease,  
 196

## Serum

- alkaline phosphatase activity  
 normal range, 326  
 test, 325 f  
 alpha amino nitrogen, normal, 308  
 bilirubin levels, and pathogenesis of  
 kernicterus, 187  
 character, with idiopathic hyperlipemia,  
 234  
 cholesterol  
 determination, 339 ff  
 in primary cholesteremia 236  
 electrolytes, with congenital adrenal  
 hyperplasia, 171

- gamma globulin, test, 296  
 iron, in thalassemia, 59, 60\*  
 lipids  
 with idiopathic hyperlipemia, 234  
 total, determination, 338 f  
 preparation, 299  
 prothrombin conversion accelerator,  
 deficiency, 99 ff  
 combined with other clotting de-  
 fects, 103  
 test for, 303

- Sex-chromosomes, 22 f.

- Sickle cell trait, 39

- with elliptocytosis, 55, 63  
 gene expression, 40  
 geographic distribution, 40  
 -hemoglobin C, 50  
 -hemoglobin D, 51  
 -hemoglobin E, 51  
 -hemoglobin G, 51 f  
 and malaria, 40  
 racial distribution, 40  
 with spherocytosis, 54  
 treatment, 43

- Sickling, 38

- demonstration, 39 f  
 physiologic effects, 43  
 test for, 289

- Skeleton changes in  
 with hypophosphatasia, 193 f  
 with resistant rickets, 214

## Skin

- with erythropoietic porphyria, 68  
 management, 70  
 with Gaucher's disease, 238  
 with H disease, 123  
 with Niemann Pick disease, 243  
 with thalassemia, 57  
 white spotting of, 120

## Skull in thalassemia, 57

- Spherocytosis, hereditary, 149  
 biochemical disturbances, 151 f  
 clinical features, 149 f  
 diagnosis, 152  
 enzyme defect, 150 ff.  
 gene expression, 24\* f  
 -hemoglobin disease, 54  
 incidence, 150  
 pedigree of causes, 151\*  
 tests for, 318 f  
 transmission, 150  
 treatment, 152

- Spielmeier-Vogt disease, 249 f

## Spleen

- with Gaucher's disease 238 242\*
- infarction with sickle cell trait 39
- with Niemann Pick disease 243 244\*
- with thalassemia 56
- Stool trypsin test 327
- Stuart clotting defect 101 f
- Sugar metabolism disturbances in 126 ff., 129 ff
- Sullivan reaction 333 f
- Suxamethonium sensitivity 204
  - diagnosis and treatment, 206
  - pseudocholinesterase determination procedure 333 f
- Sweat electrolytes
  - in cystic fibrosis of pancreas 196 f
  - sodium concentration procedure 327

## T

- Tay Sachs disease 246
  - clinical signs and symptoms 246
  - diagnosis 248
  - genetics 246 f
  - interrelationship with Niemann Pick disease 248
  - pathogenesis, 241 247\* 248
  - pathological features 246
  - treatment 248
- Teeth changes in
  - with erythropoietic porphyria 68
  - with Hurler's syndrome 251
  - with hypophosphatasia, 192 f
- Tendons xanthomatous infiltration 235
- Tetrahydro-S
  - accumulation in adrenal hyperplasia with hypertension on 169
  - test for 322
- Thalassemia 56
  - clinical features 56 f
  - diagnosis 62
  - gene expression 52 58
  - hemoglobin C 53
  - hemoglobin C<sub>2</sub> 53
  - hemoglobin G 51 f 54
  - hemoglobin S 52 f
  - heredity 52 58 f
  - incidence 59
  - major 58
  - minor 58
  - pathogenesis, 59 ff
  - syndrome 52 ff
  - tests, 291 ff 293

- treatment, 62
- Thromboplastin
  - generation test 301 f
  - partial clotting time 301
- Thyroid hormone biosynthesis 156 157\*, 162
- Thyronines iodinated formation 156
- Tissue homogenate preparation, 324
- Transmission modes of, 19 ff
- Tricalcium phosphate suspension 303
- Trypsin
  - duodenal fluid test, 328
  - lack in cystic fibrosis of pancreas, 200
  - stool gelatin test 327
- Tryptophane metabolism disorder of 123 f
- Tubular maximum for glucose glomerular filtration rate 212 213\*
- Tubules convoluted defect in Fanconi syndrome 223
- Tyrosinase
  - action 118\* 119
  - deficiency 107 117 ff
- Tyrosine metabolism 107 108\*
- Tyrosinosis 112
  - diagnosis 114
  - incidence 112
  - pathogenesis 107 112 ff
  - tests 306
  - transmission 112
  - treatment 114

## U

- Uric acid
  - excretion in gout 273 f
  - values procedure 343 f
- Urine
  - alpha amino nitrogen normal 308
  - amino acids 310
  - devaluing 309
  - formation 207
- Uroporphyrins
  - biosynthesis 182
  - excretion, total determination 294 f

## V

- Vasopressin production 268 f
- Virilism *see* Adrenal hyperplasia
- Vitamin D for resistant rickets 215, 216 f
- Von Gierke's disease 138
  - clinical features 139



Von Gierke's disease (*cont*)

- diagnosis, 140
- enzyme defect 138, 140
- incidence, 140
- pedigree of causes, 140, 141\*
- transmission, 139
- treatment, 140 f

## Von Willebrand's disease, 88

## W

## Water renal transport, defect in, 209, 210

## Werdnig Hoffmann disease, 147

## Wilson's disease, 78

- clinical features, 78, 80
- diagnosis, 80
- direct reacting copper fraction, test, 298
- incidence, 78
- pathogenesis, 79 f
- tests for, 296 ff
- transmission, 78

treatment, 80

Wollaston's test, 336

## X

## Xanthelasmatus

- with idiopathic hyperlipemia 230
- with primary hypercholesteremia, 235

## Xanthoma

- with cholesteremia, 235
- with hyperlipemia, 230, 231\*
- with Niemann Pick disease, 243
- tuberosum lesions, pathology, 235 f

Xanthomatosis, essential hypercholesteremic, *see* Hypercholesteremia primary

## XY pair, 22

## / Xylitol, 128

/ Xyloketosuria, *see* Pentosuria

## / Xylulose

- production, 128
- test for, 312 f

